---
document_datetime: 2023-09-21 20:23:23
document_pages: 178
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0090-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-3820-ii-0090-epar-assessment-report-variation_en.pdf
version: success
processing_time: 417.9672807
conversion_datetime: 2026-01-02 08:49:32.217787
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

28 January 2021 EMA/97222/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Keytruda

International non-proprietary name : pembrolizumab

Procedure No. EMEA/H/C/003820/II/0090

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 7                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................7 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................8                                                 |
| 2. Scientific discussion................................................................................                   | 9                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................9 |
| 2.1.1. Problem statement                                                                                                   | ............................................................................................9             |
| 2.1.2. About the product                                                                                                   | ........................................................................................... 11            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice......                                     | 11                                                                                                        |
| 2.1.4. General comments on compliance with GLP, GCP                                                                        | ................................................ 12                                                       |
| 2.2. Non-clinical aspects............................................................................................      | 12                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment.........................................................                  | 12                                                                                                        |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 12     |
| 2.3.1. Introduction....................................................................................................    | 12                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 14           |
| 2.3.3. Pharmacodynamics..........................................................................................          | 22                                                                                                        |
| 2.3.4. PK/PD modelling                                                                                                     | ............................................................................................. 23          |
| 2.3.5. Discussion on clinical pharmacology...................................................................              | 41                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology.................................................................               | 44                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 45     |
| 2.4.1. Dose response study(ies) .................................................................................          | 45                                                                                                        |
| 2.4.2. Main study(ies)                                                                                                     | ............................................................................................... 45        |
| 2.4.3. Discussion on clinical efficacy..........................................................................           | 112                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy ..................................................................             | 119                                                                                                       |
| 2.5. Clinical safety                                                                                                       | .................................................................................................. 119    |
| 2.5.1. Discussion on clinical safety............................................................................           | 159                                                                                                       |
| 2.5.2. Conclusions on clinical safety..........................................................................            | 166                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                          | ................................................................................................... 166   |
| 2.6. Risk management plan                                                                                                  | ..................................................................................... 167                 |
| 2.7. Update of the Product information......................................................................               | 169                                                                                                       |
| 2.7.1. User consultation ..........................................................................................        | 169                                                                                                       |
| 3. Benefit-Risk Balance...........................................................................                         | 170                                                                                                       |
| 3.1. Therapeutic Context .........................................................................................         | 170                                                                                                       |
| 3.1.1. Disease or condition                                                                                                | ...................................................................................... 170                |
| 3.1.2. Available therapies and unmet medical need.....................................................                     | 170                                                                                                       |
| 3.2. Favourable effects............................................................................................        | 171                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................         | 172                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ....................................... 173                                                               |
| 3.6. Effects Table....................................................................................................     | 174                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                 | 176                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                       | 176                                                                                                       |
| 3.7.2. Balance of benefits and risks                                                                                       | .......................................................................... 176                            |
| 3.7.3. Additional considerations on the benefit-risk balance                                                               | ......................................... 176                                                             |
| 3.8. Conclusions .....................................................................................................     | 177                                                                                                       |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations  ............................................................................... 177 5. EPAR changes ..................................................................................... 178

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADA           | Antidrug antibodies                                                                              |
|---------------|--------------------------------------------------------------------------------------------------|
| AE(s)         | Adverse event(s)                                                                                 |
| AEOSI         | Adverse event(s) of special interest                                                             |
| Allo-SCT      | Allogeneic stem cell transplant                                                                  |
| ASaT          | All Subjects as Treated                                                                          |
| AUC           | Area under the concentration-time curve                                                          |
| Auto-SCT      | Autologous-stem cell transplant                                                                  |
| BICR          | Blinded independent central radiology review                                                     |
| BOR           | Best Overall Response                                                                            |
| BV            | Brentuximab vedotin                                                                              |
| cHL           | Classical Hodgkin lymphoma                                                                       |
| CHMP          | Committee for Medicinal Products for Human Use                                                   |
| CI            | Confidence interval                                                                              |
| CR            | Complete response                                                                                |
| CRR           | Complete remission rate                                                                          |
| CSR           | Clinical Study Report                                                                            |
| CTCAE         | Common Terminology Criteria for Adverse Events                                                   |
| DLT           | Dose-limiting toxicity                                                                           |
| DOR           | Duration of response                                                                             |
| EC50          | Half-maximal effective concentration                                                             |
| ECOG          | Eastern Cooperative Oncology Group                                                               |
| EORTC QLQ-C30 | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 |
| EQ-5D         | European Quality of Life Five Dimensions Questionnaire                                           |
| EU            | European Union                                                                                   |
| FDA           | Food and Drug Administration                                                                     |
| GHS           | Global health status                                                                             |
| GVHD          | Graft versus host disease                                                                        |
| HL            | Hodgkin lymphoma                                                                                 |
| HNSCC         | Head and neck squamous cell carcinoma                                                            |
| HR            | Hazard ratio                                                                                     |

<div style=\"page-break-after: always\"></div>

| IA     | Interim analysis                               |
|--------|------------------------------------------------|
| IFNγ   | Interferon gamma                               |
| IgG4   | Immunoglobulin G4                              |
| IL-2   | Interleukin-2                                  |
| ITT    | Intention to treat                             |
| IV     | Intravenous                                    |
| KM     | Kaplan-Meier                                   |
| mAb    | Monoclonal antibody                            |
| MCC    | Merkel cell carcinoma                          |
| MSI-H  | Microsatellite instability-high                |
| NOS    | Not otherwise specified                        |
| NSCLC  | Non-small-cell lung cancer                     |
| ORR    | Objective response rate                        |
| OS     | Overall survival                               |
| PD     | Progressive disease                            |
| PD-1   | Programmed cell death 1                        |
| PD-L1  | Programmed cell death 1 ligand 1               |
| PD-L2  | Programmed cell death 1 ligand 2               |
| PFS    | Progression-free survival                      |
| PK     | Pharmacokinetic(s)                             |
| PMBCL  | Primary mediastinal B-cell lymphoma            |
| PR     | Partial response                               |
| PRO    | Patient-reported outcome                       |
| Q2W    | Every 2 weeks                                  |
| Q3W    | Every 3 weeks                                  |
| Q6W    | Every 6 weeks                                  |
| QoL    | Quality of life                                |
| RCC    | Renal cell carcinoma                           |
| RECIST | Response Evaluation Criteria in Solid Tumors   |
| rrcHL  | Relapsed/refractory classical Hodgkin lymphoma |
| SAE    | Serious adverse event(s)                       |
| SCLC   | Small-cell lung cancer                         |

<div style=\"page-break-after: always\"></div>

| SCT   | Stem cell transplant            |
|-------|---------------------------------|
| SoC   | Standard of care                |
| TNFα  | Tumor necrosis factor alpha     |
| TRAE  | Treatment-related adverse event |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 13 May 2020 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of the currently approved therapeutic indication for the treatment of relapsed or refractory classical Hodgkin lymphoma (rrcHL) in adults to an earlier line of therapy and to include paediatric patients - as follows:

KEYTRUDA as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) following at least one prior therapy when ASCT is not a treatment option. The indication is based on the study KEYNOTE-204, a randomized, open-label, Phase 3 trial evaluating KEYTRUDA monotherapy versus Brentuximab Vedotin (BV) for the treatment of patients with rrcHL and supportive data from updated analysis of KEYNOTE-087, which was the pivotal study supporting the initial rrcHL indication. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The revised RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included EMA Decisions P/0008/2018 and P/0043/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0008/2018 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

<div style=\"page-break-after: always\"></div>

## Scientific advice

Scientific Advice (SA) related to clinical development of pembrolizumab in relapsed/refractory cHL, including phase III study KN-204 was received from the CHMP (see procedure EMEA/H/SA/2437/9/2015/II).

Further SA was received on the proposed extrapolation approach to support the registration in paediatric patients with r/r cHL (see procedure EMEA/H/SA/2437/28/2019/PED/II).

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur:                                                                                   | Armando Genazzani                                                                             | Co-Rapporteur:                                                                                | Mueller-Berghaus   |
|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|--------------------|
| Timetable                                                                                     | Timetable                                                                                     | Timetable                                                                                     | Actual dates       |
| Submission date                                                                               | Submission date                                                                               | Submission date                                                                               | 13 May 2020        |
| Start of procedure:                                                                           | Start of procedure:                                                                           | Start of procedure:                                                                           | 20 June 2020       |
| CHMP Rapporteur's preliminary assessment report circulated on:                                | CHMP Rapporteur's preliminary assessment report circulated on:                                | CHMP Rapporteur's preliminary assessment report circulated on:                                | 19 August 2020     |
| CHMP Co- Rapporteur's preliminary assessment report circulated on:                            | CHMP Co- Rapporteur's preliminary assessment report circulated on:                            | CHMP Co- Rapporteur's preliminary assessment report circulated on:                            | 13 August 2020     |
| PRAC Rapporteur's preliminary assessment report circulated on:                                | PRAC Rapporteur's preliminary assessment report circulated on:                                | PRAC Rapporteur's preliminary assessment report circulated on:                                | 26 August 2020     |
| PRAC RMP advice and assessment overview adopted by PRAC on:                                   | PRAC RMP advice and assessment overview adopted by PRAC on:                                   | PRAC RMP advice and assessment overview adopted by PRAC on:                                   | 3 September 2020   |
| CHMP Rapporteurs' (Joint) Assessment Report circulated on:                                    | CHMP Rapporteurs' (Joint) Assessment Report circulated on:                                    | CHMP Rapporteurs' (Joint) Assessment Report circulated on:                                    | 11 September 2020  |
| Request for supplementary information and extension of timetable adopted by the CHMP on:      | Request for supplementary information and extension of timetable adopted by the CHMP on:      | Request for supplementary information and extension of timetable adopted by the CHMP on:      | 17 September 2020  |
| MAH's responses submitted to the CHMP on:                                                     | MAH's responses submitted to the CHMP on:                                                     | MAH's responses submitted to the CHMP on:                                                     | 9 October 2020     |
| CHMP Rapporteurs' (Joint) preliminary assessment report on the MAH's responses circulated on: | CHMP Rapporteurs' (Joint) preliminary assessment report on the MAH's responses circulated on: | CHMP Rapporteurs' (Joint) preliminary assessment report on the MAH's responses circulated on: | 19 November 2020   |
| 2 nd request for supplementary information and extension of timetable adopted by the CHMP on: | 2 nd request for supplementary information and extension of timetable adopted by the CHMP on: | 2 nd request for supplementary information and extension of timetable adopted by the CHMP on: | 10 December 2020   |
| MAH's responses submitted to the CHMP on:                                                     | MAH's responses submitted to the CHMP on:                                                     | MAH's responses submitted to the CHMP on:                                                     | 18 December 2020   |
| CHMP Rapporteurs' (Joint) preliminary assessment report on the MAH's responses circulated on: | CHMP Rapporteurs' (Joint) preliminary assessment report on the MAH's responses circulated on: | CHMP Rapporteurs' (Joint) preliminary assessment report on the MAH's responses circulated on: | 13 January 2021    |
| CHMP opinion adopted on:                                                                      | CHMP opinion adopted on:                                                                      | CHMP opinion adopted on:                                                                      | 28 January 2021    |
| The CHMP adopted a report on similarity of Keytruda with Adcetris on:                         | The CHMP adopted a report on similarity of Keytruda with Adcetris on:                         | The CHMP adopted a report on similarity of Keytruda with Adcetris on:                         | 28 January 2021    |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Classical Hodgkin Lymphoma (cHL); the claimed therapeutic indication was for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory cHL who have failed autologous stem cell transplant (ASCT) or following at least one prior therapy when ASCT is not a treatment option. Following the assessment, the agreed indication was for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory cHL who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.

## Epidemiology

cHL is a B cell lymphoproliferative disease with distinct clinic and biologic features; it accounts for approximately 10% of all lymphomas, 0.6% of all cancers and 0.2% of all cancer deaths. The incidence in Europe is approximately 2.4 cases per 100.000 persons, with a characteristic bimodal age distribution: one peak in young adults (median age of onset 20 years) and a second peak in older adults (median age of onset 65 years). Overall, the majority of patients are young adults, with a peak incidence between 15 and 35 years and a slightly higher prevalence in males. The actual incidence pattern is known to vary, however, according to race and region.

## Biologic features

cHL is characterised by the presence of Reed-Sternberg (RS) cells (i.e. CD30+, CD15+, CD45- binucleate B cells with a typical 'owl's eyes' morphology) in the context of a mixed inflammatory background, which comprises lymphocytes (T-cells are usually predominant), eosinophils, neutrophils, macrophages, plasma cells and fibroblasts. The specific inflammatory pattern has prognostic value, further classifying cHL into 4 distinct histologic subtypes: nodular sclerosis (70%), mixed cellularity (2025%), lymphocyte-rich (5%) and lymphocyte-depleted (&lt;1%) cHL. The rare lymphocyte depleted variant is associated with the most aggressive behaviour and worst prognosis. The disease has similar biology and natural history in both children and adults age groups.

Together with NFkB, JAK-STAT signalling is usually hyperactivated in cHL, with a significant impact on the differentiation, proliferation, and survival of neoplastic lymphocytes. In particular, dysregulated JAK-STAT signalling results in PD-L1 and PD-L2 hyperexpression: binding to PD1 on T cells, PD-L1 and PD-L2 are implicated in the \"exhaustion\" of cytotoxic cells and contribute to cHL cells survival. Alterations in the PDL1 and/or PD-L2 genetic loci resulting in increased PD-1 ligands expression (e.g. amplification or polysomy of chromosome 9p24.1) are also common in cHL, further highlighting how immune evasion is a key element in cHL pathogenesis.

EBV infection, obesity, high birthweight, smoking, immunosuppression, HLA-A1 and autoimmune disorders have all been associated with an increased risk of developing cHL, and in some cases a familial predisposition has been reported.

<div style=\"page-break-after: always\"></div>

## Clinical presentation and prognosis

cHL usually presents with asymptomatic enlarged lymph nodes or as a neoplastic mediastinal/abdominal mass. Systemic 'B' symptoms (i.e. fever, night sweats, unintended weight loss, recurrent infections) are present in approximately 40% of patients at the time of diagnosis. Pruritus is also common in cHL (~10 to 15% of patients) and can precede the diagnosis by months or longer.

Staging of cHL is based on the Lugano classification, which is derived from the Ann Arbor staging system. Early stages (I and IIA) are characterised by limited lymph node involvement, while advanced stage disease (IIB-IV) is defined by high disease burden in terms of extensive nodal and/or extranodal involvement or bulky disease (e.g. a mediastinal mass ≥ 10 cm or with a ≥0.33 ratio of the maximum width of the mass and the maximum intrathoracic diameter).

Prognosis is evaluated by the international prognostic score (IPS) based on serum albumin and haemoglobin levels, male gender, age, disease stage and white blood cell/absolute lymphocyte counts. Subjects with no risk factors are predicted to have a 5-year progression-free survival (PFS) and overall survival (OS) of 88% and 98%, respectively. Conversely, for patients with 5 or more risk factors the 5year PFS and OS are 62% and 67%, respectively.

## Management

Localised, early stage cHL is usually treated with a combination of abbreviated chemotherapy and low dose involved-site radiation therapy and high cure rates (~90%) are usually observed. Advanced stage cHL is treated with upfront combination chemotherapy (e.g. ABVD, BEACOPP or STANFORD-V) ± involved-field radiation therapy (e.g. in presence of bulky disease and/or residual mass). Brentuximab vedotin (BV), an immunotoxin comprised of a CD30-directed antibody linked to an anti-tubulin agent (MMAE), has been recently authorised in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL), with an overall response rate (ORR) and complete remission rate (CRR) as high as 86% and 73%, respectively, and a 82.2% 2-year modified PFS rate (see Connors JM et al, NEJM 2017). Although the majority of patients with advanced stage cHL are able to obtain disease remission with combination chemotherapy, treatment failures are not uncommon, with relapsed/refractory disease rates as high as 30-40% in some high-risk settings.

Salvage therapy is currently based on the use of non cross-resistant chemotherapy regimens (i.e. DHAP, IGeV, GemOX plus dexamethasone, ICE etc.) and is able to re-induce disease remission in approximately 50% of patients. Long-term disease control following conventional therapy alone is uncommon and further consolidation is usually needed: younger and fit patients are candidate for high dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT), which can allow for long-term disease control/cure in approximately 50% of patients. The German Hodgkin's Lymphoma Study Group (GHSG) has identified three adverse risk factors predictive of second relapse following salvage therapy and ASCT: time to first recurrence ≤12 months, stage III or IV and/or low haemoglobin levels at first relapse (i.e. &lt;10.5 g/dL for females or &lt;12.0 g/dL for males, see Josting A et al, JCO 2002). The long-term prognosis of patients not eligible ASCT, or who have failed ASCT, is poor: threeyear survival rate is 31% (see e.g. Böll B et al, JCO 2013).

BV is approved for the treatment of adult patients with relapsed or refractory (r/r) cHL following ASCT or at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, or as a 'consolidation' for the treatment of adult patients at increased risk of relapse or progression following ASCT. In a phase II trial in which 102 patients with r/r cHL after prior ASCT were treated with BV (1.8 mg/kg every three weeks for up to 16 cycles) the ORR was 75% (CRR 34%). 5-year OS was 41% (65% for patients who obtained a CR) and 5-year PFS was 22% (52% for patients in CR). Treatment with BV is

<div style=\"page-break-after: always\"></div>

not devoid of toxicities, with peripheral sensory neuropathy (42%) being the most common nonhematologic adverse event (AE). BV also proved to be an effective 'bridge' to transplant (see e.g. Chen R et al, Blood 2016; Younes A et al, JCO 2012).

Prognosis after failure of salvage chemotherapy, including BV, is poor. A selected subset of patients might be eligible to allogeneic hematopoietic stem cell transplant (allo-HSCT), which might still result in longterm remission in a subset of fit patients. However, transplant-related mortality and toxicity is not negligible.

Treatment of rrcHL in children and adolescents follows adult-based strategies, with multi-agent chemotherapy followed by myeloablative high-dose chemotherapy with auto-SCT. In patients who have previously been refractory to or relapsed from 1 or 2 lines of chemotherapy, particularly those with highrisk disease, these existing treatment options are not satisfactory, leaving little expectation of potential benefit, but unavoidable additional toxicity. Therefore, the disease burden caused by paediatric cancers remains an area with significant unmet need.

## 2.1.2. About the product

Keytruda (pembrolizumab, MK-3475) is a humanized monoclonal antibody designed to block the interaction between the programmed death-1 (PD-1) receptor and its ligands PD-L1 and PD-L2. The PD-1 immune checkpoint inhibition results in increased functional activity of cytotoxic lymphocytes which facilitates immune-mediated anti-tumour activity. The increased expression of PD-L1 and PD-L2 cHL Reed-Sternberg cells makes PD-1 an attractive target in r/r cHL. Pembrolizumab is currently approved as monotherapy for the treatment of adult patients with r/r cHL who have failed ASCT and BV, or who are transplant-ineligible and have failed BV on the basis of uncontrolled studies KN-087 and KN-013 in subjects with cHL in advanced stages of relapse.

In this application the initially claimed indication was in adult and paediatric patients who have failed autologous stem cell transplant (ASCT) or following at least one prior therapy when ASCT is not a treatment option.

The approved indication is 'KEYTRUDA as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option'.

The recommended dose of KEYTRUDA as monotherapy in paediatric patients aged 3 years and older with cHL is 2 mg/kg bodyweight (up to a maximum of 200 mg), every 3 weeks administered as an intravenous infusion over 30 minutes.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The MAH received SA from the CHMP on the clinical development of pembrolizumab in r/r cHL (EMEA/H/SA/2437/9/2015/II). In particular, the adequacy of phase 3 study KN204 was discussed in terms of patient population, comparator and magnitude of target effect. The feedback received by the CHMP was partially taken into account.

In addition, a SA was adopted by the CHMP (EMEA/H/SA/2437/28/2019/PED/II) on the proposed approach to support the registration of a new indication for paediatric patients with r/r cHL. The proposed extrapolation concept was in principle considered acceptable

<div style=\"page-break-after: always\"></div>

## 2.1.4. General comments on compliance with GLP, GCP

The MAH confirmed that all clinical studies were conducted following appropriate Good Clinical Practice (GCP) standards and considerations for the ethical treatment of human participants that were in place at the time the studies were performed.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

An environmental risk assessment has not been included. According to the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00) in all cases, except for Type I variations and renewal applications, an ERA or a justification for its absence should be provided. Vitamins, electrolytes, amino acids, proteins, carbohydrates and lipids are exempted because they are unlikely to result in significant risk to the environment. Pembrolizumab (MK-3475) is a humanized monoclonal antibody of the IgG4/kappa isotype; being a protein, it is exempt from ERA requirements.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 1 : Summary of Studies in the Hodgkin Lymphoma Clinical Development Program

| Study Number/ Status                                                                                                                                                                                                                                                                                            | Design                                                                                                                                                                                                                                                                                                          | Population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Dosage, Regimen                                                                                                                                                                                                                                                                                                 | Primary Efficacy Endpoint(s)                                                                                                                                                                                                                                                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| KN-013 Ongoing (N=31 rrHL)                                                                                                                                                                                                                                                                                      | Single- arm Phase 1b                                                                                                                                                                                                                                                                                            | Approximately 156 participants with MDS, HL NHL, PMBCL, and MM. N=31 r/r cHL                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Pembrolizumab 10 mg/kg Q2W                                                                                                                                                                                                                                                                                      | ORR for MDS, MM, NHL, and PMBCL CR for HL                                                                                                                                                                                                                                                                       |
| KN-087 Ongoing (N=210)                                                                                                                                                                                                                                                                                          | Single- arm Phase 2                                                                                                                                                                                                                                                                                             | Cohort 1: participants with r/r cHL who failed to achieve a response or progressed after ASCT and BV Cohort 2: participants with r/r cHL who failed salvage chemotherapy and were ineligible for ASCT (unable to achieve a complete or partial response to salvage chemotherapy) and failed BV therapy Cohort 3: participants with r/r cHL who failed to achieve a response or progressed after ASCT and who did not receive BV post ASCT. These participants could have received BV as part of primary or salvage treatment. | Pembrolizumab 200 mg Q3W                                                                                                                                                                                                                                                                                        | ORR                                                                                                                                                                                                                                                                                                             |
| KN-204 Ongoing (N=304; 1:1 randomizati on)                                                                                                                                                                                                                                                                      | Randomi zed, open- label Phase 3 vs BV                                                                                                                                                                                                                                                                          | Participants with r/r cHL who have not had previous treatment with BV or who had prior treatment with response to BV or BV-containing regimen, and 1) have failed to achieve a response or progressed after ASCT, or 2) are not ASCT candidates and have received at least 2 prior multi-agent chemotherapy regimens                                                                                                                                                                                                          | Pembrolizumab 200 mg Q3W or BV 1.8 mg/kg intravenously on Day 1 every 3 weeks                                                                                                                                                                                                                                   | PFS (according to the IWG response criteria as assessed by BICR) and OS                                                                                                                                                                                                                                         |
| KN-051 Ongoing (N=162 enrolled)                                                                                                                                                                                                                                                                                 | Single- arm, open- label, Phase 1/2                                                                                                                                                                                                                                                                             | Up to 310 participants 6 months to <18 years of age with advanced melanoma; r/r cHL; advanced, relapsed/refractory PD-L1 positive solid tumor or other lymphoma; or advanced relapsed/refractory MSI-H solid tumor.                                                                                                                                                                                                                                                                                                           | Dose finding was conducted in Part I, with pembrolizumab doses of 1-10 mg/kg Q3W                                                                                                                                                                                                                                | Part I: DLTs Parts I and II: Safety, ORR                                                                                                                                                                                                                                                                        |
| KN-667 Ongoing (N=11 as of 31Mar2020)                                                                                                                                                                                                                                                                           | Parallel- group open- label Phase 2                                                                                                                                                                                                                                                                             | Approximately 440 participants 3 to 25 years of age with newly diagnosed cHL or with inadequate early response to frontline chemotherapy                                                                                                                                                                                                                                                                                                                                                                                      | Group 1: 2 cycles ABVD induction chemotherapy followed by pembrolizumab in SERs. Group 2: 2 cycles of OEPA induction chemotherapy followed by pembrolizumab in SERs. Pembrolizumab dosing in both groups: 2 mg/kg up to a max of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) Q3W            | ORR                                                                                                                                                                                                                                                                                                             |
| ABVD= Adriamycin, bleomycin, vinblastine, dacarbazine; auto-SCT=autologous-stem cell transplant; BV=brentuximab vedotin; CR = complete remission; HL=Hodgkin lymphoma; IWG=International Working Group; MDS=myelodysplastic syndrome; MM=multiple myeloma; NHL=non-Hodgkin lymphoma; OEPA= vincristine sulfate, | ABVD= Adriamycin, bleomycin, vinblastine, dacarbazine; auto-SCT=autologous-stem cell transplant; BV=brentuximab vedotin; CR = complete remission; HL=Hodgkin lymphoma; IWG=International Working Group; MDS=myelodysplastic syndrome; MM=multiple myeloma; NHL=non-Hodgkin lymphoma; OEPA= vincristine sulfate, | ABVD= Adriamycin, bleomycin, vinblastine, dacarbazine; auto-SCT=autologous-stem cell transplant; BV=brentuximab vedotin; CR = complete remission; HL=Hodgkin lymphoma; IWG=International Working Group; MDS=myelodysplastic syndrome; MM=multiple myeloma; NHL=non-Hodgkin lymphoma; OEPA= vincristine sulfate,                                                                                                                                                                                                               | ABVD= Adriamycin, bleomycin, vinblastine, dacarbazine; auto-SCT=autologous-stem cell transplant; BV=brentuximab vedotin; CR = complete remission; HL=Hodgkin lymphoma; IWG=International Working Group; MDS=myelodysplastic syndrome; MM=multiple myeloma; NHL=non-Hodgkin lymphoma; OEPA= vincristine sulfate, | ABVD= Adriamycin, bleomycin, vinblastine, dacarbazine; auto-SCT=autologous-stem cell transplant; BV=brentuximab vedotin; CR = complete remission; HL=Hodgkin lymphoma; IWG=International Working Group; MDS=myelodysplastic syndrome; MM=multiple myeloma; NHL=non-Hodgkin lymphoma; OEPA= vincristine sulfate, |

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

Clinical pharmacology results are available from two clinical studies (KEYNOTE-013 and KEYNOTE-087), already included in the previous application to support 200 mg Q3W of pembrolizumab in rrcHL patients and are further informed by results obtained in study KEYNOTE-051 to support the inclusion of a paediatric indication.

The updated clinical pharmacology results specific to this submission include:

- PK data of pembrolizumab in paediatric patients with an advanced solid tumor or lymphoma treated with2mg/kg Q3W in KN051 study
- Update  of  the  existing  population  pharmacokinetic  model  with  additional  paediatric  data  from KN051 and adult classical Hodgkin lymphoma (cHL) data from KN204
- Comparison of pembrolizumab pharmacokinetics and exposures in different age groups of paediatric patients to those obtained in adult patients to justify paediatric dose regimens
- Extrapolation  of  adult  data  from  KEYNOTE-204  and  KEYNOTE-087  along  with  the  results  of KEYNOTE-051 to support the inclusion of a paediatric indication.

## Absorption

As pembrolizumab is administered intravenously, bioavailability is 100%.

## Distribution

Pooled pop PK analysis (all age ranges and several cancer indications) including cHL PK data from KN051, KN013, KN087, KN204 estimated the central volume of distribution to 3.37 L (19 %CV) and peripheral volume of distribution to 2.61 L (19% CV). Body weight (alpha = 0.540), was selected as predictive covariate on both volumes. Age (&lt; 18 years) and value: 0.292; Albumin (value: -0.258), Gender (value: -0.123) were selected as predictive covariate for Vc.

Median central volume of distribution ranged from 0.8 L (2-6 years of age), over 1.3 L (6-12 years of age) and 2.3 L (12-18 years of age) to 3.3 L (&gt; 18 years).

## Elimination

Pooled pop PK analysis (all age ranges and several cancer indications) including cHL PK data from KN051, KN013, KN087, KN204 estimated clearance to 0.252 L/day. Weight (alpha = 0.604), Cancer type (HL: 0.197), Age (&lt; 18 years; value: 0.538), Albumin (value: -0.86), Baseline ECOG (0.065), Bilirubin (value: -0.0398), Baseline tumour size (solid tumours only) with value of 0.0985, eGFR (value 0.116), and Gender were selected as statistical significant covariates on CL.

Median clearance ranged with age from 0.047 L/d (2-6 years of age), over 0.092 L/d (6-12 years of age) and 0.152 L/d (12-18 years of age) to 0.295 L/d (&gt; 18 years).

## Dose proportionality and time dependencies

Clinical pharmacology of pembrolizumab in participants with rrcHL was described in the KEYNOTE-087 application to support 200 mg Q3W as the recommended monotherapy dose of pembrolizumab in this patient population.

Following administration of pembrolizumab 200 mg Q3W in participants with cHL (KEYNOTE-087), the observed median Cmin at steady-state was up to 40% higher than that in other tumour types treated with the same dosage; however, the range of trough concentrations is similar. There are no notable differences in median Cmax between cHL and other tumour types.

<div style=\"page-break-after: always\"></div>

Following 2 mg/kg Q3W (paediatrics patients, KN051) steady state is overall reached by 15 weeks postdose, with a slight trend in ongoing accumulation (PK data by week 81).

## Pharmacokinetics in the target population

Participants  with  rrcHL  in  KEYNOTE-204  and  KEYNOTE-087  and  paediatric  participants  with  rrcHL  in KEYNOTE-051 comprise the primary participant populations for this application.

A description of the clinical pharmacology of pembrolizumab in participants with rrcHL was included in the KEYNOTE-087  application to support 200mg  Q3W  as  the recommended  monotherapy  dose  of pembrolizumab in this patient population in adults. Following administration of pembrolizumab 200 mg Q3W in participants with cHL enrolled in KEYNOTE-087, the observed median Cmin at steady-state was up to 40% higher than that in other tumor types treated with the same dosage; however, the range of trough concentrations was similar as well as there were no notable differences in median Cmax between cHL and other tumor types.

Previously, a pooled population PK analysis using KN001, KN002, KN006, and KN010 studies was performed to characterize serum concentrations over time based on a dataset including 2841 subjects across the melanoma and NSCLC indications.

A  first  extension  of  the  previous  population  PK  analysis  was  conducted  primarily  to  assess  the pharmacokinetics of pembrolizumab in adult patients with classical Hodgkin Lymphoma and in paediatric patients with solid tumors. For this purpose, paediatric PK data from study KN051 and data from adult patients with classical Hodgkin Lymphoma (cHL) from studies KN013 and KN087 were added to the dataset to enhance the relevance of the model for non-solid tumor indications.

A second extension of the population PK analysis was conducted as outlined in this report with additional paediatric data in solid tumors and cHL from KN051 and adult cHL data from KN204 to increase robustness of the first extension analysis.

Based on the extended dataset, the model was refined with a focus on an optimal characterization of the pembrolizumab concentration-time data in paediatric patients.

The final  model  was  subsequently  used  in  simulations  of  pembrolizumab  PK  parameters  and  exposure parameters in different age groups of paediatric patients and compared to the estimates in adult patients to support pembrolizumab dose regimen selection in paediatric patients.

## Pembrolizumab PK data from KEYNOTE-051 study (Paediatric patients)

KEYNOTE-051 was an ongoing Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE051). As of the data cutoff date for the submitted report (10-JAN-2020), 162 participants (N=22 rrcHL patients) were enrolled out of a total of up to 310 participants that was planned to be enrolled.

<div style=\"page-break-after: always\"></div>

Table 2 Overview of cancer types included in the KN-051 PK analysis

| Cancer type                                                                                      |   Number of Subjectsa |   Total | PK Data Cutoff   |
|--------------------------------------------------------------------------------------------------|-----------------------|---------|------------------|
| Melanoma (MEL)                                                                                   |                     8 |     152 | 13-Aug-2018      |
| Wilms Tumor Nephroblastoma                                                                       |                     3 |     152 | 13-Aug-2018      |
| Renal cell carcinoma (RCC)                                                                       |                     2 |     152 | 13-Aug-2018      |
| Hodgkin's Lymphoma (HL)                                                                          |                    17 |     152 | 13-Aug-2018      |
| Neuroblastoma, CNS primary tumor, Astrocytoma,Gliobastoma multiforme, Medulloblastoma,Ependymoma |                    43 |     152 | 13-Aug-2018      |
| Solid Tumor                                                                                      |                    29 |     152 | 13-Aug-2018      |
| Soft tissue neoplasm, alveolar soft part sarcoma                                                 |                    13 |     152 | 13-Aug-2018      |
| Osteosarcoma                                                                                     |                    10 |     152 | 13-Aug-2018      |
| Adrenocorticalcarcinoma                                                                          |                     4 |     152 | 13-Aug-2018      |
| Diffuse large B cell lymphoma,Precursor T Lymphoblastic Lymphoma, Lymphoma                       |                     2 |     152 | 13-Aug-2018      |
| Hepatoblastoma,Hepatocellular carcinoma                                                          |                     8 |     152 | 13-Aug-2018      |
| Rhabdomyosarcoma                                                                                 |                     7 |     152 | 13-Aug-2018      |
| AtypicalTeratoid Rhabdoid Tumor                                                                  |                     4 |     152 | 13-Aug-2018      |
| Non Rhabdomyosarcoma Soft Tissue Sarcoma Nos                                                     |                     1 |     152 | 13-Aug-2018      |
| Other                                                                                            |                     1 |     152 | 13-Aug-2018      |

Number of unique subject numbers in dataset

Nos: Not otherwise specified

Data Source: [052DCX: analysis-p051pkdm0pip2018v3]

PK samples in KN051 were scheduled as follow: Pre-dose pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at Cycles 1, 2, 4, 8 and every 4 cycles (12 weeks) thereafter. Post-dose serum concentrations (Cmax) were drawn within approximately 30-minutes after the end of the infusion in Cycle 1 and Cycle 8. Additional PK samples were drawn in Cycle 1 between 72 to 168 hours (4-8 days) post-dose and at 264 to 408 hours (12-18 days)-post-dose. Phoenix™ WinNonlin® (Version 6.3.0.395) software was used for pharmacokinetic analysis.

For the pharmacokinetic analysis, serum pembrolizumab concentrations with an early PK cut-off date of 13-Aug-2018 were used from the bioanalytical report. Phoenix™ WinNonlin® (Version 6.3.0.395) software was used for pharmacokinetic analysis.

In total, there were 151 participants in KEYNOTE-051 with evaluable PK samples. Observed PK concentrations in paediatric participants receiving 2 mg/kg Q3W were within the range of values for adults administered 2 mg/kg Q3W.

<div style=\"page-break-after: always\"></div>

Table 3 Summary statistics of the observed pembrolizumab trough (pre-dose) and post-dose concentrations in paediatric subjects from KN051

SummaryStatisticsofPembrolizumabPredose(Ctrough),Postdose (Cmax) and Post Cycle 1 Serum ConcentrationValues Following Administration of Multiple I.V. Doses of 2 mg/kgQ3W in KN051

| Cyele                                          | NOMTAFD                                        | N   | GM         | GM        | AM (SD)   | Min   | Median   | Max   |
|------------------------------------------------|------------------------------------------------|-----|------------|-----------|-----------|-------|----------|-------|
|                                                | day                                            |     | (%CV)      | (SD)      | (μg/mL)   |       |          |       |
| Predose (Ctrugh)                               |                                                |     |            |           |           |       |          |       |
| Cycle 2 (Week 3)                               | 21                                             | 123 | 11.1 (47)  | 11.1 (5)  | 12.1 (5)  | 1.84  | 11.6     | 28.1  |
| Cycle 4 (Week 9)                               | 63                                             | 64  | 24.5 (48)  | 24.5 (11) | 26.8 (11) | 6.05  | 26.5     | 63.0  |
| Cycle 8 (Week 21)                              | 147                                            | 36  | 29.5 (52)  | 29.5 (13) | 32.4 (13) | 6.62  | 32.9     | 58.7  |
| Cycle 12 (Week 33)                             | 231                                            | 24  | 24.0 (116) | 24.0 (17) | 31.6 (17) | 2.75  | 35.4     | 54.3  |
| Cycle 16 (Week 45)                             | 315                                            | 19  | 32.2 (58)  | 32.2 (13) | 35.6 (13) | 5.98  | 36.6     | 57.7  |
| Cycle 20 (Week 57)                             | 399                                            | 12  | 38.3 (30)  | 38.3 (10) | 39.7 (10) | 18.8  | 38.7     | 53.6  |
| Cycle 24 (Week 69)                             | 483                                            | 11  | 33.6 (87)  | 33.6 (17) | 39.5 (17) | 4.20  | 41.6     | 66.6  |
| Cycle 28 (Week 81)                             | 567                                            | 8   | 41.6 (18)  | 41.6 (7)  | 42.1 (7)  | 34.1  | 41.6     | 51.8  |
| Postdose(Cm)（within30min post end of infusion) | Postdose(Cm)（within30min post end of infusion) |     |            |           |           |       |          |       |
| Cycle 1 (Week 0)                               | 0                                              | 143 | 43.6 (28)  | 43.6 (14) | 45.4 (14) | 21.3  | 44.5     | 145   |
| Cycle 8 (Week 21)                              | 147                                            | 36  | 77.7 (30)  | 77.7 (24) | 81.1 (24) | 41.3  | 79.3     | 143   |
| Post Cycle1                                    |                                                |     |            |           |           |       |          |       |
| 72-168 hours post C1                           | 7                                              | 136 | 17.4 (40)  | 17.4 (6)  | 18.5 (6)  | 2.04  | 18.4     | 42.5  |
| 336 hours post C1                              | 14                                             | 136 | 12.4 (49)  | 12.4 (5)  | 13.4 (5)  | 0.520 | 13.2     | 31.2  |

GM= Geometric Mean;

NOMTAFD = Nominal time after first pembrolizumab adlministration;

CV%=Geometric Coefficient ofVariation; SD=Standard Deviation;

Results reported for time points with N &gt; 3.

AM = Arithmetic Mean;

Data Source:[052DCX: analysis-p051pkdm0pip2018v3]

<div style=\"page-break-after: always\"></div>

Figure 1 individual and mean pre-dose concentration-time profiles

IndividualandArithmeticMean(SE)PembrolizumabPredose Concentration-Time ProfilesFollowing Multiple I.V.Doses of 2mg/kg Q3W in StudyKN051 (a)Linear scale,(b)Log scale

<!-- image -->

Note: Grey lines represent individual concentration observations. Black dashed lines represent arithmetic mean concentrations and error bars are associated +/- SE (Standard Error). Data Source: [052DCX: analysis-p051pkdm0pip2018v3]

ArithmeticMean(SE)PembrolizumabPredose Concentration-Time ProfilesFollowingMultiple I.V.Doses of 2mg/kgQ3W toSubjects in StudyKN051 (Linearscale)

<!-- image -->

Note: This plot is Arithmetic Mean with Standard Error (SE). Data Source: [052DCX: analysis-p051pkdm0pip2018v3]

The observed and predicted pembrolizumab concentration-time profiles following  200  mg  Q3W administration at post-dose cycle 1 and at steady state (at and after cycle 8) are illustrated in the following figure:

<div style=\"page-break-after: always\"></div>

Figure 2 Observed concentration data in KN051subjects receiving 2 mg/kg Q3W pembrolizumabwith reference model - predicted PK profile for 2 mg/kg Q3W dose regimen

Observed Concentration DatainKN051Subjects Receiving 2mg/kg Q3WPembrolizumab withReference Model-PredictedPharmacokinetic Profile for 2 mg/kg Q3W Dose Regimen

<!-- image -->

a) After Ist dose on log scale; b) At and after cycle S (21 weeks) on log scale. Symbols are individual observed data (actual time) from subjects in KN051; black dashed line is median predicted concentrations from the model for a regimen of 2 mg/kg Q3W' and the grey shaded area represents the 90% prediction interval.

Data Source: [052DCX: analysis-p051pkdm0pip2018v3]

Based on the existing robust characterization of pembrolizumab PK, a comparison was conducted between the observed PK of pembrolizumab in children from study KEYNOTE-051 and the predictions from the reference PK model developed with pembrolizumab monotherapy data (KEYNOTE-001, -002, 006, -010, and -024).  New 'overlay' figures at Cycle 1 and steady state are generated for KEYNOTE-051 paediatric participants and KEYNOTE-204 adult cHL participants based on the updated popPK model including adult cHL participants and paediatric participants with solid tumours and cHL. Observed data shown in blue refer to cHL participants and data shown in green refer to paediatric participants with solid tumors.

<div style=\"page-break-after: always\"></div>

Figure 3

Observed Concentration Data in Subjects Receiving 2 mg/kg Q3W Pembrolizumab at Cycle 1 With Updated Model-Predicted Pharmacokinetic Profile for 2 mg/kg Q3W Dos Regimen

## KEYNOTE-0512mg/kgMK-3475Cycle1Pediatric

Figure 4 Observed Concentration Data in Subjects Receiving 2 mg/kg Q3W Pembrolizumab at Steady

<!-- image -->

State With Updated Model-Predicted Pharmacokinetic Profile for 2 mg/kg Q3W Dose Regimen

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 5

Observed Concentration Data in Subjects Receiving 200 mg Q3W Pembrolizumab at Cycle 1 With Updated Model-Predicted Pharmacokinetic Profile for 200 mg Q3W Dose Regimen

## KEYNOTE-204 200 mg MK-3475Cycle 1Adult cHL

<!-- image -->

*Data cutoff: November, 2017

Observed Concentration Data in Subjects Receiving 200 mg Q3W Pembrolizumab at Steady State With Updated Model-Predicted Pharmacokinetic Profile for 200 mg Q3W Dose

Figure 6 Regimen

## KEYNOTE-204 SteadyState200mg MK-3475Adult cHL

<!-- image -->

*Data cutoff: November, 2017

<div style=\"page-break-after: always\"></div>

## Overview of bio-analytical methods and assay validation

## Analytical methods

The  validation  performance  of  the  bioanalytical  assay  for  the  quantitation  of  serum  concentrations  of pembrolizumab were summarized. PK and immunogenicity data included in this submission were exclusively generated at PPD laboratories using appropriately validated assays.

The  concomitantly  administered  compounds  MK-1308,  MK-7684,  and  GSK3174998  were  evaluated  for potential interference. Data met the acceptance criteria specified in the method validation plan addendum, indicating no effect of the stated compounds on the quantitation of MK-3475 in human serum at the levels evaluated. Results from analyte interference studies presented indicate there is no effect on the quantitation of MK-3475 in human serum fortified with concomitantly administered compounds (MK-1308, MK-7684, GSK3174998)  to  the  stated  concentrations.  Results  from  all  samples  were  within  the  pre-specified acceptance criteria. Analysis of Variance (ANOVA) was conducted and the validation intra- and inter-assay data for both the fresh and frozen preparations met the acceptance criteria.

The addendum provides data on analyte stability in frozen matrix and on conjugated reagent stability.

Stability was demonstrated after 842 days and at 1218 days (in this case an intermediate calibrator was diluted in matrix to the high-level concentration prior the analysis).

Data from the analysis of MK-3475 stability samples in frozen human serum stored for up to 1217 days at -25 °C ± 5 °C and for up to 1218 days at -80 °C ± 10 °C met the criteria for demonstrating stability.

Data from the analysis of QCs using conjugated reagents stored for up to 1135 days at -80 °C ± 10 °C and for up to 30 days at 2-8 °C met the criteria; The results of selectivity assessment in small cell lung cancer human serum are reported in this validation report amendment. Results from all samples were within the pre-specified acceptance criteria.

## 2.3.3. Pharmacodynamics

## Mechanism of action

KEYTRUDA is an antibody that binds to the programmed death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. KEYTRUDA potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.

## Primary and secondary pharmacology

## Immunogenicity

There  were  no  cases  of  positive  immunogenicity  status  after  pembrolizumab  treatment  in  paediatric participants (0%), while the incidence rate (2.1%) of treatment-emergent positive immunogenicity status in adults (Report 052J8M) is low. No additional analyses were performed for the current KEYNOTE-051 CSR. The details of the immunogenicity analysis are available in the prior version of the CSR of study KN051 and reported below.

The table below presents an overview of the immunogenicity status of all assessable subjects. To evaluate immunogenicity, the overall immunogenicity was defined as the proportion of emergent positive subjects to the total number of evaluable subjects (treatment emergent positive, non-treatment emergent positive and negative immunogenicity status).

<div style=\"page-break-after: always\"></div>

Table 4 Summary ofSubjectImmunogenicityResultsafterPembrolizumabTherapy

## inChildren,2mg/kgQ3W（KN051)

| Stratifiedbytreatment            | Stratifiedbytreatment   | Stratifiedbytreatment   | Stratifiedbytreatment      | Stratifiedbytreatment   | Stratifiedbytreatment   | Stratifiedbytreatment   |
|----------------------------------|-------------------------|-------------------------|----------------------------|-------------------------|-------------------------|-------------------------|
|                                  |                         | Indication              | Indication                 | Indication              | Indication              | Indication              |
| Immunogenicity status            | AlI indications         | Hodgkin's Lymphoma      | Brain/ CNS- related Tumors | Solid Tumors            | Soft Tissue Neoplasm    | Other                   |
| Assessable subjects\"             | 133                     | 17                      | 38                         | 24                      | 12                      | 42                      |
| Inconclusivesubjects             | 8                       | 2                       | 3                          | 2                       | 0                       | 1                       |
| Evaluablesubjects                | 125                     | 15                      | 35                         | 22                      | 12                      | 41                      |
| Negatived                        | 123 (98.4%)             | 15 (%001)               | 34 (97.1%)                 | 22 (%001)               | 12 (%001)               | 40 (97.6%)              |
| Non-Treatment emergent positived | 2(1.6%)                 | 0                       | 1(2.9%)                    | 0                       | 0                       | 1(2.4%)                 |
| Neutralizing negatived           | 2(1.6%)                 | 0                       | 1 (2.9%)                   | 0                       | 0                       | 1(2.4%)                 |
| Neutralizing positived           | 0                       | 0                       | 0                          | 0                       | 0                       | 0                       |
| Treatmentemergent positivea      | 0                       | 0                       | 0                          | 0                       | 0                       | 0                       |
| Neutralizing negatived           | 0                       | 0                       | 0                          | 0                       | 0                       | 0                       |
| Neutralizingpositived            | 0                       | 0                       | 0                          | 0                       | 0                       | 0                       |

- c:Evaluable subjects are thetotalnumber ofnegative andpositive subjects(mon-treatment emergentand treatmentemergent.

d:Denominatorwastotalnumberofevaluablesubjects.

Out of the 133 subjects included in the immunogenicity assessment, 125 subjects were evaluable. The evaluable subject group contains 2 subjects with non-treatment emergent positive status (1.6%), and 123 with negative immunogenicity status (98.4%). There were no subjects with a treatment emergent positive status observed.

## 2.3.4. PK/PD modelling

## PK Bridging Analysis

Model parameters including covariate effects were re-estimated with a focus on an optimal characterization of the potential effects of age and body weight in the paediatric population.

Reliability and robustness of the subsequent final model was assessed by a range of goodness of fit plots. Post-hoc parameter estimates from the final model were used to compare pharmacokinetic parameters as well as individual pembrolizumab exposure estimates between paediatric and adult populations.

Simulations from the final model were performed to assess the exposure to pembrolizumab in paediatric patients at the dose regimens of 2 mg/kg Q3W or 200 mg Q3W and compare to the exposures in adult patients.  Paediatric  covariate  information  for  simulations  was  obtained  from  an  external  dataset  (171 paediatric oncology subjects) in combination with the paediatric subjects from the pembrolizumab dataset (152 subjects).

## Evaluation and qualification of model

The established population PK model for pembrolizumab had a two-compartment model structure with a linear  clearance  from  the  central  compartment,  parameterized  in  terms  of  clearance  (CL),  intercompartmental clearance (Q), central compartment  volume  of distribution (Vc), and peripheral

<div style=\"page-break-after: always\"></div>

compartment volume of distribution (Vp). All PK parameters were allometrically scaled based on body weight with separate exponents estimated for the clearance (CL, Q) and volume (Vc, Vp) parameters.

Additionally, a time-dependent component was estimated on the pembrolizumab clearance. The change in clearance over time (TDPK(t)) was described according to an Emax function.

In addition to body weight, the existing population PK model contained several more covariate relationships, which were established through a stepwise covariate search. Specifically, the following covariates were included in the model: Age, Gender and Albumin on CL and Vc; Bilirubin, eGFR, Baseline tumor size , ECOG performance status and Cancer type on CL.

No  formal  full  covariate  evaluation  was  planned  as  part  of  this  new  analysis.  Rather,  the  previously established covariate relationships were re-estimated and a focused reassessment of specific covariates was performed. Statistical criteria for forward addition (P&lt;0.01) and backward deletion (P&lt;0.001) were identical to previously conducted stepwise covariate model building.

## Model Performance .

The following goodness-of-fit plots were utilized to assess the adequacy of the structural model to describe the pooled dataset. All plots included a specific highlighting of the data from paediatric patients through the use of different markers to enable an assessment of the adequacy of the model specifically for this patient group.

- Observations versus population and individual predictions log-log plots overall and by study
- Population and individual weighted residuals versus time by study
- Population weighted residuals versus population predictions
- Conditional weighted residuals versus population predictions
- Individual weighted residuals versus individual predictions

## Comparison Paediatrics vs Adults

Following finalization of the population PK model on the pooled dataset, the final model was used to enable comparisons  of  the  pharmacokinetics  of  pembrolizumab  between  paediatric  and  adult  patients.  The following comparisons were included in this assessment: 1) Comparison of individual posthoc parameter estimates, through boxplots and descriptive statistics of individual parameters; 2) Comparison of derived individual PK parameters (Cmax at Cycle 1, AUC6wks, t1/2, Cmin at Cycle 1) for selected dose regimens between different populations by means of boxplots and tabular summaries of descriptive statistics.

## Simulations in Paediatrics

In order to project distributions of pembrolizumab PK parameters and exposures in a broader paediatric population, a set of simulations was performed. A dataset of individual patient covariate information was constructed from which simulation datasets were obtained through resampling.

The resampling dataset consisted of the subjects included in the analysis dataset. However, since only a relatively  small  number  of  paediatric  subjects  in  the  younger  age  groups  were  available  in  the pembrolizumab dataset and since no relevant public database containing the required covariate information was readily available,  the  resampling  dataset  was  augmented  with  a  paediatric  oncology  dataset  from another program including 171 subjects aged 0.5 - 17 years.

The  simulation  dataset  consisted  of  a  total  of  1000  paediatric  and  500  adult  patients  sampled  with replacement from the covariate dataset. As no baseline tumor size data was available for the paediatric population, no covariate effect of baseline tumor size was assumed for the paediatric subjects. Also, a 50/50 distribution of ECOG values 0 or 1 was assumed for the paediatric population. In terms of indication, the paediatric subjects were classified as either solid tumor or non-solid tumor type, with the first having the typical clearance associated with the melanoma and other indications in the model and the second having the typical clearance associated with the cHL indication.

<div style=\"page-break-after: always\"></div>

The final population PK model was used to predict the pembrolizumab concentrations following single dose and at steady state for the patients in the simulation dataset. Distributions of the PK parameters CL0 (Clearance  estimate  at  t=0),  Vc,  AUC6wks  (derived  from  CL0)  as  well  as  of  the  steady-state  Cmax (Cmax,ss)  and  Cmin  (Cmin,ss)  estimates  derived  from  the  simulated  concentration-time  profiles  were characterized through box-plots and descriptive statistics, according to the following age groups: - &lt;2 years / ≥2 -&lt;6 years / ≥6 -&lt;12 years / ≥12 -&lt;18 years / ≥18 years  and  &lt; 3years / ≥3 -&lt;6 years / ≥6 -&lt;12 years / ≥12 -&lt;18 years / ≥18 years.

## RESULTS

The final analysis data set comprised of a total of 19488 pembrolizumab concentrations from 3293 patients. Of these, 2654 concentrations were available from 301 adult cHL patients and 775 concentrations were available from 152 paediatric patients aged &lt; 18 years with solid tumors and cHL.

Table 5 Number of subjects and PK observations by dose and study in the pooled analysis dataset

Numbers of Subjects and Observations by Dose and Dosing Regimen in thePooledAnalysisDataset(KN001,KN002,KN006,KN010,KN05l, KN013,KN0S7 and KN204)

| Doses                                |   N of subjects |   % of subjects |   N of PK observations |   %of PK observations |
|--------------------------------------|-----------------|-----------------|------------------------|-----------------------|
| 1mg/kgQ2W(Adultssolidtumors)         |               4 |            0.12 |                     43 |                  0.22 |
| 1mg/kgQ3W(Adultssolidtumors)         |               6 |            0.18 |                     10 |                  0.05 |
| 2mg/kgQ3W (Adultssolid tumors)       |             761 |           23.11 |                   4077 |                 20.92 |
| 3mg/kgQ2W(Adultssolid tumors)        |               3 |            0.09 |                     55 |                  0.28 |
| 10mg/kg Q2W (Adults solid tumors)    |             660 |           20.04 |                   4117 |                 21.13 |
| 10mg/kg Q3W (Adults solid tumors)    |            1406 |           42.7  |                   7879 |                 40.43 |
| 10mg/kgQ2W(AdultscHL)                |              29 |            0.88 |                    157 |                  0.81 |
| 200mg Q3W (Adults cHL)               |             272 |            8.26 |                   2375 |                 12.19 |
| 2mg/kg Q3W (Pediatrics solid tumors) |             136 |            4.13 |                    653 |                  3.35 |
| 2mg/kg Q3W (Pediatrics cHL)          |              16 |            0.49 |                    122 |                  0.63 |

Note: some subjects received more than one dose levels under dose escalation cohorts Reviewed per SOP-QP2-005

<div style=\"page-break-after: always\"></div>

Table 6 Covariate distribution in adult and paediatric populations in the analysis dataset

<!-- image -->

Reviewedper SOp-QP2-005

Table 7 Summary of categorical covariates in paediatric and adult populations

<!-- image -->

Reviewed per SOp-Qp2-005

## Population PK Model

The existing population PK model for pembrolizumab was used as a basis for an update of the model with the addition of data from paediatric patients with solid tumors and cHL and adult cHL patients.

<div style=\"page-break-after: always\"></div>

A comparison of parameter estimates of the final model using the integrated dataset (i.e. KN001, KN002, KN006, KN010, KN051, KN013, KN087 and KN204) and the dataset used in (Report 04LL90) are shown in the table reported below. The values of parameters estimates are very similar and %RSE are within the expected range (i.e. &lt;50%). All the previously added covariate parameters are precisely estimated on the updated dataset as well.

Table 8

ComparisonofPopulationPharmacokineticParametersof Pembrolizumab(MK-3475)fromtheExistingModelvs.UpdatedModel IncludingAdditionalPediatricSubjectswithSolidTumorsandcHLand AdultcHLSubjects

|                                          | ThePrevious Mode1 N=3104 [Ref. 5.3.5.3: 04LL90]                                                                                                     | ThePrevious Mode1 N=3104 [Ref. 5.3.5.3: 04LL90]                                                                                                     | ThePrevious Mode1 N=3104 [Ref. 5.3.5.3: 04LL90]                                                                                                     | Update Mode1 N=3293                                                                                                                                        | Update Mode1 N=3293                                                                                                                                        | Update Mode1 N=3293                                                                                                                                        |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Partsand Studiesincluded in the analysis | Adult solid tumors;A,A1,A2,B1, B2,B3,C,D and F1,F2,and F3 from KN001,KN002,KN006,KN010 Pediatrics solid tumors and cHL: KN051 Adult cHL:KN013,KN087 | Adult solid tumors;A,A1,A2,B1, B2,B3,C,D and F1,F2,and F3 from KN001,KN002,KN006,KN010 Pediatrics solid tumors and cHL: KN051 Adult cHL:KN013,KN087 | Adult solid tumors;A,A1,A2,B1, B2,B3,C,D and F1,F2,and F3 from KN001,KN002,KN006,KN010 Pediatrics solid tumors and cHL: KN051 Adult cHL:KN013,KN087 | Adult solid tumors;A,A1,A2, B1,B2,B3,C,D and F1,F2,and F3 from KN001,KN002,KN006, KN010 Pediatricssolid tumors and cHL: KN051 Adult cHL:KN013,KN087, KN204 | Adult solid tumors;A,A1,A2, B1,B2,B3,C,D and F1,F2,and F3 from KN001,KN002,KN006, KN010 Pediatricssolid tumors and cHL: KN051 Adult cHL:KN013,KN087, KN204 | Adult solid tumors;A,A1,A2, B1,B2,B3,C,D and F1,F2,and F3 from KN001,KN002,KN006, KN010 Pediatricssolid tumors and cHL: KN051 Adult cHL:KN013,KN087, KN204 |
| Parameter                                | Value                                                                                                                                               | %RSE                                                                                                                                                | %CVa                                                                                                                                                | Value                                                                                                                                                      | %RSE                                                                                                                                                       | %Cva                                                                                                                                                       |
| CL (L/day)                               | 0.254                                                                                                                                               | 2.17                                                                                                                                                | 32.0                                                                                                                                                | 0.252                                                                                                                                                      | 1.91                                                                                                                                                       | 30.3                                                                                                                                                       |
| Vc(L)                                    | 3.45                                                                                                                                                | 0.694                                                                                                                                               | 19.7                                                                                                                                                | 3.37                                                                                                                                                       | 0.647                                                                                                                                                      | 19                                                                                                                                                         |
| Q(L/day)                                 | 0.889                                                                                                                                               | 3.57                                                                                                                                                | 32.0                                                                                                                                                | 0.888                                                                                                                                                      | 3.5                                                                                                                                                        | 30.3                                                                                                                                                       |
| Vp(L)                                    | 2.82                                                                                                                                                | 4.17                                                                                                                                                | 19.7                                                                                                                                                | 2.61                                                                                                                                                       | 3.14                                                                                                                                                       | 19                                                                                                                                                         |
| IMAX                                     | -0.207                                                                                                                                              | 8.19                                                                                                                                                | 17.8                                                                                                                                                | -0.25                                                                                                                                                      | 6.83                                                                                                                                                       | 17.9                                                                                                                                                       |
| TI50 (day)                               | 65.6                                                                                                                                                | 10.7                                                                                                                                                |                                                                                                                                                     | 61.6                                                                                                                                                       | 6.82                                                                                                                                                       |                                                                                                                                                            |
| Hill                                     | 3.06                                                                                                                                                | 5.19                                                                                                                                                |                                                                                                                                                     | 2.37                                                                                                                                                       | 11.6                                                                                                                                                       |                                                                                                                                                            |
| afor CL and Q                            | 0.573                                                                                                                                               | 5.50                                                                                                                                                |                                                                                                                                                     | 0.604                                                                                                                                                      | 5                                                                                                                                                          |                                                                                                                                                            |
| aforVc and Vpc                           | 0.540                                                                                                                                               | 3.92                                                                                                                                                |                                                                                                                                                     | 0.59                                                                                                                                                       | 3.24                                                                                                                                                       |                                                                                                                                                            |
| Cancer typeon CL (NSCLC)                 | 0.0596                                                                                                                                              | 25.7                                                                                                                                                |                                                                                                                                                     | 0.0594                                                                                                                                                     | 26.4                                                                                                                                                       |                                                                                                                                                            |
| Cancer type on CL (HL)                   | -0.196                                                                                                                                              | 9.93                                                                                                                                                |                                                                                                                                                     | -0.197                                                                                                                                                     | 7.9                                                                                                                                                        |                                                                                                                                                            |
| Ageon CLb                                | 0.602                                                                                                                                               | 24.9                                                                                                                                                |                                                                                                                                                     | 0.538                                                                                                                                                      | 11.7                                                                                                                                                       |                                                                                                                                                            |
| Albumin on CL                            | -0.718                                                                                                                                              | 12.0                                                                                                                                                |                                                                                                                                                     | -0.86                                                                                                                                                      | 6.29                                                                                                                                                       |                                                                                                                                                            |
| BaselineECOGon CL                        | 0.0656                                                                                                                                              | 22.0                                                                                                                                                |                                                                                                                                                     | 0.065                                                                                                                                                      | 23.4                                                                                                                                                       |                                                                                                                                                            |
| Bilirubin on CL                          | -0.0446                                                                                                                                             | 28.3                                                                                                                                                |                                                                                                                                                     | -0.0398                                                                                                                                                    | 35.8                                                                                                                                                       |                                                                                                                                                            |
| Baselinetumorsize on CL                  | 0.103                                                                                                                                               | 8.92                                                                                                                                                |                                                                                                                                                     | 0.0985                                                                                                                                                     | 8.96                                                                                                                                                       |                                                                                                                                                            |
| eGFRon CL                                | 0.118                                                                                                                                               | 16.7                                                                                                                                                |                                                                                                                                                     | 0.116                                                                                                                                                      | 17.1                                                                                                                                                       |                                                                                                                                                            |
| Gender on CL                             | -0.162                                                                                                                                              | 7.53                                                                                                                                                |                                                                                                                                                     | -0.152                                                                                                                                                     | 7.8                                                                                                                                                        |                                                                                                                                                            |
| Age on Vcb                               | 0.34                                                                                                                                                | 18.0                                                                                                                                                |                                                                                                                                                     | 0.292                                                                                                                                                      | 12.5                                                                                                                                                       |                                                                                                                                                            |
| Albumin on Vc                            | -0.204                                                                                                                                              | 19.4                                                                                                                                                |                                                                                                                                                     | -0.258                                                                                                                                                     | 14.4                                                                                                                                                       |                                                                                                                                                            |
| Genderon Vc                              | -0.131                                                                                                                                              | 7.71                                                                                                                                                |                                                                                                                                                     | -0.123                                                                                                                                                     | 7.41                                                                                                                                                       |                                                                                                                                                            |
| Residual error                           | 0.241                                                                                                                                               | 1.84                                                                                                                                                |                                                                                                                                                     | -0.221                                                                                                                                                     | 1.54                                                                                                                                                       |                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

## Model diagnostics

Figure 7 Goodness of fit plots for the final model

<!-- image -->

Time after first dose (day)

Black dots are pediatric individual data; Grey dots are individual data for adult subjects; dashed lines are zero line whilst solid lines are the smooth lines. Reviewed per SOP-QP2-005

<!-- image -->

Note:blackshaded area is theprobabilitydensity. ReviewedperSOP-QP2-005

/NonmemUpcate/Serie

<div style=\"page-break-after: always\"></div>

Figure 8 GoF plots for the final model for the paediatric population

<!-- image -->

<div style=\"page-break-after: always\"></div>

GoFs are provided for each age group (paediatric participants &lt;3 years old, 3 to &lt;6 years old, 6 to &lt;12 years old, 12 to &lt;18 years old, and adults &gt;18 years old , with gray dots representing participants with solid tumors and black dots  representing participants with cHL.

Overall, except for minor deviation, the observed data are aligned with the line of unity demonstrating that the model adequately described the data across the entire age range of the data.

In addition, VPCs for adults and paediatric participants with solid tumors and cHL are provided in different panels showing that adults and paediatrics data with both solid or cHL tumor fall within those predicted by the Model.

Figure12 Visual Predictive Check Figures for Adult (a) and Pediatric (b) Participants With cHL (Right Panels)and Solid Tumors(LeftPanels)

<!-- image -->

## PK results: Comparison of Pharmacokinetics in Paediatrics versus Adults

Post-hoc (Derived) PK Parameters

Distributions of individual post hoc parameter estimates for clearance and central volume of distribution in the paediatric and adult populations are presented in (Figure 1). Figure 2 presents distributions of derived pharmacokinetic parameters (based on the post hoc estimates) for the paediatric and adult subjects at the dose regimen of 2 mg/kg Q3W. Additionally, table 8 presents summaries of associated descriptive statistics for these post-hoc estimates of CL, Vc as well as the derived parameters at 2 mg/kg Q3W for paediatric and adult populations.

<div style=\"page-break-after: always\"></div>

Figure 9 Comparison of CL and VL using the individual empirical Bayes parameters (paediatrics vs adults)

<!-- image -->

Figure 10 Derived individual PK parameters (Cmax, AUC6wks, t1/2, Cmin) at 2 mg/kg Q3W between paediatrics and adults

<!-- image -->

Note: Cmax is concentration at time of peak sample in Cycle 1 - Cmin is the observed trough concentration in Cycle 1 eviewedperSOP-QP2-005

Overall,  the  pharmacokinetic  model  parameter  estimates  (CL  and  Vc)  are lower  for  paediatric  patients compared to adults. This was expected, since the parameters have been shown to be correlated to body weight.  Exposure  parameters  following  the  weight-based  regimen  of  2  mg/kg  Q3W  are  largely  similar between the paediatric age groups and between paediatrics and adults.

<div style=\"page-break-after: always\"></div>

Table 9 Comparison of descriptive statistics of derived individual PK parameters (CL, Vc) and Derived parameters (Cmax, AUC6wks, t1/2, Cmin) at 2 mg/kg Q3W between paediatrics and adults

| Parameter           | Population   |     Min |       Q1 |   Median | Mean   |       Q3 |      Max |   N* | Missing     |
|---------------------|--------------|---------|----------|----------|--------|----------|----------|------|-------------|
| CL (L/day)          | 2 to 6       |   0.021 |    0.032 |    0.045 | 0.047  |    0.057 |    0.088 |   22 | 0 (0.0%)    |
| CL (L/day)          | 6 to 12      |   0.036 |    0.068 |    0.092 | 660°0  |    0.109 |    0.262 |   35 | 0 (0.0%)    |
| CL (L/day)          | 12 to 18     |   0.031 |    0.127 |    0.152 | 0.196  |    0.209 |    1.616 |   92 | 0 (0.0%)    |
| CL (L/day)          | >= 18 years  |   0.11  |    0.209 |    0.265 | 0.295  |    0.347 |    1.53  |  760 | 0 (0.0%)    |
| Vc (L)              | 2 to 6       |   0.5   |    0.7   |    0.8   | 0.8    |    0.9   |    1.2   |   22 | 0 (0.0%)    |
| Vc (L)              | 6 to 12      |   0.8   |    1.2   |    1.3   | 1.4    |    1.6   |    3.2   |   35 | 0 (0.0%)    |
| Vc (L)              | 12 to 18     |   0.6   |    2.1   |    2.3   | 2.5    |    2.8   |    4.9   |   92 | 0 (0.0%)    |
| Vc (L)              | >= 18 years  |   1.2   |    2.7   |    3.3   | 3.4    |    3.8   |    8.6   |  760 | 0 (0.0%)    |
| AUC6wks (mg.day/L)  | 2 to 6       | 762     | 1271     | 1478     | 1551   | 1926     | 2412     |   22 | 0 (0.0%)    |
| AUC6wks (mg.day/L)  | 6 to 12      | 420     | 1013     | 1285     | 1376   | 1698     | 2412     |   35 | 0 (0.0%)    |
| AUC6wks (mg.day/L)  | 12 to 18     | 145     | 1012     | 1483     | 1447   | 1806     | 3109     |   92 | 0 (0.0%)    |
| AUC6wks (mg.day/L)  | >= 18 years  | 238     |  873     | 1120     | 1161   | 1411     | 3015     |  760 | 0 (0.0%)    |
| Cmin,Cyclel (μg/mL) | 2 to 6       |   7     |    9.6   |   11.1   | 10.9   |   11.8   |   15.1   |   12 | 10 (45.5%)  |
| Cmin,Cyclel (μg/mL) | 6 to 12      |   2.4   |    8     |    9.9   | 10.3   |   12.1   |   16.4   |   32 | 3 (8.6%)    |
| Cmin,Cyclel (μg/mL) | 12 to 18     |   2.6   |    9.8   |   11.9   | 11.8   |   13.9   |   21.9   |   75 | 16 (18.5%)  |
| Cmin,Cyclel (μg/mL) | >= 18 years  |   1.4   |    7.1   |    9.3   | 9.3    |   11.5   |   24.3   |  619 | 141 (18.6%) |
| Cmax,Cyclel (μg/mL) | 2 to 6       |  29.5   |   37.9   |   41.3   | 42.8   |   46.8   |   56.9   |   19 | 3 (13.6 %)  |
| Cmax,Cyclel (μg/mL) | 6 to 12      |  30.6   |   37.7   |   40     | 42.8   |   46.9   |   59.9   |   33 | 2 (5.7%)    |
| Cmax,Cyclel (μg/mL) | 12 to 18     |  26.1   |   40.7   |   45.2   | 46.4   |   53     |   79.5   |   85 | 7 (7.9%)    |
| Cmax,Cyclel (μg/mL) | >= 18 years  |  26.9   |   40     |   45.5   | 46.2   |   51.2   |  101.5   |  641 | 119 (15.6%) |
| (days)              | 2 to 6       |  16.9   |   24     |   30.3   | 30.5   |   35.8   |   46     |   22 | 0 (0.0%)    |
| (days)              | 6 to 12      |  10.2   |   20.2   |   22.7   | 23.1   |   27     |   33.7   |   35 | 0 (0.0%)    |
| (days)              | 12 to 18     |   3.2   |   16.2   |   21.3   | 20.4   |   24     |   33.6   |   92 | 0 (0.0%)    |
| (days)              | >= 18 years  |   3     |   13.7   |   16.4   | 16.5   |   19.3   |   28.9   |  760 | 0 (0.0%)    |

*N = 3 pediatric subjects &lt; 2 years old are not included in the table

Note: Cmax is concentration at time of peak sample in Cycle 1-Cmin is the observed trough concentration in Cycle 1

Reviewed per SOP-QP2-005

CL and Vd are lower in children as expected, since they correlate directly with the BW.

The exposure parameters in the box plots are similar between children and adults. A total of 152 paediatric participants were included in the updated popPK model. The breakdown of participants by age group and tumor type is shown below

Table 10 Summary of number of subjects in each paediatric age group

| Age Range   |   Solid Tumors | cHL   |
|-------------|----------------|-------|
| 3           |              8 |       |
| 3-6         |             17 |       |
| 6-≤12       |             34 | 1     |
| 12-=18      |             77 | 15    |

The majority of the paediatric participants is in older age groups 6 to &lt;12 years old (n=35) and 12 to &lt;18 years old (n=92); while in the younger age groups there are 8 patients &lt;3 years old and 17 patients in the group 3 to &lt;6 years old.

Box plots of post-hoc derived PK parameters for cHL paediatric patients in different group of age and adults shows a consistency in exposure parameters among groups except for the AUC values in age &lt;3 years old (~50%  higher  compared  to  that  in  adults).  This  was  already  noted  but  however  justified  by  the  flat exposure-safety profile of Keytruda between 2 and 10 mg/kg.

<div style=\"page-break-after: always\"></div>

The final model was subsequently used in simulations of pembrolizumab PK parameters and exposure parameters in different age groups of paediatric patients and compared to the estimates in adult patients to support pembrolizumab dose regimen selection in paediatric patients.

## Simulations

Simulations  of  pembrolizumab  pharmacokinetics  and  concentration-time  profiles  were  performed  for  a dataset of 1000 paediatric subjects and 500 adult subjects, obtained through sampling subjects from the analysis dataset, augmented with additional paediatric oncology subject data down to 0.5 years of age. A summary of covariate  information  for  the  combined  paediatric  source  dataset  used  for  re-sampling  is provided. The simulated dose regimens were the weight-based regimen of 2 mg/kg Q3W and the fixed dose regimen of 200 mg Q3W.

Table 11 Descriptive statistics of covariate information for paediatric subjects included in resampling dataset.

| Covariate       | Population     | Min   |    Q1 |   Median |   Mean |    Q3 | Max   |   N | Missing   |
|-----------------|----------------|-------|-------|----------|--------|-------|-------|-----|-----------|
| Body weight     | below 2 years  | 6.4   |   8.4 |      9.8 |    9.6 |  10.8 | 12.7  |  25 | 0 (0.0%)  |
| (a)             | 2 to 6 years   | 9.2   |  14   |     16   |   16.5 |  18   | 33.8  |  70 | 0 (0.0%)  |
| (a)             | 6 to 12 years  | 18.9  |  23.7 |     28.8 |   31.7 |  37.8 | 68.4  |  99 | 0 (0.0%)  |
| (a)             | 12 to 18 years | 18.9  |  45.4 |     52.9 |   55.9 |  64.2 | 120   | 129 | 0 (0.0%)  |
| Age (years)     | below 2 years  | 0.3   |   0.9 |      1.1 |    1.1 |   1.4 | 1.9   |  25 | 0 (0.0%)  |
|                 | 2 to 6 years   | 2     |   3   |      4   |    3.9 |   4.9 | 5.9   |  70 | 0 (0.0%)  |
|                 | 6 to 12 years  | 6     |   7.9 |      6   |    6   |  10.4 | 11.9  |  99 | 0 (0.0%)  |
|                 | 12 to 18 years | 12    |  13.1 |     15   |   14.7 |  16   | 17.5  | 129 | 0 (0.0%)  |
| Albumin (T)     | below 2 years  | 26    |  38   |     42   |   40.8 |  44   | 46.4  |  25 | 0 (0.0%)  |
| Albumin (T)     | 2 to 6 years   | 33    |  38.2 |     41.1 |   41.4 |  44   | 60.8  |  70 | 0 (0.0%)  |
| Albumin (T)     | 6 to 12 years  | 25    |  39   |     41   |   41.1 |  43.2 | 51    |  99 | 0 (0.0%)  |
| Albumin (T)     | 12 to 18 years | 25    |  39   |     42   |   41.2 |  45   | 53    | 129 | (%0:0) 0  |
| Bilirubin       | below 2 years  | 1.7   |   3.4 |      5.1 |    5.7 |   6.8 | 17.1  |  25 | 0 (0.0%)  |
| (μmol/L)        | 2 to 6 years   | o     |   3.4 |      5.1 |    5.2 |   6.8 | 11    |  69 | 1 (1.4%)  |
| (μmol/L)        | 6 to 12 years  | 1.7   |   3.4 |      5.1 |    6.1 |   7.4 | 22    |  99 | 0 (0.0%)  |
| (μmol/L)        | 12 to 18 years | 1.7   |   5.1 |      7   |    8   |  10.3 | 27.9  | 129 | 0 (0.0%)  |
| eGFR            | below 2 years  | 76.7  | 109.7 |    138.5 |  137.6 | 159.9 | 264.6 |  25 | 0 (0.0%)  |
| (ml/min/1.73m2) | 2 to 6 years   | 50    | 112.5 |    134.5 |  139.8 | 163.7 |       |  69 | 1 (1.4%)  |
| (ml/min/1.73m2) | 6 to 12 years  | 66.4  | 112.9 |    137   |  135.8 | 153.6 | 214.1 |  86 | 1 (1.0%)  |
| (ml/min/1.73m2) | 12 to 18 years | 53    |  94.1 |    111.9 |  115.4 | 134.9 | 229.2 | 128 | 1 (0.77%) |

Reviewed per SOP-OP2-005

The resampling dataset was augmented with a paediatric oncology dataset from another program and comprised of 171 participants (aged 0.5 - 17 years), included 22 different tumor types.

<div style=\"page-break-after: always\"></div>

Table 12 listing of tumour types and number of participants in augmented paediatric dataset

| Tumor Iype                   |   N |
|------------------------------|-----|
| Acute Lymphoblastic Leukemia |   4 |
| Acute Promyelocytic Leukemia |   1 |
| CNS                          |  37 |
| Endodermal Sinus Tumor       |   1 |
| Ewing Sarcoma                |   5 |
| Head and Neck                |   5 |
| Hepatobiliary                |   7 |
| Hepatoblastoma               |   2 |
| Lymphoblastie Lymphoma T     |   1 |
| Lymphoproliferative          |   5 |
| Myeloproliferative           |   1 |
| Nephroblastoma               |   2 |
| Neuroblastoma                |  12 |
| Neuroendocrine               |   3 |
| Non-Hodgkin Lymphoma         |   1 |
| Osteosarcoma                 |   4 |
| PNET                         |   2 |
| Retinoblastoma               |   3 |
| Rhabdomyosarcoma             |   3 |
| Sarcoma                      |  62 |
| Urogenital                   |   8 |
| Wilms Tumor                  |   2 |

Predicted individual CL (at time=0) and Vc values are summarized in Figure 3 and Table 10. Figure 4 and Table 11 summarize predictions of AUC6wks (based on CL at time=0), Cmax,ss and Cmin,ss for different paediatric age groups and adults. In the weight-based regimen of 2 mg/kg Q3W, exposure values are similar across the age groups of 6-12 years, 12-18 years and adults. Predicted AUC6wks, Cmin,ss, Cmax,ss were respectively 20%, 57% and 10% higher for the group of 2-6 years compared to adults. Predicted exposures for the group below 2 years are more than double those of the adult reference group.

<div style=\"page-break-after: always\"></div>

Figure 3 Pembrolizumab(MK-3475)Predicted Clearanceand CentralVolumeof DistributionforPediatricsandAdults

<!-- image -->

ReviewedperSOP-QP2-005

Figure 4 Pembrolizumab(MK-3475)PredictedExposureParametersfor PediatricsandAdults

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 13 Descriptive statistics of predicted individual PK parameters (CL, Vc) for paediatric and adult patients

|                        | <2years                | 2-6 years              | 6-12 years             | 12-18 years            | >18 years              |
|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                        | N=80                   | N=195                  | N=307                  | N=418                  | N=500                  |
| CL (at time=0) (L/day) | CL (at time=0) (L/day) | CL (at time=0) (L/day) | CL (at time=0) (L/day) | CL (at time=0) (L/day) | CL (at time=0) (L/day) |
| Median                 | 0.0156                 | 0.0442                 | 0.0949                 | 0.177                  | 0.25                   |
| Q1                     | 0.0116                 | 0.0324                 | 0.0745                 | 0.1349                 | 0.1941                 |
| Q3                     | 0.0212                 | 0.0586                 | 0.1338                 | 0.2239                 | 0.3259                 |
| Vc(L)                  | Vc(L)                  | Vc(L)                  | Vc(L)                  | Vc(L)                  | Vc(L)                  |
| Median                 | 0.407                  | 0.813                  | 1.513                  | 2.435                  | 3.251                  |
| Q1                     | 0.335                  | 0.672                  | 1.244                  | 2.046                  | 2.787                  |
| Q3                     | 0.502                  | 1.017                  | 1.858                  | 2.985                  | 3.798                  |

Reviewed per SOP-QP2-005

Table 14 Descriptive statistics of predicted individual exposure PK parameters (AUC6wks, Cmin,ss, Cmax,ss) for paediatric and adult patients at 2mg/kg Q3W

|                    | 2years             | 2-6 years          | 6-12 years         | 12-18 years        | >18 years          |
|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
|                    | N=80               | N=195              | N=307              | N=418              | N=500              |
| AUC6wks (mg.day/L) | AUC6wks (mg.day/L) | AUC6wks (mg.day/L) | AUC6wks (mg.day/L) | AUC6wks (mg.day/L) | AUC6wks (mg.day/L) |
| Median             | 2448.5             | 1413.8             | 1243.5             | 1232.6             | 1175.3             |
| Q1                 | 1864.1             | 1201               | 955                | 972.8              | 938                |
| Q3                 | 3261.7             | 1872.8             | 1583.4             | 1575.5             | 1525.8             |
| Cmin,ss (mg/L)     | Cmin,ss (mg/L)     | Cmin,ss (mg/L)     | Cmin,ss (mg/L)     | Cmin,ss (mg/L)     | Cmin,ss (mg/L)     |
| Median             | 67.6               | 40.1               | 29.3               | 26.7               | 25.6               |
| Q1                 | 51.6               | 28.5               | 20.4               | 19                 | 17.1               |
| Q3                 | 92.5               | 56.1               | 40.8               | 40.3               | 39.9               |
| Cmax,ss (mg/L)     | Cmax,ss (mg/L)     | Cmax,ss (mg/L)     | Cmax,ss (mg/L)     | Cmax,ss (mg/L)     | Cmax,ss (mg/L)     |
| Median             | 114.5              | 79.9               | 70.2               | 71                 | 72.3               |
| Q1                 | 92                 | 64.8               | 57.9               | 58.4               | 61                 |
| Q3                 | 141.2              | 100.5              | 87.4               | 87.8               | 91.2               |

Predicted individual CL (at time=0) and Vc values and predictions of AUC6wks (based on CL at time=0), Cmax,ss and Cmin,ss for another age categorization (&lt;3 years / ≥3 -&lt;6 years / ≥6 -&lt;12 years / ≥12 -&lt;18 years / ≥18 year s) are presented below.

When an age of 3 years is used as cut-off for the first age group, predicted AUC6wks, Cmin,ss, Cmax,ss become respectively 17%, 52% and 9% higher for the group of 3-6 years compared to adults. For the group  below  3  years  old,  AUC6wks,  Cmin,ss,  Cmax,ss  are  predicted  to  be  2,  2.4  and  1.5  fold  higher compared to the values in adults, respectively.

<div style=\"page-break-after: always\"></div>

Figure 11 Predicted CL and Vc

Appendix5 Pembrolizumab(MK-3475)Predicted Clearance and CentralVolume of Distribution for Pediatrics and Adults using a 3 years old cut-off

<!-- image -->

Reviewed per SOP-QP2-005

Appendix61 Pembrolizumab(MK-3475)PredictedExposureParametersfor Pediatrics and Adults usinga3years old cut-off

<!-- image -->

Reviewed per SOP-QP2-005

<div style=\"page-break-after: always\"></div>

Appendix7 Descriptive Statistics of Predicted Individual PK Parameters (CL, Vc) for PediatricandAdultPatientsusing a 3yearsold cut-off

|                        | <3 years               | 3-6 years              | 6-12 years             | 12-18 years            | >18 years              |
|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                        | N=106                  | N=169                  | N=307                  | N=418                  | N=500                  |
| CL (at time=0) (L/day) | CL (at time=0) (L/day) | CL (at time=0) (L/day) | CL (at time=0) (L/day) | CL (at time=0) (L/day) | CL (at time=0) (L/day) |
| Median                 | 0.0179                 | 0.0472                 | 0.0949                 | 0.177                  | 0.25                   |
| Q1                     | 0.0126                 | 0.038                  | 0.0745                 | 0.1349                 | 0.1941                 |
| Q3                     | 0.0249                 | 0.0608                 | 0.1338                 | 0.2239                 | 0.3259                 |
| Vc(L)                  | Vc(L)                  | Vc(L)                  | Vc(L)                  | Vc(L)                  | Vc(L)                  |
| Median                 | 0.443                  | 0.887                  | 1.513                  | 2.435                  | 3.251                  |
| Q1                     | 0.361                  | 0.724                  | 1.244                  | 2.046                  | 2.787                  |
| Q3                     | 0.568                  | 1.058                  | 1.858                  | 2.985                  | 3.798                  |

Reviewed per SOP-QP2-005

Appendix8 Descriptive Statistics of Predicted Individual Exposure Parameters (AUC6wks, Cmin,ss, Cmax,ss) for Pediatric and Adult Patients at 2 mg/kg Q3Wusinga3yearsoldcut-off

|                    | <3 years           | 3-6 years          | 6-12 years         | 12-18 years        | >18 years          |
|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
|                    | N=106              | N=169              | N=307              | N=418              | N=500              |
| AUC6wks (mg.day/L) | AUC6wks (mg.day/L) | AUC6wks (mg.day/L) | AUC6wks (mg.day/L) | AUC6wks (mg.day/L) | AUC6wks (mg.day/L) |
| Median             | 2255.1             | 1375.7             | 1243.5             | 1232.6             | 1175.3             |
| Q1                 | 1713.5             | 1157.1             | 955                | 972.8              | 866                |
| Q3                 | 3049.2             | 1747.6             | 1583.4             | 1575.5             | 1525.8             |
| Cmin,ss (mg/L)     | Cmin,ss (mg/L)     | Cmin,ss (mg/L)     | Cmin,ss (mg/L)     | Cmin,ss (mg/L)     | Cmin,ss (mg/L)     |
| Median             | 62.7               | 38.8               | 29.3               | 26.7               | 25.6               |
| Q1                 | 47.8               | 27                 | 20.4               | 19                 | 17.1               |
| Q3                 | 88.1               | 54.5               | 40.8               | 40.3               | 39.9               |
| Cmax,ss (mg/L)     | Cmax,ss (mg/L)     | Cmax,ss (mg/L)     | Cmax,ss (mg/L)     | Cmax,ss (mg/L)     | Cmax,ss (mg/L)     |
| Median             | 107.1              | 78.6               | 70.2               | 71                 | 72.3               |
| Q1                 | 88.6               | 62.5               | 57.9               | 58.4               | 61                 |
| Q3                 | 137.2              | 97.7               | 87.4               | 87.8               | 91.2               |

Reviewed per SOP-QP2-005

<div style=\"page-break-after: always\"></div>

Figure 12 Comparison of the model derived individual PK parameters for paediatric participants dosed at 2 mg/kg Q3W pembrolizumab with adult cHL participants dosed at 200 mg Q3W.

Post-hoc Derived Individual PK Parameters (Cmax, AUC6wks, Cmin and ti/2) at 2 mg/kg Q3W for Pediatric and Adult cHL Participants at 200 mg Q3W

<!-- image -->

c 3 yoars

*Black dots highlight cHL participants

Moreover box plots of post-hoc derived PK parameters for cHL paediatric patients in different group of age and adults shows a consistency in exposure parameters among groups except for the AUC values in age &lt;3 years old (~50% higher compared to that in adults), but this higher value is not of concern, considering the flat exposure-safety relationship for Keytruda. Of note, this does not relate to any conclusions regarding safety.

## Interleukin 2 (IL-2) Stimulation

The interleukin 2 (IL-2) release biomarker reflects the functional blockade of the PD-1 pathway by pembrolizumab and is utilized as a measure of target engagement. An in-vitro IL-2 stimulation assay was performed to investigate if there is a shift in the IL-2 stimulation curve between adults and children to guide the determination of the recommended Phase 2 dose (RP2D) of pembrolizumab in paediatric patients.  For the in-vitro IL-2 stimulation assay, two pre-dose baseline samples were collected in each of the first 12 subjects enrolled.  At the end, 10 subjects provided 20 evaluable samples. Each evaluable sample was divided into two aliquots. One of the aliquot from these samples was spiked with pembrolizumab concentrations at 300 ug/mL, 100 ug/mL, 33.3 ug/mL, 11.1 ug/mL, 3.70 ug/mL, 1.23 ug/mL, 0.412 ug/mL, 0.137 ug/mL, 0.0457 ug/mL, and 0 ug/mL with 1 ug/mL staphylococcal enterotoxin B (SEB). The remaining aliquots from these samples were respectively spiked with an additional 25 ug/mLof pembrolizumab (i.e., respective concentrations in these samples were 325 ug/mL, 125 ug/mL, 58.3 ug/mL 36.1 ug/mL, 28.7 ug/mL, 26.23 ug/mL 25.412 ug/mL, 25.137 ug/mL, 25.0457 ug/mL and 25 ug/mL) along with the same amount of SEB.  The stimulation ratios were calculated by measuring the IL2 concentrations in the two aliquots respectively, i.e. 300 ug/mL with 325 ug/mL, 100 ug/mL with 125 ug/mL, etc.  The IC50 of the concentration-stimulation ratio curves of in-vitro IL-2 assay in paediatric patients (figures below) were compared with that of adult patients using banked blood samples from adult cancer patients in KN001.

&lt; 3 years

<div style=\"page-break-after: always\"></div>

Interleukin 2 (IL-2) StimulationRatio as a Function of Plasma Concentration in l0 Pediatric Subjects from KN05l

<!-- image -->

Interleukin 2(IL-2) Stimulation Ratio as aFunction ofPlasma Concentration of Pembrolizumab in KN00l

<!-- image -->

Data source:

[Ref 5.4: 0534YZ]

## Exposure-response analysis

Exposure-response  analysis  for  best  percent  change  from  baseline  tumor  size,  demonstrating  similar relationships between adult and paediatric participants with cHL is shown in Figure below.

<div style=\"page-break-after: always\"></div>

## Figure 13

Exposure (Cmin at Week 6)-Response for Best Percent Change From Baseline Tumor Size Based on KEYNOTE-204 (Green Dots),KEYNOTE-051 (Red Dots) and KEYNOTE-013 and KEYNOTE-087 (Black Dots)

TroughConcentrationatweek6(ug/mL)

<!-- image -->

## 2.3.5. Discussion on clinical pharmacology

Overall,  the  PK  and  clinical  pharmacology  of  pembrolizumab  is  well-known  and  described over  a  large exposure range and various indications.

Participants  with  rrcHL  in  KEYNOTE-204  and  KEYNOTE-087  and  paediatric  participants  with  rrcHL  in KEYNOTE-051 comprise the primary participant populations for this application. KEYNOTE-051 is an ongoing  Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE051). As of the data cutoff date for the submitted report (10-JAN-2020), 162 participants (N=22 rrcHL patients) were enrolled out of a total of up to 310 participants that was planned to be enrolled. In total, there were 151 participants in KEYNOTE-051 with evaluable PK samples.

Based on the existing robust characterization of pembrolizumab PK, a comparison was conducted between the observed PK of pembrolizumab in children from study KEYNOTE-051 and the predictions from the reference PK model developed with pembrolizumab monotherapy data (KEYNOTE-001, -002, 006, -010, and -024).

New 'overlay' figures at Cycle 1 and steady state are generated for KEYNOTE-051 paediatric participants and  KEYNOTE-204  adult  cHL  participants,  based  on  the  updated  popPK  model  including  adult  cHL participants and paediatric participants with solid tumors and cHL described in Report 05G4NL. Observed data shown in blue refer to cHL participants and data shown in green refer to paediatric participants with solid tumors. The paediatric data in KEYNOTE-051 and adult data from KEYNOTE-204 remain well within the range of predicted concentration profiles using the updated popPK model.

The Applicant proposes to extrapolate the efficacy data in adult patients with rrcHL from KEYNOTE-087 and KEYNOTE-204 to paediatric patients with rrcHL using a model-based PK bridging analysis. In addition, KEYNOTE-051 will provide supportive efficacy and safety data in rrcHL paediatric patients.

<div style=\"page-break-after: always\"></div>

The  objectives  of  the  population  PK  analysis  described  in  this  report  were:  1)  to  update  the  existing population pharmacokinetic model from report 04LL90 with additional paediatric data from KN051 in solid tumors and cHL and adult cHL data from KN204 and 2) to compare pembrolizumab pharmacokinetics and exposures in different age groups of paediatric patients to those in adult patients

Specifically, data from adults with solid tumors (N = 2840) and data from 301 adult rrcHL participants in KEYNOTE-013, KEYNOTE-087, and KEYNOTE-204 were included in the analysis. In addition, 151 paediatric participants in KEYNOTE-051 receiving 2 mg/kg up to 200 mg Q3W were also included. From the study report P051V02MK3475 it is known that 22 paediatric participants with HL ranged in age from 10 to 17 years. Four participants were 10 to 13 years of age and 18 participants were 14 to 17 years of age.

Only 16 paediatric subjects are assumed to be involved the PK data analyses. In total only 122 PK samples have been included in the PK analysis (0.63%). Age of these subjects ranged from 11-17 years of age (median: 15 years). Weight ranged from 32.5 to 103.4 kg with a median weight of 50.8 kg.

Age cut-off is set to 3 years of age. This is not supported by clinical data so far. Exposure simulations have been conducted for the age groups of 2-6 years of age and 3-6 years of age. No clinical and no PK data have been measured so far in paediatric patients below the age of 11 with HL.

The existing population PK model for pembrolizumab was used as a basis for an update of the model with the addition of data from paediatric patients with solid tumors and cHL and adult cHL patients. Models parameters  including  covariate  effect  have  been  re-estimate  for  the  refined  model.    The  values  of parameters estimates are very similar between the previous popPK model and the updated one.

Goodness-of-fit plots were utilized to assess the adequacy of the structural model to describe the pooled dataset.

As a general comment the goodness of fit evaluation demonstrated the absence of a structural bias as a function  of  drug  concentration  or  time  and  showed  that  data  from  paediatric  subjects  is  equally  well described as the data from adult subjects.

However, no tornado plots (to demonstrate the single covariate effects) or (stratified) VPC have been provided.  In  general,  weight  and  age  is  incorporated.  The  inclusion  of  age  effect  on  both,  volume  of distribution and clearance seems to be necessary on top on weight to describe the paediatric data.

The MAH used the number of prior line of therapies as a stratification variable, to present the post-hoc model  predictions  of  AUC6wks  (Cmax,ss  and  Cmin,ss  and  half-life,  similar  for  paediatric  and  adult participants. In both populations (adults and paediatrics), there is not a clear trend across different prior lines of therapy.

The  reference  population  PK  model  has  been  re-run  including  weight,  allometrically  scaled  with  fixed exponents (0.75 for CL and 1.0 for V) in the model, instead of age as requested. The parameter estimates and OFV for the new model, Including Weight as Allometrically Scaled Fixed Exponents and Without Age), are compared (Run 8) with the final model with age and estimated exponents for weight (Run 6)

The difference in OFV between the new model (Run 8) and the Reference model (Run 6) is an increase of 503.861 points.

This significant increase in OFV together with the GOF plots for Run 8 and Run 6, suggests that the reference model with age and extimated exponents better describes the data respect to the new model with no age and fixed exponent.

Simulated exposures (Cmin, Cmax, and AUC) for pediatric participants dosed at 2 mg/kg Q3W obtained using the newly requested model, Run 8 showed that PK parameters across the weight range of the pediatric participants are contained within the 5th and 95th percentile of adult values.

The MAH provided the GoF plots for the paediatric population only distinguishing cHL data (black dots) and solid tumors data (gray dots), as requested.

GoFs are provided for each age group (paediatric participants &lt;3 years old, 3 to &lt;6 years old, 6 to &lt;12 years old, 12 to &lt;18 years old, and adults &gt;18 years old , with gray dots representing participants with solid tumors and black dots  representing participants with cHL. Overall, except for minor deviation, the observed data are aligned with the line of unity demonstrating that the model adequately described the

<div style=\"page-break-after: always\"></div>

data across the entire age range of the data. In addition, VPCs for adults and paediatric participants with solid tumors and cHL are provided in different panels showing that adults and paediatrics data with both solid or cHL tumor fall within those predicted by the Model.

CL and Vd are lower in children as expected, since they correlate directly with the BW.

The exposure parameters in the box plots are similar between children and adults. A total of 152 paediatric participants were included in the updated popPK model. The majority of the paediatric participants is in older age groups 6 to &lt;12 years old  (n=35) and 12 to &lt;18 years old (n=92); while in the younger age groups there are 8 patients  &lt;3 years old and 17 patients in the group 3 to &lt;6 years old.

Box plots of post-hoc derived PK parameters for cHL paediatric patients in different group of age and adults shows a consistency in exposure parameters among groups except for the AUC values in age &lt;3 years old (~50%  higher  compared  to  that  in  adults).  This  was  already  noted  but  however  justified  by  the  flat exposure-safety profile of Keytruda between 2 and 10 mg/kg.

The final model was subsequently used in simulations of pembrolizumab PK parameters and exposure parameters in different age groups of paediatric patients and compared to the estimates in adult patients to support pembrolizumab dose regimen selection in paediatric patients.

The final population PK model was used to predict the pembrolizumab concentrations following single dose and at steady state for the patients in the simulation dataset (different age groups 2-6 (3-6), 6-12, 12-18, &gt;18 years of age).

Simulations following 2 mg/kg Q3W and 200 mg Q3W support the per kg dosing as exposure at steady state is expected to be in the range of adult exposure (in terms of Cmin\\_ss, Cmax\\_ss and AUC) assuming paediatric patients of 6 years of age or older.

Below the age of 6, exposure reached at steady state is higher compared to adults.

Descriptive statistics of predicted individual exposure parameters for paediatric and adult patients shows that Cmin is about 50% higher in the 3-6 age group, although the median value is within the Q3 for adults. More explicitly, assuming a lower age limit of 3 years for the first age group, predicted AUC6wks, Cmin,ss, Cmax,ss are simulated to be respectively 17%, 52% and 9% higher for the group of 3-6 years compared to adults. There are not participants &lt;11 years old with cHL in the analysis dataset and the results in the 3 to 6 years old age group are informed by participants with solid tumors.

Simulations from the final model were performed to assess the exposure to pembrolizumab in paediatric patients at the dose regimens of 2 mg/kg Q3W or 200 mg Q3W and compared to the exposures in adult patients.

The MAH recognized that there is a small number of paediatric subjects in the younger age group (from CSR P051V02MK3475 it seems that paediatric patients ranged from 10 to 17 years) and the resampling dataset was augmented with a paediatric oncology dataset from another program.

This dataset, comprised of 171 participants (aged 0.5 - 17 years), included 22 different tumor types.

Simulations following 2 mg/kg Q3W and 200 mg Q3W support the per kg dosing as exposure at steady state is expected to be in the range of adult exposure (in terms of Cmin\\_ss, Cmax\\_ss and AUC) assuming paediatric patients of 6 years of age or older.

Below the age of 6, exposure reached at steady state is higher compared to adults.

Descriptive statistics of predicted individual exposure parameters for paediatrics and adult patients shows that Cmin is about 50% higher in the 3-6 age group, although the median value is within the Q3 for adults. More explicitly, assuming a lower age limit of 3 years for the first age group, predicted AUC6wks, Cmin,ss, Cmax,ss are simulated to be respectively 17%, 52% and 9% higher for the group of 3-6 years compared to adults.

There are not participants &lt;11 years old with cHL in the analysis dataset and the results in the 3 to 6 years old age group are informed by participants with solid tumors.

<div style=\"page-break-after: always\"></div>

In Figure 16, the model derived individual PK parameters for paediatric participants dosed at 2 mg/kg Q3W pembrolizumab are compared with adult cHL participants dosed at 200 mg Q3W. The figure demonstrates that observed exposure parameters in the paediatric participants (cHL data are shown in black dots) are generally within the range of values for adult cHL participants dosed at 200 mg Q3W.

Moreover box plots of post-hoc derived PK parameters for cHL paediatric patients in different group of age and adults shows a consistency in exposure parameters among groups except for the AUC values in age &lt;3 years old (~50% higher compared to that in adults), but this higher value is not of concern, considering the flat exposure-safety relationship for keytruda.

Of note, this does not relate to any conclusions regarding safety.

An in-vitro IL-2 stimulation assay was performed to investigate if there is a shift in the IL-2 stimulation curve between adults and children to guide the determination of the recommended Phase 2 dose (RP2D) of pembrolizumab in paediatric patients.

The relationship between IL-2 stimulation and pembrolizumab concentration was assessed based on 10 participants.  The  IC50 of  the  concentration-stimulation  ratio  curves  of  in-vitro  IL-2  assay  in  paediatric patients were compared with that of adult patients using banked blood samples from adult cancer patients in KN001.

According  to  the  MAH,  the  IC50  value  of  the  IL-2  stimulation  ratio  curves  in  paediatric  subjects  are consistent with that found in adult subjects supporting the dose of pembrolizumab 2 mg/kg Q3W. This in indicated in Figures 4 and 5, however the IC50 values are hard to compare by eye.

The MAH presented results from an Imax model that was fitted to the available limited IL-2 data. The estimated  IC50  value  was  found  to  be  0.14  ug/mL  in  paediatrics  patients  (no  measure  of  variability provided), which is in the same range to the IC50 value of 0.535 ug/mL found in adults characterized with a wide 95% CI of 0.123 - 2.33, covering the paediatric estimate at the lower end. Paediatric patients might need less exposure to reach the same level of inhibition; however the data base in paediatrics with respect to IL-2 biomarker is limited.

E-R relationship for best percent change from baseline tumour size remains very flat, also after recalculation and including adult cHL data from KEYNOTE-204 with a dosing regimen of 200 mg Q3W and paediatric cHL data from KEYNOTE-051 with a dosing regimen of 2 mg/kg Q3W.

The incidence of ADA in paediatric participants was consistent with the adult population.

## 2.3.6. Conclusions on clinical pharmacology

The data package on clinical pharmacology to support the current variation is limited. There are so far no clinical and no PK data available below the age of 10.

Observed PK concentrations in paediatric patients administered with 2 mg/kg Q3W from study KEYNOTE051 were within the range of predicted concentration (reference popPK model) for adults administered with the same dose of 2 mg/kg Q3W. However, some issues were identified about this comparison (VPC plots, pooling of subject with different tumors types, etc).

The MAH submitted a popPK analysis built on an existing population PK model for pembrolizumab in patients with various tumor types previously described in Report 04LL90 and proposed to extrapolate the efficacy and safety data in adult patients to paediatric patients with rrcHL using a model-based PK bridging analysis with supportive efficacy and safety data in rrcHL paediatric patients obtained from study KEYNOTE-051. The extrapolation is acceptable from the PK point of view.

<div style=\"page-break-after: always\"></div>

Further follow up data from the final study report from KEYNOTE -051 will be received in the context of the PIP completion.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

Pembrolizumab was initially approved for advanced melanoma at 2 mg/kg Q3W. Subsequent approvals for adult participants for multiple indications are at 200 mg Q3W dosing regimens. The 200 mg fixed dose is now the standard dose globally utilized and approved for numerous other pembrolizumab indications. This is also the recommended dose of pembrolizumab for all ongoing clinical studies except paediatric studies.

Pembrolizumab has been dosed at 200 mg Q3W in participants with cHL (KN-204 and KN-087). The clinical data in participants with cHL demonstrates efficacy at 200 mg Q3W, which in conjunction with an integrated body of evidence in previously approved indications, supports the recommendation of 200 mg Q3W as the appropriate dose for patients with cHL. An additional dosing regimen of 400 mg Q6W was approved in the EU on 28-MAR-2019 for all monotherapy indications approved at the time, including cHL.

PK exposures in paediatric patients at the 2 mg/kg (up to 200 mg) Q3W dose are expected to be similar to those in adults at 200 mg Q3W dose. The dose of 2 mg/kg (up to 200 mg) Q3W is proposed for use in paediatric patients with cHL. For additional details on paediatric PK, modeling, and extrapolation of adult data see above sections under Clinical Pharmacology.

## 2.4.2. Main study(ies)

Keynote (KN)-204 - A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma

Figure 14 Study design

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Methods

## Study participants

## Main Inclusion Criteria

- -Age ≥18 years
- -Patients have relapsed (disease progression after most recent therapy) or refractory (failure to achieve CR or PR to most recent therapy) classical HL.
- -Patients have achieved a CR or PR to BV or BV-containing regimens, if previously treated with BV.
- -Measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions  with  spiral  computed  tomography  (CT)  scan  or  combined  CT/positron  emission tomography (PET) scan. Minimum measurement must be &gt;15 mm in the longest diameter or &gt;10 mm in the short axis.
- -Provide evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy.
- -Performance status of 0 or 1 on ECOG Performance Scale.
- -Demonstrate  adequate  organ  function:  ANC  ≥1,000/mcL,  platelets  ≥75,000/mcL,  haemoglobin (Hb) &gt; 8.0 g/dl, creatinine≤1.5 X upper limit of normal (ULN) or m easured or calculated creatinine clearance (CrCl) ≥60.0 mL/min for subjects with creatinine levels &gt;1.5 X ULN, total bilirubin ≤1.5 X ULN, AST/ALT ≤2.5 X ULN O(≤5 X ULN for subjects with liver metastases), PT and PTT ≤1.5 X ULN. All screening were to be performed within 7 days of treatment initiation.

## Main exclusion criteria

- -Severe (≥ Grade 3) hypersensitivity to the active substance or to any of the excipients in BV or pembrolizumab.
- -Diagnosis of immunosuppression or the subject was receiving systemic steroid therapy (exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- -Prior monoclonal antibody within 4 weeks prior to first dose of therapy in the study or the subjects did not recover (i.e., ≤Grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier.
- -Prior chemotherapy, targeted small molecule therapy, or radiation therapy including investigational agents within 4 weeks prior to study Day 1 or the subjects did not recover (i.e., ≤Grade 1 or at baseline) from AEs due to a previously administered agent.
- -Prior allogeneic SCT (alloHSCT) within the last 5 years. Subjects who have had a transplant greater than 5 years ago are eligible as long as there are no symptoms of graft-versus-host disease (GVHD).
- -Known progressing additional malignancy or malignancy that required active treatment in the last 3 years.
- -Active central nervous system (CNS) involvement. Subjects with previously treated brain lesions could participate provided they are radiologically stable (i.e., without evidence of progression for at least 4 weeks by repeat imaging, clinically stable, and without requirement of steroid treatment for at least 14 days prior to the first dose of trial treatment).

<div style=\"page-break-after: always\"></div>

- -Active autoimmune disease that required systemic treatment in the past 2 years (i.e., with the use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
- -History of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
- -Active infection requiring systemic therapy, history of HIV infection or history of active tuberculosis, active hepatitis B (e.g. HBsAg reactive) or hepatitis C (e.g. HCV RNA is detected).
- -Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, CTLA-4 antibody (including ipilimumab), or OX-40, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- -Eligibility for allogeneic or autologous stem cell transplantation per investigator assessment.

## Treatments

Table 15 Summary of Treatments

| Drug                    | Dose/ Potency                       | Dose Frequency                             | Route of Administration   | Treatment Period                | Use          |
|-------------------------|-------------------------------------|--------------------------------------------|---------------------------|---------------------------------|--------------|
| Pembrolizumab (MK-3475) | 200 mg                              | 1 dose on Day 1 of every 3 weeks = 1 cycle | IV infusion               | Up to 35 cycles per participant | Experimental |
| Brentuximab vedotin     | 1.8 mg/kg (maximum 180 mg per dose) | 1 dose on Day 1 of every 3 weeks = 1 cycle | IV infusion               | Up to 35 cycles per participant | Comparator   |

Treatments were continued for up to 35 cycles per participant or until documented PD as described in the IWG response criteria [Cheson, 2007] by BICR, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to discontinue the participant, participant withdraws consent, pregnancy of the participant, or administrative reasons.

## Objectives

## Primary objectives:

- -to compare PFS as assessed by blinded independent central review (BICR), according to the IWG response  criteria  [Cheson,  2007]  between  treatment  arms,  including  clinical  and  imaging  data following  autologous  stem-cell  transplantation  (ASCT)  or  allogeneic  stem  cell  transplantation (alloHSCT).
- -to compare OS between treatment arms.

The study was considered to have met its primary objective if pembrolizumab is superior to BV in either PFS or OS.

Secondary objectives:

- -to compare PFS (PFS-secondary), as assessed by BICR, according to the IWG response criteria [Cheson, 2007] between treatment arms, excluding clinical and imaging data following ASCT or alloHSCT.
- -to compare the objective response rate (ORR) as assessed by BICR according to the IWG response

<div style=\"page-break-after: always\"></div>

criteria [Cheson, 2007] between treatment arms.

- -to evaluate the complete remission rate (CRR) as assessed by BICR according to the IWG response criteria [Cheson, 2007] between treatment arms.
- -to evaluate PFS, CRR, and ORR as assessed by the investigator according to the IWG response criteria [Cheson, 2007] by treatment arm.

## Exploratory objectives:

- -to determine the duration of response (DOR) as assessed by BICR and investigator assessment according to the IWG response criteria [Cheson, 2007] by treatment arm.
- -to compare the changes from baseline between the treatment arms in health-related quality-of-life (HR-QoL) assessments using the EORTC QLQ-C30 and EuroQol EQ-5D.
- -to evaluate second progression-free survival (PFS2) as assessed by the investigator according to the IWG response criteria [Cheson, 2007] by treatment arm.
- -to evaluate PFS as assessed by the investigator, according to the IWG response criteria [Cheson, 2007] by treatment arm, including clinical and imaging data following ASCT or alloHSCT.
- -To evaluate PFS, ORR, CRR, and DOR as assessed by BICR according to the Lugano criteria [Cheson, 2014] by treatment arm.

## Outcomes/endpoints

The following efficacy endpoints were assessed by treatment arm:

## Primary

Progression-free survival (PFS) - PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first, as per IWG criteria assessed by BICR, including clinical and imaging data following auto-SCT or allo-SCT.

Overall Survival (OS) - OS is defined as the time from randomization to death due to any cause. Subjects without documented death at the time of the final analysis will be censored at the date of the last followup.

## Secondary

Progression-free survival (PFS-secondary) - Progression-free-survival (PFS-secondary) is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first, as per IWG criteria assessed by BICR, excluding clinical and imaging data following auto-SCT or allo-SCT.

Objective Response Rate (ORR) - ORR is defined as the proportion of the subjects in the analysis population who achieved at least a partial response (CR+PR) as per IWG criteria assessed by BICR.

Complete Remission Rate (CRR) - CRR is defined as the proportion of the subjects in the analysis population who achieved a complete remission (CR) as per IWG criteria assessed by BICR.

## PFS, ORR, and CRR as per IWG criteria assessed by investigator

## Exploratory

<div style=\"page-break-after: always\"></div>

Duration of Response (DOR) - DOR is defined as time from first response to disease progression or death due to any cause, whichever occurs first in subjects who achieve a PR or better, as per IWG criteria assessed by BICR and by investigator.

ORR by PD-L1 Status - as per IWG criteria assessed by BICR for subjects with prepembrolizumab PD-L1 positive versus PD-L1 negative.

ORR Post-progression - as per IWG criteria assessed by investigator in subjects who achieved at least a partial response (CR+PR) after initial progression of disease.

## PFS, ORR, CRR, and DOR - as per Lugano criteria assessed by BICR

Second Progression-free Survival (PFS2) - defined as the time from randomization to subsequent disease progression after initiation of new anti-cancer therapy, or death from any cause, whichever occurs first, by investigator assessment.

PFS including clinical and imaging data after auto-SCT or allo-SCT as per IWG criteria assessed by investigator.

## Disease assessment

Following screening, lymphoma disease response assessments occurred at Week 12 (±7 days) and every 12 weeks (±7 days). CT scans were repeated every 12 weeks. PET was repeated at Week 12, Week 24, to confirm CR, and as clinically indicated. Response assessments and imaging continued to be performed until documented disease progression by BICR review, start of new anti-cancer treatment, withdrawal of consent, death or study end, whichever occurs first

For subjects receiving pembrolizumab, after the first documentation of progression, it was the discretion of the investigator to stop trial treatment or to keep a clinically stable subject on trial treatment until repeat imaging performed 4-6 weeks later confirmed progression. Clinical stability was defined as the absence of symptoms and signs indicating clinically significant progression of disease (including worsening of laboratory values), no decline in ECOG performance status and absence of rapid progression of disease or progressive tumour at critical anatomical sites (e.g., cord compression) requiring urgent medical intervention. Subjects deemed clinically unstable were not required to have repeated imaging for confirmation. If progression was confirmed, then the subject had to be discontinued from trial treatment. If progression was not confirmed, then the subject could resume/continue trial treatment provided that the sponsor was consulted and provided approval to continue treatment, no other anti-tumour therapy (e.g., chemotherapy, radiation, etc.) had been administered.

Treatment with BV was stopped at any time a lymphoma disease response assessment, verified by blinded independent central review showed PD. Although pembrolizumab could be continued, if PD was verified by blinded independent central review, the subject was considered to have progressed (i.e., counted as an event) at the initial PD assessment for the primary PFS analysis.

## PROs assessment

Patient-reported outcomes (PROs) were assessed using the eEuroQol-5D (eEQ-5D), version 1.0, as provided by the EuroQol Group, and the EORTC QLQ-C30, version 3.0, as provided by the EORTC Quality of Life Group. Patient-reported outcomes (PROs) were assessed pre-dose at Cycle 1 (baseline), Cycle 3 (Week 6), Cycle 5 (Week 12), Cycle 7 (Week 18), and Cycle 9 (Week 24) and every 12 weeks thereafter until PD or up to 1 year while the subject is receiving study treatment. Patient-reported outcomes were also obtained at discontinuation and at the 30-day Safety Follow-up Visit.

<div style=\"page-break-after: always\"></div>

## Sample size

The planned sample size was approximately 300 subjects. The study was event-driven. With 194 PFS events, the study had 85% power to detect a hazard ratio of 0.622 (pembrolizumab vs. BV) at alpha = 1.2% (one-sided). With 146 OS events, the study had 80% power to detect a hazard ratio of 0.600 at alpha = 1.25% (one-sided). It was assumed that OS and PFS followed an exponential distribution.

Power calculations assumed interim analyses (1 for PFS, 2 for OS), an enrolment period of 12 months and a cumulative dropout rate of 5% at the end of 3 years. The assumed median PFS and OS in the control arm of 5.6 and 22.4 months, respectively, were observed from a published study of subjects with relapsed/refractory HL treated with BV, all of whom had received prior SCT. The estimates of PFS and OS for BV in r/r HL subjects who have not received prior SCT were unknown at that time. However, based on limited data, the ORR and CRR for r/r HL subjects without prior SCT treated with BV were observed to be lower than those subjects with prior SCT. It was anticipated that the efficacy would be lower in the patient population not receiving SCT, so that control PFS estimate of 5.6 months and OS estimate of 22.4 months could be considered as over-estimates.

For the key secondary endpoint of ORR, which could only be tested if the PFS hypothesis was rejected, there was 90% power (1-sided 0.6% alpha) to detect an 18-20% improvement on the experimental arm assuming the true ORR for the control arm ranges between 60-70%, depending on the actual percentage of subjects without prior SCT enrolled.

## Randomisation

Treatment allocation/randomization occurred centrally using an interactive voice response system / integrated web response system (IVRS/IWRS). Subjects were randomly assigned in a 1:1 ratio to receive either 200-mg pembrolizumab or 1.8 mg/kg BV. Randomization was stratified by prior ASCT (Yes vs. No, with at least 100 subjects randomized within each level) and HL status after frontline therapy (primary refractory disease vs. relapsed disease less than 12 months after completion of frontline therapy vs. relapse 12 months or more after completion of frontline therapy).

## Blinding (masking)

Not applicable. KN-204 was an open label study.

## Statistical methods

The Intention-to-Treat (ITT) population served as the population for primary efficacy analysis. All randomized subjects were included in this population, and subjects were analysed in the treatment group to which they were randomized.

The non-parametric Kaplan-Meier (KM) method was used to estimate the PFS, PFS2 and OS curve in each treatment group. The treatment difference in PFS, PFS2 and OS was assessed by the stratified log-rank test. A stratified Cox proportional hazard (PH) model with Efron's method of tie handling was used to assess the magnitude of the treatment difference (i.e., HR) between treatment arms.

For the primary PFS analysis, for the subjects who have PD, the true date of disease progression was approximated by the date of the first assessment at which PD is objectively documented per IWG by BICR, including clinical and imaging data following auto-SCT or allo-SCT, regardless of discontinuation of study drug. Death was always considered as a confirmed PD event.

<div style=\"page-break-after: always\"></div>

Table 16 Censoring rules for primary, secondary and Sensitivity analyses of PFS

| Situation                                                                                                                                  | Primary Analysis                                                                           | Secondary Analysis                                                 | Sensitivity Analysis 1                                              | Sensitivity Analysis 2                         |
|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------|---------------------------------------------------------------------|------------------------------------------------|
| No PD and no death; new anticancer treatment is not initiated                                                                              | Censoredatlast disease assessment                                                          | Censoredatlast diseaseassessment                                   | Censoredat last disease assessment                                  | Censored at last disease assessment            |
| No PD and no death; subject receives SCT following study treatmentin the absence of PD                                                     | Censoredat last disease assessment                                                         | Censoredatlast disease assessment before SCT                       | Censored latlast disease assessment                                 | Censored at date ofSCT                         |
| No PD and no death; subject receives SCT following study treatment in the absence ofPD and new anticancer treatment is initiated after SCT | Censored at last disease assessment before new anticancer treatment                        | Censoredatlast disease assessment before SCT                       | Censored at last disease assessment before new anticancer treatment | Progressed at date of new anticancer treatment |
| No PD and no death; new anticancer treatment is initiated                                                                                  | Censored at last disease assessment before new anticancer treatment                        | Censoredat last disease assessment before new anticancer treatment | Censored at last disease assessment before new anticancer treatment | Progressed at date of new anticancer treatment |
| PD or death documented after ≤1 missed disease assessment                                                                                  | Progressed at date of documented PD or death                                               | Progressed at date of documented PD or death                       | Progressed at date of documented PD or death                        | Progressed at date of documented PD or death   |
| PD or death documented after ≥2 consecutive missed disease assessments                                                                     | Censored at last disease assessment prior tothe ≥2 consecutive missed disease assessments  | Progressed at date of documented PD or death                       | Progressed at date of documented PD or death                        | Progressed at date of documented PD or death   |
| No PD and no death and lost to follow-up after ≥2 consecutive missed disease assessments                                                   | Censored at last disease assessment prior to the ≥2 consecutive missed disease assessments | Censored at last disease assessment                                | Censored at last disease assessment                                 | Progressed at date of lost to follow- up       |

Adjustment for the effect of crossover on OS could be performed based on recognized methods, e.g., the Rank Preserving Structural Failure Time (RPSFT) model, two stage model, etc., based on an examination of the appropriateness of the data to the assumptions required by the methods.

<div style=\"page-break-after: always\"></div>

Table 17 Censoring rules for PFS2

| Outcome on initial study therapy                                                   | Receiving next line   | Outcome of next line        | Date ofevent or censoring                                                                                                                                                                                  | Outcome        |
|------------------------------------------------------------------------------------|-----------------------|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Death; with or without PD                                                          | No                    | NA                          | Death date                                                                                                                                                                                                 | Event          |
| PD                                                                                 | Yes                   | No PD,but Death followed    | Death date                                                                                                                                                                                                 | Event          |
| PD                                                                                 | Yes                   | PD                          | 2nd PD                                                                                                                                                                                                     | Event          |
| PD                                                                                 | Yes                   | No PD and No death followed | Last assessment date without progressionseen                                                                                                                                                               | Censored       |
| No PD and no Death                                                                 | No                    | NA                          | Last known alive date                                                                                                                                                                                      | Censored       |
| No PD and no Death; but end of therapy due to toxicity or other reasons not for PD | Yes                   | PD or no PD                 | Event as the PD date (if\"PD\" from next line) or Death date (if\"NoPD\"firom next line,but Death followed); Censored as the last assessment date without progression seen a ou, pue .ad ou,f) from next line) | Event/Censored |

The analysis of ORR and CRR consisted of the point estimate and 95% 2-sided exact CI using the Clopper-Pearson method with at least 95% coverage of the true rate, by treatment group. The stratified Miettinen and Nurminen's method, weighted by stratum size, was used for comparison of the ORR between the treatment groups.

Response duration (DoR), an exploratory efficacy endpoint, was summarized descriptively by treatment arm using the KM method and was defined in the subset of subjects with a CR or PR, based on IWG criteria, as the time from first documented evidence of CR or PR until the first documented sign of disease progression or death due to any cause, whichever occurred first.

Table 18 Censoring rules for DOR.

Table 3: Censoring Rules for DOR

|                                 | Primary Analysis              | Primary Analysis    | Sensitivity Analysis           | Sensitivity Analysis   |
|---------------------------------|-------------------------------|---------------------|--------------------------------|------------------------|
| Situation                       | DateofProgressionor Censoring | Outcome             | DateofProgression or Censoring | Outcome                |
| NoPDand no death;new anticancer | LDA                           | Censor (non- event) | LDA                            | Censor (non-event)     |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                                                                                                       | Primary Analysis                                                                                                                                                                                                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                                                                                                                      | Sensitivity Analysis                                                                                                                                                                                                                                                                                                                                  | Sensitivity Analysis                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Situation                                                                                                                                                                                                                                                                                                                                             | DateofProgressionor Censoring                                                                                                                                                                                                                                                                                                                         | Outcome                                                                                                                                                                                                                                                                                                                                               | Date of Progression or Censoring                                                                                                                                                                                                                                                                                                                      | Outcome                                                                                                                                                                                                                                                                                                                                               |
| treatment is not initiated                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                       |
| No PD and no death; subject receives SCT following study treatment in the absence of PD                                                                                                                                                                                                                                                               | LDA                                                                                                                                                                                                                                                                                                                                                   | Censor (non- event)                                                                                                                                                                                                                                                                                                                                   | Date of SCT                                                                                                                                                                                                                                                                                                                                           | Censor (non-event)                                                                                                                                                                                                                                                                                                                                    |
| No PD and no death; subject receives SCT following study treatment in the absence of PD and new anticancer treatment is initiated after SCT                                                                                                                                                                                                           | LDA before new anticancer treatment                                                                                                                                                                                                                                                                                                                   | Censor (non- event)                                                                                                                                                                                                                                                                                                                                   | Date of new anticancer treatment                                                                                                                                                                                                                                                                                                                      | End of response (event)                                                                                                                                                                                                                                                                                                                               |
| No PD and no death; new anticancer treatment is initiated                                                                                                                                                                                                                                                                                             | LDA before new anticancer treatment                                                                                                                                                                                                                                                                                                                   | Censor (non- event)                                                                                                                                                                                                                                                                                                                                   | Date of new anticancer treatment                                                                                                                                                                                                                                                                                                                      | End of response (event)                                                                                                                                                                                                                                                                                                                               |
| PD or death documented after ≤l missed disease assessment                                                                                                                                                                                                                                                                                             | Progression or death                                                                                                                                                                                                                                                                                                                                  | End of response (event)                                                                                                                                                                                                                                                                                                                               | Progression or death                                                                                                                                                                                                                                                                                                                                  | End of response (event)                                                                                                                                                                                                                                                                                                                               |
| PD or death documented after ≥2 consecutive missed disease assessments                                                                                                                                                                                                                                                                                | LDA prior to the ≥2 consecutive missed disease assessments                                                                                                                                                                                                                                                                                            | Censor (non- event)                                                                                                                                                                                                                                                                                                                                   | Progression or death                                                                                                                                                                                                                                                                                                                                  | End of response (event)                                                                                                                                                                                                                                                                                                                               |
| No PD and no death and lost to follow-up after ≥2 consecutive missed disease assessments                                                                                                                                                                                                                                                              | LDA prior to the ≥2 consecutive missed disease assessments                                                                                                                                                                                                                                                                                            | Censor (non- event)                                                                                                                                                                                                                                                                                                                                   | Date of lost to follow-up                                                                                                                                                                                                                                                                                                                             | End of response (event)                                                                                                                                                                                                                                                                                                                               |
| LDA =last disease assessment NOTE: Subjects are considered to have an ongoing response if censored, alive, have not progressed, and have not started a new anti-cancer therapy, have not been determined to be lost to follow-up, and the last non-NE imaging assessment is within two and half scheduled cycles (~30 weeks) of the data cutoff date. | LDA =last disease assessment NOTE: Subjects are considered to have an ongoing response if censored, alive, have not progressed, and have not started a new anti-cancer therapy, have not been determined to be lost to follow-up, and the last non-NE imaging assessment is within two and half scheduled cycles (~30 weeks) of the data cutoff date. | LDA =last disease assessment NOTE: Subjects are considered to have an ongoing response if censored, alive, have not progressed, and have not started a new anti-cancer therapy, have not been determined to be lost to follow-up, and the last non-NE imaging assessment is within two and half scheduled cycles (~30 weeks) of the data cutoff date. | LDA =last disease assessment NOTE: Subjects are considered to have an ongoing response if censored, alive, have not progressed, and have not started a new anti-cancer therapy, have not been determined to be lost to follow-up, and the last non-NE imaging assessment is within two and half scheduled cycles (~30 weeks) of the data cutoff date. | LDA =last disease assessment NOTE: Subjects are considered to have an ongoing response if censored, alive, have not progressed, and have not started a new anti-cancer therapy, have not been determined to be lost to follow-up, and the last non-NE imaging assessment is within two and half scheduled cycles (~30 weeks) of the data cutoff date. |

## Interim Analysis:

Four interim analyses were planned for the study.

<div style=\"page-break-after: always\"></div>

Table 19 Decision guidance at each efficacy analysis

| Analysis   | Key Endpoints        | Criteriafor Conduct of Analysis                                              | Value                          | Efficacy*        |
|------------|----------------------|------------------------------------------------------------------------------|--------------------------------|------------------|
| IA1        | Final PFS- secondary | Three months after all subjects are enrolled and 110 PFS events are observed | HR at bound p-value (l-sided)  | 0.51 ≤0.0002     |
| IA2        | Interim PFS          | Approximately 176 PFS events are observed                                    | HR at bound p-value (l-sided)  | 0.68 ≤0.0057     |
| IA3        | Final PFS            | Approximately 194 PFS events are observed**                                  | HR at bound p-value (l-sided)  | 0.72 ≤0.0112     |
| IA3        | Final ORR            | Time of final PFS analysist                                                  | ORR △ boundt p-value (1-sided) | ~13-14% ≤0.00600 |
| IA3        | First Interim OS     | Time of final PFS analysis (approximately 91 OS events anticipated)          | HR at bound p-value (l-sided)  | 0.51 ≤0.0006     |
| IA4        | Second Interim OS    | Approximately 119 OS events are observed                                     | HR at bound p-value (l-sided)  | 0.60 ≤0.0027     |
| FA         | Final OS             | Approximately 146 OS events are observed                                     | HR at bound p-value (l-sided)  | 0.69 ≤0.0120     |

Abbreviations: FA = final analysis; IA1 = interim analysis 1; IA2 = interim analysis 2; IA3 = interim analysis 3; IA4 = interim analysis 4; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PFS-secondary = progression-free survival secondary

**If the PFS events accrue slower than expected, the Sponsor may conduct the final PFS analysis when all subjectshavebeenfollowed upfor 36months,i.e.36months afterlast subjectrandomized q s     a s

*Actual value for OS depends on whether or not null hypotheses for PFS and ORR are rejected (see Section 3.8)

60% and 70%

ORR analysis can be conducted at time of an Interim PFS if null hypothesis for PFS is rejected early

## Multiplicity

For the superiority hypothesis, a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter was used to construct group sequential boundaries to control the type I error rate for both endpoints. With the selected gamma value of -8 selected, the HSD alpha-spending function was more conservative than the O'Brien-Fleming bound. The overall Type-I error across the testing of the OS, PFS and ORR hypotheses was controlled at 2.45% (one-sided).

Figure 15 Multiplicity control strategy

<!-- image -->

In addition (not shown in the Figure), α=0.05% (one -sided) was planned to be allocated to the PFSsecondary hypothesis, this endpoint will not be further analyzed, and the alpha level will not be reallocated to other hypotheses. Group sequential methods were used to allocate alpha between the interim and final analyses (see above).

<div style=\"page-break-after: always\"></div>

## PROs

The following PRO endpoints were assessed for KN-204 at the time of the PFS IA:

- The mean score changes in EORTC QLQ-C30 global health status/quality of life scale from baseline to week 24
- The mean score change in QLQ-C30 functional scales from baseline to week 24.
- The mean score change in EQ-5D VAS and utility score from baseline to week 24.
- The number and proportions of deterioration/stable/improvement from baseline to week 24, the time to deterioration (TTD), and the overall improvement rate during the study, i.e.: the QLQ-C30 global health status/quality of life scale (two items); the QLQ-C30 functional scales (five scales).

A change between -10 to 10 points was classified as 'stable' and greater than 10 points as 'improvement'. The change of 10 points was chosen as this magnitude of change was perceived by patients as being clinically significant. Since missing data cannot be ignored, the number and proportion of patients who 'improved', 'stable', or 'deteriorated', from baseline were summarized by treatment group at Week 24 based on MAR imputation of missing data.

## Results

## Participant flow

Figure 16 Participant flow

<!-- image -->

All 34 patients who were screened but not randomized did not meet inclusion or exclusion criteria.

<div style=\"page-break-after: always\"></div>

## Recruitment

Study KN-204 is conducted globally at 123 centres in 20 countries. The trial is currently ongoing, and the available data are based on the 2 nd  interim analysis (IA2). At the data cut-off date (17 Feb 2020), 304 participants were randomized (151 in the pembrolizumab arm and 153 in the BV arm). The date of the first patient first visit was 29 June 2016, the last patient last visit was 16 January 2020.

## Conduct of the study

The original study protocol was dated 23 December 2015, and five protocol amendments were subsequently issued.

Table 20 Summary of Protocol amendments

| Document     | Date of Issue   | OverallRationale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 05 | 18-FEB-2020     | To indicate that both clinical and imaging data following auto-SCT or allo-SCT will be collected and included in the evaluation of the primary PFS endpoint per IWG 2007 by BICR. For the primary analysis, participants who receive consolidative therapy following SCT and have not yet progressed will be censored at the date of their last assessmentpriortoinitiationofthepost- transplant consolidative therapy. Revision of the censoring rules of the primary analysis to censor participants at the last disease assessmentpriortotwoormoreconsecutive missed disease assessments if 1) PD or death occurredafterthetwoormoreconsecutivemissed assessments, or 2) 1ost-to-follow-up occurred after two or more consecutive missed disease |
| Amendment 04 | 22-NOV-2019     | Due to the larger than expected number of participants who received an autologous-SCT or allogeneic-SCT in the context of the study, the Sponsor changed the exploratory endpoint of PFS based on IWG per BICR incorporating imaging data post-SC to the primary endpoint. To conduct the PFS analysis within a reasonable timeframe, thepowerofPFSisreducedto85%and aninterim for PFS has been added.                                                                                                                                                                                                                                                                                                                                              |
| Amendment 03 | 16-NOV-2017     | Tomodify the collectionperiod for spontaneously reported pregnancy for participants receiving pembrolizumab to align with pembrolizumab template and US FDA request. Removal of PK and ADA objectives and associated blood collections as adequate data on pembrolizumab monotherapy incHLareavailable.Modification ofExclusion Criteria #11 to delete the requirement for systemic                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Document          | Date of Issue   | Overall Rationale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                   |                 | therapyfor an activeinfection tointravenously administered in order to make the criteria more stringent and align with pembrolizumabprogram standards. Addition of the exclusion of participants eligible for allogeneic or autologous SCT. Alignment of dosemodificationlanguagewith pembrolizumab label.                                                                                                                                                                                                                    |
| Amendment 02      | 01-AUG-2017     | To allow prior treatment with brentuximabvedotin (BV) or BV-containing regimens provided participant responded (achieved a complete remission[CR] or partial remission[PR]) to prior BV or BV-containing regimens. To allow enrollment of participants who have relapsed or refractoryclassicalHodgkinLymphomaandhave received at least one prior chemotherapy regimen regardless of transplant eligibility. Additional follow-up included to allow for collection of ECI data post allo-SCT was included per US FDA request. |
| Amendment 01      | 20-JUN-2016     | To exclude participants with a history of non- infectious pneumonitis requiring steroids due to a higher risk of developing pneumonitis with pembrolizumab, and to exclude participants with hypersensitivity toBV or any ofits excipients.                                                                                                                                                                                                                                                                                   |
| Original Protocol | 23-DEC-2015     | Not Applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

A total of 24 participants with 1 or more important protocol deviations were reported.

Table 21 Summary of Important Protocol Deviations (ITT Population)

|                                                                                                                                                                                                                                                                                                                                                                                                     | MK-3475 200 mg                                                             | MK-3475 200 mg                                                             | Brentuximab Vedotin                                                        | Brentuximab Vedotin                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                     | II                                                                         | (96)                                                                       | I                                                                          | (%6)                                                                       |
| Subjects in population                                                                                                                                                                                                                                                                                                                                                                              | 151                                                                        |                                                                            | 153                                                                        |                                                                            |
| With one or more important protocol deviations                                                                                                                                                                                                                                                                                                                                                      | 13                                                                         | (8.6)                                                                      | 11                                                                         | (7.2)                                                                      |
| With no important protocol deviations                                                                                                                                                                                                                                                                                                                                                               | 138                                                                        | (91.4)                                                                     | 142                                                                        | (92.8)                                                                     |
| Diseontinuation Criteria                                                                                                                                                                                                                                                                                                                                                                            | 4                                                                          | (2.6)                                                                      | 2                                                                          | (1.3)                                                                      |
| Participant developed study intervention discontinuation criteria, but was not discontinued from study intervention.                                                                                                                                                                                                                                                                                | 1                                                                          | (0.7)                                                                      | 0                                                                          | (0.0)                                                                      |
| Participant developed trial specific discontinuation criteria but was not discontinued from the trial.                                                                                                                                                                                                                                                                                              | 3                                                                          | (2.0)                                                                      | 2                                                                          | (1.3)                                                                      |
| Inclusion/Exclusion Criteria                                                                                                                                                                                                                                                                                                                                                                        |                                                                            | (1.3)                                                                      |                                                                            | (0.7)                                                                      |
| Has a dingnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form ofimmumosuppressive therapy within 7 days prior the first dose of trial drug.Protocol Exceptions: The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.                            | 0                                                                          | (0.0)                                                                      |                                                                            | (0.7)                                                                      |
| Participants entered who do not have relapsed (disease progression after most recent therapy) of refractory (failure to achieve CR or PR to most recent therapy) classical Hodgkin Ilymphoma.                                                                                                                                                                                                       | 2                                                                          | (1.3)                                                                      |                                                                            | (0.0)                                                                      |
| Prohibited Medications                                                                                                                                                                                                                                                                                                                                                                              | 0                                                                          | (0.0)                                                                      |                                                                            | (0.7)                                                                      |
| Administration of potent/strong CYP3A4 inhibitors and inducers; or P-gp inhibitors in subjects receiving BV.                                                                                                                                                                                                                                                                                        | 0                                                                          | (0.0)                                                                      |                                                                            | (0.7)                                                                      |
| Safety Reporting                                                                                                                                                                                                                                                                                                                                                                                    | 7                                                                          | (4.6)                                                                      | 4                                                                          | (2.6)                                                                      |
| Participant hnd a reportable Safety Event and/or follow up Safety Event infonnation that was not reported per the timelines outlined in the protocol.                                                                                                                                                                                                                                               | 5                                                                          | (3.3)                                                                      | 3                                                                          | (2.0)                                                                      |
| Post-allogenic-stem cell transplant events of clinical interest (ECIs) that occur after the nommal snfety follow up period must be assessed for seriousness and causality and reported to the sponsor as follows: within 24 hours if serious regardless of causality or if non-serious and considered to be drug-related; and 5 calendar days if non-serious and not considered to be dnug-related. |                                                                            | (2.0)                                                                      |                                                                            | (0.7)                                                                      |
| Study Intervention                                                                                                                                                                                                                                                                                                                                                                                  | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.7)                                                                      |
| Participant was administered improperly stored study intervention that was deemed unacceptable for use.                                                                                                                                                                                                                                                                                             | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.7)                                                                      |
| Trial Procedures                                                                                                                                                                                                                                                                                                                                                                                    |                                                                            | (0.0)                                                                      |                                                                            | (1.3)                                                                      |
| Baseline, week 12 or week 24 CT scans not performed during treatment phase to support study endpoints.                                                                                                                                                                                                                                                                                              | 0                                                                          | (0.0)                                                                      | 2                                                                          | (1.3)                                                                      |
| Every subject is counted a single time for ench applicable row and columu.                                                                                                                                                                                                                                                                                                                          | Every subject is counted a single time for ench applicable row and columu. | Every subject is counted a single time for ench applicable row and columu. | Every subject is counted a single time for ench applicable row and columu. | Every subject is counted a single time for ench applicable row and columu. |

Of these, 4 participants (3 in the pembrolizumab arm, 1 in the BV arm) had important protocol deviations that were considered to be clinically important. Clinically important deviation categories included:

- Inclusion/Exclusion criteria (n=2, pembrolizumab arm): participants entered who did not have relapsed or refractory cHL

<div style=\"page-break-after: always\"></div>

- Safety reporting (n=1, pembrolizumab arm): post alloHSCT events of clinical interest that occur after the normal safety follow-up period must be assessed for seriousness and causality and reported to the Sponsor
- Study intervention (n=1, BV arm): participant was administered improperly stored study intervention that was deemed unacceptable

These 4 deviations did not compromise study data integrity so no per-protocol analyses were performed.

## Baseline data

Baseline characteristics are summarised in Table below.

Table 22 Subject Characteristics (ITT Population)

|                                           | MK-3475 200 mg   | MK-3475 200 mg   | Brentuximab Vedotin   | Brentuximab Vedotin   | Total    | Total   |
|-------------------------------------------|------------------|------------------|-----------------------|-----------------------|----------|---------|
|                                           | n                | (%)              | n                     | (%)                   | n        | (%)     |
| Subjects in population                    | 151              |                  | 153                   |                       | 304      |         |
| Gender                                    |                  |                  |                       |                       |          |         |
| Male                                      | 84               | (55.6)           | 90                    | (58.8)                | 174      | (57.2)  |
| Female                                    | 67               | (44.4)           | 63                    | (41.2)                | 130      | (42.8)  |
| Age (Years)                               |                  |                  |                       |                       |          |         |
| < 65                                      | 124              | (82.1)           | 131                   | (85.6)                | 255      | (83.9)  |
| >= 65                                     | 27               | (17.9)           | 22                    | (14.4)                | 49       | (16.1)  |
| Mean                                      | 41.9             |                  | 40.8                  |                       | 41.4     |         |
| SD                                        | 17.5             |                  | 17.1                  |                       | 17.3     |         |
| Median                                    | 36.0             |                  | 35.0                  |                       | 35.0     |         |
| Range                                     | 18 to 84         |                  | 18 to 83              |                       | 18 to 84 |         |
| Race                                      |                  |                  |                       |                       |          |         |
| American Indian Or Alaska Native          | 1                | (0.7)            | 0                     | (0.0)                 | 1        | (0.3)   |
| Asian                                     | 13               | (8.6)            | 13                    | (8.5)                 | 26       | (8.6)   |
| Black Or African American                 | 4                | (2.6)            | 8                     | (5.2)                 | 12       | (3.9)   |
| Multiple                                  | 4                | (2.6)            | 5                     | (3.3)                 | 9        | (3.0)   |
| Black Or African American White           | 3                | (2.0)            | 5                     | (3.3)                 | 8        | (2.6)   |
| White Asian                               | 1                | (0.7)            | 0                     | (0.0)                 | 1        | (0.3)   |
| Native Hawaiian Or Other Pacific Islander | 1                | (0.7)            | 0                     | (0.0)                 | 1        | (0.3)   |
| White                                     | 119              | (78.8)           | 115                   | (75.2)                | 234      | (77.0)  |
| Missing                                   | 9                | (6.0)            | 12                    | (7.8)                 | 21       | (6.9)   |
| Race by Ethnicity                         |                  |                  |                       |                       |          |         |
| Hispanic Or Latino                        | 24               | (15.9)           | 20                    | (13.1)                | 44       | (14.5)  |
| American Indian Or Alaska Native          | 1                | (0.7)            | 0                     | (0.0)                 | 1        | (0.3)   |
| Black Or African American                 | 1                | (0.7)            | 2                     | (1.3)                 | 3        | (1.0)   |
| Multiple                                  | 3                | (2.0)            | 4                     | (2.6)                 | 7        | (2.3)   |
| White                                     | 19               | (12.6)           | 14                    | (9.2)                 | 33       | (10.9)  |
| Not Hispanic Or Latino                    | 111              | (73.5)           | 115                   | (75.2)                | 226      | (74.3)  |
| Asian                                     | 13               | (8.6)            | 13                    | (8.5)                 | 26       | (8.6)   |
| Black Or African American                 | 2                | (1.3)            | 5                     | (3.3)                 | 7        | (2.3)   |
| Multiple                                  | 1                | (0.7)            | 1                     | (0.7)                 | 2        | (0.7)   |
| Native Hawaiian Or Other Pacific Islander | 1                | (0.7)            | 0                     | (0.0)                 | 1        | (0.3)   |
| White                                     | 94               | (62.3)           | 96                    | (62.7)                | 190      | (62.5)  |
| Not Reported                              | 8                | (5.3)            | 10                    | (6.5)                 | 18       | (5.9)   |
| Black Or African American                 | 0                | (0.0)            | 1                     | (0.7)                 | 1        | (0.3)   |
| White                                     | 4                | (2.6)            | 4                     | (2.6)                 | 8        | (2.6)   |

(57.2)

(42.8)

(83.9)

(16.1)

(0.3)

(8.6)

(3.9)

(3.0)

(2.6)

(0.3)

(0.3)

(77.0)

(6.9)

(14.5)

(0.3)

(1.0)

(2.3)

(10.9)

(74.3)

(8.6)

(2.3)

(0.7)

(0.3)

(62.5)

(5.9)

(0.3)

(2.6)

<div style=\"page-break-after: always\"></div>

(3.0)

(3.6)

(0.3)

(1.0)

(2.3)

(1.6)

(77.0)

(16.1)

(6.9)

(83.9)

(11.2)

(4.9)

(7.9)

(92.1)

(31.3)

(68.8)

(18.8)

(31.3)

(5.3)

(44.7)

(13.2)

(80.9)

(2.0)

(0.7)

(3.3)

(61.2)

(38.5)

(0.3)

(36.8)

(63.2)

(40.5)

(27.6)

(31.9)

302

(99.3)

(0.7)

| Missing                                                | 4       | (2.6)   | 5   | (3.3)   | 9   | (3.0)   |
|--------------------------------------------------------|---------|---------|-----|---------|-----|---------|
| Unknown                                                | 6       | (4.0)   | 5   | (3.3)   | 11  | (3.6)   |
| Black Or African American                              | 1       | (0.7)   | 0   | (0.0)   | 1   | (0.3)   |
| White                                                  | 2       | (1.3)   | 1   | (0.7)   | 3   | (1.0)   |
| Missing                                                | 3       | (2.0)   | 4   | (2.6)   | 7   | (2.3)   |
| Missing                                                | 2       | (1.3)   | 3   | (2.0)   | 5   | (1.6)   |
| Race Group                                             |         |         |     |         |     |         |
| White                                                  | 119     | (78.8)  | 115 | (75.2)  | 234 | (77.0)  |
| All Others                                             | 23      | (15.2)  | 26  | (17.0)  | 49  | (16.1)  |
| Missing                                                | 9       | (6.0)   | 12  | (7.8)   | 21  | (6.9)   |
| Age Group (Years)                                      |         |         |     |         |     |         |
| < 65                                                   | 124     | (82.1)  | 131 | (85.6)  | 255 | (83.9)  |
| >= 65 to < 75                                          | 18      | (11.9)  | 16  | (10.5)  | 34  | (11.2)  |
| >= 75 to < 85                                          | 9       | (6.0)   | 6   | (3.9)   | 15  | (4.9)   |
| US Region                                              |         |         |     |         |     |         |
| US                                                     | 11      | (7.3)   | 13  | (8.5)   | 24  | (7.9)   |
| Ex-US                                                  | 140     | (92.7)  | 140 | (91.5)  | 280 | (92.1)  |
| EU Region                                              |         |         |     |         |     |         |
| EU                                                     | 49      | (32.5)  | 46  | (30.1)  | 95  | (31.3)  |
| Ex-EU                                                  | 102     | (67.5)  | 107 | (69.9)  | 209 | (68.8)  |
| World Region                                           |         |         |     |         |     |         |
| North America                                          | 27      | (17.9)  | 30  | (19.6)  | 57  | (18.8)  |
| Europe                                                 | 49      | (32.5)  | 46  | (30.1)  | 95  | (31.3)  |
| Japan                                                  | 9       | (6.0)   | 7   | (4.6)   | 16  | (5.3)   |
| Rest of the World                                      | 66      | (43.7)  | 70  | (45.8)  | 136 | (44.7)  |
| Disease Subtype                                        |         |         |     |         |     |         |
| Classical Hodgkin Lymphoma Mixed Cellularity           | 23      | (15.2)  | 17  | (11.1)  | 40  | (13.2)  |
| Classical Hodgkin Lymphoma Nodular Sclerosis           | 119     | (78.8)  | 127 | (83.0)  | 246 | (80.9)  |
| Classical Hodgkin Lymphoma Lymphocyte Depleted         | 3       | (2.0)   | 3   | (2.0)   | 6   | (2.0)   |
| Classical Hodgkin Lymphoma Lymphocyte Rich             | 1       | (0.7)   | 1   | (0.7)   | 2   | (0.7)   |
| Missing                                                | 5       | (3.3)   | 5   | (3.3)   | 10  | (3.3)   |
| ECOG Performance Status                                |         |         |     |         |     |         |
| 0                                                      | 86      | (57.0)  | 100 | (65.4)  | 186 | (61.2)  |
| 1                                                      | 64      | (42.4)  | 53  | (34.6)  | 117 | (38.5)  |
| 2                                                      | 1       | (0.7)   | 0   | (0.0)   | 1   | (0.3)   |
| Stratification: Prior Auto-SCT Status                  |         |         |     |         |     |         |
| Yes                                                    | 56      | (37.1)  | 56  | (36.6)  | 112 | (36.8)  |
| No                                                     | 95      | (62.9)  | 97  | (63.4)  | 192 | (63.2)  |
| Stratification: Disease Status After Frontline         | Therapy |         |     |         |     |         |
| Primary Refractory                                     | 61      | (40.4)  | 62  | (40.5)  | 123 | (40.5)  |
| Relapsed < 12 Months                                   | 42      | (27.8)  | 42  | (27.5)  | 84  | (27.6)  |
| Relapsed >= 12 Months                                  | 48      | (31.8)  | 49  | (32.0)  | 97  | (31.9)  |
| Refractory or Relapsed After Any Line of Prior Therapy |         |         |     |         |     |         |
| Yes                                                    | 149     | (98.7)  | 153 | (100.0) | 302 | (99.3)  |
| No                                                     | 2       | (1.3)   | 0   | (0.0)   | 2   | (0.7)   |
| Response to First Regimen Before Study Treatment       |         |         |     |         |     |         |

<div style=\"page-break-after: always\"></div>

(28.6)

(65.5)

(5.9)

(42.4)

(36.5)

(21.1)

(90.5)

(1.0)

(8.6)

(4.9)

(95.1)

(39.1)

(60.9)

(19.7)

(80.3)

(26.0)

(73.7)

(0.3)

(5.6)

(94.4)

| Refractory                                      | 47                                              | (31.1)                                          | 40                                              | (26.1)                                          | 87                                              | (28.6)                                          |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Relapse                                         | 97                                              | (64.2)                                          | 102                                             | (66.7)                                          | 199                                             | (65.5)                                          |
| Other                                           | 7                                               | (4.6)                                           | 11                                              | (7.2)                                           | 18                                              | (5.9)                                           |
| Response to Last Regimen Before Study Treatment | Response to Last Regimen Before Study Treatment | Response to Last Regimen Before Study Treatment | Response to Last Regimen Before Study Treatment | Response to Last Regimen Before Study Treatment | Response to Last Regimen Before Study Treatment | Response to Last Regimen Before Study Treatment |
| Refractory                                      | 65                                              | (43.0)                                          | 64                                              | (41.8)                                          | 129                                             | (42.4)                                          |
| Untreated Relapse                               | 50                                              | (33.1)                                          | 61                                              | (39.9)                                          | 111                                             | (36.5)                                          |
| Other                                           | 36                                              | (23.8)                                          | 28                                              | (18.3)                                          | 64                                              | (21.1)                                          |
| Number of Prior Lines of Therapy                |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Subjects with data                              | 151                                             |                                                 | 153                                             |                                                 | 304                                             |                                                 |
| Mean                                            | 2.7                                             |                                                 | 2.8                                             |                                                 | 2.8                                             |                                                 |
| SD                                              | 1.5                                             |                                                 | 1.6                                             |                                                 | 1.6                                             |                                                 |
| Median                                          | 2.0                                             |                                                 | 3.0                                             |                                                 | 2.0                                             |                                                 |
| Range                                           | 1 to 10                                         |                                                 | 1 to 11                                         |                                                 | 1 to 11                                         |                                                 |
| Number of Prior Regimens                        |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Subjects with data                              | 151                                             |                                                 | 153                                             |                                                 | 304                                             |                                                 |
| Mean                                            | 2.8                                             |                                                 | 2.9                                             |                                                 | 2.8                                             |                                                 |
| SD                                              | 1.5                                             |                                                 | 1.6                                             |                                                 | 1.6                                             |                                                 |
| Median                                          | 2.0                                             |                                                 | 3.0                                             |                                                 | 3.0                                             |                                                 |
| Range                                           | 1 to 10                                         |                                                 | 1 to                                            | 11                                              | 1 to 11                                         |                                                 |
| PD-L1 Status                                    |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| >=1%                                            | 142                                             | (94.0)                                          | 133                                             | (86.9)                                          | 275                                             | (90.5)                                          |
| <1%                                             | 0                                               | (0.0)                                           | 3                                               | (2.0)                                           | 3                                               | (1.0)                                           |
| Missing                                         | 9                                               | (6.0)                                           | 17                                              | (11.1)                                          | 26                                              | (8.6)                                           |
| Prior Use of Brentuximab Vedotin                |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Y                                               | 5                                               | (3.3)                                           | 10                                              | (6.5)                                           | 15                                              | (4.9)                                           |
| N                                               | 146                                             | (96.7)                                          | 143                                             | (93.5)                                          | 289                                             | (95.1)                                          |
| Prior Radiation                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Yes                                             | 58                                              | (38.4)                                          | 61                                              | (39.9)                                          | 119                                             | (39.1)                                          |
| No                                              | 93                                              | (61.6)                                          | 92                                              | (60.1)                                          | 185                                             | (60.9)                                          |
| Bulky Disease                                   |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Yes                                             | 35                                              | (23.2)                                          | 25                                              | (16.3)                                          | 60                                              | (19.7)                                          |
| No                                              | 116                                             | (76.8)                                          | 128                                             | (83.7)                                          | 244                                             | (80.3)                                          |
| Baseline B Symptoms                             |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Yes                                             | 43                                              | (28.5)                                          | 36                                              | (23.5)                                          | 79                                              | (26.0)                                          |
| No                                              | 108                                             | (71.5)                                          | 116                                             | (75.8)                                          | 224                                             | (73.7)                                          |
| Missing                                         | 0                                               | (0.0)                                           | 1                                               | (0.7)                                           | 1                                               | (0.3)                                           |
| Baseline Bone Marrow Involvement                |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Yes                                             | 12                                              | (7.9)                                           | 5                                               | (3.3)                                           | 17                                              | (5.6)                                           |
| No                                              | 139                                             | (92.1)                                          | 148                                             | (96.7)                                          | 287                                             | (94.4)                                          |
| Database Cutoff Date: 16JAN2020                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |

In KEYNOTE-204, a total of 55 participants received 1 prior line of therapy and all were considered ineligible for auto-SCT at the time of enrolment

<div style=\"page-break-after: always\"></div>

Table 23 Summary of reasons for transplant ineligibility at baseline (subjects with one prior therapy)-ITT

|                                                                                                   | MK-3475 200 mg (N=27)                                                                             | BrentuximabVedotin (N=28)                                                                         | Total (N=55)                                                                                      |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Chemorefractory anddidnotreceivepriorSCT                                                          | 11 (40.7)                                                                                         | 10 (35.7)                                                                                         | 21 (38.2)                                                                                         |
| NotChemorefractory*anddidnotreceivepriorSCT                                                       | 16 (59.3)                                                                                         | 18 (64.3)                                                                                         | 34 (61.8)                                                                                         |
| *Reasons for transplant ineligibility include age and comorbidities. DatabaseCutoffDate:16JAN2020 | *Reasons for transplant ineligibility include age and comorbidities. DatabaseCutoffDate:16JAN2020 | *Reasons for transplant ineligibility include age and comorbidities. DatabaseCutoffDate:16JAN2020 | *Reasons for transplant ineligibility include age and comorbidities. DatabaseCutoffDate:16JAN2020 |

The majority of participants (61.8%) receiving study treatment in second line were ineligible for auto-SCT due to age and/or comorbidities and a proportion of the participants (21.8%) were refractory to the primary therapy.

Table 24 Baseline characteristics of the participants with one prior line of therapy in the pembrolizumab and BV treatment arms (ITT).

|                           | MK-3475 200 mg   | MK-3475 200 mg   | Brentuximab Vedotin   | Brentuximab Vedotin   | Total    | Total   |
|---------------------------|------------------|------------------|-----------------------|-----------------------|----------|---------|
|                           | n                | (%)              | n                     | (%)                   | 1        | (%)     |
| Subjects in population    | 27               |                  | 28                    |                       | 55       |         |
| Gender                    |                  |                  |                       |                       |          |         |
| Male                      | 17               | (63.0)           | 17                    | (60.7)                | 34       | (61.8)  |
| Female                    | 10               | (37.0)           | 11                    | (39.3)                | 21       | (38.2)  |
| Age (Years)               |                  |                  |                       |                       |          |         |
| <65                       | 15               | (55.6)           | 18                    | (64.3)                | 33       | (60.0)  |
| >=65                      | 12               | (44.4)           | 10                    | (35.7)                | 22       | (40.0)  |
| Mean                      | 53.1             |                  | 51.5                  |                       | 52.3     |         |
| SD                        | 21.5             |                  | 17.9                  |                       | 19.6     |         |
| Median                    | 47.0             |                  | 50.0                  |                       | 49.0     |         |
| Range                     | 22 to 84         |                  | 22 to 81              |                       | 22 to 84 |         |
| Race                      |                  |                  |                       |                       |          |         |
| Asian                     | 5                | (18.5)           | 3                     | (10.7)                | 8        | (14.5)  |
| Black OrAfricanAmerican   | 0                | (0.0)            | 3                     | (10.7)                | 3        | (5.5)   |
| Multiple                  | 1                | (3.7)            | 0                     | (0.0)                 | 1        | (1.8)   |
| White Asian               | 1                | (3.7)            | 0                     | (0.0)                 | 1        | (1.8)   |
| White                     | 18               | (66.7)           | 18                    | (64.3)                | 36       | (65.5)  |
| Missing                   | 3                | (11.1)           | 4                     | (14.3)                | 7        | (12.7)  |
| Race by Ethnicity         |                  |                  |                       |                       |          |         |
| Not Hispanic Or Latino    | 24               | (88.9)           | 22                    | (78.6)                | 46       | (83.6)  |
| Asian                     | 5                | (18.5)           | 3                     | (10.7)                | 8        | (14.5)  |
| Black Or African American | 0                | (0.0)            | 2                     | (7.1)                 | 2        | (3.6)   |
| Multiple                  | 1                | (3.7)            | 0                     | (0.0)                 | 1        | (1.8)   |
| White                     | 18               | (66.7)           | 17                    | (60.7)                | 35       | (63.6)  |
| Not Reported              | 0                | (0.0)            | 4                     | (14.3)                | 4        | (7.3)   |
| Black Or African American | 0                | (0.0)            | 1                     | (3.6)                 | 1        | (1.8)   |
| White                     | 0                | (0.0)            | 1                     | (3.6)                 | 1        | (1.8)   |
| Missing                   | 0                | (0.0)            | 2                     | (7.1)                 | 2        | (3.6)   |
| Unknown                   | 2                | (7.4)            | 2                     | (7.1)                 | 4        | (7.3)   |
| Missing                   | 2                | (7.4)            | 2                     | (7.1)                 | 4        | (7.3)   |
| Missing                   | 1                | (3.7)            | 0                     | (0.0)                 | 1        | (1.8)   |

<div style=\"page-break-after: always\"></div>

|                                                 | MK-3475 200 mg   | MK-3475 200 mg   | BrentuximabVedotin   | BrentuximabVedotin   | Total   | Total   |
|-------------------------------------------------|------------------|------------------|----------------------|----------------------|---------|---------|
|                                                 | n                | (%)              | n                    | (%)                  | n       | (%)     |
| Race Group                                      |                  |                  |                      |                      |         |         |
| White                                           | 18               | (66.7)           | 18                   | (64.3)               | 36      | (65.5)  |
| All Others                                      | 6                | (22.2)           | 6                    | (21.4)               | 12      | (21.8)  |
| Missing                                         | 3                | (11.1)           | 4                    | (14.3)               | 7       | (12.7)  |
| Age Group (Years)                               |                  |                  |                      |                      |         |         |
| <65                                             | 15               | (55.6)           | 18                   | (64.3)               | 33      | (60.0)  |
| >= 65 to < 75                                   | 6                | (22.2)           | 9                    | (32.1)               | 15      | (27.3)  |
| >= 75 to <85                                    | 6                | (22.2)           | 1                    | (3.6)                | 7       | (12.7)  |
| US Region                                       |                  |                  |                      |                      |         |         |
| US                                              | 0                | (0.0)            | 4                    | (14.3)               | 4       | (7.3)   |
| Ex-US                                           | 27               | (100.0)          | 24                   | (85.7)               | 51      | (92.7)  |
| EU Region                                       |                  |                  |                      |                      |         |         |
| EU                                              | 9                | (33.3)           | 11                   | (39.3)               | 20      | (36.4)  |
| Ex-EU                                           | 18               | (66.7)           | 17                   | (60.7)               | 35      | (63.6)  |
| World Region                                    |                  |                  |                      |                      |         |         |
| North America                                   | 4                | (14.8)           | 5                    | (17.9)               | 9       | (16.4)  |
| Europe                                          | 9                | (33.3)           | 11                   | (39.3)               | 20      | (36.4)  |
| Japan                                           | 3                | (11.1)           | 2                    | (7.1)                | 5       | (9.1)   |
| Rest of the World                               | 11               | (40.7)           | 10                   | (35.7)               | 21      | (38.2)  |
| Disease Subtype                                 |                  |                  |                      |                      |         |         |
| Classical Hodgkin Lymphoma Mixed                | 3                | (11.1)           | 3                    | (10.7)               | 6       | (10.9)  |
| Cellularity Classical Hodgkin Lymphoma Nodular  | 22               | (81.5)           | 23                   | (82.1)               | 45      | (81.8)  |
| Sclerosis Classical Hodgkin Lymphoma Lymphocyte | 1                | (3.7)            | 0                    | (0.0)                | 1       | (1.8)   |
| Rich Missing                                    | 1                | (3.7)            | 2                    | (7.1)                | 3       | (5.5)   |
| ECOG Performance Status                         |                  |                  |                      |                      |         |         |
| 0                                               | 18               | (66.7)           | 23                   | (82.1)               | 41      | (74.5)  |
| 1                                               | 9                | (33.3)           | 5                    | (17.9)               | 14      | (25.5)  |

<div style=\"page-break-after: always\"></div>

|                                                        | MK-3475 200 mg                                         | MK-3475 200 mg   | Brentuximab Vedotin   | Brentuximab Vedotin   | Total        | Total        |
|--------------------------------------------------------|--------------------------------------------------------|------------------|-----------------------|-----------------------|--------------|--------------|
|                                                        | 1                                                      | (%)              | n                     | (%)                   | n            | (%)          |
| Stratification:PriorAuto-SCTStatus                     |                                                        |                  |                       |                       |              |              |
| No                                                     | 27                                                     | (100.0)          | 28                    | (100.0)               | 55           | (100.0)      |
| Stratification: Disease Status After Frontline Therapy | Stratification: Disease Status After Frontline Therapy |                  |                       |                       |              |              |
| Primary Refractory                                     | 11                                                     | (40.7)           | 7                     | (25.0)                | 18           | (32.7)       |
| Relapsed < 12 Months                                   | 10                                                     | (37.0)           | 8                     | (28.6)                | 18           | (32.7)       |
| Relapsed >= 12 Months                                  | 6                                                      | (22.2)           | 13                    | (46.4)                | 19           | (34.5)       |
| Refractory orRelapsed After Any Line of PriorTherapy   | Refractory orRelapsed After Any Line of PriorTherapy   |                  |                       |                       |              |              |
| Yes                                                    | 26                                                     | (96.3)           | 28                    | (100.0)               | 54           | (98.2)       |
| No                                                     | 1                                                      | (3.7)            | 0                     | (0.0)                 | 1            | (1.8)        |
| Response toFirstRegimenBefore StudyTreatment           | Response toFirstRegimenBefore StudyTreatment           |                  |                       |                       |              |              |
| Refractory                                             | 7                                                      | (25.9)           | 5                     | (17.9)                | 12           | (21.8)       |
| Relapse                                                | 19                                                     | (70.4)           | 22                    | (78.6)                | 41           | (74.5)       |
| Other                                                  | 1                                                      | (3.7)            | 1                     | (3.6)                 | 2            | (3.6)        |
| ResponsetoLast RegimenBeforeStudyTreatment             | ResponsetoLast RegimenBeforeStudyTreatment             |                  |                       |                       |              |              |
| Refractory                                             | 7                                                      | (25.9)           | 5                     | (17.9)                | 12           | (21.8)       |
| Untreated Relapse                                      | 20                                                     | (74.1)           | 23                    | (82.1)                | 43           | (78.2)       |
| Number ofPriorLines of Therapy                         | Number ofPriorLines of Therapy                         |                  |                       |                       |              |              |
| Subjects with data                                     | 27                                                     |                  | 28                    |                       | 55           |              |
| Mean                                                   | 1.0                                                    |                  | 1.0                   |                       | 1.0          |              |
| SD                                                     | 0.0                                                    |                  | 0.0                   |                       | 0.0          |              |
| Median                                                 | 1.0                                                    |                  | 1.0                   |                       | 1.0          |              |
| Range                                                  | 1 to 1                                                 |                  | 1to 1                 |                       | 1 to 1       |              |
| Number ofPriorRegimens                                 | Number ofPriorRegimens                                 |                  |                       |                       |              |              |
| Subjects with data                                     | 27                                                     |                  | 28                    |                       | 55           |              |
| Mean                                                   | 1.1                                                    |                  | 1.0                   |                       | 1.1          |              |
| SD                                                     | 0.3                                                    |                  | 0.2                   |                       | 0.2          |              |
| Median                                                 | 1.0                                                    |                  | 1.0                   |                       | 1.0          |              |
| Range                                                  | 1to2                                                   |                  | 1to2                  |                       | 1to2         |              |
| PD-L1 Status                                           | PD-L1 Status                                           | PD-L1 Status     | PD-L1 Status          | PD-L1 Status          | PD-L1 Status | PD-L1 Status |

|                                 | MK-3475 200 mg                  | MK-3475 200 mg                  | Brentuximab Vedotin             | Brentuximab Vedotin             | Total                           | Total                           |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                 | 1n                              | (%)                             |                                 | (%)                             | 1n                              | (%)                             |
| >=1%                            | 25                              | (92.6)                          | 24                              | (85.7)                          | 49                              | (89.1)                          |
| Missing                         | 2                               | (7.4)                           | 4                               | (14.3)                          | 6                               | (10.9)                          |
| PriorUseofBrentuximabVedotin    |                                 |                                 |                                 |                                 |                                 |                                 |
| N                               | 27                              | (100.0)                         | 28                              | (100.0)                         | 55                              | (100.0)                         |
| PriorRadiation                  |                                 |                                 |                                 |                                 |                                 |                                 |
| Yes                             | 3                               | (11.1)                          | 5                               | (17.9)                          | 8                               | (14.5)                          |
| No                              | 24                              | (88.9)                          | 23                              | (82.1)                          | 47                              | (85.5)                          |
| Bulky Disease                   |                                 |                                 |                                 |                                 |                                 |                                 |
| Yes                             | 6                               | (22.2)                          | 2                               | (7.1)                           | 8                               | (14.5)                          |
| No                              | 21                              | (77.8)                          | 26                              | (92.9)                          | 47                              | (85.5)                          |
| BaselineBSymptoms               |                                 |                                 |                                 |                                 |                                 |                                 |
| Yes                             | 5                               | (18.5)                          | 4                               | (14.3)                          | 9                               | (16.4)                          |
| No                              | 22                              | (81.5)                          | 23                              | (82.1)                          | 45                              | (81.8)                          |
| Missing                         | 0                               | (0.0)                           | 1                               | (3.6)                           | 1                               | (1.8)                           |
| BaselineBoneMarrowInvolvement   |                                 |                                 |                                 |                                 |                                 |                                 |
| Yes                             | 4                               | (14.8)                          | 2                               | (7.1)                           | 6                               | (10.9)                          |
| No                              | 23                              | (85.2)                          | 26                              | (92.9)                          | 49                              | (89.1)                          |
| Database Cutoff Date: 16JAN2020 | Database Cutoff Date: 16JAN2020 | Database Cutoff Date: 16JAN2020 | Database Cutoff Date: 16JAN2020 | Database Cutoff Date: 16JAN2020 | Database Cutoff Date: 16JAN2020 | Database Cutoff Date: 16JAN2020 |

Source:[P204V01MK3475:adam-adsl]

A total of 249 participants received 2 or more prior lines of therapy;

<div style=\"page-break-after: always\"></div>

Table 25 Baseline characteristics for participants who received 2 or more lines of therapy in the pembrolizumab and BV treatment arms

|                                           | MK-3475 200 mg   | MK-3475 200 mg   | BrentuximabVedotin   | BrentuximabVedotin   | Total    | Total   |
|-------------------------------------------|------------------|------------------|----------------------|----------------------|----------|---------|
|                                           |                  | (%)              | n                    | (%)                  | 1n       | (%)     |
| Subjects in population                    | 124              |                  | 125                  |                      | 249      |         |
| Gender                                    |                  |                  |                      |                      |          |         |
| Male                                      | 67               | (54.0)           | 73                   | (58.4)               | 140      | (56.2)  |
| Female                                    | 57               | (46.0)           | 52                   | (41.6)               | 109      | (43.8)  |
| Age (Years)                               |                  |                  |                      |                      |          |         |
| $9 >                                      | 109              | (87.9)           | 113                  | (90.4)               | 222      | (89.2)  |
| ≥65                                       | 15               | (12.1)           | 12                   | (9.6)                | 27       | (10.8)  |
| Mean                                      | 39.5             |                  | 38.4                 |                      | 38.9     |         |
| SD                                        | 15.6             |                  | 16.1                 |                      | 15.8     |         |
| Median                                    | 34.5             |                  | 34.0                 |                      | 34.0     |         |
| Range                                     | 18 to 79         |                  | 18 to 83             |                      | 18 to 83 |         |
| Race                                      |                  |                  |                      |                      |          |         |
| American Indian Or Alaska Native          | 1                | (0.8)            | 0                    | (0.0)                | 1        | (0.4)   |
| Asian                                     | 8                | (6.5)            | 10                   | (8.0)                | 18       | (7.2)   |
| Black Or African American                 | 4                | (3.2)            | 5                    | (4.0)                | 9        | (3.6)   |
| Multiple                                  | 3                | (2.4)            | 5                    | (4.0)                | 8        | (3.2)   |
| BlackOrAfricanAmericanWhite               | 3                | (2.4)            | 5                    | (4.0)                | 8        | (3.2)   |
| Native Hawaiian Or Other Pacific Islander | 1                | (0.8)            | 0                    | (0.0)                | 1        | (0.4)   |
| White                                     | 101              | (81.5)           | 97                   | (77.6)               | 198      | (79.5)  |
| Missing                                   | 6                | (4.8)            | 8                    | (6.4)                | 14       | (5.6)   |
| Race by Ethnicity                         |                  |                  |                      |                      |          |         |
| Hispanic Or Latino                        | 24               | (19.4)           | 20                   | (16.0)               | 44       | (17.7)  |
| American Indian Or Alaska Native          | 1                | (0.8)            | 0                    | (0.0)                | 1        | (0.4)   |
| Black Or African American                 | 1                | (0.8)            | 乙                    | (1.6)                | 3        | (1.2)   |
| Multiple                                  | 3                | (2.4)            | 4                    | (3.2)                | 7        | (2.8)   |
| White                                     | 19               | (15.3)           | 14                   | (11.2)               | 33       | (13.3)  |
| Not Hispanic Or Latino                    | 87               | (70.2)           | 93                   | (74.4)               | 180      | (72.3)  |
| Asian                                     | 8                | (6.5)            | 10                   | (8.0)                | 18       | (7.2)   |
| Black Or African American                 | 2                | (1.6)            | 3                    | (2.4)                | 5        | (2.0)   |
| Multiple                                  | 0                | (0.0)            | 1                    | (0.8)                | 1        | (0.4)   |
| Native Hawaian Or Other Pacific Islander  | 1                | (0.8)            | 0                    | (0.0)                | 1        | (0.4)   |

<div style=\"page-break-after: always\"></div>

|                                              | MK-3475 200 mg   | MK-3475 200 mg   | Brentuximab Vedotin   | Brentuximab Vedotin   | Total   | Total   |
|----------------------------------------------|------------------|------------------|-----------------------|-----------------------|---------|---------|
|                                              | n                | (%)              | n                     | (%)                   | n       | (%)     |
| White                                        | 76               | (61.3)           | 79                    | (63.2)                | 155     | (62.2)  |
| Not Reported                                 | 8                | (6.5)            | 6                     | (4.8)                 | 14      | (5.6)   |
| White                                        | 4                | (3.2)            | 3                     | (2.4)                 | 7       | (2.8)   |
| Missing                                      | 4                | (3.2)            | 3                     | (2.4)                 | 7       | (2.8)   |
| Unknown                                      | 4                | (3.2)            | 3                     | (2.4)                 | 7       | (2.8)   |
| Black Or African American                    | 1                | (0.8)            | 0                     | (0.0)                 | 1       | (0.4)   |
| White                                        | 2                | (1.6)            | 1                     | (0.8)                 | 3       | (1.2)   |
| Missing                                      | 1                | (0.8)            | 2                     | (1.6)                 | 3       | (1.2)   |
| Missing                                      | 1                | (0.8)            | 3                     | (2.4)                 | 4       | (1.6)   |
| Race Group                                   |                  |                  |                       |                       |         |         |
| White                                        | 101              | (81.5)           | 97                    | (77.6)                | 198     | (79.5)  |
| All Others                                   | 17               | (13.7)           | 20                    | (16.0)                | 37      | (14.9)  |
| Missing                                      | 6                | (4.8)            | 8                     | (6.4)                 | 14      | (5.6)   |
| Age Group (Years)                            |                  |                  |                       |                       |         |         |
| <65                                          | 109              | (87.9)           | 113                   | (90.4)                | 222     | (89.2)  |
| ≥65 to <75                                   | 12               | (9.7)            | 7                     | (5.6)                 | 19      | (7.6)   |
| ≥75to<85                                     | 3                | (2.4)            | 5                     | (4.0)                 | 8       | (3.2)   |
| US Region                                    |                  |                  |                       |                       |         |         |
| US                                           | 11               | (8.9)            | 9                     | (7.2)                 | 20      | (8.0)   |
| Ex-US                                        | 113              | (91.1)           | 116                   | (92.8)                | 229     | (92.0)  |
| EU Region                                    |                  |                  |                       |                       |         |         |
| EU                                           | 40               | (32.3)           | 35                    | (28.0)                | 75      | (30.1)  |
| Ex-EU                                        | 84               | (67.7)           | 90                    | (72.0)                | 174     | (69.9)  |
| World Region                                 |                  |                  |                       |                       |         |         |
| North America                                | 23               | (18.5)           | 25                    | (20.0)                | 48      | (19.3)  |
| Europe                                       | 40               | (32.3)           | 35                    | (28.0)                | 75      | (30.1)  |
| Japan                                        | 6                | (4.8)            | 5                     | (4.0)                 | 11      | (4.4)   |
| Rest of the World                            | 55               | (44.4)           | 60                    | (48.0)                | 115     | (46.2)  |
| Disease Subtype                              |                  |                  |                       |                       |         |         |
| Classical Hodgkin Lymphoma Mixed Cellularity | 20               | (16.1)           | 14                    | (11.2)                | 34      | (13.7)  |

<div style=\"page-break-after: always\"></div>

|                                                        | MK-3475 200 mg                                         | MK-3475 200 mg                                         | BrentuximabVedotin                                     | BrentuximabVedotin                                     | Total                                                  | Total                                                  |
|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                        | 1n                                                     | (%)                                                    | n                                                      | (%)                                                    |                                                        | (%)                                                    |
| Classical Hodgkin Lymphoma Nodular Sclerosis           | 97                                                     | (78.2)                                                 | 104                                                    | (83.2)                                                 | 201                                                    | (80.7)                                                 |
| Classical Hodgkin Lymphoma Lymphocyte Depleted         | 3                                                      | (2.4)                                                  | 3                                                      | (2.4)                                                  | 6                                                      | (2.4)                                                  |
| Classical Hodgkin Lymphoma Lymphocyte Rich             | 0                                                      | (0.0)                                                  | 1                                                      | (0.8)                                                  | 1                                                      | (0.4)                                                  |
| Missing                                                | 4                                                      | (3.2)                                                  | 3                                                      | (2.4)                                                  | 7                                                      | (2.8)                                                  |
| ECOGPerformanceStatus                                  |                                                        |                                                        |                                                        |                                                        |                                                        |                                                        |
| 0                                                      | 68                                                     | (54.8)                                                 | 77                                                     | (61.6)                                                 | 145                                                    | (58.2)                                                 |
| 1                                                      | 55                                                     | (44.4)                                                 | 48                                                     | (38.4)                                                 | 103                                                    | (41.4)                                                 |
| 2                                                      | 1                                                      | (0.8)                                                  | 0                                                      | (0.0)                                                  | 1                                                      | (0.4)                                                  |
| Stratification:PriorAuto-SCTStatus                     |                                                        |                                                        |                                                        |                                                        |                                                        |                                                        |
| Yes                                                    | 56                                                     | (45.2)                                                 | 56                                                     | (44.8)                                                 | 112                                                    | (45.0)                                                 |
| No                                                     | 68                                                     | (54.8)                                                 | 69                                                     | (55.2)                                                 | 137                                                    | (55.0)                                                 |
| Stratification: Disease Status After Frontline Therapy | Stratification: Disease Status After Frontline Therapy | Stratification: Disease Status After Frontline Therapy | Stratification: Disease Status After Frontline Therapy | Stratification: Disease Status After Frontline Therapy | Stratification: Disease Status After Frontline Therapy | Stratification: Disease Status After Frontline Therapy |
| Primary Refractory                                     | 50                                                     | (40.3)                                                 | 55                                                     | (44.0)                                                 | 105                                                    | (42.2)                                                 |
| Relapsed <12 Months                                    | 32                                                     | (25.8)                                                 | 34                                                     | (27.2)                                                 | 66                                                     | (26.5)                                                 |
| Relapsed ≥ 12 Months                                   | 42                                                     | (33.9)                                                 | 36                                                     | (28.8)                                                 | 78                                                     | (31.3)                                                 |
| Refractory or Relapsed After Any Line of Prior Therapy | Refractory or Relapsed After Any Line of Prior Therapy | Refractory or Relapsed After Any Line of Prior Therapy | Refractory or Relapsed After Any Line of Prior Therapy | Refractory or Relapsed After Any Line of Prior Therapy | Refractory or Relapsed After Any Line of Prior Therapy | Refractory or Relapsed After Any Line of Prior Therapy |
| Yes                                                    | 123                                                    | (99.2)                                                 | 125                                                    | (100.0)                                                | 248                                                    | (99.6)                                                 |
| No                                                     | 1                                                      | (0.8)                                                  | 0                                                      | (0.0)                                                  | 1                                                      | (0.4)                                                  |
| ResponsetoFirstRegimenBeforeStudyTreatment             | ResponsetoFirstRegimenBeforeStudyTreatment             | ResponsetoFirstRegimenBeforeStudyTreatment             | ResponsetoFirstRegimenBeforeStudyTreatment             | ResponsetoFirstRegimenBeforeStudyTreatment             | ResponsetoFirstRegimenBeforeStudyTreatment             | ResponsetoFirstRegimenBeforeStudyTreatment             |
| Refractory                                             | 40                                                     | (32.3)                                                 | 35                                                     | (28.0)                                                 | 75                                                     | (30.1)                                                 |
| Relapse                                                | 78                                                     | (62.9)                                                 | 80                                                     | (64.0)                                                 | 158                                                    | (63.5)                                                 |
| Other                                                  | 6                                                      | (4.8)                                                  | 10                                                     | (8.0)                                                  | 16                                                     | (6.4)                                                  |
| ResponsetoLastRegimenBeforeStudyTreatment              | ResponsetoLastRegimenBeforeStudyTreatment              | ResponsetoLastRegimenBeforeStudyTreatment              | ResponsetoLastRegimenBeforeStudyTreatment              | ResponsetoLastRegimenBeforeStudyTreatment              | ResponsetoLastRegimenBeforeStudyTreatment              | ResponsetoLastRegimenBeforeStudyTreatment              |
| Refractory                                             | 58                                                     | (46.8)                                                 | 59                                                     | (47.2)                                                 | 117                                                    | (47.0)                                                 |
| Untreated Relapse                                      | 30                                                     | (24.2)                                                 | 38                                                     | (30.4)                                                 | 68                                                     | (27.3)                                                 |
| Other                                                  | 36                                                     | (29.0)                                                 | 28                                                     | (22.4)                                                 | 64                                                     | (25.7)                                                 |
| Number of Prior Lines of Therapy                       | Number of Prior Lines of Therapy                       | Number of Prior Lines of Therapy                       | Number of Prior Lines of Therapy                       | Number of Prior Lines of Therapy                       | Number of Prior Lines of Therapy                       | Number of Prior Lines of Therapy                       |

<div style=\"page-break-after: always\"></div>

|                               | MK-3475 200 mg   | MK-3475 200 mg   | BrentuximabVedotin   | BrentuximabVedotin   | Total   | Total   |
|-------------------------------|------------------|------------------|----------------------|----------------------|---------|---------|
|                               | 1n               | (%)              | 1n                   | (%)                  | 1n      | (%)     |
| Subjects with data            | 124              |                  | 125                  |                      | 249     |         |
| Mean                          | 3.1              |                  | 3.2                  |                      | 3.1     |         |
| SD                            | 1.4              |                  | 1.5                  |                      | 1.5     |         |
| Median                        | 3.0              |                  | 3.0                  |                      | 3.0     |         |
| Range                         | 2 to 10          |                  | 2 to 11              |                      | 2 to 11 |         |
| Number of Prior Regimens      |                  |                  |                      |                      |         |         |
| Subjects with data            | 124              |                  | 125                  |                      | 249     |         |
| Mean                          | 3.1              |                  | 3.3                  |                      | 3.2     |         |
| SD                            | 1.4              |                  | 1.5                  |                      | 1.5     |         |
| Median                        | 3.0              |                  | 3.0                  |                      | 3.0     |         |
| Range                         | 2 to 10          |                  | 2 to 11              |                      | 2 to 11 |         |
| PD-L1 Status                  |                  |                  |                      |                      |         |         |
| ≥1%                           | 117              | (94.4)           | 109                  | (87.2)               | 226     | (90.8)  |
| <1%                           | 0                | (0.0)            | 3                    | (2.4)                | 3       | (1.2)   |
| Missing                       | 7                | (5.6)            | 13                   | (10.4)               | 20      | (8.0)   |
| PriorUseofBrentuximabVedotin  |                  |                  |                      |                      |         |         |
| Y                             | 5                | (4.0)            | 10                   | (8.0)                | 15      | (6.0)   |
| N                             | 119              | (96.0)           | 115                  | (92.0)               | 234     | (94.0)  |
| PriorRadiation                |                  |                  |                      |                      |         |         |
| Yes                           | 55               | (44.4)           | 56                   | (44.8)               | 111     | (44.6)  |
| No                            | 69               | (55.6)           | 69                   | (55.2)               | 138     | (55.4)  |
| Bullky Disease                |                  |                  |                      |                      |         |         |
| Yes                           | 29               | (23.4)           | 23                   | (18.4)               | 52      | (20.9)  |
| No                            | 95               | (76.6)           | 102                  | (81.6)               | 197     | (79.1)  |
| Baseline BSymptoms            |                  |                  |                      |                      |         |         |
| Yes                           | 38               | (30.6)           | 32                   | (25.6)               | 70      | (28.1)  |
| No                            | 86               | (69.4)           | 93                   | (74.4)               | 179     | (71.9)  |
| BaselineBoneMarrowInvolvement |                  |                  |                      |                      |         |         |
| Yes                           | 8                | (6.5)            | 3                    | (2.4)                | 11      | (4.4)   |

|                              | MK-3475 200 mg               | MK-3475 200 mg               | BrentuximabVedotin           | BrentuximabVedotin           | Total                        |
|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                              |                              | (%)                          | 1 (%)                        | 1n                           | (%)                          |
| No                           | 116                          | (93.5)                       | 122 (97.6)                   | 238                          | (95.6)                       |
| DatabaseCutoffDate:16JAN2020 | DatabaseCutoffDate:16JAN2020 | DatabaseCutoffDate:16JAN2020 | DatabaseCutoffDate:16JAN2020 | DatabaseCutoffDate:16JAN2020 | DatabaseCutoffDate:16JAN2020 |

Source:[P204V01MK3475: adam-adsl]

## Numbers analysed

A total of 304 participants were included in the ITT population, 151 in the pembrolizumab arm and 153 in the BV arm. Safety analyses were based on the ASaT population, which included all 300 randomized participants who received at least one dose of study treatment. A total of 148 received pembrolizumab and 152 received BV.

## Outcomes and estimation

At the data cut-off date, the median duration of follow-up was 24.9 (range: 1.8 to 42.0) and 24.3 (range: 0.6 to 42.3) months in the pembrolizumab and BV arms, respectively. Data cut-off date was 16 Jan 2020.

Table 26 Summary of Efficacy Results for KEYNOTE-204

| Pembrolizumab (N=151)   | Brentuximab Vedotin (N=153)   |
|-------------------------|-------------------------------|

<div style=\"page-break-after: always\"></div>

| Primary outcome: PFS (ITT analysis population)                                                          | Primary outcome: PFS (ITT analysis population)   | Primary outcome: PFS (ITT analysis population)   |
|---------------------------------------------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Median PFS, months (95% CI) a                                                                           | 13.2 (10.9, 19.4)                                | 8.3 (5.7, 8.8)                                   |
| Hazard Ratio (95% CI), p-value                                                                          | 0.65 (0.48, 0.88),p= 0.00271                     | 0.65 (0.48, 0.88),p= 0.00271                     |
| Secondary efficacy outcomes                                                                             | Secondary efficacy outcomes                      | Secondary efficacy outcomes                      |
| Median PFS - secondary, months (95% CI) a (no alpha spent at IA2)                                       | 12.6 (8.7, 19.2)                                 | 8.2 (5.6, 8.6)                                   |
| Hazard Ratio (95% CI)                                                                                   | 0.62 (95% CI: 0.46, 0.85)                        | 0.62 (95% CI: 0.46, 0.85)                        |
| ORR %(95% CI)                                                                                           | 65.6 (57.4, 73.1)                                | 54.2 (46.0, 62.3)                                |
| Difference estimate (95% CI),p-value                                                                    | 11.3 (0.2,22.1), p =0.022534                     | 11.3 (0.2,22.1), p =0.022534                     |
| CRR %(95% CI)                                                                                           | 24.5 (17.9, 32.2)                                | 24.2 (17.6, 31.8)                                |
| Exploratory efficacy outcomes                                                                           | Exploratory efficacy outcomes                    | Exploratory efficacy outcomes                    |
| Median DOR, months (Range) a                                                                            | 20.7 (0.0+ - 33.2+)                              | 13.8 (0.0+ - 33.9+)                              |
| Analysis of Change from Baseline in EORTC QLQ-C30 Global Health Status/QoL at Week 24, LS Mean (95% CI) | 7.29 (3.94, 10.64)                               | -1.31 (-5.17, 2.55)                              |
| Difference in LS Mean (95% CI)                                                                          | 8.60 (3.89, 13.31)                               | 8.60 (3.89, 13.31)                               |

Response was assessed based on Central Assessment (BICR = Blinded Independent Central Review) per IWG response criteria [Cheson, 2007]. The 95% CIs for response rates were calculated based on the binomial exact method.

'+' indicates there is no progressive disease by the time of last disease assessment.

- a Estimated from product-limit (Kaplan-Meier) method for censored data.

CRR=complete remission rate; DOR = duration of response; LS = least squares; NR = not reached; ORR=objective response rate; PFS=progression-free survival.

Database Cutoff Date: 16-JAN-2020.

## Primary endpoints:

## · Progression-free Survival -primary (including clinical and imaging data post-SCT)

PFS was longer in the pembrolizumab arm compared with the BV arm. The HR for PFS was 0.65 (95% CI: 0.48, 0.88): the one-sided log-rank test was p=0.00271 which crossed the pre-specified boundary for statistical significance at IA2 [≤0.0043].

An improvement in PFS was observed for participants in the pembrolizumab arm, with a median PFS of 13.2 months (95% CI: 10.9, 19.4), compared with 8.3 months (95% CI: 5.7, 8.8) for participants in the BV arm (see Table below).

<div style=\"page-break-after: always\"></div>

Table 27 Analysis of PFS based on central review per IWG 2007 (primary analysis)

| Treatment                         | N                                 | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months (%)   | Median PFS ↑ (Months) (95% CI)   | PFS Rate at Months 12 in % t (95% CI)   | PFS Rate at Months 24 in % t (95% CI)   |
|-----------------------------------|-----------------------------------|------------------------|------------------|--------------------------------------|----------------------------------|-----------------------------------------|-----------------------------------------|
| MK-3475 200mg                     | 151                               | 81 (53.6)              | 1861.2           | 4.4                                  | 13.2 (10.9, 19.4)                | 53.9 (45.0, 61.9)                       | 35.4 (26.2, 44.6)                       |
| BrentuximabVedotin                | 153                               | 88 (57.5)              | 1269.3           | 6.9                                  | 8.3 (5.7, 8.8)                   | 35.6 (26.9, 44.4)                       | 25.4 (17.1, 34.5)                       |
| PairwiseComparison                |                                   |                        |                  |                                      |                                  | Hazard Ratio (95% CI)t                  | p-values                                |
| MK-3475200mgvs.BrentuximabVedotin | MK-3475200mgvs.BrentuximabVedotin |                        |                  |                                      |                                  |                                         |                                         |

DatabaseCutoffDate:16JAN2020

The PFS rates at 12 and 24 months by KM estimation were 53.9% and 35.4%, respectively, in the pembrolizumab arm compared with 35.6% and 25.4% in the BV arm (see Figure below).

Figure 17 KM Estimates of PFS Based on Central Review per IWG 2007 (ITT)

<!-- image -->

Sensitivity analyses ignoring censoring for events occurring after ≥2 missed visits (Sensitivity analysis 1) and treating discontinuation of treatment as an event (Sensitivity analysis 2) were consistent with the primary PFS

- o Sensitivity analysis 1: PFS HR 0.66 (95% CI 0.49, 0.88), p-value 0.00265
- o Sensitivity analysis 2: PFS HR 0.62 (95% CI 0.48, 0.82)

PFS assessed by the investigator (secondary endpoint) using IWG 2007 criteria showed a more marked PFS benefit than PFS assessed by BICR (HR 0.49, 95% CI: 0.36, 0.67, p&lt;0.00001). Sensitivity analyses for PFS assessed by the investigator showed consistent results (Sensitivity analysis 1 by Inv. HR 0.50,

<div style=\"page-break-after: always\"></div>

95% CI 0.37 - 0.68, p&lt;0.00001; Sensitivity analysis 2 by Inv. HR 0.52, 95% CI 0.39 - 0.68, p&lt;0.00001).

## Secondary endpoints

## · Progression-free Survival-Secondary (excluding clinical and imaging data post-SCT)

PFS-secondary, excluding clinical and imaging data post-ASCT, indicated a clinically improvement in the pembrolizumab arm compared with the BV arm: HR 0.62 (95% CI: 0.46, 0.85), although no alpha was spent for this endpoint. Median PFS was 12.6 months (95% CI:8.7, 19.2) in the pembrolizumab arm, compared with 8.2 months (95% CI: 5.6, 8.6) for participants in the BV arm. The PFS-secondary rates at 12 and 24 months by KM estimation were 50.4% (95% CI: 41.3, 58.9) and 30.6% (95% CI: 21.5, 40.2), respectively, in the pembrolizumab arm compared with 33.3% (95% CI: 24.6, 42.2) and 19.1% (95% CI: 11.6, 28.1) in the BV arm (see Figure below).

Figure 188 KM estimates of PFS based on central review per IWG 2007 (secondary analysis)

<!-- image -->

Results of PFS-secondary assessed by investigator remained consistent with PFS-secondary based on BICR.

The HR for PFS secondary was 0.47 (95% CI: 0.35, 0.64). The PFS secondary rates at 12 and 24 months by KM estimation were 59.4% and 38.9%, respectively, in the pembrolizumab arm compared with 32.1% and 17.0% in the BV arm.

## Stem Cell Transplant Pre and Post-Study Therapy

Nearly equal percentages of participants in both the pembrolizumab and BV arms underwent auto-SCT or allo-SCT following study treatment.

Table 28 Summary of Subsequent Stem Cell Transplant

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                     | MK-3475200 mg (N=148)                                                                                                                               | BrentuximabVedotin (N=152)                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Autologous Transplant (%6)                                                                                                                          | 30 (20.3)                                                                                                                                           | 34 (22.4)                                                                                                                                           |
| Allogeneic Transplant (%)                                                                                                                           | 14 ( 9.5)                                                                                                                                           | 13 ( 8.6)                                                                                                                                           |
| The following subjects lhad one autologous transplant and one allogeneic transplant, and is counted in both rows: PPO Database CutoffDate:16JAN2020 | The following subjects lhad one autologous transplant and one allogeneic transplant, and is counted in both rows: PPO Database CutoffDate:16JAN2020 | The following subjects lhad one autologous transplant and one allogeneic transplant, and is counted in both rows: PPO Database CutoffDate:16JAN2020 |

Sensitivity analyses with consideration of SCT indicate that the results are consistent with the primary analysis, regardless of baseline SCT and chemorefractory status or whether participants received SCT post study treatment.

Table 29: PFS by BCIR per IWG 2007 (Sensitivity Analyses with Consideration of SCT)

| PFS Analysis   | Description                                                                      | HRt (95% CI)t     |
|----------------|----------------------------------------------------------------------------------|-------------------|
| 1              | Baseline SCT and chemorefractory status+ as a subgroup                           |                   |
|                | Received prior SCT                                                               | 0.72 (0.42, 1.23) |
|                | Chemorefractory and did not receive prior SCT                                    | 0.65 (0.42, 1.03) |
|                | Not chemorefractory and did not receive prior SCT                                | 0.53 (0.26, 1.06) |
| 2              | Baseline SCT and chemorefractory status+ as a covariate                          | 0.65 (0.48, 0.88) |
| 3              | Post study treatment SCT* as a time-dependent covariate                          | 0.61 (0.45, 0.83) |
| 4              | Post study treatment SCT* as a time-dependent covariate withtreatmentinteraction | 0.62 (0.45, 0.86) |

SCT: stem cell transplant

HR: hazard ratio

Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Hodgkin lymphoma status after frontline therapy (primary refractory versus relapsed less than 12 months after completion of frontline therapy versus relapse 12 months or more after completion of frontline therapy).

Baseline SCT and chemorefractory status has three levels: received prior SCT versus chemorefractory and did not receive prior SCT versus not chemorefractory and did not receive prior SCT.

Based on the first autologous or allogeneic stem cell transplant received after study treatment.

## · Objective Response Rate (ORR) and complete response rate (CRR)

The ORR (BICR per IWG response criteria) was 65.6% (95% CI: 57.4, 73.1) for pembrolizumab and 54.2% (95% CI: 46.0, 62.3) for BV. The 11.3% (95% CI: 0.2, 22.1) difference in response rates was not statistically significant (stratified Miettinen and Nurminen's method p-value: 0.022534).

Results of ORR assessed by the investigator were consistent with ORR based on BICR. The CRR (BICR per IWG response criteria) was 24.5% (95% CI: 17.9%, 32.2%) for pembrolizumab and 24.2% (95% CI: 17.6%, 31.8%) for BV. CRR assessed by the investigator was consistent with the primary analysis of CRR.

ORR based on investigator review per IWG 2007 including responses post-PD (exploratory endpoint) demonstrated a similar ORR of 68.9% [95% CI 60.8, 76.2] in the pembrolizumab arm.

Table 29: Summary of Best Overall Response Based on Central Review per IWG 2007 (ITT)

<div style=\"page-break-after: always\"></div>

|                              | MK-3475200mg   | MK-3475200mg   | MK-3475200mg   | BrentuximabVedotin   | BrentuximabVedotin   | BrentuximabVedotin   |
|------------------------------|----------------|----------------|----------------|----------------------|----------------------|----------------------|
|                              | n              | (%)            | (95% CI)t      | n                    | (%)                  | (95% CI)t            |
| NumberofSubjectsinPopulation | 151            |                |                | 153                  |                      |                      |
| Complete Response (CR)       | 37             | (24.5)         | (17.9,32.2)    | 37                   | (24.2)               | (17.6, 31.8)         |
| Partial Response (PR)        | 62             | (41.1)         | (33.1, 49.3)   | 46                   | (30.1)               | (22.9, 38.0)         |
| Objective Response (CR+PR)   | 99             | (65.6)         | (57.4, 73.1)   | 83                   | (54.2)               | (46.0, 62.3)         |
| Stable Disease (SD)          | 21             | (13.9)         | (8.8, 20.5)    | 36                   | (23.5)               | (17.1, 31.1)         |
| Progressive Disease (PD)     | 26             | (17.2)         | (11.6, 24.2)   | 28                   | (18.3)               | (12.5, 25.4)         |
| Not Evaluable (NE)           | 1              | (0.7)          | (0.0, 3.6)     | 1                    | (0.7)                | (0.0, 3.6)           |
| No Assessment (NA)           | 4              | (2.6)          | (0.7, 6.6)     | 5                    | (3.3)                | (1.1, 7.5)           |

## Exploratory endpoints

## Progression-free Survival Exploratory - per Lugano Criteria

The HR for PFS was 0.61 (95% CI: 0.45, 0.83). The median PFS was 13.8 months in the pembrolizumab arm (95% CI: 8.8, 17.9) and 8.3 months in the BV arm (95% CI: 5.7, 8.4).

Table 32 Analysis of PFS per Lugano 2014 (primary analysis) and IWG - ITT

| Treatment                         | N                                 | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months (%)   | Median PFS ↑ (Months) (95% CI)   | PFS Rate at Months 12 in % t (95% CI)   | PFS Rate at Months 24 in % t (95% CI)   |
|-----------------------------------|-----------------------------------|------------------------|------------------|--------------------------------------|----------------------------------|-----------------------------------------|-----------------------------------------|
| MK-3475 200 mg                    | 151                               | 81 (53.6)              | 1843.6           | 4.4                                  | 13.8 (8.8, 17.9)                 | 53.0 (44.1, 61.1)                       | 36.1 (27.1, 45.2)                       |
| BrentuximabVedotin                | 153                               | 89 (58.2)              | 1243.5           | 7.2                                  | 8.3 (5.7, 8.4)                   | 34.5 (25.8, 43.4)                       | 24.8 (16.7, 33.7)                       |
| Pairwise Comparison               |                                   |                        |                  |                                      |                                  | Hazard Ratio+ (95% CI)*                 | p-values                                |
| MK-3475200mgvs.BrentuximabVedotin | MK-3475200mgvs.BrentuximabVedotin |                        |                  |                                      |                                  | 0.61 (0.45, 0.83)                       |                                         |

Database Cutoff Date:16JAN2020

The  PFS  rates  at  12  and  24  months  by  KM  estimation  were  53.0%  and  36.1%,  respectively,  in  the pembrolizumab arm compared with 34.5% and 24.8% in the BV arm.

<div style=\"page-break-after: always\"></div>

Figure 21 Kaplan- Meier Estimates of PFS per Lugano 2014 (primary analysis), ITT

<!-- image -->

Sensitivity analyses per Lugano, considering PD or death after ≥2 missed visits as an event (Sensitivity Analysis  1)  and  treating  the  initiation  of  new  anticancer  therapy  (other  than  SCT)  as  an  event  for participants without PD or death (Sensitivity Analysis 2), were consistent with the primary PFS result.

## Objective Response Rate per Lugano Criteria - Exploratory endpoint

Table 30 Analysis of ORR based on BICR per Lugano criteria.

|                     |     |                              |                                      | Difference inPercentage MK-3475 200mg vs.BrentuximabVedotin   | Difference inPercentage MK-3475 200mg vs.BrentuximabVedotin   |
|---------------------|-----|------------------------------|--------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Treatment           | N   | Number of Objective Response | Objective Response Rate (%) (95% CI) | Estimate (95% CI)t                                            | p-Valuelt                                                     |
| MK-3475200mg        | 151 | 110                          | 72.8 (65.0,79.8)                     | 5.5 (-4.7,15.7)                                               | 0.145516                                                      |
| Brentuximab Vedotin | 153 | 103                          | 67.3 (59.3,74.7)                     |                                                               |                                                               |

<div style=\"page-break-after: always\"></div>

## Complete Remission Rate per Lugano Criteria

Table 31 Summary of Best Overall response per Lugano Criteria

|                                  | MK-3475 200 mg   | MK-3475 200 mg   | MK-3475 200 mg   | BrentuximabVedotin   | BrentuximabVedotin   | BrentuximabVedotin   |
|----------------------------------|------------------|------------------|------------------|----------------------|----------------------|----------------------|
|                                  |                  | (%)              | (95% CI)t        |                      | (%)                  | (95% CI)f            |
| Number of Subjects in Population | 151              |                  |                  | 153                  |                      |                      |
| Complete Response (CR)           | 42               | (27.8)           | (20.8, 35.7)     | 47                   | (30.7)               | (23.5, 38.7)         |
| Partial Response (PR)            | 68               | (45.0)           | (36.9, 53.3)     | 56                   | (36.6)               | (29.0, 44.8)         |
| Objective Response (CR+PR)       | 110              | (72.8)           | (65.0, 79.8)     | 103                  | (67.3)               | (59.3, 74.7)         |
| Stable Disease (SD)              | 10               | (6.6)            | (3.2, 11.8)      | 18                   | (11.8)               | (7.1, 18.0)          |
| Progressive Disease (PD)         | 27               | (17.9)           | (12.1, 24.9)     | 25                   | (16.3)               | (10.9, 23.2)         |
| Not Evaluable (NE)               | 0                | (0.0)            | (0.0, 2.4)       | 2                    | (1.3)                | (0.2,4.6)            |
| No Assessment (NA)               | 4                | (2.6)            | (0.7, 6.6)       | 5                    | (3.3)                | (1.1, 7.5)           |

## · Time to response (TTR) and Duration of response (DoR)

The median time to response was 2.8 months in both treatment arms. Median DOR was longer in the pembrolizumab arm compared with BV, 20.7 months (range: 0.0+ to 33.2+ months) and 13.8 months (range: 0.0+ to 33.9+), respectively.

Table 325 : Time to Response and DOR based on Central Review in Subjects with Response

|                                                       | MK-3475 200 mg (N=151)   | BrentuximabVedotin (N=153)   |
|-------------------------------------------------------|--------------------------|------------------------------|
| Number of subjects with responset                     | 100                      | 83                           |
| Time toResponse(months)                               |                          |                              |
| Mean (SD)                                             | 3.7 (3.9)                | 2.9 (0.6)                    |
| Median (Range)                                        | 2.8 (1.0-31.2)           | 2.8 (1.3-7.3)                |
| ResponseDuration*(months)                             |                          |                              |
| Median (Range)                                        | 20.7 (0.0+ -33.2+)       | 13.8 (0.0+ -33.9+)           |
| Number(%*)of Subjects withExtended Response Duration: |                          |                              |
| ≥6 months                                             | 66 (79.9)                | 34 (59.6)                    |
| ≥12 months                                            | 48 (62.4)                | 23 (50.0)                    |
| ≥18 months                                            | 31 (53.7)                | 13 (42.8)                    |
| ≥24months                                             | 11 (47.4)                | 7 (42.8)                     |

In the pembrolizumab arm, a higher percentage of participants had extended responses for ≥12 months (62.4% for pembrolizumab, 50.0% for BV) and ≥24 months (47.4% for pembrolizumab, 42.8% for BV) by KM estimation, compared with the BV arm (see Figure below).

<div style=\"page-break-after: always\"></div>

Figure 19 KM Estimates of DOR; Central Review per IWG 2007 in Subjects with Response

<!-- image -->

Table 331 Time to response and Duration of response for participants who achieved CR per BICR

|                                                                                                                                                                                                                                                             | MK-3475 200 mg (N=151)                                                                                                                                                                                                                                      | BrentuximabVedotin (N=153)                                                                                                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number of subjects with responset                                                                                                                                                                                                                           | 37                                                                                                                                                                                                                                                          | 37                                                                                                                                                                                                                                                          |
| Time to Response (months)                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |
| Mean (SD)                                                                                                                                                                                                                                                   | 3.1 (1.3)                                                                                                                                                                                                                                                   | 2.8 (0.3)                                                                                                                                                                                                                                                   |
| Median (Range)                                                                                                                                                                                                                                              | 2.8 (1.0-8.4)                                                                                                                                                                                                                                               | 2.8 (1.3-3.3)                                                                                                                                                                                                                                               |
| Response Duration(months)                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |
| Median (Range)                                                                                                                                                                                                                                              | NR (0.0+ - 33.2+)                                                                                                                                                                                                                                           | NR (0.0+ - 33.9+)                                                                                                                                                                                                                                           |
| Nunber(%+)of Subjects withExtended Response Duration:                                                                                                                                                                                                       |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |
| ≥6 months                                                                                                                                                                                                                                                   | 27 (85.4)                                                                                                                                                                                                                                                   | 24 (76.4)                                                                                                                                                                                                                                                   |
| ≥12 months                                                                                                                                                                                                                                                  | 24 (75.9)                                                                                                                                                                                                                                                   | 18 (69.5)                                                                                                                                                                                                                                                   |
| ≥18 months                                                                                                                                                                                                                                                  | 18 (69.4)                                                                                                                                                                                                                                                   | 12 (65.7)                                                                                                                                                                                                                                                   |
| ≥24 months                                                                                                                                                                                                                                                  | 6 (69.4)                                                                                                                                                                                                                                                    | 6 (65.7)                                                                                                                                                                                                                                                    |
| Includes subjects with best overall response as complete response or partial response.  From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. NR = Not Reached. | Includes subjects with best overall response as complete response or partial response.  From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. NR = Not Reached. | Includes subjects with best overall response as complete response or partial response.  From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. NR = Not Reached. |

Source: [P204V01MK3475: adam-adsl; adrs; adtte]

<div style=\"page-break-after: always\"></div>

Figure 190 Kaplan - Meier estimates of Duration of response for participants who achieved CR per BICR

<!-- image -->

DatabaseCutoffDate:16JAN2020

Source:[P204V01MK3475:adam-adsl;adrs;adtte]

## Time to Response and Duration of Response per Lugano Criteria

Median time to response was 2.8 months in both the pembrolizumab arm and the BV arm. Median response duration was notably longer for pembrolizumab (16.8 months; range: 0.0+ to 33.2+ months) compared with  BV  (5.8  months;  range:  0.0+  to  33.9+  months).  A  larger  proportion  of  participants  in  the pembrolizumab arm experienced extended response duration: 44.8% of participants in the pembrolizumab arm had response duration ≥24 months, compared with 30.5% in the BV arm.

<div style=\"page-break-after: always\"></div>

Table 36 Summary of Time to Response and Duration of Response per Lugano Criteria

|                                                          | MK-3475 200 mg (N=151)   | BrentuximabVedotin (N=153)   |
|----------------------------------------------------------|--------------------------|------------------------------|
| Number of subjects with response!                        | 110                      | 103                          |
| Time to Response (months)                                |                          |                              |
| Mean (SD)                                                | 2.9 (0.6)                | 2.9 (0.5)                    |
| Median (Range)                                           | 2.8 (1.0-6.7)            | 2.8 (1.3-5.8)                |
| Response Duration(months)                                |                          |                              |
| Median (Range)                                           | 16.8 (0.0+ - 33.2+)      | 5.8 (0.0+ - 33.9+)           |
| Number (%+) of Subjects with Extended Response Duration: |                          |                              |
| ≥6 months                                                | 69 (74.0)                | 33 (46.2)                    |
| ≥12 months                                               | 49 (58.5)                | 23 (39.6)                    |
| ≥18 months                                               | 33 (49.5)                | 15 (34.3)                    |
| ≥24 months                                               | 13 (44.8)                | 7 (30.5)                     |

Figure 20 Kaplan - Meier Estimates of Duration of response based on central review per Lugano 2014 in subjects with response

KEYNOTE-204 Kaplan-Meier Estimates of Duration of Response Based on Central Review per Lugano 2014 in Subjects with Response (ITT Population)

<!-- image -->

DatabaseCutoffDate:16JAN2020

Source:[P204V01MK3475:adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

## Second progression-free survival (PFS2)

Median PFS2 was not reached in either arm (pembrolizumab 95% CI: 33.5, not reached; BV 95% CI: 20.9, not reached). The PFS2 rates at 12 and 24 months by KM estimation were 92.4% (95% CI: 86.8, 95.7) and 71.3% (95% CI: 62.6, 78.3), respectively, in the pembrolizumab arm compared with 77.0% (95% CI: 69.2, 83.1) and 59.1% (95% CI: 49.5, 67.4) in the BV arm (see Table and Figure below).

Table 37 Analysis of Second PFS Based on Investigator Review per IWG 2007

| Treatment                                 | N                                         | Number of Events (%)   | Person- Months   | Event Rate/ 100Person- Months (%)   | MedianPFS (Months) (95% CI)   | PFSRate at Months 12in%↑ (95% CI)   | PFSRate at Months24in%↑ (95% CI)   |
|-------------------------------------------|-------------------------------------------|------------------------|------------------|-------------------------------------|-------------------------------|-------------------------------------|------------------------------------|
| MK-3475200 mg                             | 151                                       | 42 (27.8)              | 3242.5           | 1.3                                 | NR (33.5,NR)                  | 92.4 (86.8,95.7)                    | 71.3 (62.6, 78.3)                  |
| BrentuximabVedotin                        | 153                                       | 54 (35.3)              | 2477.7           | 2.2                                 | NR (20.9,NR)                  | 77.0 (69.2,83.1)                    | 59.1 (49.5,67.4)                   |
| PairwiseComparison                        |                                           |                        |                  |                                     |                               | Hazard Ratio+(95% CI)               |                                    |
| Primary MK-3475200mgvs.BrentuximabVedotin | Primary MK-3475200mgvs.BrentuximabVedotin |                        |                  |                                     |                               | 0.58 (0.38,0.87)                    | p-values 0.00374                   |

Figure 21 KM Estimates of Second PFS Based on Investigator Review per IWG 2007

<!-- image -->

## Patient Reported Outcomes (PROs)

EORTC QLQ-C30

Compliance rates for the EORTC QLQ-C30 remained high from baseline (~92%) to Week 48 (87 to 77%, per protocol). At baseline EORTC QLQ-C30 mean scores were similar across treatment arms, but by Week 24 they had improved in the pembrolizumab arm and deteriorated in the BV arm.

For GHS/QOL, a difference in LS means between the pembrolizumab arm and the BV arm at Week 24 was observed; the difference was 8.60 points, favouring pembrolizumab (95% CI: 3.89, 13.31; two-sided p=0.0004, not controlled for multiplicity). For physical functioning, a difference in LS means between the pembrolizumab arm and the BV arm at Week 24 was also observed; the difference was 6.24 points, favouring pembrolizumab (95% CI: 1.87, 10.62; two-sided p=0.0054, not controlled for multiplicity).

<div style=\"page-break-after: always\"></div>

Figure 22 EORTC QLQ-C30 GHS/QOL and 5 functional scales based on mean score over time

<!-- image -->

The HR for the time to true deterioration for Pembrolizumab when compared with BV for the EORTC QLQC30 GHS/QOL scores was HR = 0.40; 95% CI: 0.22, 0.74; two-sided p=0.003, not controlled for multiplicity and for the physical functioning scores HR = 0.56; 95% CI: 0.32, 0.97; two-sided p=0.034, not controlled for multiplicity.

<div style=\"page-break-after: always\"></div>

Figure 23 Change from Baseline for EORTC QLQ-C30 Functional Scale/Global Health Status/QoL at Week 24* LS Mean Change and 95% CI

<!-- image -->

## EQ-5D

Results from EQ-5D analyses were consistent with the results of EORTC QLQ-C30 analyses. For EQ-5D utility scores, a difference in LS means between the pembrolizumab arm and the BV arm at Week 24 was observed; the difference was 0.09 points (95% CI: 0.04, 0.14; two-sided p=0.0004, not controlled for multiplicity). For EQ-5D visual analog scores, a difference in LS means between pembrolizumab and the BV arm at Week 24 was observed; the difference was 6.12 points, favouring pembrolizumab (95% CI: 1.91, 10.34; two-sided p=0.0046, not controlled for multiplicity).

## Ancillary analyses

## Subgroup analyses for PFS

PFS for pre-specified subgroups, including participants with and without prior ASCT, participants with primary refractory disease, and participants who are BV-naïve are consistent with the primary analysis:

<div style=\"page-break-after: always\"></div>

Figure 24 Forest Plot of PFS Based on Central Review per IWG 2007 by Subgroup Factors

|                                        | #Events/N   | HR   | I %S6        |
|----------------------------------------|-------------|------|--------------|
| Overall                                | 169/304     | 0.65 | (0.48, 0.88) |
| Prior Auto-SCT                         |             |      |              |
| Yes                                    | 57/112      | 0.72 | 1842.1289    |
| No                                     | 112/192     | 0.61 |              |
| Disease Status After Frontline Therapy |             |      |              |
| PrimaryRefractory                      | 72/123      | 0.52 | (0.33, 0.83) |
| Relapsed <12 M onths                   | 46/84       | 0.82 | (0.45,1.48)  |
| Relapsed >= 12 M onths                 | 51/97       | 0.72 | (0.41, 1.25) |
| Sex                                    |             |      |              |
| Female                                 | 81/130      | 0.49 | (0.31, 0.78) |
| Male                                   | 88/174      | 0.75 | (0.49, 1.14) |
| Age                                    |             |      |              |
| <65 Years                              | 132/255     | 0.59 | (0.42, 0.84) |
| >= 65 Years                            | 37/49       | 0.64 | (0.32, 1.30) |
| Age                                    |             |      |              |
| < 65 years                             | 132/255     | 0.59 | (0.42, 0.84) |
| >=65 to <75 years                      | 26/34       | 0.79 | 0.31,1.98    |
| >= 75 to<85 years                      | 11/15       | 0.25 | (0.05,1.30)  |
| ECOGPerformanceStatus                  |             |      |              |
|                                        | 91/186      | 0.54 | (0.35, 0.83) |
| 01                                     | 77/117      | 0.76 | (0.48, 1.21) |
| GeographicRegion(US)                   |             |      |              |
| Us                                     | 9/24        | 8.88 | (8:48: :98)  |
| Ex-US                                  | 160/280     |      |              |
| Geographic Region (EU)                 |             |      |              |
| EU                                     | 43/95       | 0.93 |              |
| Ex-EU                                  | 126/209     | 0.53 | (826         |
| PriorUse ofBrentuximabVedotin          |             |      |              |
| Yes                                    | 7/15        | 0.34 | (0.04, 3.10) |
| No                                     | 162/289     | 0.67 | (0.49, 0.92) |
| PD-L1Status                            |             |      |              |
| >=1%                                   | 155/275     | 0.66 | (0.48,0.91)  |
| <1%                                    | 1/3         | NR   | (NR,NR)      |

<!-- image -->

## NR = Not Reached

Hazard ratio and 95% CI are based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin lymphoma status after frontline therapy (primary refractory versus relapsed less than 12 months after completion of frontline therapy versus relapse 12 months or more after completion of frontline therapy)

Database Cutoff Date: 16JAN2020

## Post-hoc subgroup analyses stratified by prognostic factors

Post-hoc  exploratory  analyses  for  PFS  and  ORR  according  to  recognised  prognostic  factors  in  cHL  are summarised in Figures and Tables below:

<div style=\"page-break-after: always\"></div>

Figure 25 Forest plot of PFS based on IWG 2007 by subgroup factors

<!-- image -->

R=NotReached

azardratioand95%CIarebasedonCoxregressionmodelwithEfron'smethodoftiehandlingwithtreatment ; a covariate stratified by prior auto-SCT (yes, no)and Hodgkin lymphoma status after frontline therapy rimaryrefractoryversusrelapsed1essthan12monthsaftercompletionoffrontlinetherapyversusrelapse 2monthsormoreaftercompletionoffrontlinetherapy) atabaseCutoffDate:16JAN2020

Figure 26 Forest plot of ORR based on IWG 2007 by subgroup factors

<!-- image -->

CI=confidenceinterval;IWG=IntemationalWorkingGroup;NR=NotReached;ORR=objectiveresponserate; ITT=intentiontotreat.

Based on Miettinen&amp; Nurminen method stratified by prior auto-SCT (yes, no)and Hodgkin lymphoma status afterfrontline therapy(primaryrefractoryversusrelapsedlessthan12months after completionof frontline therapyversusrelapse12monthsormoreaftercompletionoffrontlinetherapy).

DatabaseCutoffDate:16JAN2020

Excludes data afterautologousSCTor allogeneicSCT.

<div style=\"page-break-after: always\"></div>

Table 348 Subject characteristics for select risk factors subgroups

|                                                       | MK-3475 200 mg                                        | MK-3475 200 mg                                        | BrentuximabVedotin           | BrentuximabVedotin           | Total                        | Total                        |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                       | n                                                     | (%)                                                   | n                            | (%)                          | n                            | (%)                          |
| Subjects in population                                | 151                                                   |                                                       | 153                          |                              | 304                          |                              |
| Age Group (Years)                                     |                                                       |                                                       |                              |                              |                              |                              |
| 50                                                    | 109                                                   | (72.2)                                                | 114                          | (74.5)                       | 223                          | (73.4)                       |
| >=50                                                  | 42                                                    | (27.8)                                                | 39                           | (25.5)                       | 81                           | (26.6)                       |
| Bulky Disease                                         |                                                       |                                                       |                              |                              |                              |                              |
| Yes                                                   | 35                                                    | (23.2)                                                | 25                           | (16.3)                       | 60                           | (19.7)                       |
| No                                                    | 116                                                   | (76.8)                                                | 128                          | (83.7)                       | 244                          | (80.3)                       |
| B Symptoms                                            |                                                       |                                                       |                              |                              |                              |                              |
| Yes                                                   | 43                                                    | (28.5)                                                | 36                           | (23.5)                       | 79                           | (26.0)                       |
| No                                                    | 108                                                   | (71.5)                                                | 116                          | (75.8)                       | 224                          | (73.7)                       |
| Missing                                               | 0                                                     | (0.0)                                                 | 1                            | (0.7)                        | 1                            | (0.3)                        |
| Anemia                                                |                                                       |                                                       |                              |                              |                              |                              |
| Yes                                                   | 40                                                    | (26.5)                                                | 25                           | (16.3)                       | 65                           | (21.4)                       |
| No                                                    | 108                                                   | (71.5)                                                | 127                          | (83.0)                       | 235                          | (77.3)                       |
| Missing                                               | 3                                                     | (2.0)                                                 | 1                            | (0.7)                        | 4                            | (1.3)                        |
| Disease Status After Completion of First Line Therapy | Disease Status After Completion of First Line Therapy | Disease Status After Completion of First Line Therapy |                              |                              |                              |                              |
| refractory                                            | 68                                                    | (45.0)                                                | 81                           | (52.9)                       | 149                          | (49.0)                       |
| early relapse                                         | 36                                                    | (23.8)                                                | 30                           | (19.6)                       | 66                           | (21.7)                       |
| late relapse                                          | 46                                                    | (30.5)                                                | 42                           | (27.5)                       | 88                           | (28.9)                       |
| Missing                                               | 1                                                     | (0.7)                                                 | 0                            | (0.0)                        | 1                            | (0.3)                        |
| DatabaseCutoffDate:16JAN2020                          | DatabaseCutoffDate:16JAN2020                          | DatabaseCutoffDate:16JAN2020                          | DatabaseCutoffDate:16JAN2020 | DatabaseCutoffDate:16JAN2020 | DatabaseCutoffDate:16JAN2020 | DatabaseCutoffDate:16JAN2020 |

Source:[P204V01MK3475:adam-adsl]

These subgroup analyses are intended to provide additional context for the primary results and should be interpreted with caution as the study was not powered for a definitive demonstration of efficacy in these subgroups.

## Age group

The &lt;50 years group had better PFS and ORR results than the ≥50 years group (HR: 0.53 vs 0.84, ORR % difference: 16.20 vs 0.10).

## Bulky disease

The PFS and ORR results were better in the group with bulky disease at baseline than the group without bulky disease (HR: 0.26 vs 0.79, ORR % difference: 37.04 vs 4.03).

## B symptoms

The PFS and ORR results were similar between groups with and without B symptoms at baseline (HR: 0.66 vs 0.62, ORR % difference: 9.99 vs 12.83).

## Anaemia

The PFS and ORR results were better in the group with anaemia at baseline than the group without anaemia (HR: 0.47 vs 0.64, ORR % difference: 39.91 vs 4.68). Baseline anaemia was defined as haemoglobin &lt;12 g/dl (Male) or haemoglobin &lt;10.5 g/dl (Female).

## Disease status after completion of first-line therapy

In this analysis, participants with best response of PR to first-line therapy, in addition to CR, were considered as remission, and remission of less than 3 months, in addition to any response less than PR to first-line therapy, was considered as refractory. Based on this categorization, the refractory, early relapse and late relapse groups have 149, 66 and 88 participants, respectively; 1 participant with missing information was excluded. Results were as follows: refractory (PFS HR: 0.57, ORR % difference: 16.06), early relapse (PFS HR: 0.91, ORR % difference: -2.41), and late relapse (PFS HR: 0.61, ORR % difference: 14.99).

<div style=\"page-break-after: always\"></div>

## Efficacy by region (EU vs. Ex-EU subgroup)

Subgroup Analysis of PFS in EU vs. EX-EU subgroup (primary analysis)

The PFS HR for participants enrolled in the EU was 0.93 (95% CI: 0.50, 1.74), compared with 0.53 (95% CI: 0.37, 0.76) in Ex-EU participants.

Table 35 Analysis of PFS Based on Central Review per IWG 2007 (primary analysis) (EU)

| Treatment                                                                                                                                                                                                       | N                                                                                                                                                                                                               | Number of Events (%)                                                                                                                                                                                            | Person- Months                                                                                                                                                                                                  | Event Rate/ 100Person- Months (%)                                                                                                                                                                               | Median PFS t (Months) (95% CI)                                                                                                                                                                                  | PFS Rate at Months 12 in % t (95% CI)                                                                                                                                                                           | PFS Rate at Months 24 in % t (95% CI)                                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MK-3475 200 mg                                                                                                                                                                                                  | 49                                                                                                                                                                                                              | 24 (49.0)                                                                                                                                                                                                       | 577.2                                                                                                                                                                                                           | 4.2                                                                                                                                                                                                             | 16.4 (6.4, NR)                                                                                                                                                                                                  | 54.7 (38.7, 68.2)                                                                                                                                                                                               | 40.9 (24.7, 56.5)                                                                                                                                                                                               |
| BrentuximabVedotin                                                                                                                                                                                              | 46                                                                                                                                                                                                              | 19 (41.3)                                                                                                                                                                                                       | 396.1                                                                                                                                                                                                           | 4.8                                                                                                                                                                                                             | 8.3 (5.6, NR)                                                                                                                                                                                                   | 40.3 (23.0, 57.0)                                                                                                                                                                                               | 40.3 (23.0, 57.0)                                                                                                                                                                                               |
| PairwiseComparison                                                                                                                                                                                              | PairwiseComparison                                                                                                                                                                                              | PairwiseComparison                                                                                                                                                                                              | PairwiseComparison                                                                                                                                                                                              | PairwiseComparison                                                                                                                                                                                              | PairwiseComparison                                                                                                                                                                                              | PairwiseComparison                                                                                                                                                                                              | Hazard Ratio+(95% C1)+                                                                                                                                                                                          |
| Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                       | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                       | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                       | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                       | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                       | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                       | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                       | 0.93 (0.50, 1.74)                                                                                                                                                                                               |
| From product-limit (Kaplan-Meier) method for censored data.  Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin | From product-limit (Kaplan-Meier) method for censored data.  Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin | From product-limit (Kaplan-Meier) method for censored data.  Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin | From product-limit (Kaplan-Meier) method for censored data.  Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin | From product-limit (Kaplan-Meier) method for censored data.  Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin | From product-limit (Kaplan-Meier) method for censored data.  Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin | From product-limit (Kaplan-Meier) method for censored data.  Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin | From product-limit (Kaplan-Meier) method for censored data.  Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin |

Figure 27 K-M estimates of PFS based on central review per IWG 2007 in EU vs ex-EU study sites

<!-- image -->

Database Cutoff Date: 16JAN2020

Database: Cutoff Date: 16JAN2020

Most baseline characteristics in EU versus Ex-EU participants were well-balanced (data not shown). The magnitude and nature of noted differences in baseline characteristics in EU versus Ex-EU participants do not present a clear pattern to account for the higher HR in the EU population: more participants in the EU subgroup had prior use of BV (13.7% vs. 1.0%), fewer participants in the EU subgroup had baseline B symptoms (17.9% vs. 29.7%), and the median number of prior lines of therapy was lower in the EU subgroup (median 2.0 vs. 3.0, in the EU vs. EX-EU, respectively).

Subgroup Analysis of PFS-secondary in EU vs. EX-EU subgroup

The observed HR for PFS-secondary, excluding clinical and imaging data post-SCT, favoured pembrolizumab monotherapy over BV in both EU and Ex-EU subgroups. The HR for PFS secondary was 0.75 (95% CI: 0.41, 1.39) in the EU subgroup and 0.57 (95% CI: 0.40, 0.81) in the Ex-EU subgroup.

<div style=\"page-break-after: always\"></div>

Table 36 Analysis of PFS Based on Central Review per IWG 2007 (secondary analysis) (EU)

| Treatment                                 | N                                         | Number of Events (%)                      | Person- Months                            | EventRate/ 100Person- Months (%)          | MedianPFS ↑ (Months) (95% CI)             | PFSRate at Months 12 in % ↑ (95% CI)   | PFSRate at Months 24 in %↑ (95% CI)   |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|----------------------------------------|---------------------------------------|
| MK-3475200mg                              | 49                                        | 23 (46.9)                                 | 459.4                                     | 5.0                                       | 10.6 (6.4, NR)                            | 49.4 (32.1, 64.6)                      | 32.4 (14.8, 51.4)                     |
| BrentuximabVedotin                        | 46                                        | 23 (50.0)                                 | 336.9                                     | 6.8                                       | 6.6 (5.6, 10.6)                           | 30.6 (15.0,47.8)                       | 13.4 (1.4, 38.9)                      |
| PairwiseComparison                        | PairwiseComparison                        | PairwiseComparison                        | PairwiseComparison                        | PairwiseComparison                        | PairwiseComparison                        | Hazard Ratio+(95% CI)                  | Hazard Ratio+(95% CI)                 |
| Primary MK-3475200mgvs.BrentuximabVedotin | Primary MK-3475200mgvs.BrentuximabVedotin | Primary MK-3475200mgvs.BrentuximabVedotin | Primary MK-3475200mgvs.BrentuximabVedotin | Primary MK-3475200mgvs.BrentuximabVedotin | Primary MK-3475200mgvs.BrentuximabVedotin | 0.75 (0.41, 1.39)                      | 0.75 (0.41, 1.39)                     |

Figure 28 KM Estimates of PFS; Central Review per IWG 2007 (secondary analysis) (EU)

<!-- image -->

## Efficacy in transplant-ineligible patients by line of therapy

With Amendment 2, participants ineligible for auto-SCT were allowed to enrol in the study after failing just 1 prior line of treatment. It was further clarified in protocol Amendment 3 that participants who were eligible for auto SCT were excluded from enrolment. Of the 304 participants in KEYNOTE-204, 192 were ineligible for a transplant at the time of enrolment, and 112 had failed a transplant before enrolling; of the 192 ineligible participants, 55 had failed 1 prior therapy and 137 failed 2 or more prior therapies. Many treating physicians considered primary refractory disease patients as chemorefractory and rather than performing an auto-SCT that is unlikely to be of benefit, opted to enrol these participants into the study with the goal of achieving a better response and minimizing treatment-related toxicity.

In an exploratory post-hoc analysis of the 55 participants, 27 were in the pembrolizumab arm and achieved an ORR of 66.7% (95% CI: 46.0, 83.5) with a CR rate of 14.8% and 28 were in the BV arm and achieved an ORR of 53.6% (95% CI: 33.9, 72.5) with a CR rate of 35.7%. The PFS HR was 0.70 (95% CI: 0.31, 1.59); median PFS was 16.4 months (95% CI: 8.3, NR) and 8.4 months (95% CI: 5.4, NR) and PFS rates at 12 months were 58.9% (95% CI: 36.8, 75.5) and 37.4% (95% CI: 16.1, 58.9) in the pembrolizumab and BV arms, respectively (see Tables and Figure below)

<div style=\"page-break-after: always\"></div>

Table 37 Summary of Best Overall Response Based on Central Review per IWG 2007 (subjects with one prior line of therapy)

Table 38 Analysis of PFS based on central review per IWG 2007

|                                                                                                                                    | MK-3475 200 mg                                                                                                                     | MK-3475 200 mg   | MK-3475 200 mg   | BrentuximabVedotin   | BrentuximabVedotin   | BrentuximabVedotin   |
|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|------------------|------------------|----------------------|----------------------|----------------------|
|                                                                                                                                    | n                                                                                                                                  | (%)              | (95% CIt         | n                    | (%)                  | (95% CI)t            |
| Number of Subjects in Population                                                                                                   | 27                                                                                                                                 |                  |                  | 28                   |                      |                      |
| Complete Response (CR)                                                                                                             | 4                                                                                                                                  | (14.8)           | (4.2, 33.7)      | 10                   | (35.7)               | (18.6, 55.9)         |
| Partial Response (PR)                                                                                                              | 14                                                                                                                                 | (51.9)           | (31.9, 71.3)     | 5                    | (17.9)               | (6.1, 36.9)          |
| Objective Response (CR+PR)                                                                                                         | 18                                                                                                                                 | (66.7)           | (46.0, 83.5)     | 15                   | (53.6)               | (33.9, 72.5)         |
| Stable Disease (SD)                                                                                                                | 6                                                                                                                                  | (22.2)           | (8.6, 42.3)      | 7                    | (25.0)               | (10.7, 44.9)         |
| Progressive Disease (PD)                                                                                                           | 3                                                                                                                                  | (11.1)           | (2.4, 29.2)      | 4                    | (14.3)               | (4.0, 32.7)          |
| Not Evaluable (NE)                                                                                                                 | 0                                                                                                                                  | (0.0)            | (0.0, 12.8)      | 0                    | (0.0)                | (0.0, 12.3)          |
| No Assessment (NA)                                                                                                                 | 0                                                                                                                                  | (0.0)            | (0.0, 12.8)      | 2                    | (7.1)                | (0.9, 23.5)          |
| Basedonbinomial exactconfidenceinterval method. Excludes data after autologous SCT or allogeneic SCT. DatabaseCutoffDate:16JAN2020 | Basedonbinomial exactconfidenceinterval method. Excludes data after autologous SCT or allogeneic SCT. DatabaseCutoffDate:16JAN2020 |                  |                  |                      |                      |                      |

<!-- formula-not-decoded -->

Figure 29 K-M estimates of PFS based on central review per IWG 2007

| Treatment                                                                                                                                                                                                                                                         | N                                                                                                                                                                                                                                                                 | Number of Events (%)                                                                                                                                                                                                                                              | Person- Months                                                                                                                                                                                                                                                    | Event Rate/ 100 Person- Months (%)                                                                                                                                                                                                                                | Median PFS t (Months) (95% CI)                                                                                                                                                                                                                                    | PFS Rate at Months 12 in % t (95% CI)                                                                                                                                                                                                                             | PFS Rate at Months 24 in % t (95% CI)                                                                                                                                                                                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MK-3475 200 mg                                                                                                                                                                                                                                                    | 27                                                                                                                                                                                                                                                                | 13 (48.1)                                                                                                                                                                                                                                                         | 346.7                                                                                                                                                                                                                                                             | 3.7                                                                                                                                                                                                                                                               | 16.4 (8.3, NR)                                                                                                                                                                                                                                                    | 58.9 (36.8, 75.5)                                                                                                                                                                                                                                                 | 24.9 (2.0, 61.2)                                                                                                                                                                                                                                                  |
| BrentuximabVedotin                                                                                                                                                                                                                                                | 28                                                                                                                                                                                                                                                                | 13 (46.4)                                                                                                                                                                                                                                                         | 217.9                                                                                                                                                                                                                                                             | 6.0                                                                                                                                                                                                                                                               | 8.4 (5.4, NR)                                                                                                                                                                                                                                                     | 37.4 (16.1, 58.9)                                                                                                                                                                                                                                                 | 31.2 (11.8, 53.0)                                                                                                                                                                                                                                                 |
| Pairwise Comparison                                                                                                                                                                                                                                               | Pairwise Comparison                                                                                                                                                                                                                                               | Pairwise Comparison                                                                                                                                                                                                                                               | Pairwise Comparison                                                                                                                                                                                                                                               | Pairwise Comparison                                                                                                                                                                                                                                               | Pairwise Comparison                                                                                                                                                                                                                                               | Pairwise Comparison                                                                                                                                                                                                                                               | Hazard Ratio+(95% CI)+                                                                                                                                                                                                                                            |
| Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                         | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                         | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                         | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                         | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                         | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                         | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                         | 0.70 (0.31, 1.59)                                                                                                                                                                                                                                                 |
| From product-limit (Kaplan-Meier) method for censored data. + Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin  or more after completion of frontline therapy). | From product-limit (Kaplan-Meier) method for censored data. + Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin  or more after completion of frontline therapy). | From product-limit (Kaplan-Meier) method for censored data. + Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin  or more after completion of frontline therapy). | From product-limit (Kaplan-Meier) method for censored data. + Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin  or more after completion of frontline therapy). | From product-limit (Kaplan-Meier) method for censored data. + Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin  or more after completion of frontline therapy). | From product-limit (Kaplan-Meier) method for censored data. + Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin  or more after completion of frontline therapy). | From product-limit (Kaplan-Meier) method for censored data. + Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin  or more after completion of frontline therapy). | From product-limit (Kaplan-Meier) method for censored data. + Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin  or more after completion of frontline therapy). |

<!-- formula-not-decoded -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

Efficacy results in subjects with 2 or more prior lines of therapy in study KN-204 were summarised in Tables and Figure below.

Table 39 Summary of best Overall Response based on central review per IWG 2007

(Subjects With Two or More Prior Lines of Therapy) (ITT Population)

|                                  | MK-3475 200 mg   | MK-3475 200 mg   | MK-3475 200 mg   | BrentuximabVedotin   | BrentuximabVedotin   | BrentuximabVedotin   |
|----------------------------------|------------------|------------------|------------------|----------------------|----------------------|----------------------|
|                                  | 1n               | (%)              | (95% CI)t        |                      | (%)                  | (95% CI)t            |
| Number of Subjects in Population | 124              |                  |                  | 125                  |                      |                      |
| Complete Response (CR)           | 33               | (26.6)           | (19.1, 35.3)     | 27                   | (21.6)               | (14.7, 29.8)         |
| Partial Response (PR)            | 48               | (38.7)           | (30.1, 47.9)     | 41                   | (32.8)               | (24.7, 41.8)         |
| Objective Response (CR+PR)       | 81               | (65.3)           | (56.3, 73.6)     | 68                   | (54.4)               | (45.3,63.3)          |
| Stable Disease (SD)              | 15               | (12.1)           | (6.9, 19.2)      | 29                   | (23.2)               | (16.1, 31.6)         |
| Progressive Disease (PD)         | 23               | (18.5)           | (12.1, 26.5)     | 24                   | (19.2)               | (12.7,27.2)          |
| Not Evaluable (NE)               | 1                | (0.8)            | (0.0, 4.4)       | 1                    | (0.8)                | (0.0, 4.4)           |
| No Assessment (NA)               | 4                | (3.2)            | (0.9, 8.1)       | 3                    | (2.4)                | (0.5, 6.9)           |

Table 40 Analysis of PFS based on central review per IWG 2007

## (Primary Analysis)

(Subjects With Two or More Prior Lines of Therapy)

(ITT Population)

| Treatment                                                     | N                                                             | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months (%)   | Median PFS t (Months) (95% CI)   | PFS Rate at Months 12 in % t (95% CI)   | PFS Rate at Months 24 in % t (95% CI)   |
|---------------------------------------------------------------|---------------------------------------------------------------|------------------------|------------------|--------------------------------------|----------------------------------|-----------------------------------------|-----------------------------------------|
| MK-3475 200 mg                                                | 124                                                           | 68 (54.8)              | 1514.5           | 4.5                                  | 12.6 (8.7, 19.4)                 | 52.8 (43.0, 61.7)                       | 34.9 (25.2, 44.7)                       |
| 3rentuximabVedotin                                            | 125                                                           | 75 (60.0)              | 1051.4           | 7.1                                  | 8.2 (5.6, 8.8)                   | 35.3 (25.9, 44.8)                       | 24.4 (15.6, 34.4)                       |
|                                                               |                                                               |                        |                  |                                      |                                  |                                         | Hazard Ratio+ (95% CI)+                 |
| ?airwise Comparison 'rimary MK-3475200mgvs.BrentuximabVedotin | ?airwise Comparison 'rimary MK-3475200mgvs.BrentuximabVedotin |                        |                  |                                      |                                  |                                         | 0.66 (0.47, 0.92)                       |

From product-limit (Kaplan-Meier) method for censored data.

Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin or more after completion of frontline therapy).

NR=Not Reached

DatabaseCutoffDate:16JAN2020

<div style=\"page-break-after: always\"></div>

Figure 30 K-M estimates of PFS based on central review per IWG 2007, primary analysis, subjects with 2 or more prior lines of therapy

<!-- image -->

Of the 249 subjects with 2 or more prior lines of therapy, 137 were considered ineligible for auto-SCT at the time of enrolment [see Table below].

Table 41 Summary of reasons for transplant inegibility at baseline

(Subjects With Two or More Prior Lines of Therapy) (ITT Population)

|                                                                                                   | MK-3475 200 mg (N=124)   | BrentuximabVedotin (N=125)   | Total (N=249)   |
|---------------------------------------------------------------------------------------------------|--------------------------|------------------------------|-----------------|
| Chemorefractory anddidnotreceivepriorSCT                                                          | 56 (45.2)                | 56 (44.8)                    | 112 (45.0)      |
| NotChemorefractory*anddidnotreceivepriorSCT                                                       | 12 (9.7)                 | 13 (10.4)                    | 25 (10.0)       |
| *Reasons for transplant ineligibility include age and comorbidities. DatabaseCutoffDate:16JAN2020 |                          |                              |                 |

Source:[P204V01MK3475:adam-ads1]

In an exploratory post-hoc analysis for the 137 transplant-ineligible participants with 2 or more prior lines of therapy, 68 were in the pembrolizumab arm and achieved an ORR of 61.8% (95% CI: 49.2, 73.3) with a CR rate of 26.5% and 69 were in the BV arm and achieved an ORR of 46.4% (95% CI: 34.3, 58.8) with a CR rate of 18.8% [see Table below].

<div style=\"page-break-after: always\"></div>

Table 42 Summary of best overall response based on central review per IWG 2007

(Subjects with Two or More Prior Lines of Therapy and Not Received Prior Stem Cell Transplant) (ITT Population)

|                               | MK-3475 200 mg   | MK-3475 200 mg   | MK-3475 200 mg   | BrentuximabVedotin   | BrentuximabVedotin   | BrentuximabVedotin   |
|-------------------------------|------------------|------------------|------------------|----------------------|----------------------|----------------------|
|                               | n                | (%)              | (95% CI)t        | 1n                   | (%)                  | (95% CI)t            |
| Number ofSubjectsinPopulation | 68               |                  |                  | 69                   |                      |                      |
| Complete Response (CR)        | 18               | (26.5)           | (16.5, 38.6)     | 13                   | (18.8)               | (10.4, 30.1)         |
| Partial Response (PR)         | 24               | (35.3)           | (24.1, 47.8)     | 19                   | (27.5)               | (17.5, 39.6)         |
| Objective Response (CR+PR)    | 42               | (61.8)           | (49.2, 73.3)     | 32                   | (46.4)               | (34.3, 58.8)         |
| Stable Disease (SD)           | 8                | (11.8)           | (5.2,21.9)       | 17                   | (24.6)               | (15.1, 36.5)         |
| Progressive Disease (PD)      | 15               | (22.1)           | (12.9, 33.8)     | 18                   | (26.1)               | (16.3, 38.1)         |
| Not Evaluable (NE)            | 1                | (1.5)            | (0.0, 7.9)       | 1                    | (1.4)                | (0.0, 7.8)           |
| No Assessment (NA)            | 2                | (2.9)            | (0.4, 10.2)      | 1                    | (1.4)                | (0.0, 7.8)           |

The PFS HR was 0.62; median PFS was 11.1 months (95% CI: 7.0, 19.2) and 5.7 months (95% CI: 5.3, 8.2) in the pembrolizumab and BV arms, respectively [see Table and Figure below].

Table 43 Analysis of PFS based on central review per IWG 2007

(Primary Analysis)

(Subjects with Two or More Prior Lines of Therapy and Not Received Prior Stem Cell Transplant) (ITT Population)

| Treatment                                                                                                                                                                                                                                                                                                                                                            | N                                                                                                                                                                                                                                                                                                                                                                    | Number of Events (%)                                                                                                                                                                                                                                                                                                                                                 | Person- Months                                                                                                                                                                                                                                                                                                                                                       | Event Rate/ 100 Person- Months (%)                                                                                                                                                                                                                                                                                                                                   | Median PFS t (Months) (95% CI)                                                                                                                                                                                                                                                                                                                                       | PFS Rate at Months 12 in % t (95% CI)                                                                                                                                                                                                                                                                                                                                | PFS Rate at Months 24 in % t (95% CI)                                                                                                                                                                                                                                                                                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MK-3475 200 mg                                                                                                                                                                                                                                                                                                                                                       | 68                                                                                                                                                                                                                                                                                                                                                                   | 38 (55.9)                                                                                                                                                                                                                                                                                                                                                            | 759.9                                                                                                                                                                                                                                                                                                                                                                | 5.0                                                                                                                                                                                                                                                                                                                                                                  | 11.1 (7.0, 19.2)                                                                                                                                                                                                                                                                                                                                                     | 49.8 (36.3, 61.9)                                                                                                                                                                                                                                                                                                                                                    | 32.4 (20.0, 45.3)                                                                                                                                                                                                                                                                                                                                                    |
| BrentuximabVedotin                                                                                                                                                                                                                                                                                                                                                   | 69                                                                                                                                                                                                                                                                                                                                                                   | 48 (69.6)                                                                                                                                                                                                                                                                                                                                                            | 568.4                                                                                                                                                                                                                                                                                                                                                                | 8.4                                                                                                                                                                                                                                                                                                                                                                  | 5.7 (5.3, 8.2)                                                                                                                                                                                                                                                                                                                                                       | 28.6 (17.6, 40.6)                                                                                                                                                                                                                                                                                                                                                    | 20.6 (11.0, 32.2)                                                                                                                                                                                                                                                                                                                                                    |
| PairwiseComparison                                                                                                                                                                                                                                                                                                                                                   | PairwiseComparison                                                                                                                                                                                                                                                                                                                                                   | PairwiseComparison                                                                                                                                                                                                                                                                                                                                                   | PairwiseComparison                                                                                                                                                                                                                                                                                                                                                   | PairwiseComparison                                                                                                                                                                                                                                                                                                                                                   | PairwiseComparison                                                                                                                                                                                                                                                                                                                                                   | PairwiseComparison                                                                                                                                                                                                                                                                                                                                                   | HazardRatio+(95%CI)+                                                                                                                                                                                                                                                                                                                                                 |
| Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                                                                                                                            | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                                                                                                                            | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                                                                                                                            | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                                                                                                                            | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                                                                                                                            | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                                                                                                                            | Primary MK-3475200mgvs.BrentuximabVedotin                                                                                                                                                                                                                                                                                                                            | 0.62 (0.40, 0.95)                                                                                                                                                                                                                                                                                                                                                    |
| Fromproduct-limit(Kaplan-Meier)methodforcensoreddata.                                                                                                                                                                                                                                                                                                                | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata.                                                                                                                                                                                                                                                                                                                | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata.                                                                                                                                                                                                                                                                                                                | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata.                                                                                                                                                                                                                                                                                                                | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata.                                                                                                                                                                                                                                                                                                                | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata.                                                                                                                                                                                                                                                                                                                | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata.                                                                                                                                                                                                                                                                                                                | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata.                                                                                                                                                                                                                                                                                                                |
| + Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin lymphoma status after frontline therapy (primary refractory versus relapsed less than 12 months after completion of frontline therapy versus relapse 12 months  or more after completion of frontline therapy). | + Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin lymphoma status after frontline therapy (primary refractory versus relapsed less than 12 months after completion of frontline therapy versus relapse 12 months  or more after completion of frontline therapy). | + Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin lymphoma status after frontline therapy (primary refractory versus relapsed less than 12 months after completion of frontline therapy versus relapse 12 months  or more after completion of frontline therapy). | + Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin lymphoma status after frontline therapy (primary refractory versus relapsed less than 12 months after completion of frontline therapy versus relapse 12 months  or more after completion of frontline therapy). | + Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin lymphoma status after frontline therapy (primary refractory versus relapsed less than 12 months after completion of frontline therapy versus relapse 12 months  or more after completion of frontline therapy). | + Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin lymphoma status after frontline therapy (primary refractory versus relapsed less than 12 months after completion of frontline therapy versus relapse 12 months  or more after completion of frontline therapy). | + Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin lymphoma status after frontline therapy (primary refractory versus relapsed less than 12 months after completion of frontline therapy versus relapse 12 months  or more after completion of frontline therapy). | + Based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by prior auto-SCT (yes, no) and Hodgkin lymphoma status after frontline therapy (primary refractory versus relapsed less than 12 months after completion of frontline therapy versus relapse 12 months  or more after completion of frontline therapy). |
| NR=Not Reached                                                                                                                                                                                                                                                                                                                                                       | NR=Not Reached                                                                                                                                                                                                                                                                                                                                                       | NR=Not Reached                                                                                                                                                                                                                                                                                                                                                       | NR=Not Reached                                                                                                                                                                                                                                                                                                                                                       | NR=Not Reached                                                                                                                                                                                                                                                                                                                                                       | NR=Not Reached                                                                                                                                                                                                                                                                                                                                                       | NR=Not Reached                                                                                                                                                                                                                                                                                                                                                       | NR=Not Reached                                                                                                                                                                                                                                                                                                                                                       |
| DatabaseCutoffDate:16JAN2020                                                                                                                                                                                                                                                                                                                                         | DatabaseCutoffDate:16JAN2020                                                                                                                                                                                                                                                                                                                                         | DatabaseCutoffDate:16JAN2020                                                                                                                                                                                                                                                                                                                                         | DatabaseCutoffDate:16JAN2020                                                                                                                                                                                                                                                                                                                                         | DatabaseCutoffDate:16JAN2020                                                                                                                                                                                                                                                                                                                                         | DatabaseCutoffDate:16JAN2020                                                                                                                                                                                                                                                                                                                                         | DatabaseCutoffDate:16JAN2020                                                                                                                                                                                                                                                                                                                                         | DatabaseCutoffDate:16JAN2020                                                                                                                                                                                                                                                                                                                                         |

Source:[P204V01MK3475:adam-adsl;adtte]

<div style=\"page-break-after: always\"></div>

Figure 31 K-M estimates of PFS based on central review per IWG 2007

(Subjects with Two or More Prior Lines of Therapy and Not Received Prior Stem Cell Transplant) (ITT Population)

<!-- image -->

DatabaseCutoffDate:16JAN2020

While these are unplanned analyses with limited numbers of participants in each subgroup of prior therapy, the PFS and response rates in participants who received 1 or 2 or more prior lines of therapy and in subjects who were ineligible for auto-SCT were consistent with those observed in the overall study results.

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table: Summary of Efficacy for trial KEYNOTE-204

| Title: A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin (BV) in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (r/r cHL)   | Title: A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin (BV) in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (r/r cHL)                                                                                                                                                                                                            | Title: A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin (BV) in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (r/r cHL)                                                                                                                                                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                 | P204V01MK3475                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                           |
| Design                                                                                                                                                                                           | KEYNOTE-204 is an ongoing, randomized, open-label, Phase 3 study of pembrolizumab vs. BV. To be eligible, participants were to have relapsed or refractory cHL and received at least 1 prior multi-agent chemotherapy regimen. Prior treatment with BV or a BV-containing regimen was allowed, provided the participants had responded (partial or complete response) to the BV or BV-containing regimen. | KEYNOTE-204 is an ongoing, randomized, open-label, Phase 3 study of pembrolizumab vs. BV. To be eligible, participants were to have relapsed or refractory cHL and received at least 1 prior multi-agent chemotherapy regimen. Prior treatment with BV or a BV-containing regimen was allowed, provided the participants had responded (partial or complete response) to the BV or BV-containing regimen. |
|                                                                                                                                                                                                  | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                   | Up to three years 29-JUN-2016 (first patient first visit) 16-JAN-2020 (last patient, last visit)                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                                                 | Duration of Run-in phase: Duration of Extension phase:                                | Duration of Run-in phase: Duration of Extension phase:                                | NA NA                                                                                                                                                                                                                                                                                      | NA NA                                                                                                                                                                                                                                                                                      |                                                                                       |
|-------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Hypothesis                                      | Superiority                                                                           | Superiority                                                                           | Superiority                                                                                                                                                                                                                                                                                | Superiority                                                                                                                                                                                                                                                                                | Superiority                                                                           |
| Treatments groups                               | Pembrolizumab                                                                         | Pembrolizumab                                                                         | N=151, pembrolizumab 200 IV mg Q3W up to 35 cycles                                                                                                                                                                                                                                         | N=151, pembrolizumab 200 IV mg Q3W up to 35 cycles                                                                                                                                                                                                                                         |                                                                                       |
| Treatments groups                               | BV                                                                                    | BV                                                                                    | N=153, brentuximab vedotin 1.8 mg/kg (max                                                                                                                                                                                                                                                  | N=153, brentuximab vedotin 1.8 mg/kg (max                                                                                                                                                                                                                                                  |                                                                                       |
| Endpoints and definitions                       | Dual Primary endpoint                                                                 | PFS primary                                                                           | 180 mg) IV Q3W up to 35 cycles PFS as assessed by BICR defined as the time from randomization to the first documentation of lymphoma progression or death as a result of any cause [Cheson, 2007] and including clinical and imaging data following ASCT or                                | 180 mg) IV Q3W up to 35 cycles PFS as assessed by BICR defined as the time from randomization to the first documentation of lymphoma progression or death as a result of any cause [Cheson, 2007] and including clinical and imaging data following ASCT or                                |                                                                                       |
| Endpoints and definitions                       | Dual Primary endpoint                                                                 | OS                                                                                    | allogeneic HSCT OS is defined as the time from randomization to death due to any cause.                                                                                                                                                                                                    | allogeneic HSCT OS is defined as the time from randomization to death due to any cause.                                                                                                                                                                                                    |                                                                                       |
| Endpoints and definitions                       | Secondary endpoint                                                                    | ORR                                                                                   | ORR is defined as the proportion of the participants in the analysis population who have a complete response (CR) or partial response (PR) according to the IWG criteria.                                                                                                                  | ORR is defined as the proportion of the participants in the analysis population who have a complete response (CR) or partial response (PR) according to the IWG criteria.                                                                                                                  |                                                                                       |
| Endpoints and definitions                       | Secondary endpoint                                                                    | CRR                                                                                   | CRR is defined as the proportion of subjects in the analysis population who achieved a complete remission according to the IWG criteria.                                                                                                                                                   | CRR is defined as the proportion of subjects in the analysis population who achieved a complete remission according to the IWG criteria.                                                                                                                                                   |                                                                                       |
|                                                 | Secondary endpoint                                                                    | PFS secondary                                                                         | PFS as assessed by BICR defined as the time from randomization to the first documentation of lymphoma progression or death as a result of any cause [Cheson, 2007] not including clinical and imaging data following ASCT or allogeneic HSCT DOR is defined as time from first response to | PFS as assessed by BICR defined as the time from randomization to the first documentation of lymphoma progression or death as a result of any cause [Cheson, 2007] not including clinical and imaging data following ASCT or allogeneic HSCT DOR is defined as time from first response to |                                                                                       |
|                                                 | Exploratory endpoint                                                                  | DoR                                                                                   | disease progression or death due to any cause, whichever occurs first, in subjects who achieve a PR or better according to the IWG criteria.                                                                                                                                               | disease progression or death due to any cause, whichever occurs first, in subjects who achieve a PR or better according to the IWG criteria.                                                                                                                                               |                                                                                       |
|                                                 | Exploratory endpoint                                                                  | PFS2                                                                                  | PFS2 is defined as the time from randomization to subsequent disease progression after initiation of new anti-cancer therapy, or death from any cause, whichever occurs first, by investigator assessment                                                                                  | PFS2 is defined as the time from randomization to subsequent disease progression after initiation of new anti-cancer therapy, or death from any cause, whichever occurs first, by investigator assessment                                                                                  |                                                                                       |
| Database lock                                   | 16-JAN-2020 (median survival follow-up about 25 months)                               | 16-JAN-2020 (median survival follow-up about 25 months)                               | 16-JAN-2020 (median survival follow-up about 25 months)                                                                                                                                                                                                                                    | 16-JAN-2020 (median survival follow-up about 25 months)                                                                                                                                                                                                                                    | 16-JAN-2020 (median survival follow-up about 25 months)                               |
| Results and Analysis                            | Results and Analysis                                                                  | Results and Analysis                                                                  | Results and Analysis                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                       | Results and Analysis                                                                  |
| Analysis description                            | Primary Analysis time point: IA2 , primary PFS analysis, OS analysis only descriptive | Primary Analysis time point: IA2 , primary PFS analysis, OS analysis only descriptive | Primary Analysis time point: IA2 , primary PFS analysis, OS analysis only descriptive                                                                                                                                                                                                      | Primary Analysis time point: IA2 , primary PFS analysis, OS analysis only descriptive                                                                                                                                                                                                      | Primary Analysis time point: IA2 , primary PFS analysis, OS analysis only descriptive |
| Analysis population and time point description  | Intent to treat                                                                       | Intent to treat                                                                       | Intent to treat                                                                                                                                                                                                                                                                            | Intent to treat                                                                                                                                                                                                                                                                            | Intent to treat                                                                       |
| Descriptive statistics and estimate variability | Treatment group                                                                       | Treatment group                                                                       | Pembrolizumab                                                                                                                                                                                                                                                                              | BV                                                                                                                                                                                                                                                                                         |                                                                                       |
|                                                 | Number of subjects                                                                    | Number of subjects                                                                    | N=151                                                                                                                                                                                                                                                                                      | N=153                                                                                                                                                                                                                                                                                      |                                                                                       |
|                                                 | mPFS Primary                                                                          | mPFS Primary                                                                          | 13.2                                                                                                                                                                                                                                                                                       | 8.3                                                                                                                                                                                                                                                                                        |                                                                                       |
|                                                 | (95%CI)                                                                               | (95%CI)                                                                               | (10.9, 19.4)                                                                                                                                                                                                                                                                               | (5.7, 8.8)                                                                                                                                                                                                                                                                                 |                                                                                       |
|                                                 | ORR %                                                                                 | ORR %                                                                                 | 65.6%                                                                                                                                                                                                                                                                                      | 54.2%                                                                                                                                                                                                                                                                                      |                                                                                       |
|                                                 | (95%CI)                                                                               | (95%CI)                                                                               | (57.4, 73.1)                                                                                                                                                                                                                                                                               | (46.0, 62.3)                                                                                                                                                                                                                                                                               |                                                                                       |
|                                                 | CRR %                                                                                 | CRR %                                                                                 | 24.5%                                                                                                                                                                                                                                                                                      | 24.2%                                                                                                                                                                                                                                                                                      |                                                                                       |
|                                                 | 95%CI                                                                                 | 95%CI                                                                                 | (17.9, 32.2)                                                                                                                                                                                                                                                                               | (17.6, 31.8)                                                                                                                                                                                                                                                                               |                                                                                       |
|                                                 | mPFS Secondary                                                                        | mPFS Secondary                                                                        | 12.6                                                                                                                                                                                                                                                                                       | 8.2                                                                                                                                                                                                                                                                                        |                                                                                       |

<div style=\"page-break-after: always\"></div>

|                     | (95%CI)                                                                        | (8.7, 19.2)                                                                                 | (5.6, 8.6)                                                        |
|---------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
|                     | DoR (months)                                                                   | 20.7                                                                                        | 13.8                                                              |
|                     | (range)                                                                        | (0.0+, 33.2+)                                                                               | (0.0+, 33.9+)                                                     |
|                     | PFS2 (months)                                                                  | NR                                                                                          | NR                                                                |
|                     | (95%CI)                                                                        | (33.5, NR)                                                                                  | (20.9, NR)                                                        |
| Effect estimate per |                                                                                | Comparison groups                                                                           | Pembrolizumab vs. BV                                              |
|                     | Dual Primary endpoint PFS primary                                              |                                                                                             |                                                                   |
|                     |                                                                                | HR 95%CI                                                                                    | 0.65 0.48, 0.88                                                   |
|                     | Secondary endpoint ORR Secondary endpoint ORR Secondary endpoint PFS secondary | Comparison groups Difference in Percentage 95%CI P-value Comparison groups HR 95%CI P-value | Pembrolizumab vs. BV 11.3 0.2, 22.1 0.022534 Pembrolizumab vs. BV |
|                     | Secondary endpoint PFS secondary Secondary                                     | Comparison groups                                                                           | Pembrolizumab vs. BV 0.58 0.38, 0.87                              |
|                     |                                                                                |                                                                                             | 0.62 0.46, 0.85 0.00110                                           |
|                     | PFS2                                                                           | HR 95%CI P-value                                                                            | 0.00374                                                           |
| Analysis            |                                                                                |                                                                                             |                                                                   |
|                     | endpoint                                                                       |                                                                                             |                                                                   |
|                     | description                                                                    |                                                                                             |                                                                   |

## Analysis performed across trials (pooled analyses and meta-analysis)

## Efficacy analyses by cHL histology

Efficacy analyses by disease subtype at baseline are provided in Tables below in the HL population of studies KEYNOTE-204 (pembrolizumab arm) and KEYNOTE-087, both individually and pooled. Data on HL disease subtype were not collected in KEYNOTE-051 and therefore KEYNOTE-051 is not included in the integrated analysis.

<div style=\"page-break-after: always\"></div>

Table 45

KEYNOTE-204 Integrated Analysis of PFS Based on BICR per IWG 2007 by Disease Subtype at Baseline

|        | Mixed Cellularity   | Mixed Cellularity             | Nodular Sclerosis   | Nodular Sclerosis            | Lymphocyte Depleted   | Lymphocyte Depleted           | Lymphocyte Rich   | Lymphocyte Rich               |
|--------|---------------------|-------------------------------|---------------------|------------------------------|-----------------------|-------------------------------|-------------------|-------------------------------|
| Study  | N                   | PFS Mediant (months) (95% CI) | N                   | PFS Median (months) (95% CI) | N                     | PFS Mediant (months) (95% CI) | N                 | PFS Mediant (months) (95% CI) |
| KN-204 | 23                  | 8.1 (5.4, 13.2)               | 119                 | 12.7 (10.6, 22.6)            | 3                     | 16.4*                         | 1                 | 16.4*                         |
| KN-087 | 24                  | 10.9 (3.1, 22.1)              | 169                 | 13.7 (11.2, 19.4)            | 5                     | 8.4 (5.7, 11.1)               | 8                 | 13.8 (2.5, NR)                |
| Total  | 47                  | 8.3 (5.5, 13.2)               | 288                 | 13.7 (11.3, 19.3)            | 8                     | 11.1 (5.7, 16.4)              | 9                 | 13.8 (2.5, NR)                |

BICR=blinded independent central review; CI=confidence interval; IWG=intermational working group; KN=KEYNOTE; N=number of subjects; NR=Not Reached; PFS=progression-free survival

From product-limit (Kaplan-Meier) method for censored data.

Based onPFS secondary analysis of KN-204 and PFS primary analysis ofKN-087.

*CIs for subgroups where N&lt;5 were not calculated.

N: ITT population in KN-204 (pembrolizumab arm) and ASaT population in KN-087 with non-missing histology data.

Database CutoffDates:16JAN2020 (KN-204),21MAR2019 (KN-087))

KEYNOTE-204 Integrated Analysis of ORR Based on BICR per IWG 2007 by Disease Subtype at Baseline

| Study   | Mixed Cellularity   | Mixed Cellularity   | Nodular Sclerosis   | Nodular Sclerosis   | Lymphocyte Depleted   | Lymphocyte Depleted   | Lymphocyte Rich   | Lymphocyte Rich   |
|---------|---------------------|---------------------|---------------------|---------------------|-----------------------|-----------------------|-------------------|-------------------|
|         | N                   | ORR (%) (95% CI)t   | N                   | ORR (%) (95% CI)t   | N                     | ORR (%) (95% CI)t     | N                 | ORR (%) (95% CI)t |
| KN-204  | 23                  | 56.5 (34.5, 76.8)   | 119                 | 67.2 (58.0, 75.6)   | 3                     | 100.0*                | 1                 | 100.0*            |
| KN-087  | 24                  | 62.5 (40.6, 81.2)   | 169                 | 71.0 (63.5, 77.7)   | 5                     | 80.0 (28.4, 99.5)     | 8                 | 75.0 (34.9, 96.8) |
| Total   | 47                  | 59.6 (44.3, 73.6)   | 288                 | 69.4 (63.8, 74.7)   | 8                     | 87.5 (47.3, 99.7)     | 9                 | 77.8 (40.0, 97.2) |

BICR=blinded independent central review; CI=confidence interval; IWG=intermational working group; KN=KEYNOTE; N=number of subjects; NR=Not Reached; ORR=objective response rate.

fBasedonbinomialexactconfidenceintervalmethod.

*CIs for subgroups where N&lt;5 were not calculated

N: ITT population in KN-204 (pembrolizumab arm) and ASaT population in KN-087 with non-missing histology data.

Database Cutoff Dates: 16JAN2020 (KN-204), 21MAR2019 (KN-087)

Four participants in KEYNOTE-087 and 5 in KEYNOTE-204 are missing disease subtype and not included in the analyses. Participants from the 2 studies were pooled without adjustments. Since a randomized study (KEYNOTE-204) is pooled with a single arm study (KEYNOTE-087), there are limits to the interpretability of time to event endpoints given potential differences in the patient populations.

## Efficacy by EU vs. Ex-EU participants

Efficacy analyses of PFS and ORR are provided in Tables below in the cHL population pooled across studies KEYNOTE-204 (pembrolizumab arm), KEYNOTE-087 and KEYNOTE-051 by region (EU vs ex-EU).

The analysis common to all 3 studies was used in the integrated analysis, ie, 'PFS secondary analysis' in KEYNOTE-204, which censors at last disease assessment before SCT or new anti-cancer therapy in the absence of PD, and considers PD or death after 2 or more missed assessments as an event. This was the primary PFS analysis in KEYNOTE-087 and KEYNOTE-051 and selected since both studies did not collect scans beyond SCT. Assessment by BICR per IWG 2007 was used for all 3 studies. The trend is generally

<div style=\"page-break-after: always\"></div>

consistent across all 3 studies and in the pooled population and although the PFS median is lower in EU, the 95% CI is wide and overlaps that of the overall population and the medians observed in KEYNOTE-051 are based on small numbers compared to the other 2 studies. In the analyses, participants were pooled without adjustment for the individual study. Since a randomized study (KEYNOTE-204) is pooled with two single-arm studies (KEYNOTE-087 and KEYNOTE-051), there are limits to the interpretability of time-toevent endpoints given potential differences in the participant populations.

Table 46

## KEYNOTE-204, KEYNOTE-087, and KEYNOTE-051 Integrated Analysis of PFS Based on BICR per IWG 2007 by Region

|        | All   | All                           | EU   | EU                            | Ex-EU   | Ex-EU                         |
|--------|-------|-------------------------------|------|-------------------------------|---------|-------------------------------|
| Study  | N     | PFS Median? (months) (95% CI) | N    | PFS Mediant (months) (95% CI) | N       | PFS Median? (months) (95% CI) |
| KN-204 | 151   | 12.6 (8.7, 19.2)              | 49   | 10.6 (6.4, NR)                | 102     | 12.6 (8.3, 19.4)              |
| KN-087 | 210   | 13.6 (11.1, 16.7)             | 108  | 11.3 (8.2, 16.3)              | 102     | 15.6 (11.1, 22.1)             |
| KN-051 | 22    | 8.3 (4.0, 19.2)               | 7    | 4.0 (1.8, 19.2)               | 15      | 13.9 (4.4, 30.5)              |
| Total  | 383   | 13.3 (11.1, 15.6)             | 164  | 11.3 (8.3, 16.3)              | 219     | 13.8 (11.1, 19.3)             |

Based on PFS secondary analysis of KN-204, and PFS primary analysis of KN-087 and KN-051. The \"A1l\" column c0rresponds to[Ref. 5.3.5.1:P204V01MK3475: Table 11-3]for KN-204,[Ref. 5.3.5.2: P087V02MK3475: Table 11-5] for KN-087, and [Table 51] for KN-051.

N: ITT population in KN-204 (pembrolizumab arm) and ASaT population in KN-087, KN-051(cHL) Database Cutoff Dates: 16JAN2020 (KN-204), 21MAR2019 (KN-087), 10JAN2020 (KN-051)

Table 47

## KEYNOTE-204, KEYNOTE-087, and KEYNOTE-051 s

|        | A1l   | A1l               | EU   | EU                | Ex-EU   | Ex-EU             |
|--------|-------|-------------------|------|-------------------|---------|-------------------|
| Study  | N     | ORR (%) (95% CI)t | N    | ORR (%) (95% CI)t | N       | ORR (%) (95% CI)t |
| KN-204 | 151   | 65.6 (57.4, 73.1) | 49   | 59.2 (44.2, 73.0) | 102     | 68.6 (58.7, 77.5) |
| KN-087 | 210   | 71.0 (64.3, 77.0) | 108  | 67.6 (57.9, 76.3) | 102     | 74.5 (64.9, 82.6) |
| KN-051 | 22    | 54.5 (32.2, 75.6) | 7    | 42.9 (9.9, 81.6)  | 15      | 60.0 (32.3, 83.7) |
| Total  | 383   | 67.9 (63.0, 72.5) | 164  | 64.0 (56.2, 71.4) | 219     | 70.8 (64.3, 76.7) |

N: ITT population in KN-204 (pembrolizumab arm) and ASaT population in KN-087, KN-051(cHL).

\"A11\" column c0rresponds to [Ref. 5.3.5.1: P204V01MK3475: Table 11-5] for KN-204, [Ref. 5.3.5.2: P087V02MK3475: Table 11-1] for KN-087, and [Table 45] for KN-051.

Database Cutoff Dates: 16JAN2020 (KN-204), 21MAR2019 (KN-087), 10JAN2020 (KN-051)

For KEYNOTE-204, PFS Sensitivity Analysis 1 is provided by region in Tables below. This analysis considers PD or death after 2 or more missed assessments as an event and is otherwise the same as the primary analysis. The KM plots for these 2 analyses appear below. Results are generally consistent with the primary analysis by region in KEYNOTE-204.

<div style=\"page-break-after: always\"></div>

## KEYNOTE-204 Analysis of Progression-Free Survival Based on Central Review per IWG 2007 (Sensitivity Analysis 1) (EU) (ITT Population)

| Treatment                                 | N                                         | Number of Events (%)                      | Person- Months                            | Event Rate/ 100 Person- Months (%)        | Median PFS t (Months) (95% CI)            | PFS Rate at Months 12 in % t (95% CI)   | PFS Rate at Months 24 in % t (95% CI)   |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-----------------------------------------|-----------------------------------------|
| MK-3475 200 mg                            | 49                                        | 24 (49.0)                                 | 577.2                                     | 4.2                                       | 16.4 (6.4, NR)                            | 54.7 (38.7, 68.2)                       | 40.9 (24.7, 56.5)                       |
| BrentuximabVedotin                        | 46                                        | 23 (50.0)                                 | 440.6                                     | 5.2                                       | 8.8 (5.7, 22.2)                           | 40.7 (24.3, 56.4)                       | 28.2 (10.8, 48.6)                       |
| Pairwise Comparison                       | Pairwise Comparison                       | Pairwise Comparison                       | Pairwise Comparison                       | Pairwise Comparison                       | Pairwise Comparison                       | Hazard Ratio+ (95% CI)+                 | Hazard Ratio+ (95% CI)+                 |
| Primary MK-3475200mgvs.BrentuximabVedotin | Primary MK-3475200mgvs.BrentuximabVedotin | Primary MK-3475200mgvs.BrentuximabVedotin | Primary MK-3475200mgvs.BrentuximabVedotin | Primary MK-3475200mgvs.BrentuximabVedotin | Primary MK-3475200mgvs.BrentuximabVedotin | 0.87 (0.49, 1.57)                       | 0.87 (0.49, 1.57)                       |

NR=Not Reached

DatabaseCutoff Date:16JAN2020

Table 49

## KEYNOTE-204

## Analysis of Progression-Free Survival Based on Central Review per IWG 2007 (Sensitivity Analysis 1) (Ex-EU) (ITT Population)

| Treatment                   | N                           | Number of Events (%)        | Person- Months              | Event Rate/ 100 Person- Months (%)   | Median PFS t (Months) (95% CI)   | PFS Rate at Months 12 in % t (95% CI)   | PFS Rate at Months 24 in % t (95% CI)   |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|--------------------------------------|----------------------------------|-----------------------------------------|-----------------------------------------|
| MK-3475 200 mg              | 102                         | 59 (57.8)                   | 1304.1                      | 4.5                                  | 12.7 (10.9, 19.4)                | 52.9 (42.2, 62.5)                       | 31.4 (21.0, 42.4)                       |
| Brentuximab Vedotin         | 107                         | 72 (67.3)                   | 929.2                       | 7.7                                  | 8.3 (5.6, 10.8)                  | 34.9 (25.0, 45.0)                       | 20.3 (11.9, 30.4)                       |
|                             |                             |                             |                             |                                      |                                  |                                         | Hazard Ratio+ (95% CI)+                 |
| Pairwise Comparison Primary | Pairwise Comparison Primary | Pairwise Comparison Primary | Pairwise Comparison Primary | Pairwise Comparison Primary          | Pairwise Comparison Primary      |                                         |                                         |

NR=Not Reached

Database Cutoff Date: 16JAN2020

<div style=\"page-break-after: always\"></div>

Figure 32 K-M of PFS in EU vs ex-EU

<!-- image -->

The impact of SCT on PFS in KEYNOTE-204 is complex because a participant could have progressed prior to receiving SCT or not progressed but received anti-cancer therapy resulting in being censored prior to SCT. Furthermore, there is an analytical complication because the investigator decides whether to go to SCT whereas the primary assessment of PFS is by central review. Because the main difference between the PFS primary and secondary definition involves SCT, the MAH has looked more into their relationship and SCT.

Using the PFS secondary definition, there were 26 censored observations in the pembrolizumab arm and 23 in the BV arm in the EU subgroup of 95 participants, based on central review. Among those censored, the number receiving a subsequent SCT was similar across the 2 arms, 26 in total (14 in pembrolizumab arm, 12 in BV arm).

Looking into the possible magnitude of SCT on PFS, 'additional' PFS time beyond the censoring date was considered based on the primary PFS definition, which does not censor at the time of SCT. For these 26 participants, approximately half (7 pembrolizumab, 5 BV) had additional PFS time ignoring the censoring due to SCT, slightly favoring the pembrolizumab arm. Of note, the arithmetic median 'additional' PFS time was similar, 16.6 months (including 1 death) in the pembrolizumab arm compared with 18.5 months in the BV arm [Table 44]. For the remaining 14 participants, their PFS time is the same, either by the primary or secondary definition; 11 of these 14 participants had received other new anticancer therapy before receiving the SCT and were censored at the last assessment before the new anticancer therapy in both analyses.

Although the treatment effect in the EU subgroup using PFS secondary compared with PFS primary definition was stronger, it is unlikely this is explained by subsequent SCT.

<div style=\"page-break-after: always\"></div>

Table 44 KEYNOTE-204

## Additional PFS timeinEU censored subjects receivingSCT

| Treatment                             | Participant                           | Additional-PFStimeafterSCT            |
|---------------------------------------|---------------------------------------|---------------------------------------|
| Pembrolizumab                         |                                       | 33.1 months                           |
|                                       |                                       | 18.4months                            |
|                                       |                                       | 17.4 months                           |
|                                       |                                       | 16.6months                            |
|                                       |                                       | 14.7months                            |
|                                       |                                       | 13.3months                            |
|                                       |                                       | 4.4 months*                           |
| BV                                    |                                       | 33.9 months                           |
|                                       |                                       | 25.1 months                           |
|                                       |                                       | 18.5months                            |
|                                       |                                       | 14.5months                            |
|                                       |                                       | 11.7months                            |
| PFS primary minusPFS secondary *death | PFS primary minusPFS secondary *death | PFS primary minusPFS secondary *death |

## Clinical studies in special populations (paediatrics)

Keynote (KN)-051 - A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumour or Lymphoma

Figure 33 Study design

<!-- image -->

## Methods

Study design and population

Study KN-051 is an ongoing, combined Phase 1 and Phase 2 (Part I and Part II), non-randomized, openlabel, single-arm, multi-centre study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), toxicity, safety, and antitumor activity of pembrolizumab in in paediatric participants aged 6 months to &lt;18 years of age with multiple tumour types.

<div style=\"page-break-after: always\"></div>

Part I (dose finding and dose confirmation) has been completed. It used a modified 3+3 design (dose finding) and dose confirmation design according to a modified Toxicity Probability Interval approach. Part I also evaluated the safety, PK, PD, toxicity, and preliminary efficacy in paediatric participants with advanced melanoma or programmed cell death ligand 1-positive (PD-L1-positive) advanced, relapsed or refractory solid tumour or other lymphoma.

Part II (tumour cohort expansion at the RP2D) is ongoing. It further evaluates the safety and efficacy at the established RP2D in paediatric participants. In Part 2 participants were enrolled into one of the following tumour expansion Cohorts:

- PD-L1 positive advanced, relapsed or refractory solid tumors or other lymphoma;
- Advanced melanoma;
- rrcHL
- Advanced, relapsed or refractory MSI-H solid tumors.

Participants with melanoma, rrcHL, and MSI-H solid tumors were enrolled irrespective of PD-L1 status.

Participants with HL were initially enrolled in the Cohort of PD-L1-positive solid tumors and other lymphoma (n=15). After implementation of protocol Amendment 7, participants with HL were enrolled in the new, dedicated rrcHL Cohort (n=7).

Male and female participants aged 6 months to less than 18 years of age were eligible for this study.

Participants were required to have histologically or cytologically documented, locally advanced, or metastatic solid malignancy that was incurable and for which (a) participants failed prior standard therapy, (b) no standard therapy exists, or (c) standard therapy was not considered appropriate by the participant and treating physician. The Inclusion Criteria for the rrcHL Cohort were:

- Refractory to front-line therapy;
- High-risk and relapsed from front-line therapy; or
- Relapsed or refractory to second-line therapy.

As of protocol Amendment 08, enrolment was stopped for most solid tumours because signals of efficacy were not met in solid tumour target cohorts. However, enrolment continued for adolescent participants with melanoma (aged 12 to less than 18 years) and paediatric participants with rrcHL (aged 3 to less than 18 years) or MSI-H solid tumours (aged 6 months to less than 18 years), irrespective of PD-L1 status.

## Treatments

The initial dose in Part I was pembrolizumab 2 mg/kg every 3 weeks (Q3W), the equivalent of the clinical adult dose. No dose escalation or de-escalation occurred. Therefore, Part I established 2 mg/kg Q3W as the paediatric recommended Phase 2 dose (RP2D) for Part II of the study.

## Efficacy objectives and endpoints

ORR based on RECIST 1.1 per site assessment was the primary efficacy endpoint for solid tumors or lymphoma. Secondary efficacy endpoints included DOR, DCR, PFS by RECIST 1.1 and irRECIST, OS, and biomarkers.

<div style=\"page-break-after: always\"></div>

For  the  dedicated  rrcHL  Cohort  (post  Amendment  7),  primary  efficacy  endpoints  was  ORR  per  BICR assessment according to the IWG response criteria ( Note : For the current interim analysis only results per investigator assessment were provided).

Secondary efficacy objectives were: to evaluate duration of response (DOR, defined as the time from first RECIST 1.1 response to documented progressive disease or death due to any cause, whichever occurs first, in participants who achieve a PR or better), disease control rate (DCR, defined as the proportion of participants with a response of CR, PR, or SD) and progression-free survival (PFS) by RECIST 1.1; to evaluate ORR, DOR, DCR, and PFS by irRECIST (i.e. immune-related RECIST) and overall survival (OS).

The primary efficacy objective in Part II was to evaluate antitumor activity of pembrolizumab in the rrcHL Cohort based on the ORR per blinded independent central radiology review (BICR) assessment according to the International Working Group (IWG) response criteria, based on assessments every 12 weeks. Secondary objectives in part II were to evaluate antitumor activity of pembrolizumab in the rrcHL Cohort according to the IWG response criteria based on assessments every 12 weeks by the following endpoints: ORR, DOR, and PFS per site assessment; ORR, DOR, and PFS per BICR; OS. Assessing the ORR of pembrolizumab by BICR using the Lugano Classification was an additional exploratory objective.

Disease response in paediatric participants in the PD-L1-positive solid tumours and other lymphoma cohort was retrospectively re-assessed using IWG 2007 criteria. In addition, Lugano criteria was also used for disease response re-assessment for both 'PD-L1-positive solid tumors and other lymphoma' and 'dedicated rrcHL' cohorts.

## Sample size and statistical methods

A total of up to 310 participants was planned to be enrolled. The primary efficacy and safety population was the All Subjects as Treated population, which included all allocated participants who received ≥1 dose of pembrolizumab. ORR as assessed by the investigator was evaluated separately for each tumour type, and participants without response data were counted as non-responders. For DOR, PFS, and OS endpoints, Kaplan-Meier (KM) curves and median estimates from the KM curves were provided. Participants without efficacy evaluation data or without survival data were censored at Day 1 in the PFS and OS analyses. Participants who did not achieve a response were excluded from the DOR analyses.

## Results

## Disposition, Demographics, and Baseline Characteristics

Median age was 13 years (range 1 to 17 years). Participants were enrolled across approximately 29 tumour type s by primary diagnosis. The most common primary diagnoses (in ≥5% of participants) were solid tumour NOS (18.0%), HL NOS (9.3%), glioblastoma multiforme (9.3%), soft tissue neoplasm NOS (7.5%), neuroblastoma (6.2%), osteosarcoma (6.2%), melanoma (5.6%), and CNS primary tumour NOS (5.0%). The 22 participants with HL ranged in age from 10 to 17 years. Four participants were 10 to 13 years of age and 18 participants were 14 to 17 years of age. 3 participants were between 6 months and 2 years.

<div style=\"page-break-after: always\"></div>

Table 50 Baseline characteristics of the 22 participants in KEYNOTE-051 with cHL All Relapsed/Refractory Hodgkin Lymphoma

(All Subjects as Treated Population - Part II)

|                                                                   | All Subjects as Treated   | All Subjects as Treated   |
|-------------------------------------------------------------------|---------------------------|---------------------------|
|                                                                   | n                         | (%)                       |
| Subjects in population                                            | 22                        |                           |
| Gender                                                            |                           |                           |
| Male                                                              | 14                        | (63.6)                    |
| Female                                                            | 8                         | (36.4)                    |
| Age (Years)                                                       |                           |                           |
| 10 - 13 years                                                     | 4                         | (18.2)                    |
| 14 -17 years                                                      | 18                        | (81.8)                    |
| Mean                                                              | 14.9                      |                           |
| SD                                                                | 1.7                       |                           |
| Median                                                            | 15.0                      |                           |
| Range                                                             | 11 to 17                  |                           |
| Race                                                              |                           |                           |
| Asian                                                             | 1                         | (4.5)                     |
| Multi-Racial                                                      | 6                         | (27.3)                    |
| Black, White                                                      | 6                         | (27.3)                    |
| White                                                             | 15                        | (68.2)                    |
| Ethnicity                                                         |                           |                           |
| Hispanic Or Latino                                                | 9                         | (40.9)                    |
| Not Hispanic Or Latino                                            | 10                        | (45.5)                    |
| Not Reported                                                      | 3                         | (13.6)                    |
| Primary Diagnosis                                                 |                           |                           |
| Hodgkin Lymphoma Nos                                              | 15                        | (68.2)                    |
| Relapsed Refractory Classical Hodgkin Lymphoma (Post-Amendment 7) | 7                         | (31.8)                    |
| Lansky /KarnofskyPlayScore                                        |                           |                           |
| 100                                                               | 14                        | (63.6)                    |
| 90                                                                | 3                         | (13.6)                    |
| 80                                                                | 5                         | (22.7)                    |
| Overall Staging#                                                  |                           |                           |
| IA                                                                | 2                         | (9.1)                     |
| I                                                                 | 1                         | (4.5)                     |

<div style=\"page-break-after: always\"></div>

|                                                                                                           | All Subjects as Treated                                                                                   | All Subjects as Treated                                                                                   |
|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
|                                                                                                           | n                                                                                                         | (%)                                                                                                       |
| IIA                                                                                                       | 3                                                                                                         | (13.6)                                                                                                    |
| IIB                                                                                                       | 1                                                                                                         | (4.5)                                                                                                     |
| IIE                                                                                                       | 1                                                                                                         | (4.5)                                                                                                     |
| IⅢ                                                                                                        | 1                                                                                                         | (4.5)                                                                                                     |
| IIIA                                                                                                      | 3                                                                                                         | (13.6)                                                                                                    |
| IIIB                                                                                                      | 4                                                                                                         | (18.2)                                                                                                    |
| IV                                                                                                        | 4                                                                                                         | (18.2)                                                                                                    |
| IVB                                                                                                       | 2                                                                                                         | (9.1)                                                                                                     |
| BrainMetastasesPresent                                                                                    |                                                                                                           |                                                                                                           |
| No                                                                                                        | 22                                                                                                        | (100.0)                                                                                                   |
| PriorAdjuvant/Neoadjuvanttherapy                                                                          |                                                                                                           |                                                                                                           |
| Yes                                                                                                       | 1                                                                                                         | (4.5)                                                                                                     |
| No                                                                                                        | 21                                                                                                        | (95.5)                                                                                                    |
| Treatment Naive                                                                                           |                                                                                                           |                                                                                                           |
| No                                                                                                        | 22                                                                                                        | (100.0)                                                                                                   |
| Number ofPriorTherapiesforrecurrent/MetastaticDisease                                                     |                                                                                                           |                                                                                                           |
| 1                                                                                                         | 3                                                                                                         | (13.6)                                                                                                    |
| 2                                                                                                         | 10                                                                                                        | (45.5)                                                                                                    |
| 3                                                                                                         | 2                                                                                                         | (9.1)                                                                                                     |
| 4                                                                                                         | 3                                                                                                         | (13.6)                                                                                                    |
| 5 or more                                                                                                 | 4                                                                                                         | (18.2)                                                                                                    |
| # Overall Staging not required for diagnoses lacking standard staging systems. (DataCutoffDate:10JAN2020) | # Overall Staging not required for diagnoses lacking standard staging systems. (DataCutoffDate:10JAN2020) | # Overall Staging not required for diagnoses lacking standard staging systems. (DataCutoffDate:10JAN2020) |

Source:[P051V02MK3475:adam-adsl]

## Study recruitment

The study is ongoing; first participant first visit was on 23-MAR-2015; at the data cut-off 10-JAN-2020 (IA9) 162 participants were enrolled, 161 were treated, 8 (5.0%) completed the protocol-specified maximum treatment duration of 35 administrations (approximately 2 years), 4 (2.5%) were continuing study treatment, and 157 (97.5%) discontinued study treatment. Fifty-one (31.7%) participants were ongoing in the study.

The median duration of follow-up was approximately 3-fold longer for participants with HL (23.7 months) than for participants with all other tumour types (8.3 months), primarily due to the large number of early deaths among the other tumour types.

Subsequent Oncologic Treatments - Relapsed/Refractory Hodgkin Lymphoma: 14 of the 22 participants with HL received subsequent oncologic therapies after discontinuing treatment with pembrolizumab (including chemotherapy, BV, pembrolizumab and nivolumab).

## Efficacy outcomes

## ORR (INV-assessed)

- rrcHL (n=22)

The ORR by Investigator Review was 42.9% (per IWG 2007 criteria) for the 7 participants in the dedicated rrcHL Cohort and 66.7% (confirmed responses per RECIST 1.1) for 15 participants with HL in the PD-L1-positive solid tumours and other lymphoma Cohort (see Tables below).

<div style=\"page-break-after: always\"></div>

Table 51 Summary of BOR based on IWG 2007 per Investigator assessment - R/RHL (postamendment 7) - all subjects as treated population part II

| Response Evaluation            | All Subjects as Treated (N=7)   | All Subjects as Treated (N=7)   | All Subjects as Treated (N=7)   |
|--------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                | n                               | %                               | 95% CIt                         |
| Complete Response (CR)         | 2                               | 28.6                            | (3.7, 71.0)                     |
| Partial Response (PR)          | 1                               | 14.3                            | (0.4, 57.9)                     |
| Best Overall Response (CR+PR)  | 3                               | 42.9                            | (9.9, 81.6)                     |
| Stable Disease (SD)            | 3                               | 42.9                            | (9.9, 81.6)                     |
| Disease Control Rate(SD+CR+PR) | 6                               | 85.7                            | (42.1, 99.6)                    |
| Progressive Disease (PD)       |                                 | 14.3                            | (0.4, 57.9)                     |

Source:[P051V02MK3475:adam-adsl;adrs]

Table 52 Summary of BOR based on IWG 2007 per Investigator assessment - R/RHL (postamendment 7) - all subjects as treated population - parts I and II

| Response Evaluation                                                                                                                   | All Subjects as Treated (N=15)   | All Subjects as Treated (N=15)   | All Subjects as Treated (N=15)   |
|---------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                                                                                                                       |                                  | %                                | 95% CI                           |
| Complete Response (CR)                                                                                                                | 1                                | 6.7                              | (0.2, 31.9)                      |
| Partial Response (PR)                                                                                                                 | 9                                | 60.0                             | (32.3, 83.7)                     |
| Best Overall Response (CR+PR)                                                                                                         | 10                               | 66.7                             | (38.4, 88.2)                     |
| Stable Disease (SD)                                                                                                                   | 2                                | 13.3                             | (1.7, 40.5)                      |
| Disease Control Rate (SD+CR+PR)                                                                                                       | 12                               | 80.0                             | (51.9, 95.7)                     |
| Progressive Disease (PD)                                                                                                              | 3                                | 20.0                             | (4.3, 48.1)                      |
| Confinmed responses by RECIST 1.1 are included. Based on binomial exact confidence interval method. (Database Cutoff Date: 10JAN2020) |                                  |                                  |                                  |

Souce: [P051V02MK3475: adam-adsl; adrs]

Among the 22 cHL participants, the ORR was 54.5% based on IWG 2007 criteria and 63.6% based on Lugano criteria.

Table 53

## KEYNOTE-051

Summary of Best Overall Response Based on IWG 2007 per BICR Assessment All Relapsed/Refiractory Hodgkin Lymphoma (All Subjects as Treated Population - Part II)

| Response Evaluation             | All Subjects as Treated (77=N)   | All Subjects as Treated (77=N)   | All Subjects as Treated (77=N)   |
|---------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                 |                                  | %                                | ID %56                           |
| Complete Response (CR)          | 1                                | 4.5                              | (0.1, 22.8)                      |
| Partial Response (PR)           | 11                               | 50.0                             | (28.2, 71.8)                     |
| Best Overall Response (CR+PR)   | 12                               | 54.5                             | (32.2,75.6)                      |
| Stable Disease (SD)             | 6                                | 27.3                             | (10.7, 50.2)                     |
| Disease Control Rate (SD+CR+PR) | 18                               | 81.8                             | (59.7, 94.8)                     |
| Progressive Disease (PD)        | 3                                | 13.6                             | (2.9, 34.9)                      |
| Non-evaluable (NE)              | 1                                | 4.5                              | (0.1, 22.8)                      |

Based onbinomial exact confidence interval method.

BICR = Blinded independent central review.

(Data Cutoff Date: 10JAN2020).

Source: [P051V02MK3475: adam-adsl; adrs]

<div style=\"page-break-after: always\"></div>

## Summary of Best Overall Response Based on Lugano per BICR Assessment

KEYNOTE-051 All Relapsed/Refractory Hodgkin Lymphoma (All Subjects as Treated Population - Part II)

| Response Evaluation             | All Subjects as Treated (N=22)   | All Subjects as Treated (N=22)   | All Subjects as Treated (N=22)   |
|---------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                 | n                                | %                                | 10 %56                           |
| Complete Response (CR)          | 4                                | 18.2                             | (5.2, 40.3)                      |
| Partial Response (PR)           | 10                               | 45.5                             | (24.4, 67.8)                     |
| Best Overall Response (CR+PR)   | 14                               | 63.6                             | (40.7, 82.8)                     |
| Stable Disease (SD)             | 6                                | 27.3                             | (10.7, 50.2)                     |
| Disease Control Rate (SD+CR+PR) | 20                               | 90.9                             | (70.8, 98.9)                     |
| Progressive Disease (PD)        | 2                                | 9.1                              | (1.1, 29.2)                      |

f Based on binomial exact confidence interval method.

BICR = Blinded independent central review.

(Data Cutoff Date: 10JAN2020).

Source: [P051V02MK3475: adam-adsl; adrs]

All 22 participants with HL had at least 1 post-baseline assessment of measurable tumour size in target lesions, and all had a reduction in tumour size post baseline. Eighteen participants had a maximum reduction in tumour siz e ≥30% (see Figure below).

Figure 34 waterfall plot of best tumor change from baseline per investigator assessmentR/RHL (all subjects as treated population - parts I and II)

<!-- image -->

Percentage changes &gt;100% were truncated at 100%.

(Data Cutoff Date:10JAN2020)

Source:[P051V02MK3475: adam-adsl; adrs; adtl]

- All Relapsed/Refractory Tumours Except Hodgkin Lymphoma (n=139)

<div style=\"page-break-after: always\"></div>

The ORR based on RECIST 1.1/MIBG was 5.8% for confirmed responses (8 PRs) and 6.5% for confirmed plus unconfirmed responses (9 PRs) for 139 participants with relapsed/refractory tumors other than HL.

The 8 participants with a confirmed PR had the following tumor types by histology:

- o Adenocarcinoma and mesothelioma (2 participants each); and
- o Malignant ganglioma, epithelioid sarcoma, lymphoepithelial carcinoma, and malignant rhabdoid tumor (1 participant each)

The DCR was 25.9% (confirmed responses) and 28.1% (confirmed plus unconfirmed responses).

- TTR and DOR: rrcHL (n=22)

The median time to response based on RECIST 1.1 was 1.9 months for the 10 confirmed responders with HL. The median DOR was 17.4 months by KM estimation. Two of the 10 confirmed responses were ongoing at the time of data cutoff.

The median time to response based on IWG 2007 criteria was 2.6 months for the 3 responders in the dedicated rrcHL cohort (post Amendment 7). The DOR ranged from 0.0+ to 6.1+ months. One responder had a DOR of 6 months or longer.

Among the 12 responders by IWG 2007 criteria, the median time to response was 2.3 months and the median response duration was 17.3 months. There were 77.8% of participants with response duration ≥ 9 months. Three of the 12 responses were ongoing as of the data cutoff date [see Tables and Figure below].

Table 55

## KEYNOTE-051

Summary of Time to Response and Duration of Response Based on IWG 2007 per BICR Assessment in Subjects with a Response All Relapsed/Refractory Hodgkin Lymphoma (All Subjects as Treated Population - Part II)

|                                                          | All Subjects as Treated (N=22)   |
|----------------------------------------------------------|----------------------------------|
| Number of subjects with responset                        | 12                               |
| Time to Response (months)                                |                                  |
| Mean (SD)                                                | 2.7 (1.4)                        |
| Median (Range)                                           | 2.3 (1.1-6.2)                    |
| ResponseDuration(months)                                 |                                  |
| Median (Range)                                           | 17.3 (0.0+ - 28.7)               |
| Number (%+) of Subjects with Extended Response Duration: |                                  |
| ≥3 months                                                | 8 (88.9)                         |
| ≥6 months                                                | 8 (88.9)                         |
| ≥9 months                                                | 7 (77.8)                         |

Source: [P051V02MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

Figure 35

## KEYNOTE-051

## Summary of Response Outcome in Subjects with Censored from the DOR Analysis Response Based on IWG 2007 per BICR Assessment

## All Relapsed/Refractory Hodgkin Lymphoma

(All Subjects as Treated Population - Part II)

|                                                                                | MK3475 2 mg/kg Q3W (N=22)   |
|--------------------------------------------------------------------------------|-----------------------------|
| Number of Subjects with Responset                                              | 12                          |
| Subjects WhoProgressedl orDiedl(%)                                             | 6 (50.0)                    |
| Range of DOR (months)                                                          | 2.1 to 28.7                 |
| Censorerl Subjects (%)                                                         | 6 (50.0)                    |
| Subjectswhomissed2ormoreconsecutivediseaseassessments                          | 0 (0.0)                     |
| Subjectswhostartednewanti-cancertreatment                                      | 3 (25.0)                    |
| Subjects who were lost to follow-up                                            | 0 (0.0)                     |
| Subjects whose last adequate assessment was≥ 5 monthsprior to data cutoff date | 0 (0.0)                     |
| Ongoing response$                                                              | 3 (25.0)                    |
| ≥5months                                                                       | 2 (16.7)                    |
| <5months                                                                       | 1 (8.3)                     |
| Range of DOR (months)                                                          | Range of DOR (months)       |

- Includes subjects with a confirmed complete response or partial response.
+ Includes subjects who progressed or died without previously missing 2 or more consecutive disease assessments.
- $ Includes subjects who are alive, have not progressed, have not initiated new anti-cancer treatment, are not lost to follow-up, and whose last disease assessment was &lt;5 months prior to data cutoff date.
- For censored subjects who met multiple criteria for censoring and do not have ongoing response, subjects are included in the censoring criterion that occurred earliest.
- 't' indicates there was no progressive disease by the time of last disease assessment.

BICR =Blinded independent central review.

(Data Cutoff Date:10JAN2020).

KEYNOTE-051 Kaplan-Meier Estimates of Response and Duration of Response Based on IWG 2007 per BICR Assessment in subjects with a response All Relapsed/RefractoryHodgkin Lymphoma (All Subjects as Treated Population - Part II)

Cumulative Event Rate (%)

<!-- image -->

Number of subjects at risk

AllSubjects asTreated 12 9 8 8 5 3 2

BICR=Blindedindependent centralreview. (DataCutoffDate:10JAN2020). Source:[P051V02MK3475:adam-adsl;adtte]

<div style=\"page-break-after: always\"></div>

Among the 14 responders by Lugano criteria, the median time to response was 2.1 months and the median response duration was 8.8 months. There were 45.5% of participants with response duration ≥ 9 months. Three of the 14 responses were ongoing as of the data cutoff date [see Tables and Figure below].

Table 57

Figure 36

KEYNOTE-051

Summary of Time to Response and Duration of Response Based on Lugano per BICR Assessment in Subjects with a Response All Relapsed/Refractory Hodgkin Lymphoma (All Subjects as Treated Population - Part II)

|                                                     | All Subjects as Treated (N=22)   |
|-----------------------------------------------------|----------------------------------|
| Number of subjects with responset                   | 14                               |
| Time to Response (months)                           |                                  |
| Mean (SD)                                           | 2.2 (0.7)                        |
| Median (Range)                                      | 2.1 (1.1-3.9)                    |
| ResponseDuration+(months)                           |                                  |
| Median (Range)                                      | 8.8 (0.0+ - 28.7)                |
| Nunber(%+)of SubjectswithExtended ResponseDuration: |                                  |
| ≥3 months                                           | 9 (81.8)                         |
| ≥6 months                                           | 8 (72.7)                         |
| ≥9 months                                           |                                  |

KEYNOTE-051 Kaplan-Meier Estimates of Response and Duration of Response Based on Lugano per BICR Assessment in subjects with a response All Relapsed/Refractory Hodgkin Lymphoma (All Subjects as Treated Population - Part II)

<!-- image -->

Numberofsubjects atrisk

AllSubjectsasTreated14108864 43 2

<div style=\"page-break-after: always\"></div>

## Summary of Response Outcome in Subjects with Censored from the DOR Analysis

## KEYNOTE-051 Response Based on IWG 2007 per BICR Assessment All Relapsed/Refractory Hodgkin Lymphoma

(All Subjects as Treated Population - Part II)

|                                                                                 | MK3475 2 mg/kg Q3W (N=22)   |
|---------------------------------------------------------------------------------|-----------------------------|
| Number of Subjects with Response                                                | 12                          |
| Subjects Who Progresseil or Diedl (%)                                           | 6 (50.0)                    |
| Range of DOR (months)                                                           | 2.1 to 28.7                 |
| Censorerdl Subjects (%)                                                         | 6 (50.0)                    |
| Subjectswhomissed 2ormore consecutive diseaseassessments                        | 0 (0.0)                     |
| Subjects whostarted new anti-cancer treatment                                   | 3 (25.0)                    |
| Subjects who were lost to follow-up                                             | 0 (0.0)                     |
| Subjects whose last adequate assessment was≥ 5 months prior to data cutoff date | 0 (0.0)                     |
| Ongoing responses                                                               | 3 (25.0)                    |
| ≥5 months                                                                       | 2 (16.7)                    |
| < 5 months                                                                      | 1 (8.3)                     |
| Range of DOR (months)                                                           |                             |

BICR = Blinded independent central review.

(Data Cutoff Date:10JAN2020).

## PFS:

## · rrcHL (n=22)

The median PFS based on IWG 2007 criteria was 11.2 months by KM estimation for the 7 participants in the dedicated rrcHL Cohort. PFS rates at 6 and 12 months were 55.6% and 27.8%, respectively.

The median PFS based on RECIST 1.1 was 12.2 months by KM estimation for 15 participants with HL in the PD-L1-positive solid tumors and other lymphoma Cohort. PFS rates at 6 and 12 months were 73.3% and 53.3%, respectively.

Among the 22 cHL participants, the median PFS based on IWG 2007 criteria was 8.3 months based on KM estimation. PFS rates at 6 and 12 months were 55.1% and 42.9% [see Table and Figure below].

<div style=\"page-break-after: always\"></div>

Figure 37

## Summary ofProgression-FreeSurvival(PFS)byIWG 2007perBICR Assessment

## KEYNOTE-051 All Relapsed/Refiractory Hodgkin Lymphoma

(All Subjects as Treated Population - Part II)

|                                  | All Subjects as Treated (N=22)   |
|----------------------------------|----------------------------------|
| Number (%) of PFS Events         | 14 (63.6)                        |
| Person-Months                    | 193                              |
| Event Rate/100 Person-Months (%) | 7.2                              |
| Median PFS (Months)$             | 8.3                              |
| 95% CI for Median PFS$           | (4.0,19.2)                       |
| PFS rate at 6 Months in % $      | 55.1                             |
| PFS rate at 12 Months in % §     | 42.9                             |

(Data Cutoff Date: 10JAN2020).

Source: [P051V02MK3475: adam-adsl; adtte]

## KEYNOTE-051

Kaplan-Meier Estimates of Progression-Free Survival (PFS) by IWG 2007 per BICR Assessment

All Relapsed/Refractory Hodgkin Lymphoma (All Subjects as Treated Population - Part II)

<!-- image -->

All Subjects as Treated  22 9 5 0

Data Cutoff Date: 10JAN2020).

source: [P051V02MK3475: adam-adsl; adtte]

The median PFS based on Lugano criteria was 8.2 months based on KM estimation and PFS rates at 6 and 12 months were 53.0% and 24.2% [see Table and Figure below].

<div style=\"page-break-after: always\"></div>

Figure 38

## KEYNOTE-051 Summary of Progression-Free Survival (PFS) by Lugano per BICR Assessment All Relapsed/Refractory Hodgkin Lymphoma (All Subjects as Treated Population - Part II)

|                                  | All Subjects as Treated (N=22)   |
|----------------------------------|----------------------------------|
| Number (%) ofPFS Events          | 16 (72.7)                        |
| Person-Months                    | 195                              |
| Event Rate/100 Person-Months (%) | 8.2                              |
| Median PFS (Months)$             | 8.2                              |
| 95% CI for Median PFS$           | (4.0,11.6)                       |
| PFS rate at 6 Months in % §      | 53.0                             |
| PFS rate at 12 Months in % §     | 24.2                             |

(Data Cutoff Date: 10JAN2020).

Source: [P051V02MK3475: adam-adsl; adtte]

## KEYNOTE-051

Kaplan-Meier Estimates of Progression-Free Survival (PFS) by Lugano per BICR Assessment

All Relapsed/Refractory Hodgkin Lymphoma (All Subjects as Treated Population - Part II)

<!-- image -->

Data Cutoff Date: 10JAN2020).

Source: [P051V02MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

- All Relapsed/Refractory Tumours Except Hodgkin Lymphoma (n=139)

The median PFS based on RECIST 1.1 was 1.8 months by KM estimation for 139 participants with relapsed/refractory tumors other than HL. PFS rates at 6 and 12 months were 18.7% and 13.2%, respectively.

## OS:

- rrcHL (n=22)

For the 22 participants with HL, the median OS had not been reached at the time of data cutoff for this report. The OS rate was 100% at both 6 and 12 months by KM estimation. One participant died shortly after 12 months.

- All Relapsed/Refractory Tumors Except Hodgkin Lymphoma (n=139)

The median OS was 9.0 months by KM estimation for the 139 participants with relapsed/refractory tumors other than HL. OS rates at 6 and 12 months were 57.8% and 45.0%, respectively.

## Supportive study(ies)

Keynote (KN)-087 - A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects with Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (cHL).

Figure 39 Study design

<!-- image -->

N=60participantswithR/R cHL/cohort

Cohort l: Participants who failed to achieve a response or progressed after auto-SCT and relapsed after treatment with, or failed to respond to treatment with, BV post-auto-SCT Cohort 2: Participants who were unable to achieve a CR or PR to salvage chemotherapy and did not receive auto-SCT, but relapsed after treatment with, or failed to respond to treatment with,BV

Cohort 3: Participants who failed to achieve a response to, or progressed after, auto-SCT, and had not received BV after auto-SCT and did, or did not, receive BV as part of primary treatment or salvage treatment auto-SCT=autologous stem cell transplant; BVbrentuximab vedotin; cHL=elassical Hodgkin lymphoma; CR=complete response or remission; IV=intravenous(ly); PD=progressive disease; PR=partial response or remission; Q3W=once every 3 weeks; R/R=relapsed/refractory; SFU=safety follow-up

## Methods

## Study design and population

KN-087 is an ongoing, multicenter, single-arm, multi-cohort, non-randomized Phase 2 study of IV pembrolizumab in adult patients with R/R cHL who failed to achieve a response or progressed after autologous stem cell transplant (auto-SCT) and relapsed after treatment with, or failed to respond to treatment with, brentuximab vedotin (BV) post-ASCT (Cohort 1); who were unable to achieve a complete

<div style=\"page-break-after: always\"></div>

response (CR) or partial response (PR) to salvage chemotherapy and did not receive ASCT, but relapsed after treatment with, or failed to respond to treatment with, BV (Cohort 2); and who failed to achieve a response to, or progressed after, ASCT, and had not received BV after ASCT and did or did not, receive BV as part of primary treatment or salvage treatment (Cohort 3).

## Treatment

Pembrolizumab was administered at the dose of 200 mg once every 3 weeks.

## Efficacy objectives and endpoints

The study primary efficacy objective was to evaluate the objective response rate (ORR) of pembrolizumab by blinded, independent central review (BICR) according to the International Working Group (IWG) response criteria within each of the 3 cohorts of participants with R/R cHL. Secondary objectives were to evaluate: the ORR using the Lugano Classification, the CRR by the IWG criteria and the Lugano Classification, to evaluate PFS, DoR and OS.

## Sample size and statistical methods

Approximately 60 participants were planned to be enrolled per cohort. The primary population for efficacy analysis was the All-Subjects-as-Treated (ASaT) population: all enrolled participants were included if they received at least 1 dose of study treatment.

ORR analysis consisted of the point estimate and 95% 2-sided exact confidence interval (CI) using the Clopper-Pearson method. An exact binomial test was conducted versus a fixed control rate. CRR analysis consisted of the point estimate and 95% 2-sided exact CI using the Clopper-Pearson method. DOR was analysed in all responders by summary statistics using the Kaplan-Meier (KM) method, with participants in response censored at their last assessment. PFS was analysed in all responders by summary statistics using the KM method, with missing data censored at last assessment. OS was analysed by summary statistics using the KM method, with missing data censored at last assessment.

## Results

## Disposition, Demographics, and Baseline Characteristics

Per protocol, all study participants had cHL, participants in Cohorts 1 and 3 were post-auto-SCT, and participants in Cohort 2 had not received an auto-SCT. The most common subgroup of cHL was nodular sclerosing Hodgkin Lymphoma (169 participants [80.5%]). All participants were heavily pre-treated, with a median of 4.0 prior lines of therapy (range: 1 to 12). A total of 175 participants (83.3%) had previously failed to respond to or relapsed after treatment with BV. Seventy-seven participants (36.7%) had prior radiation therapy. Median Age (Range) was 34 years (19 to 64 years) in cohort 1; 40 years (20 to 76 years) in cohorts 2; 32 years (18 to 73 years) in cohort 3.

## Number of Participants Randomized/Treated/Ongoing/Discontinued

A total of 210 participants were allocated and treated in this study: 69 in Cohort 1; 81 in Cohort 2, and 60 in Cohort 3. As of the data cutoff date of 21-MAR-2019, 46 participants (21.9%) had completed the protocol-specified maximum treatment duration of 35 administrations (approximately 2 years) and 164 participants (78.1%) had discontinued study treatment. The most common reason for treatment discontinuation was disease progression (including events of clinical progression; [n=91]). The median duration of follow-up was 39.5 months (range: 1.0 to 44.8).

<div style=\"page-break-after: always\"></div>

Outcomes Table 61 Efficacy results

|                            | COHORT 1             | COHORT 2             | COHORT 3             | Total                 |
|----------------------------|----------------------|----------------------|----------------------|-----------------------|
| ORR by BICR, n (%, 95% CI) | n=69                 | n=81                 | n=60                 | N=210                 |
| Based on IWG criteria      | 54 (78.3, 66.7-87.3) | 52 (64.2, 52.8-74.6) | 43 (71.7, 58.6-82.5) | 149 (71.0, 64.3-77.0) |
| Based on Lugano criteria   | 58 (84.1, 73.3-91.8) | 55 (67.9, 56.6-77.8) | 41 (68.3, 55.0-79.7) | 154 (73.3, 66.8-79.2) |
| CRR by BICR, n (%)         | n=69                 | n=81                 | n=60                 | N=210                 |
| Based on IWG criteria      | 18 (26.1)            | 21 (25.9)            | 19 (31.7)            | 58 (27.6)             |
| Based on Lugano criteria   | 25 (36.2)            | 23 (28.4)            | 21 (35.0)            | 69 (32.9)             |
| DOR, months                | n=54                 | n=52                 | n=43                 | N=149                 |
| Median (range)a            | 25.0 (0.0+, 36.1+)   | 11.1 (0.0+, 35.9+)   | 16.8 (0.0+, 39.1+)   | 16.6 (0.0+, 39.1+)    |
| PFS by BICR                | n=43                 | n=54                 | n=36                 | N=133                 |
| Median (95% CI), months    | 16.4 (11.3, 27.6)    | 11.1 (7.3,13.5)      | 19.4 (8.4, 22.1)     | 13.6 (11.1, 16.7)     |
| Rate at 12 monthsb, %      | 61.3                 | 43.0                 | 53.9                 | 52.3                  |
| Rate at 24 monthsb, %      | 41.6                 | 21.9                 | 34.0                 | 32.2                  |
| OS                         | n=69                 | n=81                 | n=60                 | N=210                 |
| Median, months             | Not reached          | Not reached          | Not reached          | Not reached           |
| Rate at 12 monthsb, %      | 95.7                 | 96.2                 | 96.6                 | 96.1                  |
| Rate at 24 monthsb, %      | 92.6                 | 91.0                 | 89.4                 | 91.1                  |

- a. \"+' indicates there was no progressive disease at the time of the last disease assessment.

b. By KM estimation.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

Pivotal  study  KN-204  is  a  phase  III,  randomised,  open-label  clinical  trial  designed  to  compare pembrolizumab vs. BV in subjects with r/r cHL. All patients with r/r cHL could be enrolled irrespectively of number of prior lines of therapy or refractory/relapsed disease status. Out of safety concerns subjects who received allogeneic HSCT within the last 5 years or had clinically relevant autoimmune conditions, active infection, CNS localization or current/previous pneumonitis were excluded: this is in line with the currently approved Keytruda SmPC and acceptable.

The study population underwent several changes over the course of the study, eventually resulting in high heterogeneity: under protocol amendment 2, e.g., subjects who previously responded to BV-containing regimens became eligible. Re-treatment of responders to BV is reflected in the current SmPC of Adcetris and is not controversial. Diverging form previous CHMP SA, however, protocol amendment 2 also allowed for the inclusion of patients with one single prior line of therapy, regardless of their transplant eligibility status.  Then,  following  Amendment  03,  patients  considered  by  the  Investigator  to  be  eligible  to ASCT/alloHSCT were definitely excluded from trial participation.

The main aim of salvage treatment in r/r cHL is to obtain a second remission and proceed to ASCT. Salvage chemotherapy followed by ASCT can allow for long-term disease control/cure in up to 50% of patients. Transplant  eligibility  is  usually  evaluated  based  on  response  to  salvage  treatment  and  residual chemosensitivity. Subjects with chemoresistant disease (i.e. patients unable to achieve a second remission or at least a significant reduction of disease bulk with salvage regimens) are not considered eligible to ASCT, since the expected benefit of transplant in this subgroup is limited. Some patients can be considered upfront ineligible to ASCT because of age and/or significant comorbidities.

Although the prognostic impact of refractoriness to frontline chemotherapy is recognised, it cannot be

<div style=\"page-break-after: always\"></div>

considered, per se, a major criterium to define transplant ineligibility  (see  e.g.  Hoppe  RT  et  al,  NCCN guidelines for HL v.2.2020).

Subjects were randomised 1:1 to receive up to 35 cycles of either pembrolizumab at the approved 200mg Q3W dose regimen or BV at the standard 1.8 mg/kg dose Q3W. According to the current Keytruda SmPC (section 4.2), patients are expected to continue pembrolizumab until disease progression or unacceptable toxicity. However, no subject received pembrolizumab for more than 35 cycles in study KN-204 and limited data are currently available on response duration following pembrolizumab discontinuation at cycle 35. Consistent recommendations are included in the SmPC.

BV could also be continued up to 35 cycle, yet, the currently approved SmPC for Adcetris specifies that r/r cHL patients who achieve stable disease (SD) or better could receive a minimum of 8 cycles and up to a maximum of 16 cycles of BV. Since a limited number of subjects received less than 8 or more than 16 cycles of BV in study KN-204 and no significant efficacy/safety issues have been observed in these subsets, the impact of prolonged BV administration on B/R evaluations is considered limited.

The choice of BV as comparator is acceptable for subjects not eligible to additional chemotherapy, being the current standard for patients who have failed ASCT or at least two lines of therapy.

The prognostic impact of the chosen stratification factors for randomisation (prior ASCT and disease status after  frontline  therapy)  is  recognised.  The  role  of  other  factors  with  known  prognostic  relevance  (e.g. presence of bulky or extranodal disease, response to prior therapy and anaemia at relapse), was also investigated in dedicated post-hoc subgroup analyses.

PFS (assessed by BICR according to IWG response criteria [Cheson, 2007], including clinical and imaging data following auto-SCT or allo-SCT) and OS were selected as dual primary efficacy endpoints to assess clinical  benefit:  this  is  agreed.  Although  study  KN-204  was  designed  to  claim  success  in  the  case pembrolizumab was confirmed superior to BV in either PFS or OS, consistency of results across primary endpoints is nonetheless expected. In this regard, since BV and pembrolizumab are both approved in the EU for the treatment of cHL patients in advanced settings of relapse, the possibility of a confounding effect of systematic off-study cross-over on OS cannot be excluded.

The other secondary/exploratory endpoints (e.g. ORR, CRR, DoR, ORR post-progression, PFS2 and PROs explored using the validated EQ-5D and EORTC QLQ-C30 instruments) are considered overall adequate to further characterize pembrolizumab efficacy in the target population. Although the older 2007 IWG response criteria were used for the primary efficacy analyses, additional analyses using the 2014 Lugano response criteria were also provided.

From a methodological perspective, the planned sample size (n=300) in study KN-204 is congruent with clinical assumptions and adequate to allow for the detection of a HR of 0.62 for PFS with a 85% power at alpha 1.2% (one-sided), a HR of 0.6 for OS with a 80% power at alpha 1.25% (one-sided) and a 18-20% improvement in ORR with a 90% power at alpha of 0.6% (one-sided and provided that the PFS hypothesis is  rejected).  Four  interim  analyses  (IAs)  and  one  final  analysis  (FA)  were  pre-specified.  The  statistical methods used to test time to event and binary endpoints are standard and the overall strategy to control multiplicity is not controversial. With respect to PROs, the EQ-5D and EORTC QLQ-C30 instruments are validated and acceptable. The 10-point change considered as minimal important difference (MID) was, however,  poorly  justified  beyond  a  generic  statement  that  this  difference  was  perceived  as  clinically meaningful by the patients. Imputation under MAR was also planned to address missing data, yet no reason was provided to justify the MAR assumption. Most importantly, no strategy to control multiplicity was put in place for PROs analyses, and the open-label study design further questions results reliability.

Supportive study KN-087 is an ongoing, single-arm, multi-cohort, non-randomized Phase 2 study investigating the efficacy of pembrolizumab monotherapy in a heterogeneous population of patients with cHL in advanced settings of relapse. Cohort 3, which also included BV-naïve patients, can be considered

<div style=\"page-break-after: always\"></div>

the most informative for the claimed indication. Results for study KN-087 were pivotal in supporting the initial indication of pembrolizumab for the treatment of r/r cHL (see EPAR for procedure EMEA/H/C/003820/II/0014).

## Efficacy data and additional analyses

Three-hundred and thirty-eight  subjects  were  screened  in  study  KN-204  and  304/338  (~89.9%)  were eventually randomised to receive either pembrolizumab (n=151) or BV (n=153). At the time of the data cut-off date the vast majority of subjects had discontinued study treatment.

Sixty-four (~21%) subjects underwent subsequent ASCT and 27 (~9%) allogeneic HSCT, with no significant differences across study arms. Considering that transplant-eligibility was an exclusion criterion, the high rate  of  patients  receiving  subsequent  transplant  in  study  KN-204  further  highlights  the  difficulties  in prospectively defining transplant eligibility in cHL.

Demographic characteristics were generally well balanced across treatment arms and overall consistent with what expected in a population of patients with r/r cHL. Nearly all subjects had a good performance status at the time of study entry (ECOG score was 0-1 in 99.7% of subjects), the majority had no Bsymptoms  (73.7%)  and  only  19.7%  and  5.6%  had  bulky  disease  and  bone  marrow  involvement, respectively.

The median number of prior lines of therapy was 2, with a median of 3 prior regimens received, and approximately 40% and 37% in both treatment arms had received prior radiotherapy (RT) and ASCT, respectively. Only a minority of patients had received prior BV (~5%, 10 patients in the BV and 5 in the pembrolizumab arm). Overall, nearly 70% of patients had primary refractory or early relapsed disease (i.e. response duration ≤12 months), identifying a high -risk clinical setting.

Taking into account the broad claimed indication and the significant heterogeneity in the study population, baseline characteristics stratified by number of prior lines of therapy and transplant eligibility were also provided. Overall, despite the fact that under protocol versions 1 and ≥3 inclusion was limited to transplant ineligible patients, only 192/304 (63%) patients in study KN204 were deemed transplant ineligible at the time of enrolment. As expected based on current guidelines, most transplant-ineligible patients (137/192 [~71%]) had received ≥2 prior lines of systemic therapy and only 55 patients (29% of all transplant -ineligible patients and 18% of the overall study population) were deemed transplant ineligible after one single line of therapy.

With respect to transplantineligible subjects with ≥2 prior therapies, median age was 34 years (range 18 to 83), only 10.8% of patients were aged ≥65 years (3.2% aged ≥75) and most subjects had a baseline ECOG score of 0 or 1 (58.2% and 41.4%, respectively). Approximately 30% were refractory to frontline chemotherapy  and  ~37%  had  received  prior  ASCT.  Nodular-sclerosis  was  the  more  represented  cHL histological subtype (~81%) and bulky disease, B symptoms and bone marrow involvement were present in approximately 21%, 28% and 4% of patients, respectively.

Transplant-ineligible subjects with one single prior line of therapy were older (median age at baseline was 49 years), with 40% of patients aged ≥65 years and 12.7% (7/55) ≥75 years. Baseline ECOG PS score was 0 (74.5%) or 1 (25.5%) in all subjects. The proportion of patients in this subgroup that were refractory to frontline chemotherapy was ~22% and, as expected, none had received prior ASCT. Most patients had nodular-sclerosis cHL (~82%) and only ~15% had bulky disease, 16% reported B symptoms at baseline and ~11% had bone marrow involvement.

With a median follow-up of approximately 2 years, the primary PFS analysis can be considered sufficiently mature (e.g. 55% of patents having experienced at least one PFS event). Study KN-204 met the primary PFS endpoint: pembrolizumab demonstrated a statistically significant superiority in PFS compared to BV.

<div style=\"page-break-after: always\"></div>

Median PFS was 13.2 months (95%CI 10.9, 19.4) and 8.3 months (95%CI 5.7, 8.8) in the pembrolizumab and in the BV arms, respectively (HR 0.65, 95%CI 0.48, 0.88, p=0.00271). The external validity of the data is supported by the fact that PFS outcomes observed in the BV arm of study KN-204 were overall in line with those reported in the Adcetris registrational trial (study SG035-0003), where a ~6 months median PFS was observed in a more advanced patient population. The estimated 24-month PFS rate was 35.4% and 25.4% for pembrolizumab and BV, respectively. Results from the planned sensitivity analyses and secondary  PFS  endpoints  were  consistent  with  the  primary  analysis;  in  particular,  results  from  the secondary PFS analysis censoring patients at the time of transplant confirmed study outcomes (HR 0.62, 95%CI  0.46,  0.85),  showing  that  the  impact  of  subsequent  transplant  on  the  relative  efficacy  of pembrolizumab vs. BV was overall limited.

In a population often characterised by significant chemoresistance, ORR was numerically higher with pembrolizumab compared to BV (65.6% [95%CI: 57.4, 73.1] and 54.2% [95%CI: 46.0, 62.3], respectively), yet confidence intervals largely overlapped and no significant differences could be observed in terms of CR rates (24.5% [95%CI 17.9%, 32.2%] with pembrolizumab and 24.2% [95% CI 17.6%, 31.8%] with BV). DoR data were not sufficiently mature, yet a possible trend towards longer response duration with pembrolizumab could be observed (mDoR 20.7 vs. 13.8 months). The fraction of patients with response duration longer than 24 months was, however, similar across treatment arms (47.4% vs. 42.8%, respectively).

Higher ORRs were observed in both treatment arms when the Lugano response criteria were applied: 72.8% and 67.3% with pembrolizumab and BV, respectively. The analysis applying the Lugano criteria also resulted in higher rates of remission, in particular in the BV arm (CRR 30.7%). Despite similar PFS, DoR according to the Lugano criteria was significantly shorter in both treatment arms (16.8 and 5.8 months, with pembrolizumab and BV, respectively).

Pembrolizumab and BV are both authorised in the EU for the treatment of cHL patients in advanced settings of relapse, making uncontrolled cross-over a possible issue. In this regard, PFS2 data are considered of value. Unfortunately, at the time of data cut-off date, the PFS2 analysis was still largely immature, with just 27.8% and 35.3% of events observed in the pembrolizumab and BV arms, respectively. Reassuringly, a favourable trend could still be observed (HR 0.58, 95%CI 0.38, 0.87, p=0.0037), yet updated data and detailed information on subsequent treatments are needed to exclude significant differences in treatment patterns across study arms.

The MAH remains blinded to subsequent efficacy data post-IA2 and the first planned formal OS analysis is to occur at ~91 events (IA3), which is not expected to occur until the second quarter of 2022 based on the event rate observed at the data cutoff used for IA2 (16-JAN-2020). An update for PFS2, as well as preplanned analyses assessing effect of crossover on OS will be provided.

With respect to PROs, a trend towards an improvement could generally be observed with pembrolizumab, yet the open-label design of study KN-204 and the absence of any multiplicity control strategy do not allow to uphold formal superiority claims.

Overall, pembrolizumab demonstrated a consistent benefit across subgroups with the main exception of regional differences. Despite there were no obvious imbalances in baseline characteristics that could explain the negative trend in EU vs. ex-EU participants, subgroup analyses suggested inferior efficacy (HR 0.93) [95% CI: 0.50, 1.74], compared with for participants in the EU (n=95) compared to Ex-EU participants (n=209); HR 0.53 [95% CI: 0.37, 0.76]. Median PFS in this subgroup (16.4 months with pembrolizumab and 8.3 months in the BV arm) was in line with what observed in the overall population, yet KM plots showed that, after an initial separation, PFS curves re-joined to remain overlapped in a sort of plateau configuration. No similar trend could be observed in the overall population or in the ex-EU subset. PFS and ORR results stratified by region for the pooled HL population across studies KEYNOTE204, KEYNOTE-087 and KEYNOTE-051 were also provided. The methodological limitations, especially

<div style=\"page-break-after: always\"></div>

regarding interpretability of time-to-event endpoints and the overlapping of the confidence intervals, are acknowledged; nonetheless, also in the relatively large study KN-087 (n=210) a similar trend towards reduced benefit in the EU vs. ex-EU population was observed (ORR difference 7% and median PFS difference 2.5 months in the pooled dataset). Results of PFS Sensitivity Analysis 1 in KEYNOTE-204 confirmed the primary analysis by region. Since the observed regional differences appeared to be less pronounced in the PFS secondary subgroup analysis (PFS censored at the time of transplant), the MAH also evaluated the impact of SCT on PFS in the KEYNOTE-204 EU participants. However inter-treatment arm differences in the arithmetic median of 'additional' PFS time after SCT (i.e. beyond the censoring date of the PFS secondary analysis that was considered based on the primary PFS definition) were only small and therefore, differences between PFS primary and secondary analyses cannot be easily explained by subsequent SCT: the observed differences across regions remain unclear.

Similar clinical outcomes were observed in subjects with 1 and ≥2 prior lines of therapy: the ORRs with pembrolizumab ranged between 61.8% and 66.7% across all subsets defined by number of prior therapies and transplant eligibility vs. 46.4%-54.4% with BV. PFS also consistently favoured the pembrolizumab arm across  all  prior  lines  of  therapy  subgroups,  with  mPFS  ranging  between  16.4  and  11.1  months  with pembrolizumab vs. 8.4-5.7 months with BV (HR 0.62-0.70). Overall, efficacy results were usually more favourable  in  less  pre-treated  subjects  with  one  notable  exception:  a  lower  CRR  was  observed  with pembrolizumab in patients with 1 prior line of therapy (14.8% vs. 25.7% with BV).

Updated  results  with  a  median  follow-up  of  approximately  40  months  were  also  provided  from  the uncontrolled supportive study KN-087, showing an IWG ORR by BICR of 71% (95%CI 64.3, 77) and 71.7% (95%CI 58.6, 82.5) in the overall population and in cohort 3, respectively. CRRs were 27.6% and 31.7%, median DoR 16.6 and 16.8 months and median PFS 13.6 and 16.8 months, respectively. Median OS was not reached in all cohorts. With the limits of indirect comparisons, efficacy results in study KN-087 can be considered supportive of the activity of pembrolizumab in r/r cHL.

BV is a recognised option for subjects who have failed salvage chemotherapy +/- ASCT (i.e. 3 rd  line), so the ~5month Δ in median PFS observed in the pivotal study with pembrolizumab vs. BV, which is equivalent to ~35% reduction in the risk for progression or death, can be considered of clinical relevance in such advanced clinical setting. PFS K-M plots did not show any clear plateau, however, confirming how cure is rarely achieved in advanced relapse settings. However, assessing clinical benefit with pembrolizumab in subjects who have failed one single line of therapy was, less straightforward. According to current EU guidelines (see e.g. the ESMO guidelines for cHL, Eichenauer DA et al, Ann Oncol 2018), non-cross resistant chemotherapy is still  the  recommended  option  for  patients  failing  frontline  treatment,  while  BV  is  not currently authorised in EU as 2 nd  line treatment. In this regard, published data show that ORR as high as 80% (CRR 20-70%) can be observed with salvage polychemotherapy, with 4-year EFS rates of 50% and 10% in transplant-naïve and non-transplant eligible patients, respectively, and 4-year OS rates as high as 70% and 30% for patients who received or not consolidation ASCT, respectively (see e.g. Bartlett NL et al, Ann Oncol. 2007; Kuruvilla J et al, Cancer 2006; Santoro A et al, JCO 2016). For less intensive regimens based on single-agent gemcitabine or bendamustine the reported ORRs were still in the range 40-55% (CRRs 7% and 37%, respectively). A median TTP of 3 months (range, 2-7 months) has been reported with single-agent gemcitabine, while the median DoR with bendamustine monotherapy was as high as 8 months, although this analysis was still immature, with all responders maintaining a continuous response at the last follow-up examination (see e.g. Ozdemir E et al, Blood 2015; Zinzani PL et al, Clin Lymphoma Myeloma Leuk 2015). Even considering patient heterogeneity and the known limits of indirect comparisons, clinical benefit with pembrolizumab in 2 nd  line patients not eligible to transplant is not considered established.

With  respect  to  2nd  line  patients  (n=55),  a  heterogeneous  population  was  included  in  study  KN-204 encompassing both upfront transplant-ineligible patients (e.g. due to age and comorbidities) and subjects who were refractory  to  frontline  chemotherapy.  Only  34/55  2 nd   line  patients  were  deemed  transplantineligible for reasons other than chemorefractoriness, just 22/55 (40%) were aged ≥65 and 7/55 (12.7%)

<div style=\"page-break-after: always\"></div>

≥75 years. No information was provided on concurrent comorbidities that contraindicated ASCT and most patients (74.5%) had a baseline ECOG score of 0. Overall, it is uncertain whether 2 nd  line patients in study KN-204 can be considered representative of real-world transplant ineligible patients and to what extent the observed results can be generalised to such frail population.

With  respect  to  subjects  refractory  to  frontline  chemotherapy,  published  data  suggest  that  autologous transplant  remains  the  best  strategy  to  achieve  long-term  disease  control  (see  e.g.  Sibon  D  et  al, Haematologica 2016): the need for novel salvage therapies characterised by high CRR rates to improve transplant access for primary refractory patients is recognised. In this regard, however, only 21 2 nd  line patients were deemed ineligible to ASCT due to primary chemoresistance in study KN-204 and the CRR rate observed in this 2 nd  line subgroup (14.8%) was not sufficiently compelling.

The limited available data in 2 nd  line transplant-ineligible patients are not considered adequate to conclude for clinical benefit in this subgroup. The indication was eventually revised to reflect this.

## Assessment of paediatric data on clinical efficacy

Study  KN-051  is  an  ongoing  Phase  I/II  study  investigating  pembrolizumab  monotherapy  in  paediatric patients with solid tumours and malignant lymphomas. Paediatric subjects with r/r cHL could be enrolled in the dedicated r/r cHL expansion cohort or in the PD-L1 positive advanced, relapsed or refractory solid tumour or other lymphoma cohort, provided that they had failed standard therapy and no other treatment option  was  considered  appropriate.  The  IWG  response  criteria  were  used  to  assess  response  in  the dedicated cHL cohort, while response in the PD-L1 positive cohort was assessed according to the RECIST 1.1 criteria. Efficacy data were also retrospectively re-assessed using the IWG 2007 and the 2014 Lugano response criteria for all patients.

Overall, 22 paediatric patients with r/r cHL were treated in study KN-051: 7 patients enrolled in the dedicated cHL cohort and 15 in the PD-L1 positive cohort. The median number of prior lines of therapy in the paediatric population was 2 vs. 3 in study KN-204, most patients (13/22, ~60%) had received ABVDlike regimens in first line, which is not unexpected taking into account that adolescents made up for the majority of the studied population and they are often treated according to adult standards in real world clinical practice. In line with the high-risk population studied in the KN-204 trial, most cHL patients in study KN-051 (14/22, ~64%) were refractory to frontline chemotherapy. Overall, the studied population can be considered representative of real-world cHL paediatric patients, in particular adolescents, in an advanced setting of relapse. cHL is rarer in infants and children, which are indeed poorly or not at all represented in the studied population. Clinical benefit evaluations in these settings have to rely on extrapolation from the adult and adolescent setting.

The ORR per IWG criteria observed in the 7 patients treated in the dedicated r/r cHL cohort was 42.9% (3/7), which is numerically lower than what observed in adults in pivotal study KN-204 (i.e. 65.6%). Two out of 7 subjects achieved a CR. Median DoR in this cohort was not reached due to limited follow-up (only one patient had an ongoing DoR ≥6 months). Median PFS in th e r/r cHL cohort (11.2 months) was in line with that observed in study KN-204 (13.2 months), yet the estimated 12-month PFS rate was lower than that reported in adults (27.8% vs. 53.9%, respectively). The ORR per RECIST criteria was 66.7% (10/15 with only one patient reaching a CR), with median DoR and PFS of 17.4 and 12.2 months, respectively. The actual clinical value of these results is, however, unknown because of the limited generalisability of RECIST responses in cHL. OS data are still immature to draw meaningful conclusions.

With respect to the pooled population, higher ORR and CRR were observed with the Lugano criteria (54.5% [12/22] and 4.5% [1/22], respectively) compared to the IWG criteria (63.6% [14/22] and 18.2% [4/22], respectively), possibly reflecting the increased relevance of PET activity vs. TC lesion measures in the 2014 Lugano criteria. As in the adult setting, despite similar median PFS (8.3 and 8.2 months with

<div style=\"page-break-after: always\"></div>

the IWG 2007 and Lugano criteria, respectively) a significant difference in response duration was assessed when the IWG 2007 (17.3 months) and the Lugano criteria (8.8 months) were applied. Again, increased reliance on PET activity rather than dimensional increase of target lesions with the Lugano criteria might explain the shorter response duration. The provided KM curves failed to show any clear plateau, irrespectively of response criteria.

The available efficacy data in paediatric patients with r/r cHL are limited (e.g. because of poor numbers, heterogeneity in response criteria, intrinsic difficulties in assessing time-to-event endpoints in uncontrolled studies and limited information on the possible impact of prognostic characteristics and prior treatments on the  results)  yet  overall  consistent  with  what  observed  in  adults  and,  in  principle,  supportive  of pembrolizumab  activity  in  this  subgroup.  The  totality  of  the  information  presented  provides  reliable evidence to support the extrapolation approach in the paediatric cHL population 3 years old and above. Based on this, the MAH conducted a model-based bridging analysis to identify a dosing regimen that would provide exposures in paediatric patients similar to those in adults as described in this submission.

In line with the framework proposed in the 'Reflection paper on the use of extrapolation in the development of  medicines  for  paediatrics'  the  MAH  has  applied  the  extrapolation  approach  based  on  the  following comparisons between adults and paediatrics 1) similarity of HL disease, 2) similar pharmacology of drug effect, 3) similar exposure-response for efficacy and safety. The totality of evidence allowed the MAH to conduct a model-based bridging analysis to identify a dosing regimen that would provide exposures in paediatric patients similar to those in adults.

HL is recognized as a cancer that affects both children and adults. The disease has the same biology and natural history in both categories. HL has a bimodal age distribution, with peaks at 15 to 35 years of age and again after 50 years of age. While children younger than 14 years old have a higher incidence of nodular lymphocyte predominant HL, cHL is the most common histologic subtype similar to the adult population. Considering data on the incidence of HL in the paediatric population, children 3 years and older was used as an inclusion criteria in KEYNOTE-051.

Classical HL is the population being studied in adult pembrolizumab clinical studies, where the median age of enrolled participants has been in their 30s. The continuity of cHL disease across patients younger than 18 years of age and older than 18 years of age confers that it is essentially the same disease in children and adolescents as in adults. This is underscored by the same prognostic factors associated with success of therapy such as advanced stage disease, presence of B symptoms, bulky disease, ESR, haematocrit, and response to initial chemotherapy. Because of this, no difference in the mechanism of action and activity of pembrolizumab in this setting is expected to be observed between children and adults.

Historically, treatment of cHL in childhood and adults generally utilized the same strategy and agents, with high cure rates especially in younger patients. Treatment of rrcHL similarly follows adult-based strategies, with multi-agent chemotherapy followed by myeloablative high-dose chemotherapy with auto-SCT. Frontline  treatment for children and adolescents with cHL is highly effective, with many patients essentially cured. However, children and adolescents with relapsed or refractory cHL need improved therapies. Their currently available treatment options are typically more multi-agent chemotherapy regimens, including high dose therapy with auto-SCT. In patients who have previously been refractory to or relapsed from 1 or 2 lines of chemotherapy, particularly those with high-risk disease, these existing treatment options are not satisfactory;  while  there  is  little  expectation  of  potential  benefit,  additional  toxicity  is  certain  and unavoidable.  The  other  option  at  that  point  is  investigational  agents  in  clinical  studies.  The  MAH  has identified a clear unmet medical need in this subset.

The IL-2 release biomarker reflects the functional blockade of the PD-1 pathway by pembrolizumab and is utilized as a measure of target engagement - in support of a similar pharmacology drug effect;. Overall, even though the data in paediatric participants are limited, the estimates of IC50 values are similar between adults and paediatric participants.

<div style=\"page-break-after: always\"></div>

Exposure-response  analysis  for  best  percent  change  from  baseline  tumor  size,  demonstrated  similar relationships between adult and paediatric participants with cHL.

Efficacy in cHL paediatric patients is supported by extrapolation of efficacy data in adults (KEYNOTE-204, KEYNOTE-087). In addition, KEYNOTE-051 provides supportive efficacy data in cHL paediatric patients and safety data in paediatric patients with different tumor types. Overall, the evidence supports a positive B/R in the target population of children 3 years and older.

## 2.4.4. Conclusions on the clinical efficacy

Based on the available efficacy data, clinical benefit with pembrolizumab vs. BV is considered established for adult patients with r/r cHL who have failed 2 nd  line salvage chemotherapy +/- ASCT.

Efficacy data in the paediatric setting are limited, however, when the rarity of cHL in the paediatric age and the consistent disease biology across age classes are taken into account, the available data can be considered adequate to confirm the activity of pembrolizumab in paediatric patients and support the proposed extrapolation strategy of results observed in the adult setting.

Therefore, the indication was eventually revised to 'KEYTRUDA as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option'.

The final study report for study P204 is already included as a Post-authorisation efficacy study (PAES) in the Annex II; the deadline for the submission of the CSR has been extended to Q4 of 2025 in order for the MAH to generate OS data as requested by the CHMP.

## 2.5. Clinical safety

## Introduction

In the context of the extension of the currently approved therapeutic indication of pembrolizumab for the treatment of relapsed or refractory classical Hodgkin lymphoma (r/r cHL) in adults to an earlier line of therapy and to include paediatric patients, safety results have been presented by:

- Indication Population, including overall 300 r/r cHL patients treated in the study KEYNOTE-204, a randomized, open-label, Phase 3 trial evaluating pembrolizumab in monotherapy (KEYNOTE-204 Pembrolizumab Safety Dataset; n=148 patients) versus Brentuximab Vedotin (BV) (KEYNOTE-204 BV Safety Dataset; n=152 patients);
- cHL Safety Dataset for Pembrolizumab, a pooled safety data from KEYNOTE 204 (148 patients), updated analysis of KEYNOTE-087 (210 patients) and KEYNOTE-013 cohort 3 (31 patients);
- Pembrolizumab Monotherapy Reference Safety Dataset (RSD), a pooled population including overall 5884 patients treated with pembrolizumab in monotherapy; this dataset consists of mostly solid tumour data and represents the established safety profile for pembrolizumab;
- Cumulative Safety Dataset (CSD), a pooled population including overall 8093 patients who received pembrolizumab in other studies, including cHL in KEYNOTE-013, KEYNOTE-087 and KEYNOTE-204. The CSD was provided only to show that no clinically meaningful change from the RSD occurred, supporting the consistency of the safety data of pembrolizumab across indications.
- To support the extension of the indication to r/r cHL paediatric patients, safety data from KEYNOTE-

<div style=\"page-break-after: always\"></div>

051 were also provided.

Table 62 Safety Datasets

| Dataset (N)                                                | N     | Population 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Nomenclature in Tables/Figures                      | Nomenclature in Text                      |
|------------------------------------------------------------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|-------------------------------------------|
| KEYNOTE-204 Pembrolizumab Safety Dataset                   | 148   | Participants with relapsed or refractory cHL who received pembrolizumab in KEYNOTE-204.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | KEYNOTE-204 Data for Pembrolizumab                  | KEYNOTE- 204 Pembrolizumab Safety Dataset |
| KEYNOTE-204 BV Safety Dataset                              | 152   | Participants with relapsed or refractory cHL who received BV in KEYNOTE-204.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | KEYNOTE-204 Data for BV                             | KEYNOTE- 204 BV Safety Dataset            |
| cHL Safety Dataset for Pembrolizumab                       | 389   | Participants with relapsed or refractory cHL who received pembrolizumab in KEYNOTE-204 (n=148), KEYNOTE-087 (n=210), and KEYNOTE-013, Cohort 3 (n=31).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | cHL Safety Dataset for Pembrolizumab                | cHL Safety Dataset                        |
| Pembrolizumab Monotherapy Reference Safety Dataset 2       | 588 4 | Participants who received pembrolizumab in the following populations and studies: melanoma (n=2076) in KEYNOTE-001, KEYNOTE-002, KEYNOTE-006 and KEYNOTE-054; NSCLC (n=2022) in KEYNOTE-001, KEYNOTE-002, KEYNOTE-006, KEYNOTE-010, KEYNOTE-024 and KEYNOTE-42; HNSCC (n=909) in KEYNOTE- 012, KEYNOTE-040, KEYNOTE-048 and KEYNOTE-055; HL (n=241) in KEYNOTE-013 and KEYNOTE-087; Bladder (n=636) in KEYNOTE-045 and KEYNOTE-052.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Reference Safety Dataset for Pembrolizumab          | RSD                                       |
| Cumulative Safety Dataset for Pembrolizumab in Monotherapy | 809 3 | Participants who received pembrolizumab in the following populations and studies: advanced melanoma in KEYNOTE-001, KEYNOTE-002, KEYNOTE-006, and KEYNOTE-054; NSCLC in KEYNOTE-001, KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042; HNSCC in KEYNOTE-012 (Cohort B; Cohort B2), KEYNOTE-040, KEYNOTE- 048, and KEYNOTE-055; gastric cancer in KEYNOTE-012 (Cohort D), KEYNOTE-059 (Cohort 1), and KEYNOTE-062; cHL in KEYNOTE- 013 (Cohort 3), KEYNOTE-087, KEYNOTE-204; bladder cancer in KEYNOTE-012 (Cohort C, urothelial carcinoma ), KEYNOTE-045, and KEYNOTE-052; colorectal cancer in KEYNOTE-164 (Cohort A); PMBCL in KEYNOTE-013 (Cohort 4A) and KEYNOTE-170; cervical cancer in KEYNOTE- 028 (Cohort B4) and KEYNOTE-158 (Cohort E); advanced HCC in KEYNOTE-224; MCC in KEYNOTE-017; esophageal cancer in KEYNOTE- 024 and KEYNOTE-028 (Cohort A4); RCC in KEYNOTE-427; SCLC in KEYNOTE-028 (Cohort C1) KEYNOTE-158 (Cohort G); NMIBC in KEYNOTE-057; and TMB-H in KEYNOTE-158. | Cumulative Running Safety Dataset for Pembrolizumab | Cumulative Safety Dataset                 |

Abbreviations: BV=brentuximab vedotin; cHL=Classical hodgkin lymphoma; HCC=Hepatocellular carcinoma; HL=Hodgkin lymphoma;

HNSCC=Head and neck squamous  cell carcinoma; MCC=Merkel cell carcinoma; NMIBC=Non-muscle invasive bladder cancer; NSCLC=Non-small cell lung cancer; RCC=Renal cell carcinoma; RSD=Reference safety dataset; SCLC=Small-cell lung cancer; TMB-H=high tumor mutation burden.

1 All participants in the listed populations received at least 1 dose of the study treatment.

2 The Pembrolizumab Monotherapy RSD represents the established safety profile of pembrolizumab in monotherapy.

## Patient exposure

Demographic and other characteristics of Study Population in the different Safety Datasets are reported in Table  2.  Gender,  race  and  ECOG  performance  were  generally  similar  across  the  KEYNOTE-204  safety datasets,  the  cHL  Safety  Dataset  and  the  RSD.  Most  patients  were  male,  white  and  had  an  ECOG

<div style=\"page-break-after: always\"></div>

performance status score of 0. However, differences in age and region were observed between the different datasets: in the KEYNOTE-204 and in the cHL Safety Dataset, the median age of patients was less than that in the RSD, and more than 80% of patients were &lt;65 years old compared with 57.5% of patients in the RSD. Lower age is expected based on the epidemiology of cHL compared to solid tumors included in the RSD. In addition, in KEYNOTE-204, more patients in both arms (pembrolizumab and BV) were enrolled at ex-EU sites than in the cHL Safety Dataset (68.2% and 70.4% vs 56.8%), as observed for enrolment in the RSD (64.4%).

Table 63 Patients Characteristics

|                                           | KN204 Data for Pembrolizuma b ‡‡   | KN204 Data for Pembrolizuma b ‡‡   | KN204 Data for Brentuximab Vedotin ¶   | KN204 Data for Brentuximab Vedotin ¶   | cHL Safety Data for Pembrolizuma b ║   | cHL Safety Data for Pembrolizuma b ║   | Reference Safety Dataset for Pembrolizuma b ††   | Reference Safety Dataset for Pembrolizuma b ††   | Cumulative Running Safety Dataset for Pembrolizuma b §§   | Cumulative Running Safety Dataset for Pembrolizuma b §§   |
|-------------------------------------------|------------------------------------|------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|--------------------------------------------------|--------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                                           | n                                  | (%)                                | n                                      | (%)                                    | n                                      | (%)                                    | n                                                | (%)                                              | n                                                         | (%)                                                       |
| Subjects in population                    | 148                                |                                    | 152                                    |                                        | 389                                    |                                        | 5,884                                            |                                                  | 8,093                                                     |                                                           |
| Gender                                    |                                    |                                    |                                        |                                        |                                        |                                        |                                                  |                                                  |                                                           |                                                           |
| Male                                      | 81                                 | (54.7)                             | 89                                     | (58.6)                                 | 212                                    | (54.5)                                 | 3,887                                            | (66.1)                                           | 5,416                                                     | (66.9)                                                    |
| Female                                    | 67                                 | (45.3)                             | 63                                     | (41.4)                                 | 177                                    | (45.5)                                 | 1,997                                            | (33.9)                                           | 2,677                                                     | (33.1)                                                    |
| Age (Years)                               |                                    |                                    |                                        |                                        |                                        |                                        |                                                  |                                                  |                                                           |                                                           |
| <65                                       | 122                                | (82.4)                             | 130                                    | (85.5)                                 | 343                                    | (88.2)                                 | 3,385                                            | (57.5)                                           | 4,640                                                     | (57.3)                                                    |
| >=65                                      | 26                                 | (17.6)                             | 22                                     | (14.5)                                 | 46                                     | (11.8)                                 | 2,499                                            | (42.5)                                           | 3,453                                                     | (42.7)                                                    |
| Mean                                      | 41.8                               |                                    | 40.9                                   |                                        | 39.7                                   |                                        | 60.6                                             |                                                  | 60.4                                                      |                                                           |
| SD                                        | 17.6                               |                                    | 17.2                                   |                                        | 15.7                                   |                                        | 13.2                                             |                                                  | 13.4                                                      |                                                           |
| Median                                    | 35.5                               |                                    | 35.0                                   |                                        | 35.0                                   |                                        | 62.0                                             |                                                  | 62.0                                                      |                                                           |
| Range                                     | 18 to 84                           |                                    | 18 to 83                               |                                        | 18 to 84                               |                                        | 15 to 94                                         |                                                  | 15 to 94                                                  |                                                           |
| Race                                      |                                    |                                    |                                        |                                        |                                        |                                        |                                                  |                                                  |                                                           |                                                           |
| American Indian Or Alaska Native          | 1                                  | (0.7)                              | 0                                      | (0.0)                                  | 2                                      | (0.5)                                  | 29                                               | (0.5)                                            | 42                                                        | (0.5)                                                     |
| Asian                                     | 13                                 | (8.8)                              | 13                                     | (8.6)                                  | 25                                     | (6.4)                                  | 658                                              | (11.2)                                           | 1,209                                                     | (14.9)                                                    |
| Black Or African American                 | 4                                  | (2.7)                              | 8                                      | (5.3)                                  | 11                                     | (2.8)                                  | 108                                              | (1.8)                                            | 138                                                       | (1.7)                                                     |
| Multiracial                               | 4                                  | (2.7)                              | 5                                      | (3.3)                                  | 7                                      | (1.8)                                  | 66                                               | (1.1)                                            | 85                                                        | (1.1)                                                     |
| Native Hawaiian Or Other Pacific Islander | 1                                  | (0.7)                              | 0                                      | (0.0)                                  | 1                                      | (0.3)                                  | 4                                                | (0.1)                                            | 9                                                         | (0.1)                                                     |
| Unknown                                   | 0                                  | (0.0)                              | 0                                      | (0.0)                                  | 0                                      | (0.0)                                  | 0                                                | (0.0)                                            | 4                                                         | (0.0)                                                     |
| White                                     | 116                                | (78.4)                             | 114                                    | (75.0)                                 | 330                                    | (84.8)                                 | 4,444                                            | (75.5)                                           | 5,957                                                     | (73.6)                                                    |
| Missing                                   | 9                                  | (6.1)                              | 12                                     | (7.9)                                  | 13                                     | (3.3)                                  | 575                                              | (9.8)                                            | 649                                                       | (8.0)                                                     |
| Ethnicity                                 |                                    |                                    |                                        |                                        |                                        |                                        |                                                  |                                                  |                                                           |                                                           |
| Hispanic Or Latino                        | 24                                 | (16.2)                             | 20                                     | (13.2)                                 | 41                                     | (10.5)                                 | 389                                              | (6.6)                                            | 531                                                       | (6.6)                                                     |
| Not Hispanic Or Latino                    | 109                                | (73.6)                             | 114                                    | (75.0)                                 | 288                                    | (74.0)                                 | 4,690                                            | (79.7)                                           | 6,588                                                     | (81.4)                                                    |
| Not Reported                              | 8                                  | (5.4)                              | 10                                     | (6.6)                                  | 34                                     | (8.7)                                  | 181                                              | (3.1)                                            | 291                                                       | (3.6)                                                     |
| Unknown                                   | 5                                  | (3.4)                              | 5                                      | (3.3)                                  | 24                                     | (6.2)                                  | 110                                              | (1.9)                                            | 156                                                       | (1.9)                                                     |
| Missing                                   | 2                                  | (1.4)                              | 3                                      | (2.0)                                  | 2                                      | (0.5)                                  | 514                                              | (8.7)                                            | 527                                                       | (6.5)                                                     |
| Age Class (Years)                         |                                    |                                    |                                        |                                        |                                        |                                        |                                                  |                                                  |                                                           |                                                           |
| <65                                       | 122                                | (82.4)                             | 130                                    | (85.5)                                 | 343                                    | (88.2)                                 | 3,385                                            | (57.5)                                           | 4,640                                                     | (57.3)                                                    |
| 65-74                                     | 17                                 | (11.5)                             | 16                                     | (10.5)                                 | 36                                     | (9.3)                                  | 1,737                                            | (29.5)                                           | 2,419                                                     | (29.9)                                                    |
| 75-84                                     | 9                                  | (6.1)                              | 6                                      | (3.9)                                  | 10                                     | (2.6)                                  | 663                                              | (11.3)                                           | 905                                                       | (11.2)                                                    |
| >=85                                      | 0                                  | (0.0)                              | 0                                      | (0.0)                                  | 0                                      | (0.0)                                  | 99                                               | (1.7)                                            | 129                                                       | (1.6)                                                     |

5,416

2,677

4,640

3,453

94

5,957

6,588

4,640

<div style=\"page-break-after: always\"></div>

2,801

5,292

3,723

4,059

| Geographic Region            | Geographic Region      | Geographic Region      | Geographic Region      | Geographic Region      | Geographic Region      | Geographic Region      | Geographic Region      | Geographic Region      | Geographic Region      | Geographic Region      |
|------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| EU                           | 47                     | (31.8)                 | 45                     | (29.6)                 | 168                    | (43.2)                 | 2,092                  | (35.6)                 | 2,801                  | (34.6)                 |
| Ex-EU                        | 101                    | (68.2)                 | 107                    | (70.4)                 | 221                    | (56.8)                 | 3,792                  | (64.4)                 | 5,292                  | (65.4)                 |
| ECOG Performance Scale       | ECOG Performance Scale | ECOG Performance Scale | ECOG Performance Scale | ECOG Performance Scale | ECOG Performance Scale | ECOG Performance Scale | ECOG Performance Scale | ECOG Performance Scale | ECOG Performance Scale | ECOG Performance Scale |
| [0] Normal Activity          | 84                     | (56.8)                 | 99                     | (65.1)                 | 200                    | (51.4)                 | 2,761                  | (46.9)                 | 3,723                  | (46.0)                 |
| [1] Symptoms, but ambulatory | 63                     | (42.6)                 | 53                     | (34.9)                 | 187                    | (48.1)                 | 2,931                  | (49.8)                 | 4,059                  | (50.2)                 |
| Other/Missing                | 1                      | (0.7)                  | 0                      | (0.0)                  | 2                      | (0.5)                  | 192                    | (3.3)                  | 201                    | (2.5)                  |
| Not Collected per Protocol   | 0                      | (0.0)                  | 0                      | (0.0)                  | 0                      | (0.0)                  | 0                      | (0.0)                  | 110                    | (1.4)                  |

Safety results from participants treated with pembrolizumab in KEYNOTE-204 was the primary focus of this submission. KEYNOTE-204 is an ongoing, Phase 3, randomized, open-label study of pembrolizumab (200 mg Q3W) compared with BV (1.8 mg/kg Q3W) in participants with cHL. All participants had either failed treatment that included auto-SCT or had received at least 1 multi-agent chemotherapy regimen if they were not candidates for auto-SCT before enrolling in KEYNOTE-204. Participants who had received BV or BV containing regimen were enrolled in the study if they had responded (partial or complete) to the BV or BV-containing regimen.

In KEYNOTE-204, the median exposure to pembrolizumab was twice as long as the median exposure to BV (10.02  months  vs  4.81  months).  Overall,  48%  (71/148)  of  participants  in  the  KEYNOTE-204  were  on treatment  for  ≥12  months,  with  a  median  of  15  administrations  compared  with  11.2%  (17/152)  of participants in the BV group on treatment for ≥12 months and a median of 7 administrations (Table 3b). The median duration of follow-up was 24.9 months (range: 1.8 to 42.0 months) in the pembrolizumab arm and 24.3 months (range: 0.6 to 42.3 months) in the BV arm. Median exposure to pembrolizumab was similar between the KEYNOTE-204 pembrolizumab arm and the cHL Safety Dataset, in which 389 patients received at  le ast  1  dose  of  pembrolizumab,  46.8%  (182/389) remained on treatment for ≥12 months (median  of  10.65  months)  and  received  a  median  of  16  administrations.  In  the  RSD,  exposure  to pembrolizumab was lower (median of 4.86 months), with 21.8% of the participants on treatment for ≥12 months and a median of 8 administrations.

Table 64 Summary of Drug Exposure

|                              | KN204 Data for Pembrolizumabtt (N=148)   | KN204 Data for BrentuximabVedotin (N=152)   | cHL Safety Data for Pembrolizumabll (N=389)   | Reference Safety Dataset for Pembrolizumab*+ (N=5884)   | CumulativeRumning Safety Dataset for Pembrolizumab (N=8093)   |
|------------------------------|------------------------------------------|---------------------------------------------|-----------------------------------------------|---------------------------------------------------------|---------------------------------------------------------------|
| Duration on therapy (Months) |                                          |                                             |                                               |                                                         |                                                               |
| Mean                         | 12.2                                     | 6.1 4.81                                    | 12.5 8.25                                     | 7.3                                                     | 7.1                                                           |
| Median                       | 10.02                                    |                                             | 10.65                                         | 4.86                                                    | 4.24                                                          |
| SD                           | 8.18                                     | 5.43                                        |                                               | 6.79                                                    | 7.20                                                          |
| Range                        | 0.03 to 26.74                            | 0.03 to 26.09                               | 0.03 to 27.93                                 | 0.03 to 32.46                                           | 0.03 to 53.42                                                 |
| Number of Administrations    |                                          |                                             |                                               |                                                         |                                                               |
| Mean                         | 18.1                                     | 9.3                                         | 19.0                                          | 11.6                                                    | 11.4                                                          |
| Median                       | 15.00                                    | 7.00                                        | 16.00                                         | 8.00                                                    | 7.00                                                          |
| SD                           | 11.61                                    | 7.32                                        | 12.16                                         | 10.17                                                   | 10.65                                                         |

<div style=\"page-break-after: always\"></div>

Table 65 Drug Exposure by Duration

<!-- image -->

## Adverse events

Safety and tolerability have been evaluated during the treatment period up to the cut-off date of 16-Jun2020 for KEYNOTE-204. Adverse events, occurred from the first dose up to 30 days after the last dose, were coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 22.1 and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03.

Most AEs were of low-grade toxicity, as evidenced by the low rate of subjects with toxicity Grade 3 to 5 drug-related AEs (62 [15.9%]) and with serious drug-related adverse events (46 [11.8%]) in the 389subject cHL population (cHL Safety Dataset).

In study KEYNOTE-204, some differences were observed in AEs between the KEYNOTE-204 pembrolizumab safety dataset and the BV group, as the incidence of SAEs and the drug-related SAEs was higher in the pembrolizumab arm than in the BV group (SAEs 29.7% vs 21.1%, respectively; drug-related SAEs 16.2% vs 10.5%, respectively). However, when adjusted for exposure, the event rates for SAEs and drug-related SAEs were similar between groups, whereas the event rates for AEs and Grade 3 to 5 AEs were higher in the  BV  arm  than  in  the  KEYNOTE-204  pembrolizumab  group.  Deaths  due  to  AEs  occurred  in  3  (2%) pembrolizumab participants vs 2 (1.3%) BV participants; for 1 (0.7%) pembrolizumab participant, death was reported as drug related, while none of the 2 BV death was attributed to the drug.

Table 66 Summary of Adverse Events

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Souree: [ISS: adam-sdksl, adne]

Table 67 Summary of Exposure-Adjusted Adverse Event

<!-- image -->

In KEYNOTE-204, participants had received a median of 2 (range: 1 to 10) or 3 (range: 1 to 11) prior lines of therapy for pembrolizumab and BV, respectively, and the percentage of patients with primary refractory disease and prior auto-SCT was 40.4% and 37.1% in the pembrolizumab arm versus 40.5% and 36.6% in the BV arm. Prior use of BV was reported for 3.3% of patients in the pembrolizumab arm vs 6.5% in the BV group. Considering the inclusion criteria, a quite heterogeneous population in terms of prior exposure and response to previous therapy (including brentuximab, radiation therapy and auto-SCT), was enrolled in the KEYNOTE-204. As only 5 participants received prior BV in the pembrolizumab arm in KEYNOTE-204, comparison of AEs by prior BV status does not allow for a meaningful comparison.

<div style=\"page-break-after: always\"></div>

Table 68: AE summary by prior BV status (ASaT population)

<!-- image -->

|                                                                                                                                              | Prior BV                                                                                                                                     | Prior BV                                                                                                                                     | No Prior BV                                                                                                                                  | No Prior BV                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                              | n                                                                                                                                            | (%)                                                                                                                                          | n                                                                                                                                            | (%)                                                                                                                                          |
| Subjects in population                                                                                                                       | 5                                                                                                                                            |                                                                                                                                              | 143                                                                                                                                          |                                                                                                                                              |
| with one or more adverse events                                                                                                              | 4                                                                                                                                            | (80.0)                                                                                                                                       | 141                                                                                                                                          | (98.6)                                                                                                                                       |
| with no adverse event                                                                                                                        | 1                                                                                                                                            | (20.0)                                                                                                                                       | 2                                                                                                                                            | (1.4)                                                                                                                                        |
| with drug-related adverse events                                                                                                             | 3                                                                                                                                            | (60.0)                                                                                                                                       | 107                                                                                                                                          | (74.8)                                                                                                                                       |
| with toxicity grade 3-5 adverse events                                                                                                       | 4                                                                                                                                            | (80.0)                                                                                                                                       | 19                                                                                                                                           | (42.7)                                                                                                                                       |
| with toxicity grade 3-5 drug-related adverse events                                                                                          | 0                                                                                                                                            | (0.0)                                                                                                                                        | 29                                                                                                                                           | (20.3)                                                                                                                                       |
| with non-serious adverse events                                                                                                              | 4                                                                                                                                            | (80.0)                                                                                                                                       | 140                                                                                                                                          | (97.9)                                                                                                                                       |
| with serious adverse events                                                                                                                  | 3                                                                                                                                            | (60.0)                                                                                                                                       | 41                                                                                                                                           | (28.7)                                                                                                                                       |
| with serious drug-related adverse events                                                                                                     | 0                                                                                                                                            | (0.0)                                                                                                                                        | 24                                                                                                                                           | (16.8)                                                                                                                                       |
| who died                                                                                                                                     | 0                                                                                                                                            | (0.0)                                                                                                                                        | 3                                                                                                                                            | (2.1)                                                                                                                                        |
| who died due to a drug-related adverse event                                                                                                 | 0                                                                                                                                            | (0.0)                                                                                                                                        | 1                                                                                                                                            | (0.7)                                                                                                                                        |
| discontinued drug due to an adverse event                                                                                                    | 0                                                                                                                                            | (0.0)                                                                                                                                        | 20                                                                                                                                           | (14.0)                                                                                                                                       |
| discontinued drugdue toa drug-related adverseevent                                                                                           | 0                                                                                                                                            | (0.0)                                                                                                                                        | 19                                                                                                                                           | (13.3)                                                                                                                                       |
| discontinued drug due to a serious adverse event                                                                                             | 0                                                                                                                                            | (0.0)                                                                                                                                        | 14                                                                                                                                           | (9.8)                                                                                                                                        |
| discontinueddugduetoasenious drug-related adverse event                                                                                      | 0                                                                                                                                            | (0.0)                                                                                                                                        | 13                                                                                                                                           | (9.1)                                                                                                                                        |
| tDetermined by the investigator to be related to the drug. Grades arebased on NCICTCAE.                                                      | tDetermined by the investigator to be related to the drug. Grades arebased on NCICTCAE.                                                      | tDetermined by the investigator to be related to the drug. Grades arebased on NCICTCAE.                                                      | tDetermined by the investigator to be related to the drug. Grades arebased on NCICTCAE.                                                      | tDetermined by the investigator to be related to the drug. Grades arebased on NCICTCAE.                                                      |
| Non-senious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.                    | Non-senious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.                    | Non-senious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.                    | Non-senious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.                    | Non-senious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.                    |
| MedDRA preferred tems \"Neoplasm progression\",\"Malignant neoplasm progression\" and \"Disease progression\" notrelated to the drug are excluded. | MedDRA preferred tems \"Neoplasm progression\",\"Malignant neoplasm progression\" and \"Disease progression\" notrelated to the drug are excluded. | MedDRA preferred tems \"Neoplasm progression\",\"Malignant neoplasm progression\" and \"Disease progression\" notrelated to the drug are excluded. | MedDRA preferred tems \"Neoplasm progression\",\"Malignant neoplasm progression\" and \"Disease progression\" notrelated to the drug are excluded. | MedDRA preferred tems \"Neoplasm progression\",\"Malignant neoplasm progression\" and \"Disease progression\" notrelated to the drug are excluded. |

Source:[P204V01MK3475:adam-adsl; adae]

Table 69: AEs by prior radiation status

<!-- image -->

|                                                                                                                                                                                                                                                                        | Prior Radiation                                                                                                                                                                                                                                                        | Prior Radiation                                                                                                                                                                                                                                                        | NoPrior Radiation                                                                                                                                                                                                                                                      | NoPrior Radiation                                                                                                                                                                                                                                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                        | n                                                                                                                                                                                                                                                                      | (%)                                                                                                                                                                                                                                                                    | n                                                                                                                                                                                                                                                                      | (%)                                                                                                                                                                                                                                                                    |
| Subjects inpopulation                                                                                                                                                                                                                                                  | 58                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                        | 90                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                        |
| with one or more adverse events                                                                                                                                                                                                                                        | 58                                                                                                                                                                                                                                                                     | (100.0)                                                                                                                                                                                                                                                                | 87                                                                                                                                                                                                                                                                     | (96.7)                                                                                                                                                                                                                                                                 |
| with no adverse event                                                                                                                                                                                                                                                  | 0                                                                                                                                                                                                                                                                      | (0.0)                                                                                                                                                                                                                                                                  | 3                                                                                                                                                                                                                                                                      | (3.3)                                                                                                                                                                                                                                                                  |
| with drug-related adverse events                                                                                                                                                                                                                                       | 43                                                                                                                                                                                                                                                                     | (74.1)                                                                                                                                                                                                                                                                 | 67                                                                                                                                                                                                                                                                     | (74.4)                                                                                                                                                                                                                                                                 |
| with toxicity grade 3-5 adverse events                                                                                                                                                                                                                                 | 27                                                                                                                                                                                                                                                                     | (46.6)                                                                                                                                                                                                                                                                 | 38                                                                                                                                                                                                                                                                     | (42.2)                                                                                                                                                                                                                                                                 |
| with toxicity grade 3-5 drug-related adverse events                                                                                                                                                                                                                    | 13                                                                                                                                                                                                                                                                     | (22.4)                                                                                                                                                                                                                                                                 | 16                                                                                                                                                                                                                                                                     | (17.8)                                                                                                                                                                                                                                                                 |
| with non-serious adverse events                                                                                                                                                                                                                                        | 58                                                                                                                                                                                                                                                                     | (100.0)                                                                                                                                                                                                                                                                | 86                                                                                                                                                                                                                                                                     | (95.6)                                                                                                                                                                                                                                                                 |
| with serious adverse events                                                                                                                                                                                                                                            | 19                                                                                                                                                                                                                                                                     | (32.8)                                                                                                                                                                                                                                                                 | 25                                                                                                                                                                                                                                                                     | (27.8)                                                                                                                                                                                                                                                                 |
| with serious dug-related adverse events                                                                                                                                                                                                                                | 12                                                                                                                                                                                                                                                                     | (20.7)                                                                                                                                                                                                                                                                 | 12                                                                                                                                                                                                                                                                     | (13.3)                                                                                                                                                                                                                                                                 |
| who died                                                                                                                                                                                                                                                               | 2                                                                                                                                                                                                                                                                      | (3.4)                                                                                                                                                                                                                                                                  | 1                                                                                                                                                                                                                                                                      | (1.1)                                                                                                                                                                                                                                                                  |
| who died due to a drug-related adverse event                                                                                                                                                                                                                           | 1                                                                                                                                                                                                                                                                      | (1.7)                                                                                                                                                                                                                                                                  | 0                                                                                                                                                                                                                                                                      | (0.0)                                                                                                                                                                                                                                                                  |
| discontinued drug due to an adverse event                                                                                                                                                                                                                              | 9                                                                                                                                                                                                                                                                      | (15.5)                                                                                                                                                                                                                                                                 | 11                                                                                                                                                                                                                                                                     | (12.2)                                                                                                                                                                                                                                                                 |
| discontinued drug due to a drug-related adverse event                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                                                                      | (15.5)                                                                                                                                                                                                                                                                 | 10                                                                                                                                                                                                                                                                     | (11.1)                                                                                                                                                                                                                                                                 |
| discontinued drug due to a serious adverse event                                                                                                                                                                                                                       | 8                                                                                                                                                                                                                                                                      | (13.8)                                                                                                                                                                                                                                                                 | 6                                                                                                                                                                                                                                                                      | (6.7)                                                                                                                                                                                                                                                                  |
| discontinued drug due to a senious drug-related adverse event                                                                                                                                                                                                          | 8                                                                                                                                                                                                                                                                      | (13.8)                                                                                                                                                                                                                                                                 | 5                                                                                                                                                                                                                                                                      | (5.6)                                                                                                                                                                                                                                                                  |
| Determined by the investigator to be related to the drug.                                                                                                                                                                                                              | Determined by the investigator to be related to the drug.                                                                                                                                                                                                              | Determined by the investigator to be related to the drug.                                                                                                                                                                                                              | Determined by the investigator to be related to the drug.                                                                                                                                                                                                              | Determined by the investigator to be related to the drug.                                                                                                                                                                                                              |
| Grades are based on NCI CTCAE                                                                                                                                                                                                                                          | Grades are based on NCI CTCAE                                                                                                                                                                                                                                          | Grades are based on NCI CTCAE                                                                                                                                                                                                                                          | Grades are based on NCI CTCAE                                                                                                                                                                                                                                          | Grades are based on NCI CTCAE                                                                                                                                                                                                                                          |
| Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression” and\"Disease progression\" notrelated to the drug are excluded. | Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression” and\"Disease progression\" notrelated to the drug are excluded. | Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression” and\"Disease progression\" notrelated to the drug are excluded. | Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression” and\"Disease progression\" notrelated to the drug are excluded. | Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression” and\"Disease progression\" notrelated to the drug are excluded. |

Source:[P204V01MK3475:adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Table 70 AEs by prior auto-SCT status.

<!-- image -->

|                                                                                                                                               | Prior Auto-SCT                                                                                                                                | Prior Auto-SCT                                                                                                                                | No Prior Auto-SCT                                                                                                                             | No Prior Auto-SCT                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                               | n                                                                                                                                             | (%)                                                                                                                                           | n                                                                                                                                             | (%)                                                                                                                                           |
| Subjects in population                                                                                                                        | 55                                                                                                                                            |                                                                                                                                               | 93                                                                                                                                            |                                                                                                                                               |
| with one or more adverse events                                                                                                               | 53                                                                                                                                            | (96.4)                                                                                                                                        | 92                                                                                                                                            | (98.9)                                                                                                                                        |
| with no adverse event                                                                                                                         | 2                                                                                                                                             | (3.6)                                                                                                                                         | 1                                                                                                                                             | (1.1)                                                                                                                                         |
| with drug-related adverse events                                                                                                              | 42                                                                                                                                            | (76.4)                                                                                                                                        | 68                                                                                                                                            | (73.1)                                                                                                                                        |
| with toxicity grade 3-5 adverse events                                                                                                        | 26                                                                                                                                            | (47.3)                                                                                                                                        | 39                                                                                                                                            | (41.9)                                                                                                                                        |
| with toxicity grade 3-5 dug-related adverse events                                                                                            | 14                                                                                                                                            | (25.5)                                                                                                                                        | 15                                                                                                                                            | (16.1)                                                                                                                                        |
| with non-serious adverse events                                                                                                               | 53                                                                                                                                            | (96.4)                                                                                                                                        | 16                                                                                                                                            | (97.8)                                                                                                                                        |
| with serious adverse events                                                                                                                   | 21                                                                                                                                            | (38.2)                                                                                                                                        | 23                                                                                                                                            | (24.7)                                                                                                                                        |
| with serious drug-related adverse events                                                                                                      | 10                                                                                                                                            | (18.2)                                                                                                                                        | 14                                                                                                                                            | (15.1)                                                                                                                                        |
| who died                                                                                                                                      | 2                                                                                                                                             | (3.6)                                                                                                                                         | 1                                                                                                                                             | (1.1)                                                                                                                                         |
| whodieddue to a drug-related adverse event                                                                                                    | 1                                                                                                                                             | (1.8)                                                                                                                                         | 0                                                                                                                                             | (0.0)                                                                                                                                         |
| discontinued drug due to an adverse event                                                                                                     | 7                                                                                                                                             | (12.7)                                                                                                                                        | 13                                                                                                                                            | (14.0)                                                                                                                                        |
| discontinued drug due to a dug-related adverse event                                                                                          | 6                                                                                                                                             | (6'01)                                                                                                                                        | 13                                                                                                                                            | (14.0)                                                                                                                                        |
| discontinued drug due to a serious adverse event                                                                                              | 7                                                                                                                                             | (12.7)                                                                                                                                        | 7                                                                                                                                             | (SL)                                                                                                                                          |
| discontinued dug due to a serious drug-related adverse event                                                                                  | 6                                                                                                                                             | (6'01)                                                                                                                                        | 7                                                                                                                                             | (SL)                                                                                                                                          |
| t Determined by the investigator to be related to the drug. Grades are based onNCICTCAE                                                       | t Determined by the investigator to be related to the drug. Grades are based onNCICTCAE                                                       | t Determined by the investigator to be related to the drug. Grades are based onNCICTCAE                                                       | t Determined by the investigator to be related to the drug. Grades are based onNCICTCAE                                                       | t Determined by the investigator to be related to the drug. Grades are based onNCICTCAE                                                       |
| Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.                     | Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.                     | Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.                     | Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.                     | Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.                     |
| MedDRA preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression\" and \"Disease progression\" notrelated to the drug are excluded. | MedDRA preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression\" and \"Disease progression\" notrelated to the drug are excluded. | MedDRA preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression\" and \"Disease progression\" notrelated to the drug are excluded. | MedDRA preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression\" and \"Disease progression\" notrelated to the drug are excluded. | MedDRA preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression\" and \"Disease progression\" notrelated to the drug are excluded. |

Source:[P204V01MK3475:adam-adsl;adae]

Table 71 AEs by prior line of therapy

<!-- image -->

|                                                                                                                                                                                 | One Prior Line                                                                                                                                                                  | One Prior Line                                                                                                                                                                  | Two Pnor Lines                                                                                                                                                                  | Two Pnor Lines                                                                                                                                                                  | Three or More Prior Lines                                                                                                                                                       | Three or More Prior Lines                                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                 | n                                                                                                                                                                               | (%)                                                                                                                                                                             | n                                                                                                                                                                               | (%)                                                                                                                                                                             | n                                                                                                                                                                               | (%)                                                                                                                                                                             |
| Subjects inpopulation                                                                                                                                                           | 27                                                                                                                                                                              |                                                                                                                                                                                 | 50                                                                                                                                                                              |                                                                                                                                                                                 | 71                                                                                                                                                                              |                                                                                                                                                                                 |
| with one or more adverse events                                                                                                                                                 | 27                                                                                                                                                                              | (100.0)                                                                                                                                                                         | 49                                                                                                                                                                              | (98.0)                                                                                                                                                                          | 69                                                                                                                                                                              | (97.2)                                                                                                                                                                          |
| with no adverse event                                                                                                                                                           | 0                                                                                                                                                                               | (0.0)                                                                                                                                                                           | 1                                                                                                                                                                               | (2.0)                                                                                                                                                                           | 2                                                                                                                                                                               | (2.8)                                                                                                                                                                           |
| with drug-related adverse events                                                                                                                                                | 21                                                                                                                                                                              | (77.8)                                                                                                                                                                          | 34                                                                                                                                                                              | (68.0)                                                                                                                                                                          | 55                                                                                                                                                                              | (77.5)                                                                                                                                                                          |
| with toxicity grade 3-5 adverse events                                                                                                                                          | 10                                                                                                                                                                              | (37.0)                                                                                                                                                                          | 22                                                                                                                                                                              | (44.0)                                                                                                                                                                          | 33                                                                                                                                                                              | (46.5)                                                                                                                                                                          |
| with toxicity grade 3-5 dug-related adverse events                                                                                                                              | 1                                                                                                                                                                               | (3.7)                                                                                                                                                                           | 12                                                                                                                                                                              | (24.0)                                                                                                                                                                          | 16                                                                                                                                                                              | (22.5)                                                                                                                                                                          |
| with non-serious adverse events                                                                                                                                                 | 26                                                                                                                                                                              | (96.3)                                                                                                                                                                          | 49                                                                                                                                                                              | (98.0)                                                                                                                                                                          | 69                                                                                                                                                                              | (97.2)                                                                                                                                                                          |
| with serious adverse events                                                                                                                                                     | 8                                                                                                                                                                               | (29.6)                                                                                                                                                                          | 12                                                                                                                                                                              | (24.0)                                                                                                                                                                          | 24                                                                                                                                                                              | (33.8)                                                                                                                                                                          |
| with senious drug-related adverse events                                                                                                                                        | 3                                                                                                                                                                               | (11.1)                                                                                                                                                                          | 8                                                                                                                                                                               | (16.0)                                                                                                                                                                          | 13                                                                                                                                                                              | (18.3)                                                                                                                                                                          |
| who died                                                                                                                                                                        | 0                                                                                                                                                                               | (0.0)                                                                                                                                                                           | 1                                                                                                                                                                               | (2.0)                                                                                                                                                                           | 2                                                                                                                                                                               | (2.8)                                                                                                                                                                           |
| who died due to a drug-related adverse event                                                                                                                                    | 0                                                                                                                                                                               | (0.0)                                                                                                                                                                           | 0                                                                                                                                                                               | (0.0)                                                                                                                                                                           | 1                                                                                                                                                                               | (1.4)                                                                                                                                                                           |
| discontinued drug due to an adverse event                                                                                                                                       | 4                                                                                                                                                                               | (14.8)                                                                                                                                                                          | 8                                                                                                                                                                               | (16.0)                                                                                                                                                                          | 8                                                                                                                                                                               | (11.3)                                                                                                                                                                          |
| discontinued drug due to a drug-related adverse event                                                                                                                           | 4                                                                                                                                                                               | (14.8)                                                                                                                                                                          | 7                                                                                                                                                                               | (14.0)                                                                                                                                                                          | 8                                                                                                                                                                               | (11.3)                                                                                                                                                                          |
| discontinued drug due to a senious adverse event                                                                                                                                | 1                                                                                                                                                                               | (3.7)                                                                                                                                                                           | 6                                                                                                                                                                               | (12.0)                                                                                                                                                                          | 7                                                                                                                                                                               | (9.9)                                                                                                                                                                           |
| discontinued drug due to a serious drug- related adverse event                                                                                                                  | 1                                                                                                                                                                               | (3.7)                                                                                                                                                                           | 5                                                                                                                                                                               | (10.0)                                                                                                                                                                          | 7                                                                                                                                                                               | (9.9)                                                                                                                                                                           |
| t Determined by the investigator to be related to the drug. Grades are based on NCICTCAE.                                                                                       | t Determined by the investigator to be related to the drug. Grades are based on NCICTCAE.                                                                                       | t Determined by the investigator to be related to the drug. Grades are based on NCICTCAE.                                                                                       | t Determined by the investigator to be related to the drug. Grades are based on NCICTCAE.                                                                                       | t Determined by the investigator to be related to the drug. Grades are based on NCICTCAE.                                                                                       | t Determined by the investigator to be related to the drug. Grades are based on NCICTCAE.                                                                                       | t Determined by the investigator to be related to the drug. Grades are based on NCICTCAE.                                                                                       |
| Non-senious adverse events up to 30 days of last dose and senious adverse events up to 90 days of last dose are included.                                                       | Non-senious adverse events up to 30 days of last dose and senious adverse events up to 90 days of last dose are included.                                                       | Non-senious adverse events up to 30 days of last dose and senious adverse events up to 90 days of last dose are included.                                                       | Non-senious adverse events up to 30 days of last dose and senious adverse events up to 90 days of last dose are included.                                                       | Non-senious adverse events up to 30 days of last dose and senious adverse events up to 90 days of last dose are included.                                                       | Non-senious adverse events up to 30 days of last dose and senious adverse events up to 90 days of last dose are included.                                                       | Non-senious adverse events up to 30 days of last dose and senious adverse events up to 90 days of last dose are included.                                                       |
| MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. Database Cutoff Date: 16JAN2020 | MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. Database Cutoff Date: 16JAN2020 | MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. Database Cutoff Date: 16JAN2020 | MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. Database Cutoff Date: 16JAN2020 | MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. Database Cutoff Date: 16JAN2020 | MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. Database Cutoff Date: 16JAN2020 | MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. Database Cutoff Date: 16JAN2020 |

Summaries of AEs by subgroups (i.e., age [&lt;65 vs ≥65 years; &lt;65 vs ≥65 to &lt;75 vs ≥75 to &lt;85 years], gender, race, ECOG status and region [North America vs Europe vs Japan; US vs non-US; EU vs non-EU]) are provided in the KEYNOTE-204 CSR.

<div style=\"page-break-after: always\"></div>

Table 72 Comparison of the safety data of KEYNOTE-204 ,KEYNOTE-087, KEYNOTE-013

<!-- image -->

Table 73 Exposure adjusted Comparison of KEYNOTE-204, KEYNOTE-087, KEYNOTE-013 safety data

<!-- image -->

<!-- image -->

|                                                                      | RN204Data for Pabroliamabt   | KN087Doa foc Penbroliamsb'   | JN013Daa for Poabrcliamsbl   | Refereaco Safoty Daavet for Peebrolizmsbt   | Refereaco Safoty Daavet for Peebrolizmsbt   | Cuambatho Ruwning Safoty Datnot for Peasbrolirumabi   | Cuambatho Ruwning Safoty Datnot for Peasbrolirumabi   |
|----------------------------------------------------------------------|------------------------------|------------------------------|------------------------------|---------------------------------------------|---------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                                      |                              | ?                            |                              |                                             |                                             | 8,093                                                 |                                                       |
| Subjects in popution uith cnecrmoore adwrre ert: uithno sdhoro eueat | 148 53                       | (35.8) (642)                 | 210 72 (343) 138 (65.7)      | 31 14 (45.2) 17 ($4.8)                      | 5,884 1,474 4,410                           | (25.1) 1,973 (74.9) 6.120                             | (24.4) (osL)                                          |
|                                                                      | 95                           |                              | 68                           | 12                                          |                                             | (21.8)                                                |                                                       |
| uith dngrelanodadhwero oveats                                        | 43                           | (29.1)                       | (32.4)                       | (38.7)                                      | 1,281                                       | 1,718                                                 | (212)                                                 |
| u tocityg3-5se ouects                                                |                              | (7.4)                        | 9 (4.3)                      | m (9.7)                                     | 381                                         | (6.5) 517                                             | (6.4)                                                 |
| u tygad3-dugtd                                                       | 9                            | (6.1)                        | 7 (3.3)                      | 2 (6.5)                                     | 331                                         | (3.6) 454                                             | (5.0)                                                 |
| uith soricue sdrere eveats                                           | 13                           | (8.8)                        | 9 (4.3)                      | 3 (6)                                       | 381                                         | (6.5) 502                                             | (6.2)                                                 |
| uith corious drugrolatodadhwree                                      | 12                           | (8.1)                        | 8 (3.)                       | 2 (6.5)                                     | 337                                         | (3.7) 4$9                                             | (52)                                                  |
| oueets ui domodiScatoi dto                                           | 21                           | (142)                        | 2s (11.9)                    | 3 (26.1)                                    | 534                                         | (9.1) 707                                             | (3.7)                                                 |
| ubodiod                                                              |                              | (0.0)                        | (0.0)                        | (0.0)                                       | 11 11                                       | 17                                                    | (0.2)                                                 |
| uo diod dno to a dng-relasod sdverre oront                           |                              | (o0)                         | (o0)                         | 0 (0.0)                                     | (0.2) (0.2)                                 | 17                                                    | (0.2)                                                 |
| dicondioned drugdho to sn adene oveat                                | 13                           | (8.5)                        | 14 (6.7)                     | m (9.7)                                     | 232 (3.9)                                   | 311                                                   | (3.8)                                                 |
| dicontioned dug de toadng roltod sdhuno oteat                        | 13                           | (8.8)                        | 13 (6.2)                     | 3 (9.7)                                     | 228 (3.9)                                   | 307                                                   | (3.)                                                  |
| dicctddug da toaerus                                                 | 10                           | (6.8)                        | 7 (3.3)                      | (0.0)                                       | 156 (2.7)                                   | 204                                                   | (2)                                                   |
| dicddug da toanous dug-rolared adioo otaat                           | 10                           | (6.8)                        | 7 (33)                       | (0.0)                                       | 154 (2.0)                                   | 202                                                   | (2)                                                   |

## Common adverse events

In the KEYNOTE-204, the most frequent reported AEs (incidence &gt;10%) were as follows:

<div style=\"page-break-after: always\"></div>

- diarrhea (19.6%), pyrexia (19.6%), hypothyroidism (18.9%) and upper respiratory tract infection (18.9%) in the Pembrolizumab Safety Dataset;
- nausea (24.3%), vomiting (19.7%), fatigue (18.4%) and neuropathy peripheral (18.4%) in the BV arm.

The overall frequency and the type of AEs reported in the KEYNOTE-204 pembrolizumab arm were generally consistent with the cHL Safety Dataset.

In comparison with the RSD and the CSD , the AEs that were most frequently reported (≥5 percentage point difference) in the KEYNOTE-204 pembrolizumab arm than in the RSD were:

- pyrexia (19.6% vs 12.7% and 12.6%, respectively), hypothyroidism (18.9% vs 11.1% and 10.8%, respectively), upper  respiratory  tract  infection (18.9%  vs  6.6%  and  6.4%,  respectively)  and nasopharyngitis (11.5% vs 6.1 and 5.8%, respectively).

Table 74 Subjects with Adverse Events (incidence &gt; 0% in one or more treatment groups) by decreasing frequency of preferred term

<!-- image -->

|                                    | KN204 Daia for Pembrolirmabit   | KN204 Daia for Pembrolirmabit   | KN204 Data for Brentuximab Vedotin   | KN204 Data for Brentuximab Vedotin   | cHL Safety Dala for Pembroliamebl   | cHL Safety Dala for Pembroliamebl   | Reference Safety Datusdt for Pembrolirmabl!   | Reference Safety Datusdt for Pembrolirmabl!   | Cumlatve Running Safety Daaetfor Pembroliamsb     | Cumlatve Running Safety Daaetfor Pembroliamsb     |
|------------------------------------|---------------------------------|---------------------------------|--------------------------------------|--------------------------------------|-------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                    |                                 |                                 |                                      | (5)                                  |                                     | (2)                                 |                                               | ()                                            |                                                   | (9)                                               |
| Subecp in popultion                | 148                             |                                 | 251                                  |                                      | 389                                 |                                     | 5.,014                                        |                                               | 8,093                                             |                                                   |
| with one or more sdvense cvenls    | 145                             | (086)                           | 143                                  | (94.1)                               | 381                                 | (97.9)                              | 5,690                                         | (96.7)                                        | 7,811                                             | (96.5)                                            |
| wih no adverso evens               | 3                               | (2.0)                           | 9                                    | (5.9)                                | &                                   | (2.1)                               | 194                                           | (3.3)                                         | 282                                               | (3.5)                                             |
| Diunloei                           | 6                               | (19.6)                          | 25                                   | (16.4)                               | 14                                  | (21.6)                              | 1,200                                         | (20.4)                                        | 1,596                                             | (19.7)                                            |
| Pyrexla                            | 6                               | (19.6)                          | 20                                   | (13.2)                               | 98                                  | (252)                               | 746                                           | (z)                                           | 1,021                                             | (12.6)                                            |
| Hypotlyroidism                     |                                 | (681)                           | 4                                    | (2.0)                                | 66                                  | (17.0)                              | 651                                           | (11.1)                                        | 873                                               | (10.8)                                            |
|                                    |                                 | (681)                           | 22                                   | (14.5)                               | 74                                  | (061)                               | 387                                           | (6.6)                                         | 518                                               | (6.4)                                             |
| Prurilus                           | 26                              | (17.6)                          | 18                                   | (11.8)                               | 64                                  | (165)                               | 1,060                                         | (18.0)                                        | 1,379                                             | (17.0)                                            |
| (Congh                             | 25                              | (691)                           | 20                                   | (13.2)                               | 92                                  | (23.7)                              | 1,148                                         | (195)                                         | 1,493                                             | (18.4)                                            |
| Fatigue                            | 23                              | (15.5)                          | 28                                   | (18.4)                               | 76                                  | (19.5)                              | 1,884                                         | (32.0)                                        | 2,462                                             | (30.4)                                            |
| Niuse                              | 21                              | (14.2)                          | 37                                   | (24.3)                               | 67                                  | (172)                               | 1,213                                         | (20.6)                                        | 1,637                                             | (20.2)                                            |
| Vomiting                           | 20                              | (13.5)                          | 30                                   | (19.7)                               | 64                                  | (165)                               | 732                                           | (12.4)                                        | 1,023                                             | (12.6)                                            |
| Back Pain                          | 19                              | (12.8)                          | 18                                   | (11.8)                               | 48                                  | (123)                               | 662                                           | (113)                                         | 896                                               | (11.1)                                            |
| Mtophuryngitis                     | 17                              | (11.5)                          | &                                    | (3.3)                                | 35                                  | (14.1)                              | 360                                           | (6.1)                                         | 472                                               | (38)                                              |
| Urinay Tnct lnfection              | 16                              | (10.8)                          | 4                                    | (2.6)                                | 31                                  | (8.0)                               | 384                                           | (6.5)                                         | 519                                               | (6.4)                                             |
| Heudache                           | 15                              | (10.1)                          | 15                                   | (9.9)                                | 47                                  | (1z1)                               | 711                                           | (12.1)                                        | 870                                               | (10.8)                                            |
| Almine Aminctnusfenss herersed     | 13                              | (8.8)                           | 15                                   | (9.9)                                | 27                                  | (6.9)                               | 66E                                           | (6.7)                                         | 363                                               | (7.0)                                             |
| Arthralgia                         | 13                              | (8.8)                           | I1                                   | (7.2)                                | 44                                  | (113)                               | 851                                           | (14.5)                                        | 1,073                                             | (13.3)                                            |
| Pain lh Extrenity                  | 13                              | (8.8)                           | 7                                    | (4.6)                                |                                     | (6.2)                               | 391                                           | (6.6)                                         | 486                                               | (6.0)                                             |
| Paeumonitis                        | 13                              | (8.8)                           | 3                                    | (2.0)                                | 27                                  | (6.9)                               | 242                                           | (4.1)                                         | 305                                               | (3.8)                                             |
| Rah                                | 13                              | (.8)                            | 13                                   | (8.0)                                | 50                                  | (12.9)                              | 904                                           | (15.4)                                        | 1,117                                             | (13.8)                                            |
| Asputate Aminotransferse Inerensed | 12                              | (8.1)                           | II                                   | (7.2)                                | 24                                  | (6.2)                               | 384                                           | (6.5)                                         | 396                                               | (7.4)                                             |
|                                    | KN204 Daia for Penbroliamabit   | KN204 Daia for Penbroliamabit   | KN204 Daia for Brentuximab Vedotin   | KN204 Daia for Brentuximab Vedotin   | CHL Safety Dhin for Fembroliamb!    | CHL Safety Dhin for Fembroliamb!    | Reference Safety Datnsst for Pembrolirumahll  | Reference Safety Datnsst for Pembrolirumahll  | Curulathe Ranning Safety Duset for PembrolizumabM | Curulathe Ranning Safety Duset for PembrolizumabM |
|                                    |                                 |                                 |                                      |                                      |                                     |                                     |                                               |                                               |                                                   | ()                                                |
| Omophuryngeal Pain                 | 12                              | (8.1)                           |                                      | (3.31                                | 36                                  | (9.3)                               | 196                                           | (3.3)                                         | 265                                               | (3.3)                                             |
| Paeumonia                          | 12                              | (8.1)                           | 9                                    | (5.9)                                | DE                                  | (7.7)                               | 433                                           | (7.4)                                         | 563                                               | (7.0)                                             |
| Consipation                        | 11                              | (7.4)                           | 19                                   | (sz1)                                | 42                                  | (10.8)                              | 995                                           | (691)                                         | 1,361                                             | (16.8)                                            |
| Dyupuoet                           | 11                              | (7.4)                           | 9                                    | (3.9)                                | 47                                  | (12.1)                              | 989                                           | (16.8)                                        | 1,227                                             | (15.2)                                            |
| Alhminal Pain                      | 01                              | (6.8)                           | 15                                   | (9.9)                                | 27                                  | (6.9)                               | 480                                           | (1.2)                                         | 762                                               | (9.4)                                             |
| Neulopenin                         | 10                              | (6.8)                           | 20                                   | (13.2)                               | 23                                  | (5.9)                               | 49                                            | (0.8)                                         | 86                                                | (1.1)                                             |
| Weight lnerenwsd                   | 10                              | (6.8)                           | 2                                    | (1.3)                                | 21                                  | (3.4)                               | 190                                           | (β.2)                                         | 225                                               | (2.8)                                             |
| Ansemin                            | 9                               | (6.1)                           | 13                                   | (4.6)                                | 36                                  | (9.3)                               | 836                                           | (14.2)                                        | 1,215                                             | (15.0)                                            |
| Docretsed Appetite                 | 9                               | (6.1)                           | 14                                   | (9.2)                                | 25                                  | (6.4)                               | 1,136                                         | (E61)                                         | 1,564                                             | (193)                                             |
| Thmmbcylopenia                     | 9                               | (6.1)                           | 8                                    | (5.3)                                | 12                                  | (5.4)                               | 89                                            | (1.5)                                         | 132                                               | (1.6)                                             |
| Astlenln                           | 8                               | (5.4)                           | 7                                    | (4.6)                                | 33                                  | (8.5)                               | 666                                           | (11.3)                                        | 16                                                | (113)                                             |
| Hyperlyroidism                     |                                 | (5.4)                           | 1                                    | (0.7)                                | 17                                  | (4.4)                               | 247                                           | (4.2)                                         | ZSE                                               | (43)                                              |
| Rhinitis                           | 8                               | (5.4)                           | 5                                    |                                      | 19                                  |                                     | 107                                           |                                               | 137                                               |                                                   |
| Shusilis                           | 8                               | (5.4)                           | 3                                    | (3.3) (2.0)                          | 31                                  | (4.9)                               | 146                                           | (1.8) (2.5)                                   | 186                                               | (1.7) (23)                                        |
| Amxicly                            | 7                               |                                 | 12                                   | (7.9)                                | 20                                  | (8.0)                               |                                               | (4.2)                                         | 326                                               |                                                   |
|                                    |                                 | (4.7)                           |                                      |                                      |                                     | (3.1)                               |                                               |                                               |                                                   | (4.0)                                             |
| (hills                             | 7                               | (4.7)                           | 4                                    | (2.6)                                | 24                                  | (6.2)                               | 249                                           | (4.2)                                         | 313                                               | (3.9)                                             |
| Depresion Dyppin                   | 7 7                             | (4.7) (4.7)                     | 4 9                                  | (2.6) (5.9)                          | 17 16                               | (4.4) (4.1)                         | 187 149                                       | (3.2) (2.5)                                   | 237 226                                           | (2.9)                                             |
|                                    |                                 |                                 | 3                                    |                                      | 16                                  |                                     |                                               |                                               | 504                                               | (2.8)                                             |
| Mnseuloskelenl Pain                | 7                               | (4.7)                           |                                      | (3.3)                                |                                     | (4.1)                               | 395                                           | (6.7)                                         |                                                   | (6.2)                                             |
| Myalgia                            | L                               | (4.7)                           | 10                                   | (6.6)                                | 30                                  | (7.7)                               | 430                                           | (7.3)                                         | 552                                               | (6.8)                                             |
| Nwal Congetion                     | 7                               | (4.7)                           | 3                                    | (2.0)                                | 34                                  | (8.7)                               | 150                                           | (2.5)                                         | 192                                               | (2.4)                                             |
| Oedemn Peripherl Pumesllesin       | 7 7                             | (4.7) (4.7)                     | 3 10                                 | (2.0) [6.6]                          | 21 13                               | (5.4) [3.3)                         | 512 157                                       | (8.7) [2.7)                                   | 707 187                                           | (8.7) [2.3)                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                             | KN204 Dalai for Pembolamabit   | KN204 Data for Brentuximab Vedotin   | cHL. Safety Dala or Pembroliamh!   | cHL. Safety Dala or Pembroliamh!   | Refercnce Safety Dalset for Pembroliamahll   | Refercnce Safety Dalset for Pembroliamahll   | Cumulative Running Safety Dalwet for Pembroliaumahu   | Cumulative Running Safety Dalwet for Pembroliaumahu   |
|---------------------------------------------|--------------------------------|--------------------------------------|------------------------------------|------------------------------------|----------------------------------------------|----------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                             |                                | (5)                                  |                                    |                                    |                                              |                                              |                                                       |                                                       |
| Abdominal Pain Upper                        | 6 (4.1)                        | 5 (3.3)                              | 13                                 | (3.3)                              | 213                                          | (3.6)                                        | 319                                                   | (3.9)                                                 |
| Diuines                                     | 6 (4.1)                        | 5 (3.3)                              | 15                                 | (3.9)                              | 430                                          | (7.3)                                        | 543                                                   | (6.7)                                                 |
| Erythema                                    | 6 (4.1)                        | 3 (2.0)                              | 13                                 | (3.3)                              | 167                                          | (2.0)                                        | 196                                                   | (2.4)                                                 |
| Inllhenra                                   | 6 (4.1)                        | 1 (0.7)                              | 14                                 | (3.6)                              | 811                                          | (2.0)                                        | 153                                                   | (1.9)                                                 |
| Insomnla                                    | 6 (4.1)                        | 7 (4.6)                              | 31                                 | (8.0)                              | 429                                          | (7.3)                                        | 569                                                   | (7.0)                                                 |
| Neck Pain                                   | (4.1)                          | 3 (3.3)                              | 9                                  | (2.3)                              | 200                                          | (3.4)                                        | 250                                                   | (3.1)                                                 |
| Neuropatly Feripheml                        | 6 (4.1)                        | 28 (18.4)                            | 18                                 | (4.6)                              | 116                                          | (2.0)                                        | 156                                                   | (1.9)                                                 |
| Prodhctive Cough                            | 6 (4.1)                        | 7 (4.6)                              | 22                                 | (5.7)                              | 266                                          | (4.5)                                        | 344                                                   | (4.3)                                                 |
| Blood Crentinine hereised                   | 5 (3.4)                        | 2                                    | 13                                 | (3.3)                              | 256                                          | (4.4)                                        | 379                                                   | (4.7)                                                 |
| Infision Relried Renction                   | 3 (3.4)                        | (1.3) 12 (6L)                        | 16                                 | (4.1)                              | 56                                           | (1.0)                                        | 80                                                    | (1.0)                                                 |
| Phuyngitis                                  | 3 (3.4)                        | 2                                    | 11                                 | (2.8)                              | 52                                           | (0.9)                                        | 70                                                    | (0.9)                                                 |
| Rhiniis Allergie                            | 3 (3.4)                        | (1.3) 2 (1.3) (7.2)                  | 8                                  | (2.1)                              | 69                                           | (1.2)                                        | 86                                                    | (1.1)                                                 |
| Weigh Deereused                             | 5 (3.4)                        | 11                                   | 14                                 | (3.6)                              | 561                                          | (9.5)                                        | 746                                                   | (9.2)                                                 |
| Aeute Kidney lnjury                         | 4 (2.7)                        | 1 (0.7)                              | &                                  | (2.1)                              | 113                                          | (1.9)                                        | 173                                                   | (2.1)                                                 |
| Blood Alleline Phosphrive Ineretsed         | 4 (2.7)                        | 7 (4.6)                              | 12                                 | (3.1)                              | 240                                          | (4.1)                                        | 369                                                   | (4.6)                                                 |
| Blocd Thyroid Stimulsling Hormone Deercased | 4 (2.7)                        | D                                    | 4                                  | (1.0)                              | 56                                           | (1.0)                                        | 73                                                    | (0.9)                                                 |
| Blood Thyroid Stimulating Homone hereased   | 4 (2.7)                        | (0.0) 0 (o0)                         | 11                                 | (2.8)                              | 97                                           | (1.6)                                        | 132                                                   | (1.6)                                                 |
| Bronchitis                                  | 4 (2.7)                        | 4 (2.6)                              | 24                                 | (6.2)                              | TLI                                          | (2.9)                                        | 214                                                   | (2.0)                                                 |
| Cheat Pan                                   | 4 (2.7)                        | 2 (1.3)                              | 14                                 | (3.6)                              | 307                                          | (5.2)                                        | 384                                                   | (4.7)                                                 |
| 419 A0                                      | 4 (2.7)                        | 3 (2.0)                              | 18                                 | (4.6)                              | 304                                          | (5.2)                                        | 390                                                   | (4.8)                                                 |
| Dyepnoen Exertional                         | 4 (2.7)                        | 0 (0.0)                              | &                                  | (2.1)                              | 120                                          | (2.0)                                        | 145                                                   | (1.8)                                                 |
| Dysuria                                     | 4 (2.7)                        | 1 (0.7)                              | 11                                 | (2.0)                              | 90                                           | (1.5)                                        | 144                                                   | (1.8)                                                 |
| Gtairoenlerilia                             | 4 (2.7)                        | D (0.0)                              | 13                                 | (3.3)                              | 50                                           | (0.8)                                        | 65                                                    | (0.8)                                                 |

<!-- image -->

|                                 | KN204Dhia for Pembroliamabit   | KN204 Dsia for Brentusimab Vedotin   | cHL Salety Dala or Pembroliaumch!   | Reference Safety Dalset for Pembroliamah!!   | Reference Safety Dalset for Pembroliamah!!   | Curulative Running Safely Duset for Pembroliamabh   | Curulative Running Safely Duset for Pembroliamabh   |
|---------------------------------|--------------------------------|--------------------------------------|-------------------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                 |                                |                                      | )                                   |                                              |                                              |                                                     | ()                                                  |
| Hepes Zosier                    | 4 (2.7)                        | 5 (3.3)                              | 17 (4.4)                            | 55                                           | (0.9)                                        | 84                                                  | (1.0)                                               |
| Hypegleenin                     | 4 (2.7)                        | 3 (2.0)                              | 16 (4.1)                            | 289                                          | (4.9)                                        | 413                                                 | (5.1)                                               |
| Lymphopenia                     | 十 (2.7)                        | 4 (2.6)                              | 3 (1.3)                             | 66                                           | (1.1)                                        | 82                                                  | (1.0)                                               |
| Mele Spsma                      | 4 (2.7)                        | 6 (3.9)                              | 19 (4.9)                            | 147                                          | (2.5)                                        | 188                                                 | (23)                                                |
| Oml Hopei                       | 4 (2.7)                        | 1 (0.7)                              | 11 (2.8)                            | 49                                           | (0.8)                                        | 65                                                  | (0.8)                                               |
| Peripheal Sensory Neumoputhy    | 4 (2.7)                        | 21 (13.8)                            | 13                                  | 64                                           | (1.1)                                        | 90                                                  | (11)                                                |
| Skin Leion                      | 4 (2.7)                        | 1 (0.7)                              | 7                                   | (3.3) (1.8) 89                               | (1.5)                                        | 107                                                 | (13)                                                |
| Slomrils                        | 4 (2.7)                        | 4 (2.6)                              | 14 (3.6)                            | 144                                          | (2.4)                                        | 198                                                 | (2.4)                                               |
| Demstitis Allergic              | 3 (2.0)                        | (0.0)                                | 4 (1.0)                             | 12                                           | (0.2)                                        | 19                                                  | (0.2)                                               |
| Dry Mouth                       | E (2.0)                        | 3 (2.0)                              | 9 (2.3)                             | 284                                          | (4.8)                                        | 373                                                 | (4.6)                                               |
| Ew Infection                    | 3 (2.0)                        | 2 (13)                               | 8                                   | 29                                           | (0.5)                                        | 36                                                  | (0.4)                                               |
| Eerema                          | 3 (2.0)                        | 3 (2.0)                              | (2.1) & (2.1)                       | 94                                           | (1.6)                                        | 129                                                 | (1.6)                                               |
| Grstrocesphigeal Rellux Diseise | E (2.0)                        | 4 (2.6)                              | 4 (1.0)                             |                                              | (2.0)                                        | 173                                                 | (2.1)                                               |
| Haemaluria                      | E (2.0)                        | (0.7)                                | 8 (2.1)                             | 155                                          | (2.6)                                        | 231                                                 | (2.9)                                               |
| Hepea Simplea                   | (2.0)                          | (0.7)                                | 3                                   | 9                                            | (0.2)                                        | 16                                                  | (0.2)                                               |
| Hyperkalhemia                   | 3 (2.0)                        | (0.7)                                | (1.3) 4 (1.0)                       | 6P1                                          | (2.5)                                        | 212                                                 | (2.6)                                               |
| Hypokalaemia                    | 3 (2.0)                        | 6 (3.9)                              | 14 (3.6)                            | 270                                          | (4.6)                                        | 377                                                 | (4.7)                                               |
| Hypolension                     | 3 (2.0)                        | 1 (0.7)                              | & (2.1)                             | 166                                          | (2.8)                                        | 226                                                 | (2.8)                                               |
| Immune Thnmbocylopenie Purpura  | E (2.0)                        | (0.0)                                | 3 (0.8)                             | E                                            | (0.1)                                        | 7                                                   | (0.1)                                               |
| Ifloenra Like Illed             | 3 (2.0)                        | E (2.0)                              | 12 (3.1)                            | 227                                          | (3.9)                                        | 286                                                 | (3.5)                                               |
| Inlertitisl Long Diseave        | E (2.0)                        | (P0.7)                               | 4 (1.0)                             | 22                                           | (0.4)                                        | 36                                                  | (0.4)                                               |
| Neutophil Count Deereasod       | E (2.0)                        | 10 (6.6)                             | 3 (0.8)                             | 37                                           | (0.6)                                        | 56                                                  | (0.7)                                               |
| Pain                            | 3 (2.0)                        | 2 (1.3)                              | I1 (2.8)                            | 180                                          | (3.1)                                        | 216                                                 | (2.7)                                               |

<!-- image -->

|                        | KN204 Dhla for Penbroliaimabit   | KN204 Data for Brenluximab Vedotin?   | CHL Safety Data for Pembroliamch!   | Refercice Safety Datuct for Penbrolrimah!   | Refercice Safety Datuct for Penbrolrimah!   | Cumnlathve Ranning Safely Dnuet for Pembroliamsbn   | Cumnlathve Ranning Safely Dnuet for Pembroliamsbn   |
|------------------------|----------------------------------|---------------------------------------|-------------------------------------|---------------------------------------------|---------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                        |                                  | 191                                   |                                     |                                             |                                             |                                                     |                                                     |
| Pelvle Pain            | 3 (2.0)                          | (0.0)                                 | 4 (1.0)                             | 43                                          | (0.7)                                       | 60                                                  | (0.7)                                               |
| Rash Maculo-Papular    | 3 (2.0)                          | 5 (3.3)                               | 9 (23)                              | 202                                         | (β.4)                                       | 282                                                 | (3.5)                                               |
| Renal mpaiment         | (2.0)                            | (0.0)                                 | 3 (0.8)                             | 18                                          | (0.3)                                       | 25                                                  | (0.3)                                               |
|                        | 3 (2.0)                          | 2 (1.3)                               | 14 (3.6)                            | 56                                          | (1.6)                                       | 115                                                 | (1.4)                                               |
| Rhinonhoea             | E (2.0)                          | (0.7)                                 | 22 (5.7)                            | 114                                         | (1.9)                                       | 140                                                 | (1.7)                                               |
| Tachyeanlia            | 3 (2.0)                          | (0.7)                                 | 6 (1.5)                             | 85                                          | (1.4)                                       | 128                                                 | (1.6)                                               |
| Tinnitus               | 3 (2.0)                          | 1 (0.7)                               | & (2.1)                             | 53                                          | (0.9)                                       | 64                                                  | (0.8)                                               |
| Tumour Pain            | E (2.0)                          | (0.0)                                 | 3 (1.3)                             | 97                                          | (1.6)                                       | 128                                                 | (1.6)                                               |
| Urtiearia              | 3 (2.0)                          | (0.0)                                 | 10 (2.6)                            | 51                                          | (0.9)                                       | 73                                                  | (0.9)                                               |
| Wheerng                | E (2.0)                          | 2 (1.3)                               | & (2.1)                             | 88                                          | (1.5)                                       | 107                                                 | (13)                                                |
| Aeamdematitis          | 2 (1.4)                          | D (0.0)                               | 2 (0.5)                             | 2                                           | (0.0)                                       | 6                                                   | (0.1)                                               |
| Anlle Fmclure          | 2 (1.4)                          | 1 (0.7)                               | 2 (0.5)                             | 3                                           | (0.)                                        | 5                                                   | (0.1)                                               |
| Blod Bilinbin hereased | 2 (1.4)                          | (0.0)                                 | 4 (1.0)                             | 125                                         | (2.1)                                       | 198                                                 | (2.4)                                               |
| Confusional Sune       | 2 (1.4)                          | (0.0)                                 | 3 (0.8)                             | 99                                          | (1.7)                                       | 136                                                 | (1.7)                                               |
| Conjunctihvitis        | 2 (1.4)                          | 1 (0.7)                               | 11 (2.8)                            | 76                                          | (1.3)                                       | 90                                                  | (11)                                                |
| Dehydration            | 2 (1.4)                          | E (2.0)                               | 6 (1.5)                             | 208                                         | (3.5)                                       | 293                                                 | (3.6)                                               |
| Dental Curies          | 2 (1.4)                          | (0.0)                                 | 6 (1.5)                             | 22                                          | (0.4)                                       | 30                                                  | (10.4)                                              |
| Demsliis Aeneifom      | 2 (1.4)                          | 2 (13)                                | 4 (1.0)                             | 73                                          | (1.2)                                       | 87                                                  | (11)                                                |
| Dyugeisin              | 2 (14)                           | 1 (0.7)                               | (13)                                | 011                                         | (1.9)                                       | 148                                                 | (1.8)                                               |
| Febrile Neutopenia     | 2 (1.4)                          | (0.7)                                 | 4 (1.0)                             | 7                                           | (0.1)                                       | 13                                                  | (0.2)                                               |
| Feeling Cold           | 2 (1.4)                          | (0.0)                                 | 6 (1.3)                             | 22                                          | (0.4)                                       | 28                                                  | (0.3)                                               |
| Follieulilla           | 2 (1.4)                          | (0.7)                                 | 2 (0.5)                             | 30                                          | (0.5)                                       | 36                                                  | (0.4)                                               |
| Gait Disurbanos        | 2 (1.4)                          | (0.0)                                 | 3 (0.8)                             | 37                                          | (0.6]                                       | 55                                                  | (0.7)                                               |

<div style=\"page-break-after: always\"></div>

Figure 40 Between-treatment Comparisons in Selected Adverse Events (incidence &gt;=10% in one or more treatment groups) and sorted by risk difference

MK-3475 200 mg (N=148) vs. Brentuximab Vedotin (N=152)

<!-- image -->

The incidence of urinary tract infection (10.8%) reported in the KEYNOTE-204 pembrolizumab arm was higher than the cHL safety dataset (8%), the RSD (6.5%), the CSD (6.4%) and slightly higher compared to the incidence of urinary tract infection (7.1%) reported in KEYNOTE-087. This discrepancy was also observed for pneumonitis (8.8% in the pembrolizumab arm vs 6.9% in the cHL safety dataset, 4.1% in the RSD and 3.8% in the CSD).

## Drug-related Adverse Events

In KEYNOTE-204, the most frequently reported drug-related AEs in the pembrolizumab safety dataset, compared with the BV arm, were hypothyroidism (15.5% vs 1.3%), pyrexia (12.8% vs 5.9%) and pruritus (10.8%  vs  5.3%).  Conversely,  the  BV  group  showed  higher  incidences  of  drug-related neuropathy peripheral (2% vs 18.4%), nausea (4.1% vs 13.2%) and peripheral sensory neuropathy (2% vs 13.2%).

<div style=\"page-break-after: always\"></div>

Table 75 Subjects with Drug-related Adverse Events (incidence &gt;5% in one or more treatment groups) by decreasing frequency of preferred term

<!-- image -->

## Grade 3 to 5 Adverse Events

The  overall  incidence  of  Grade  3  to  5  AEs  in  KEYNOTE-204  was  generally  similar  between  the pembrolizumab  arm  (43.9%)  and  the  BV  group  (43.4%).  In  the  KEYNOTE-204,  the  most  frequently reported Grade 3 to 5 AEs by decreasing incidence were as follows:

- pneumonia (5.4%), anemia (4.1%), pneumonitis (4.1%), neutropenia (2.7%) and thrombocytopenia (2.7%) for the pembrolizumab arm;
- neutropenia (8.6%), neutrophil count decreased (4.6%), pneumonia (3.3%), anaemia (3.3%) and neuropathy peripheral (3.3%) in the BV group.

<div style=\"page-break-after: always\"></div>

Table 76 Subjects with Grade 3 to 5 Adverse Events (incidence ≥ 1% in one or more treatment groups) by decreasing frequency of preferred term

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 8 displays the number and percentage of subjects with Grade 3 to 5 drug-related AEs (incidence ≥1%) in different safety datasets. The overall incidence of Grade 3 to 5 drug -related AEs in the KEYNOTE204 was lower in the pembrolizumab arm (19.6%) than in the BV group (25%). The most frequently reported drug-related Grade 3 to 5 AEs were:

- pneumonitis (4.1%), pneumonia (2%) and neutropenia (2%) in the pembrolizumab arm;
- neutropenia (7.2%), neutrophil count decreased (4.6%) and neuropathy peripheral (3.3%) in the BV arm.

The Grade 3 to 5 drug-related AE reported more frequently was pneumonitis (4.1% in the KEYNOTE-204 pembrolizumab arm vs 1.8% in the cHL Safety Dataset, 1.3% in the RSD and 1.2% in the CSD).

Table 80. Subjects with drug-related Grade 3-5 adverse events (incidence ≥ 1% in one or more treatment groups) by decreasing frequency of preferred term

<!-- image -->

|                                | KN204 Dala for Pembroliamahll   | KN204 Dala for Pembroliamahll   | KN204 Data for Brenuximsb Vedatin   | KN204 Data for Brenuximsb Vedatin   | cHL Safety Data for Fembmliamahl   | cHL Safety Data for Fembmliamahl   | Refercnce Safety Datnsat for Penbroliamahl   | Refercnce Safety Datnsat for Penbroliamahl   | Cumulatise Rurning Safely Daliss for Pembroliamhu   | Cumulatise Rurning Safely Daliss for Pembroliamhu   |
|--------------------------------|---------------------------------|---------------------------------|-------------------------------------|-------------------------------------|------------------------------------|------------------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                |                                 |                                 |                                     | (59)                                |                                    | (2)                                |                                              | (2)                                          |                                                     | ()                                                  |
| Subjeets in ppulhion           | 148                             |                                 | 132                                 |                                     | 389                                |                                    | 5,114                                        |                                              | 8,093                                               |                                                     |
| with one or more odvene cvenks | 6                               | (19.6)                          | 38                                  | (25.0)                              | 62                                 | (15.9)                             | 913                                          | (15.5)                                       | 1,297                                               | (16.0)                                              |
| wilh no adrerse cvenla         | 611                             | (80.4)                          | 114                                 | (75.0)                              | 327                                | (84.1)                             | 4,971                                        | (84.5)                                       | 6,796                                               | (84.0)                                              |
| Paeumonitis                    | 6                               | (4.1)                           | 1                                   | (P.7)                               | 7                                  | (1.8)                              | 78                                           | (1.3)                                        | 86                                                  | (1.2)                                               |
| Neuiopenin                     | 3                               | (2.0)                           | II                                  | (7.2)                               | &                                  | (2.1)                              | 9                                            | (0.2)                                        | 23                                                  | (0.3)                                               |
| Pucumonia                      | 3                               | (2.0)                           | 2                                   | (1.3)                               | 3                                  | (0.8)                              | 13                                           | (0.2)                                        | 27                                                  | (0.3)                                               |
| Aeute Kidney Injury            | 2                               | (1.4)                           |                                     | (0.0)                               | 2                                  | (0.5)                              | 8                                            | (0.1)                                        | 15                                                  | (0.2)                                               |
| Diunhoei                       | 2                               | (1.4)                           | 0                                   | (0.0)                               | 4                                  | (1.0)                              | 55                                           | (0.9)                                        | 74                                                  | (0.9)                                               |
| Immue Thnmbosylopenik: Pupun   | 2                               | (1.4)                           |                                     | (0.0)                               | 2                                  | (1.5)                              | 2                                            | (0.0)                                        | 5                                                   | (p.1)                                               |
| Intertitisl Long Disease       | 2                               | (1.4)                           | 1                                   | (0.7)                               | 2                                  | (0.5)                              | 7                                            | (0.1)                                        | II                                                  | (p.1)                                               |
| Thrombocylopenia               | 2                               | (1.4)                           | D                                   | (0.0)                               | 3                                  | (0.8)                              | 6                                            | (0.1)                                        | II                                                  | (1)                                                 |
| Neuroputhy Fenpheral           |                                 | (0.7)                           | 5                                   | (3.3)                               | 2                                  | (0.5)                              | 1                                            | (0.0)                                        | 3                                                   | (0.0)                                               |
| Neulophil Count Decreusod      |                                 | ()                              | 7                                   | (4.6)                               |                                    | (0.3)                              | 4                                            | (0.1)                                        | 9                                                   | (01)                                                |
| Fatligue                       |                                 | (0.0)                           | D                                   | (P0.0)                              | I                                  | (0.3)                              |                                              | (L.1)                                        | 85                                                  | (1.1)                                               |
| Ihfhsion Relhied Rerction      |                                 | (0.0)                           | E                                   | (2.0)                               |                                    | (0.0)                              | 0                                            | (0.0)                                        | 1                                                   | (0.0)                                               |
| Leukopenla                     |                                 | (0.0)                           | 3                                   | (2.0)                               |                                    | (0.0)                              | 3                                            | (0.1)                                        | 3                                                   | (0.0)                                               |
| Panesthesin                    |                                 | (0.0)                           | 2                                   | (1.3)                               |                                    | (0.0)                              | D                                            | (0.0)                                        |                                                     | (0.0)                                               |

<!-- image -->

Sourec [ISS: adm-dal; ade]

<div style=\"page-break-after: always\"></div>

Acute kidney injury was reported more frequently as Grade 3 to 5 drug-related AE in the KEYNOTE-204 pembrolizumab arm than in the cHL Safety Dataset, the RSD and the CSD (1.4%, 0.5%, 0.1% and 0.2%, respectively). The observed imbalance across the datasets may be explained by the longer duration of exposure in  the  KEYNOTE-204  pembrolizumab  arm  and  cHL  safety  dataset  (10.02  and  10.65  months, respectively) relative to the RSD and CSD (4.86 and 4.24 months, respectively. Of note, these percentages in the KEYNOTE-204 pembrolizumab arm and the cHL safety dataset are based on 2 participants in each group from populations of 148 and 389 participants, respectively.  These events were resolved.

## Serious adverse event/deaths/other significant events

The incidence of SAEs from 90 days of last dose in KEYNOTE-204 was higher for pembrolizumab compared with  BV  (29.7%  vs  21.1%),  but  the  rates  were  similar  after  adjustment  for  exposure. Pneumonia , Pneumonitis and Pyrexia were  most  frequently  reported  (incidence  ≥1%)  in  the  cHL  population  after pembrolizumab  (5.4%,  5.4%  and  2.7%,  respectively  in  the  KN-204  pembrolizumab  arm),  whereas pneumonia , infusion  related  reaction , pulmonary  embolism and neuropathy  peripheral were  the  most frequent SAEs after BV (3.3%, 2%, 1.3% and 1.3%, respectively).

Pneumonitis was the only most frequently reported SAE (≥ 2 percentage points difference) in the KEYNOTE -204 pembrolizumab group than the other safety datasets (5.4% vs 3.3% in the cHL Safety Dataset, 2.0% in the RSD and 1.8% in the CSD).

Table 771: Subjects with serious adverse events up to 90 days of last dose (incidence ≥ 1% in one or more treatment groups) by decreasing frequency of preferred term

<!-- image -->

|                                  | KN204 Data for Penbrolizumahtt   | KN204 Data for Penbrolizumahtt   | KN204 Dala for Brenluximsb Vedotin   | KN204 Dala for Brenluximsb Vedotin   | cHL Safety Data for Pembroliaumsb!   | cHL Safety Data for Pembroliaumsb!   | Refercnce Safety Datvet for Pembrollzumahtt   | Refercnce Safety Datvet for Pembrollzumahtt   | Cunulative Running Pembrolizumah   | Cunulative Running Pembrolizumah   |
|----------------------------------|----------------------------------|----------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------|------------------------------------|
|                                  |                                  | ()                               | (9)                                  | (9)                                  | ()                                   | ()                                   | ()                                            | ()                                            | (9)                                | (9)                                |
| Subjects in populstion           | 148                              |                                  | 152                                  |                                      | 389                                  |                                      | 5,884                                         |                                               | 8,093                              |                                    |
| with one or more adverse cvcnls  | 44                               | (29.7)                           | 32                                   | (21.1)                               | 104                                  | (26.7)                               | 2,266                                         | (38.5)                                        | 3,090                              | (38.2)                             |
| with no adverse cvenb            | 104                              | (70.3)                           | 120                                  | (6 82)                               | 285                                  | (73.3)                               | 3,618                                         | (61.5)                                        | 5,003                              | (61.8)                             |
| Pncumonia                        | &                                | (5.4)                            | 5                                    | (3.3)                                | 16                                   | (4.1)                                | 246                                           | (4.2)                                         | 323                                | (4.0)                              |
| Pacumonitia                      | 8                                | (5.4)                            | 1                                    | (0.7)                                | 13                                   | (3.3)                                | 117                                           | (2.0)                                         | 148                                | (1.8)                              |
| Pyrexia                          | 4                                | (2.7)                            | 1                                    | (0.7)                                | 9                                    | (2.3)                                | 67                                            | (1.1)                                         | Z6                                 | (1.1)                              |
| Aente Kidhey Injury              | 2                                | (1.4)                            | D                                    | (0.0)                                | 3                                    | (0.8)                                | 50                                            | (0.8)                                         | 81                                 | (1.0)                              |
| Febrile Neulmopenia              | 2                                | (1.4)                            | D                                    | (0.0)                                | 2                                    | (0.5)                                | 4                                             | (0.1)                                         | 9                                  | (0.1)                              |
| Interstitial Long Disease        | 2                                | (1.4)                            | 1                                    | (0.7)                                | 2                                    | (0.5)                                | 13                                            | (0.2)                                         | 18                                 | (0.2)                              |
| Myocanitis                       | 2                                | (1.4)                            | 0                                    | (0.0)                                | E                                    | (0.8)                                | 5                                             | (0.1)                                         | 9                                  | (0.1)                              |
| Acule Giraft Versus Host Diserse | 1                                | (0.7)                            | D                                    | (0.0)                                | 6                                    | (1.5)                                | 5                                             | (0.1)                                         | 6                                  | (0.1)                              |
| Ansemia                          |                                  | (0.7)                            | D                                    | (0.0)                                | 3                                    | (0.8)                                | 59                                            | (1.0)                                         | 86                                 | (1.1)                              |
| Colitis                          | D                                | (0.0)                            | 1                                    | (0.7)                                | 2                                    | (0.5)                                | 59                                            | (1.0)                                         | 76                                 | (0.9)                              |
| Dianhoca                         |                                  | (0.0)                            | D                                    | (0.0)                                | 2                                    | (0.5)                                | 59                                            | (1.0)                                         | 78                                 | (1.0)                              |
| Dyepnoea                         |                                  | (0.0)                            | 0                                    | (0.0)                                | 1                                    | (0.3)                                | 81                                            | (1.4)                                         | 93                                 | (1.1)                              |
| Inffsion Relted Rerction         |                                  | (0.0)                            | 3                                    | (2.0)                                |                                      | (0.3)                                | 4                                             | (0.1)                                         | 6                                  | (0.1)                              |
| Neuroputly Feripherl             | D                                | (0.0)                            | 2                                    | (1.3)                                | D                                    | (0.0)                                | 2                                             | (0.0)                                         | 3                                  | (0.0)                              |
| Plewrd Effusion                  |                                  | (0.0)                            | 1                                    | (0.7)                                | D                                    | (0.0)                                | 83                                            | (1.4)                                         | 107                                | (1.3)                              |
| Pulmonuy Embolism                |                                  | (0.0)                            | 2                                    | (1.3)                                | 1                                    | (0.3)                                | 71                                            | (1.2)                                         | E6                                 | (11)                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Drug-related Serious Adverse Events

In the KEYNOTE-204, the overall incidence of drug-related SAEs from 90 days of last dose was higher for pembrolizumab than BV (16.2% vs 10.5%) but the incidences were similar after adjustment for exposure. Pneumonitis was the only drugrelated SAE more frequently reported (≥2 percentage points differences) in the KEYNOTE-204 pembrolizumab arm than the cHL Safety dataset and the RSD (5.4% vs 3.3% and 1.9%, respectively)

Table 782: Subjects with drug-related serious adverse events up to 90 days of last dose (incidence ≥ 1% in one or more t reatment groups) by decreasing frequency of preferred term

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Deaths due to adverse events

The incidence of AEs resulting in death was low and comparable across the safety datasets. Deaths due to AEs in KEYNOTE-204 occurred in 3 patients (2%) in the pembrolizumab arm and in 2 BV patients (1.3%).

Table 793 Subjects with adverse events resulting in death up to 90 days of last dose (incidence &gt; 0% in one or more treatment groups) by decreasing frequency of preferred term

<!-- image -->

|                                 | KN204 Dala for Pembroliamablt   | KN204 Dala for Pembroliamablt   | KN204 Drla for Brentuximab Vedotin   | KN204 Drla for Brentuximab Vedotin   | CHL Safety Data for Pembmliamb!   | CHL Safety Data for Pembmliamb!   | Reference Safety Dalisct for Pembroliamah!   | Reference Safety Dalisct for Pembroliamah!   | Curulative Ruaning Penbroliamab   | Curulative Ruaning Penbroliamab   |
|---------------------------------|---------------------------------|---------------------------------|--------------------------------------|--------------------------------------|-----------------------------------|-----------------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------|-----------------------------------|
|                                 |                                 | (6)                             |                                      | (9)                                  |                                   | (2)                               |                                              |                                              |                                   | (95)                              |
| Subjects in population          | 148                             |                                 | 152                                  |                                      | 389                               |                                   | 5,184                                        |                                              | 8,093                             |                                   |
| with one or moreedversg cvenls  | 3                               | (2.0)                           | 2                                    | (1.3)                                | 6                                 | (1.5)                             | 312                                          | (33)                                         | 444                               | (5.5)                             |
| with no adreno cvenk            | 145                             | (086)                           | 150                                  | (98.7)                               | 383                               | (98.5)                            | 5,572                                        | (94.7)                                       | 7,649                             | (94.5)                            |
| Death                           |                                 | (0.7)                           |                                      | (0.7)                                | 1                                 | (0.3)                             | 42                                           | (0.7)                                        | 63                                | (0.8)                             |
| Hypovolaemie Shock              | 1                               | (0.7)                           | 0                                    | (0.0)                                | 1                                 | (0.3)                             | 0                                            | (0.0)                                        | 2                                 | (0.0)                             |
| Pncumonia                       |                                 | (0.7)                           | 0                                    | (0.0)                                | 1                                 | (0.3)                             | 36                                           | (0.6)                                        | 48                                | (0.6)                             |
| Albominal Pan                   | 0                               | (0.0)                           | 0                                    | (0.0)                                |                                   | (0.0)                             | 0                                            | (0.0)                                        | 1                                 | (0.0)                             |
| Alominal Sepsis                 | D                               | (0.0)                           | 0                                    | (0.0)                                | D                                 | (0.0)                             | D                                            | (10.0)                                       | 1                                 | (0.0)                             |
| Aecidentl Denth                 |                                 | (0.0)                           | 0                                    | (0.0)                                | D                                 | (0.0)                             | 1                                            | (0.0)                                        | 1                                 | (0.0)                             |
| Acute Coronary Syndrome         |                                 | (0.0)                           | 0                                    | (0.0)                                | D                                 | (0.0)                             |                                              | (0.0)                                        | 1                                 | (1.0)                             |
| Aeute Grelt Versus Host Diserso |                                 | (0.0)                           | 0                                    | (0.0)                                | 1                                 | (0.3)                             | 1                                            | (1.0)                                        | 1                                 | (0.0)                             |
| Acute Kidney Injury             |                                 | (0.0)                           | 0                                    | (0.0)                                |                                   | (0.0)                             | 3                                            | (0.1)                                        | 5                                 | (0.1)                             |
| AeuleLef Venuiculur Failure     |                                 | (0.0)                           |                                      | (0.0)                                | D                                 | (0.0)                             |                                              | (0.0)                                        | 1                                 | (0.0)                             |
| Aeute Myocudial nfretion        |                                 | (0.0)                           | 0                                    | (0.0)                                |                                   | (0.0)                             |                                              | (0.0)                                        | 2                                 | (0.0)                             |
| Acuie Respinlory Failure        |                                 | (0.0)                           | 0                                    | (0.0)                                | D                                 | (0.0)                             | 5                                            | (1.1)                                        | 6                                 | (0.1)                             |
| Adencercinoma Gasile            | 0                               | (0.0)                           | 0                                    | (0.0)                                | D                                 | (0.0)                             | 1                                            | (0.0)                                        | 1                                 | (0.0)                             |
| Aleohol Poisoning               | 0                               | (0.0)                           | 0                                    | (0.0)                                | D                                 | (0.0)                             | 1                                            | (0.0)                                        | 1                                 | (0.0)                             |
| Ansemla                         |                                 | (0.0)                           | 0                                    | (0.0)                                | D                                 | (0.0)                             | 1                                            | (0.0)                                        | 1                                 | (0.0)                             |
| Amphyletie Shock                | 0                               | (0.0)                           |                                      | (0.0)                                |                                   | (0.0)                             | 1                                            | (0.0)                                        | 1                                 | (0.0)                             |
| Arierisd Injury                 |                                 | (0.0)                           | 0                                    | (0.0)                                | D                                 | (0.0)                             |                                              | (0.0)                                        |                                   | (0.0)                             |
| Aspergillns Infection           |                                 | (0.0)                           | 0                                    | (0.0)                                | D                                 | (0.0)                             |                                              | (0.0)                                        | 1                                 | (0.0)                             |
| Aspinlion                       |                                 | (0.0)                           | 0                                    | (0.0)                                | D                                 | (0.0)                             | 3                                            | (0.1)                                        | 5                                 | (0.1)                             |

<div style=\"page-break-after: always\"></div>

Table 804 Subjects with adverse events resulting in death up to 90 days of last dose (incidence &gt; 0% in one or more treatment groups)

<!-- image -->

|                                                                                                                                                                                                                                                   | MK-3475200mg                                                                                                                                                                                                                                      | MK-3475200mg                                                                                                                                                                                                                                      | Brenhrimnb Tedotin                                                                                                                                                                                                                                | Brenhrimnb Tedotin                                                                                                                                                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                   | ()                                                                                                                                                                                                                                                | 口                                                                                                                                                                                                                                                 | (6)                                                                                                                                                                                                                                               |
| Subjects inpopuation                                                                                                                                                                                                                              | 148                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                   | 152                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                   |
| wilh one or more adver evenls                                                                                                                                                                                                                     | 3                                                                                                                                                                                                                                                 | (2.0)                                                                                                                                                                                                                                             | 2                                                                                                                                                                                                                                                 | (1.3)                                                                                                                                                                                                                                             |
| with no advorso owonta                                                                                                                                                                                                                            | 145                                                                                                                                                                                                                                               | (98.0)                                                                                                                                                                                                                                            | 150                                                                                                                                                                                                                                               | (98.7)                                                                                                                                                                                                                                            |
| Deth                                                                                                                                                                                                                                              | 1                                                                                                                                                                                                                                                 | (0.7)                                                                                                                                                                                                                                             | 1                                                                                                                                                                                                                                                 | (0.7)                                                                                                                                                                                                                                             |
| Hypovolhemie shock                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                   | (0.7)                                                                                                                                                                                                                                             | 0                                                                                                                                                                                                                                                 | (0.0)                                                                                                                                                                                                                                             |
| Puoumonia                                                                                                                                                                                                                                         | 1                                                                                                                                                                                                                                                 | (0.7)                                                                                                                                                                                                                                             | 0                                                                                                                                                                                                                                                 | (0.0)                                                                                                                                                                                                                                             |
| Reapiratory failure                                                                                                                                                                                                                               | 0                                                                                                                                                                                                                                                 | (0.0)                                                                                                                                                                                                                                             | 1                                                                                                                                                                                                                                                 | (0.7)                                                                                                                                                                                                                                             |
| Every subject in coumled a single time for each applieable specife adveno event. A spaciic advene event appoar on this report only ifitns incidence in one or more of he cohimns meeti tho incidenoo cnilenion in tbhoreport tite, after romding. | Every subject in coumled a single time for each applieable specife adveno event. A spaciic advene event appoar on this report only ifitns incidence in one or more of he cohimns meeti tho incidenoo cnilenion in tbhoreport tite, after romding. | Every subject in coumled a single time for each applieable specife adveno event. A spaciic advene event appoar on this report only ifitns incidence in one or more of he cohimns meeti tho incidenoo cnilenion in tbhoreport tite, after romding. | Every subject in coumled a single time for each applieable specife adveno event. A spaciic advene event appoar on this report only ifitns incidence in one or more of he cohimns meeti tho incidenoo cnilenion in tbhoreport tite, after romding. | Every subject in coumled a single time for each applieable specife adveno event. A spaciic advene event appoar on this report only ifitns incidence in one or more of he cohimns meeti tho incidenoo cnilenion in tbhoreport tite, after romding. |

Source:[P204V01MK3475:adam-adel; adae]

The narratives of 2 death cases from the KEYNOTE-204 pembrolizumab arm were presented.

In One patient the primary reported cause of death was pneumonia, considered related to pembrolizumab, but  interstitial  myocarditis,  interstitial  hepatitis,  and  tubulointerstitial  nephritis  were  also  noted  in  the autopsy report. The second subject died due to hypovolemic shock (Grade 5), considered not drug-related by the investigator; however the patient also presented with autoimmune hemolytic anemia, acute kidney injury, acute GVHD, and pneumonia at the time of death. The narrative for a patient who died due to an unknown cause, was also provided.

## Adverse Events of Special Interest (AEOSI)

Summary of Adverse Event of Special Interest

The  summary  of  AEOSIs,  immune-mediated  events  and  infusion-related  reactions  associated  with pembrolizumab, are reported below.

Table 815 Adverse Event Summary: AEOSI

<!-- image -->

|                                                    | KN204 Data for Pembrolioumabit   | KN204 Data for Pembrolioumabit   | KN204 Dalai for HrenluximabVedotin   | KN204 Dalai for HrenluximabVedotin   | cHL Safety Dita for Pembliamab!   | cHL Safety Dita for Pembliamab!   | Referonce Safety Daluet for Pembroliamabl!   | Referonce Safety Daluet for Pembroliamabl!   | Cunulative Ranning SafetyDutsetfor PembroliaumahW   | Cunulative Ranning SafetyDutsetfor PembroliaumahW   |
|----------------------------------------------------|----------------------------------|----------------------------------|--------------------------------------|--------------------------------------|-----------------------------------|-----------------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                    |                                  |                                  |                                      |                                      |                                   |                                   |                                              |                                              |                                                     | (9)                                                 |
| Subjects in population                             | 148                              |                                  | 152                                  |                                      | 389                               |                                   | 5,884                                        |                                              | 8,093                                               |                                                     |
| with ono or more sdveisc cvenk                     | 53                               | (35.8)                           | 21                                   | (13.8)                               | GE1                               | (35.7)                            | 1,474                                        | (25.1)                                       | 1,973                                               | (24.4)                                              |
| wilh no adherso cvent                              | 95                               | (64.2)                           | 131                                  | (86.2)                               |                                   | (64.3)                            | 4,410                                        | (74.9)                                       | 6,120                                               | (75.6)                                              |
| with dnug-relnieddverse events                     | 43                               | (29.1)                           | L1                                   | (11.2)                               | 123                               | (31.6)                            | 1,281                                        | (21.8)                                       | 1,718                                               | (21.2)                                              |
| wilh toxicity grnde3-5 alverse cvents              | II                               | (7.4)                            | 5                                    | (3.3)                                | 23                                | (5.9)                             | 381                                          | (6.5)                                        | 517                                                 | (6.4)                                               |
| with toxicity grnde3-5 drug-related adverse events | 9                                | (6.1)                            | 5                                    | (3.3)                                | 18                                | (4.6)                             | 331                                          | (5.6)                                        | 454                                                 | (5.6)                                               |
| with serionu advorse evenls                        | 13                               | (8.8)                            | 5                                    | (3.3)                                | 25                                | (6.4)                             | 381                                          | (6.5)                                        | 502                                                 | (6.2)                                               |
| wilh serioms dnug-relied sdveise cvenls            |                                  | (8.1)                            | 5                                    | (3.3)                                | 22                                | (5.7)                             | 337                                          | (5.7)                                        | 449                                                 | (5.5)                                               |
| Wih dose modifeation due toan adverse erent        | 21                               | (14.2)                           | EI                                   | (8.6)                                | 51                                | (13.1)                            | 534                                          | (9.1)                                        | 707                                                 | (8.7)                                               |
| who died                                           |                                  | (0.0)                            | D                                    | (0.0)                                |                                   | (0.0)                             | 11                                           | (0.2)                                        | 17                                                  | (0.2)                                               |
| who diod due to a drug-relaled adverse event       |                                  | (0.0)                            | D                                    | (0.0)                                | 0                                 | (0.0)                             | 11                                           | (0.2)                                        | 17                                                  | (0.2)                                               |
|                                                    | 13                               | (8.8)                            | 5                                    | (3.3)                                | 30                                | (7.7)                             | 232                                          | (3.9)                                        | IIE                                                 | (3.8)                                               |
| dissonlinued dmg due to adrug-related advene crenl | 13                               | (8.8)                            |                                      | (3.3)                                | 29                                | (7.5)                             | 278                                          | (3.9)                                        | 307                                                 | (3.8)                                               |
| dicsontimued dmg dhe loasenious mdverse crent      | 10                               | (6.8)                            | 4                                    | (2.6)                                | 17                                | (4.4)                             | 156                                          | (2.7)                                        | 204                                                 | (2.5)                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Overall Adverse Event of Special Interest (AEOSI)

The overall incidence of AEOSI was comparable between the KEYNOTE-204 pembrolizumab arm (n=53, 35.8%) and the cHL Safety Dataset (n=139, 35.7%), including those considered as drug-related (n=43, 29.1% and n= 123, 31.6%, respectively), but with a slightly higher prevalence of serious-drug related AEs compared with the cHL Safety Datase (n=12, 8.1% vs n=22, 5.7% respectively). No deaths occurred in the KEYNOTE pembrolizumab arm or in the cHL Safety Dataset, related to a fatal AEOSI.

Most  immune-mediated AEOSIs were mild to moderate in severity and were managed with treatment interruptions and/or corticosteroids. At the time of the data cut-off, 50.9% of patients were reported to have  AEOSIs  resolved,  9.4%  were  resolving  and  37.7%  were  not  resolved  (most  AEOSIs  related  to endocrine abnormalities) in the KEYNOTE-204 pembrolizumab arm.

In KEYNOTE-204, a higher incidence of AEOSIs was observed in the pembrolizumab arm compared with the  BV  group  (35.8%  vs  13.8%).  The  most  frequent  AEOSIs  were hypothyroidism (n=28  [18.9%]), pneumonitis (n=13 [8.8%]), and hyperthyroidism (n=8 [5.4%]) in the pembrolizumab arm, and infusionrelated reaction (n=12 [7.9]), hypothyroidism (n=4 [2.6%]), and pneumonitis (n=3 [2%]) in the BV arm.

Table 826 Summary of outcome for subjects with AEOSI (incidence &gt; 0% in one or more treatment groups)

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                      | KN204 Dala for Pembroliamablt   | KN204 Dala for Pembroliamablt   | KN204 Dala for Brentuximab Vedotn?   | KN204 Dala for Brentuximab Vedotn?   | cHL Safety Data for Pembroliamb!   | cHL Safety Data for Pembroliamb!   | Reference Safety Daluset for Pembrollamahll   | Reference Safety Daluset for Pembrollamahll   | Cumnlative Running Safety Drtset for Pembrolizimabu   | Cumnlative Running Safety Drtset for Pembrolizimabu   |
|--------------------------------------|---------------------------------|---------------------------------|--------------------------------------|--------------------------------------|------------------------------------|------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                      |                                 | (6)                             |                                      | (9)                                  |                                    | (2)                                |                                               | (M)                                           |                                                       | (9)                                                   |
| Subjeets in population               | 148                             |                                 | 152                                  |                                      | 389                                |                                    | 5,884                                         |                                               | 8,093                                                 |                                                       |
| with one or more dverse cvenls       | 53                              | (35.8)                          | 21                                   | (13.8)                               | 139                                | (35.7)                             | 1,474                                         | (25.1)                                        | 1,973                                                 | (24.4)                                                |
| with no advere cvents                | 95                              | (64.2)                          | 131                                  | (86.2)                               | 250                                | (643)                              | 4,410                                         | (74.9)                                        | 6,120                                                 | (75.6)                                                |
| Adrensl Insuficieey                  |                                 | (0.7)                           |                                      | (0.0)                                |                                    | (0.3)                              | 47                                            | (0.8)                                         | 63                                                    | (0.8)                                                 |
| Addisns Dierse                       | 0                               | (0.0)                           | 0                                    | (0.0)                                |                                    | (0.0)                              | 2                                             | (0.0)                                         | 3                                                     | (0.0)                                                 |
| Aoospusq poapy                       |                                 | (0.7)                           | 0                                    | (0.0)                                |                                    | (0.3)                              | 42                                            | (0.7)                                         | 53                                                    | (0.7)                                                 |
| Adrenocortical Ihsufficiency Aeuie   | 0                               | (0.0)                           | 0                                    | (0.0)                                |                                    | (0.0)                              | 2                                             | (0.0)                                         | 2                                                     | (0.0)                                                 |
| Prinny Adreml Ihsuliciency           |                                 | (0.0)                           |                                      | (0.0)                                |                                    | (0.0)                              | 0                                             | (0.0)                                         | 2                                                     | (0.0)                                                 |
| Seconday Adrenoeortieal Insulfeiency |                                 | (0.0)                           | 0                                    | (0.0)                                | 0                                  | (0.0)                              | 1                                             | (0.0)                                         | 3                                                     | (0.0)                                                 |
| Colitis                              |                                 | (0.7)                           |                                      | (0.7)                                | 6                                  | (1.5)                              | 110                                           | (.9)                                          | 154                                                   | (1.9)                                                 |
| Arloinmune Colitis                   |                                 | (0.0)                           |                                      | (0.0)                                |                                    | (0.0)                              | 3                                             | (0.1)                                         | 4                                                     | (0.0)                                                 |
| Colitis                              |                                 | (0.7)                           | 1                                    | (0.7)                                | 5                                  | (1.3)                              | 93                                            | (1.6)                                         | 132                                                   | (1.6)                                                 |
| Colitis Miemscopie                   |                                 | (0.0)                           |                                      | (0.0)                                |                                    | (0.0)                              | 4                                             | (0.1)                                         | 4                                                     | (0.0)                                                 |
| Enlcrocolitis                        |                                 | (10.0)                          | 0                                    | (0.0)                                | 1                                  | (0.3)                              | &                                             | (0.1)                                         | 14                                                    | (0.2)                                                 |
| Immune-Medinied Enieroeoliis         | 0                               | (0.0)                           |                                      | (0.0)                                | D                                  | (0.0)                              | 3                                             | (0.1)                                         | 3                                                     | (0.0)                                                 |
| Encephalitis                         |                                 | (Lm)                            |                                      | (0.0)                                | 2                                  | (0.5)                              | 3                                             | (0.1)                                         | 6                                                     | (0.1)                                                 |
| Encephalitis                         | 0                               | (0.0)                           | D                                    | (0.0)                                | 1                                  | (0.3)                              | 3                                             | (0.1)                                         | 5                                                     | (0.1)                                                 |
| Encephalitis Autoimnune              |                                 | (0.7)                           | 0                                    | (0.0)                                |                                    | (0.3)                              | 0                                             | (0.0)                                         | 1                                                     | (0.0)                                                 |
| Guillsin-Barre Syndrome              |                                 | (0.0)                           |                                      | (0.0)                                |                                    | (0.0)                              |                                               | (0.1)                                         |                                                       | (0.1)                                                 |

Table 837 Subjects with Adverse Events of Special Interest (incidence &gt; 0% in one or more treatment groups) by AEOSI category and preferred term

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                   | KN204 Data for Pembrolimabit   | KN204 Daa for Brentuximab Vedotm?   | CHL Safcty Dan for Pembroliamb!   | Reference Safety Datuset for Pembrolirmahl   | Reference Safety Datuset for Pembrolirmahl   | Cumulative Running Safety Daset for Pembroliamh   | Cumulative Running Safety Daset for Pembroliamh   |
|-----------------------------------|--------------------------------|-------------------------------------|-----------------------------------|----------------------------------------------|----------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                   |                                | (99)                                |                                   |                                              |                                              |                                                   | 19)                                               |
| Paeumonitis                       | 16 (8'o1)                      | 4 (2.0)                             | 31 (8.0)                          | 264                                          | (4.5)                                        | 341                                               | (1.2)                                             |
| Orgunising Pneumonla              | 0 (0.0)                        | 0 (0.0)                             | I (0.3)                           | E                                            | (0.1)                                        | 3                                                 | (0.0)                                             |
| Paeumonitia                       | 13 (8.8)                       | 3 (2.0)                             | 27 (6.9)                          |                                              | (4.1)                                        | S0E                                               | (3.8)                                             |
| Sareniduia                        | (0.0)                          | (0.0)                               | (0.3)                             | 10                                           | (0.2)                                        | 11                                                | (0.1)                                             |
| Sarcoidosla                       | (0.0)                          | 0 (1.0)                             | (0.3)                             | 10                                           | (0.2)                                        | I1                                                | (0.)                                              |
| Severe Skin Reactions             | 3 (2.0)                        | 3 (2.0)                             | 5 (1.3)                           | 97                                           | (1.6)                                        | 128                                               | (1.6)                                             |
| Demrtilis Bullons                 | (0.0)                          | D (0.0)                             | (0.0)                             |                                              | (0.1)                                        | 9                                                 | (0.1)                                             |
| Demstlis Exfolistive              | (0.0)                          | 1 (0.7)                             | (0.0)                             | 5                                            | (0.1)                                        | 5                                                 | (P.1)                                             |
| Demmstitis Exfolistive Generlised | (0.0)                          | 1 (0.7)                             | (0.0)                             | 2                                            | (0.0)                                        | 2                                                 | (0.0)                                             |
| Erythemn Mulifomme                | (00)                           | 0 (0.0)                             | D (0.0)                           | 5                                            | (0.1)                                        | 7                                                 | (0.1)                                             |
| Exfolintive Resh                  | (0.0)                          | D (0.0)                             | (0.0)                             | 2                                            | (0.0)                                        | 5                                                 | (0.1)                                             |
| Lichen Plams                      | (0.0)                          | 0 (0.0)                             | (0.3)                             | 5                                            | (0.1)                                        | 6                                                 | (0.1)                                             |
| Oml Lichen Plaa                   | (0.0)                          | 0 (0.0)                             | (0.0)                             | 1                                            | (0.0)                                        | 1                                                 | (0.0)                                             |
| Penphigoid                        | (o0)                           | 0 (1.0)                             | D (10.0)                          | 3                                            | (0.1)                                        | 6                                                 | (p.1)                                             |
| Pemphigui                         | (0.0)                          | D (0.0)                             | (0.0)                             | 2                                            | (0.0)                                        | 2                                                 | (0.0)                                             |
| Prurius                           | (0.0)                          | 0 (0.0)                             | (0.3)                             | 12                                           | (0.2)                                        | 14                                                | (0.2)                                             |
| Prunitus Geniial                  | (0.7)                          | (0.0)                               | (0.3)                             | 1                                            | (0.0)                                        | 2                                                 | (0.0)                                             |
| Rash                              | (0.0)                          | 0 (0.0)                             | D (0.0)                           | 30                                           | (0.5)                                        | 38                                                | (0.5)                                             |
| Rash Erythemslous                 | (0.0)                          | D (0.0)                             | (0.0)                             | 1                                            | (0.0)                                        | 1                                                 | (0.0)                                             |
| Rash Maculo-Papular               | (oo)                           | 0 (0.0)                             | (0.0)                             | 16                                           | (0.3)                                        | 23                                                | (0.3)                                             |
| Rash Prurilic                     | (0.0)                          | 0 (0.0)                             | (0.0)                             | 2                                            | (0.0)                                        | 3                                                 | (0.0)                                             |

|                                | KN204 Data for Pembrolimmabit   | KN204 Dhla for Brentuximsb Vedoun?   | CHL Safety Data for Pembroliamb!   | Reference Safety Datasst for Penbrolamah!t   | Reference Safety Datasst for Penbrolamah!t   | Cumulatve Running Safety Daset for Penbroliamab   | Cumulatve Running Safety Daset for Penbroliamab   |
|--------------------------------|---------------------------------|--------------------------------------|------------------------------------|----------------------------------------------|----------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                | (2)                             |                                      | (2)                                |                                              | (2)                                          |                                                   | (9)                                               |
| Severe Skin Reactions          | 3 (2.0)                         | 3 (2.0)                              | 5 (1.3)                            | L6                                           | (1.6)                                        | 128                                               | (1.6)                                             |
| Rash Pusulu                    | 0 (0.0)                         | 0 (0.0)                              | (0.0)                              | 1                                            | (0.0)                                        | 1                                                 | (0.0)                                             |
| Skin Neemsis                   | D (0.0)                         | 0 (0.0)                              | (0.0)                              | 2                                            | (0.0)                                        | 2                                                 | (0.0)                                             |
| Slevens-Johnson Syndrme        | 0 (0.0)                         | 0 (0.0)                              | 0 (0.0)                            | 3                                            | (0.1)                                        | 3                                                 | (0.0)                                             |
| Toxic Skin Enpion              | 2 (1.4)                         | 1 (0.7)                              | 2 (0.5)                            | 2                                            | (0.0)                                        | 4                                                 | (0.0)                                             |
| Thyroidis                      | 2 (1.4)                         | 0 (0.0)                              | 5 (1.3)                            | 58                                           | (1.0)                                        | 76                                                | (0.9)                                             |
| Artoinmune Thyroiditis         | 0 (0.0)                         | 0 (0.0)                              | (0.3)                              | 14                                           | (0.2)                                        | 17                                                | (0.2)                                             |
| Thymid Diorder                 | (0.0)                           | 0 (0.0)                              | 0 (0.0)                            | 5                                            | (0.1)                                        | 6                                                 | (0.1)                                             |
| Thymiditis                     | 2 (1.4)                         | 0 (0.0)                              | 4 (1.0)                            | 41                                           | (0.7)                                        | 55                                                | (0.7)                                             |
| Type1 Dinbctes Mellins         | (0.)                            | 0 (0.0)                              | (0.0)                              | 20                                           | (0.3)                                        | 28                                                | (10.3)                                            |
| Dibetie Ketoucidosis           | D (0.0)                         | 0 (0.0)                              | (0.0)                              | 9                                            | (0.2)                                        | 12                                                | (0.1)                                             |
| Fulminnt Type 1 Dibetes Melius | D (0.0)                         | 0 (0.0)                              | (0.0)                              | D                                            | (0.0)                                        | 1                                                 | (0.0)                                             |
| Type 1 Dirleles Mellilus       | D (0.0)                         | (0.0)                                | (0.0)                              | 16                                           | (0.3)                                        | 22                                                | (0.3)                                             |
| Uveitis                        | 2 (1.4)                         | 0 (0.0)                              | 5 (1.3)                            | 21                                           | (0.4)                                        | 28                                                | (0.3)                                             |
| Chorioretinitis                | D (1.0)                         | 0 (0.0)                              | 1 (0.3)                            | 1                                            | (0.0)                                        | 1                                                 | (0.0)                                             |
| Iridocydlia                    | 0 (1.0)                         | 0 (0.0)                              | (0.3)                              | 4                                            | (0.1)                                        | 4                                                 | (0.0)                                             |
| Irilla                         | D (0.0)                         | 0 (0.0)                              | (0.3)                              | 3                                            | (0.1)                                        | 4                                                 | (0.0)                                             |

<!-- image -->

## Hypothyroidism

In KEYNOTE-204, the most common AEOSI reported was hypothyroidism , which occurred in 28 patients (18.9%) in the pembrolizumab arm compared to 4 patients (2.6%) in the BV group. Of these, 23 patients (15.5%)  in  the  pembrolizumab  arm  had  AEOSI  assessed  as  drug-related  and  were  Grade  1  or  2. Hypothyroidism was managed through observation and/or thyroid replacement hormone and no patients received corticosteroid treatment. Less than half of patients had a revolved or resolving status.

In  KEYNOTE-204,  out  of  28  participants,  11  participants  had  a  past  medical  history  of  prior  radiation

<div style=\"page-break-after: always\"></div>

therapy.  In  the  pembrolizumab  arm  of  KEYNOTE-204,  58  participants  had  received  prior  radiation  at baseline  while  93  participants  had  not  received  prior  radiation  in  the  ITT  population.  The  incidence  of hypothyroidism in participants who received prior radiation was thus 19.0% (11/58) compared to 18.3% (17/93) in participants who had not received prior radiation. TSH levels reported at baseline for these 28 participants were as follows: 20 participants with normal, 7 participants with high and 1 participant with low TSH levels at baseline, respectively.

Table 848 Adverse Event Summary: AEOSI - Hypothyroidism

<!-- image -->

Table 859 Time to onset and duration of AEOSI - Hypothyroidism

<!-- image -->

|                                                                                              | KN204Dalfor Pembrolizimabt 日 (W)   | KN204Dalaor BrenlximabVedotin 日 (W)   | cHL SafelyDala for Pembroliaimabl (W)   | Refercice Safety Dhlivel TorPembroliaimabll (M)   | Cunulative Running Safety Dalaset for PembrolizumabH 日 (W)   |
|----------------------------------------------------------------------------------------------|------------------------------------|---------------------------------------|-----------------------------------------|---------------------------------------------------|--------------------------------------------------------------|
| Subjects in population Subjecta withHypothyroidism Timeto Onsetof Fist Hypothyroidism (drys) | 28 (18.9)                          | 152 (2.6) 336.5 (246.2) 319.0         | 389 66 (17.0) 133.6 (140.5) 85.0        | 5884 652 (11.1) 122.7 (97.5) 105.0 11o 664        | 8093 877 (10.8) 123.3 (100.4) 103.0                          |
| Men (Sd) Median Range                                                                        | 138.9 (150.3) 89.5 20 1o741        | 64644                                 | 20 1o741 76                             |                                                   | 1o 741                                                       |
| Totaleplsodesof Hypothyroidism Avenge Episodes per patient                                   | EE 81'1                            | 4 1.00                                | 1.15                                    | 720 1.10                                          | 965 1.10                                                     |
| Episodedurntion (days)t Median                                                               | Not renched                        |                                       | 246.0                                   |                                                   | Notreached                                                   |
|                                                                                              |                                    | Not reached                           |                                         | Not resched                                       |                                                              |

<div style=\"page-break-after: always\"></div>

Table 860 Summary of outcome for subjects with AEOSI - Hypothyroidism

<!-- image -->

|                | Ouleome   | KN204Datafor Pembrolinmabn (6)   | KN204Drnor BrenlximabVadotinl (m)   | cHL Safety Data for Pembroliaumabl (9)   | Reference Safety Datwetfor Pembmllamablt (m)   | CumnltiveRunning Safety Datsct for Pembrolizimabl (3)   |
|----------------|-----------|----------------------------------|-------------------------------------|------------------------------------------|------------------------------------------------|---------------------------------------------------------|
| Hypothyroidism | Reolving  | 1 (17.9)                         | (0.0)                               | 8 (12.1)                                 | (6.9)                                          | 80 (9.1)                                                |
| Hypothyroidism | Uhknown   | (0.0)                            | (0.0)                               | 口 (0.0)                                  | 20 (3.1)                                       | 22 (2.5)                                                |
| Hypothyroidism | Seqielie  | (0.0)                            | (0.0)                               | 中 (6.1)                                  | (2.1)                                          | 14 (1.6)                                                |
| Hypothyroidism | Rerlved   | (28.6)                           | (25.0)                              | 27 (60)                                  | (22.1)                                         | 184 (21.0)                                              |

## Pneumonitis

In KEYNOTE-204, the overall incidence of pneumonitis was higher in the pembrolizumab arm than in the BV group (n=16, 10.8% vs n=4, 2.6%) and most cases were considered as drug-related (10.1% vs 1.3%). One-half of the patients (8/16) had Grade 3 or 4 events; no patients died due to pneumonitis . Pneumonitis was more frequent than observed in the cHL Safety Dataset (8%) and in the RSD (4.5%), but it was resolved for 12 out of 16 (75%) pembrolizumab patients in KEYNOTE-204, for 24 out of 31 patients (77.4%) in the cHL Safety Dataset and for 148 out of 264 patients (56.1%) in the RSD. The majority of patients were treated with systemic corticosteroid.

|                                                              | KN204 Dala for Pemboliamabit   | KN204 Dala for Pemboliamabit   | KN204 Dala for Brenximsb Velotin   | KN204 Dala for Brenximsb Velotin   | CHL Safety Dala for Pembmliamnh!   | CHL Safety Dala for Pembmliamnh!   | Reference Safety Dalaset for Pembrolirumahll   | Reference Safety Dalaset for Pembrolirumahll   | Cumulative Running Snfety Dnset for PembrolirambM   | Cumulative Running Snfety Dnset for PembrolirambM   |
|--------------------------------------------------------------|--------------------------------|--------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------------------|------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                              |                                | ()                             | 口                                  | (2)                                |                                    | (2)                                |                                                |                                                |                                                     | (9)                                                 |
| Sutjeets in popultion                                        | 148                            |                                | 152                                |                                    | 389                                |                                    | 5,884                                          |                                                | 8,093                                               |                                                     |
| with one or more edverse cvenls                              | 16                             | (10.8)                         | 4                                  | (2.6)                              | 31                                 | (8.0)                              | 264                                            | (4.5)                                          | 341                                                 | (4.2)                                               |
| wih no aderse event                                          | 132                            | (89.2)                         | 148                                | (+16)                              | 358                                | (92.0)                             | 5,620                                          | (95.5)                                         | 7,752                                               | (95.8)                                              |
| with dng-rclhied' sdverse events                             | 15                             | (10.1)                         | 2                                  | (1.3)                              | DE                                 | (7.7)                              | 244                                            | (4.1)                                          | 318                                                 | (3.9)                                               |
| wih toxicily grnde3-5 ndverse cvents                         | 8                              | (5.4)                          | 2                                  | (1.3)                              | 9                                  | (23)                               | 91                                             | (1.5)                                          | 116                                                 | (1.4)                                               |
| with toxicity gnde 3-5 drug-reliod advere events             | 8                              | (5.4)                          | 2                                  | (1.3)                              | 9                                  | (2.3)                              | 85                                             | (1.4)                                          | 109                                                 | (13)                                                |
| willh serions adverse evenli                                 | 10                             | (6.8)                          | 2                                  | (1.3)                              | 15                                 | (3.9)                              | 130                                            | (2.2)                                          | 166                                                 | (2.1)                                               |
| wilh serions drug-relried sdverse cvents                     | 10                             | (6.0)                          | 2                                  | (1.3)                              | 15                                 | (3.9)                              | 123                                            | (2.1)                                          | 158                                                 | (2.0)                                               |
| wo died                                                      |                                | (0.0)                          | 0                                  | (0.0)                              | D                                  | (0.0)                              | 9                                              | (0.2)                                          | 14                                                  | (0.2)                                               |
| wllo died due to a dmg-rclited adverse event                 | 0                              | (0.0)                          | 0                                  | (0.0)                              | 0                                  | (0.0)                              | 9                                              | (0.2)                                          | 14                                                  | (0.2)                                               |
| discontinued dg dhe lo an dverse cvent                       | 11                             | (7.4)                          | 1                                  | (0.7)                              | 21                                 | (5.4)                              | 105                                            | (1.8)                                          | 140                                                 | (1.7)                                               |
| discontinued drug due tWo adrug-elried edverse crent         | 11                             | (7.4)                          |                                    | (0.7)                              | 21                                 | (5.4)                              | 103                                            | (1.8)                                          | 138                                                 | (1.7)                                               |
| discontinuod dmg due to a serious mdverse cvent              | 9                              | (6.1)                          |                                    | (0.7)                              | 13                                 | (3.3)                              | 77                                             | (1.3)                                          | 97                                                  | (1.2)                                               |
|                                                              | KN204 Dala for Pembrollamatit  | KN204 Dala for Pembrollamatit  | KN204 Dala for Brenluximab Vedotin | KN204 Dala for Brenluximab Vedotin | cHL Safety Dala for Pembrolameb!   | cHL Safety Dala for Pembrolameb!   | Refercnce Safety Dalnsa for Penbrollamal       | Refercnce Safety Dalnsa for Penbrollamal       | Cumnlative Running Safety Datset for PenbroliamsbW  | Cumnlative Running Safety Datset for PenbroliamsbW  |
|                                                              |                                |                                |                                    | (99)                               |                                    |                                    |                                                |                                                | (2)                                                 | (2)                                                 |
| dissontimued dng dhe to a serious drug-related Bdverse cvent | 9                              | (6.1)                          | 1                                  | (0.7)                              | 13                                 | (3.3)                              | 76 (1.3)                                       | 76 (1.3)                                       | 96 (1.2)                                            | 96 (1.2)                                            |

Table 871 Adverse Event Summary: AEOSI - Pneumonitis

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 882 Summary of outcome for subjects with AEOSI - Pneumonitis

<!-- image -->

Table 893 Summary of concomitant corticosteroid use for AEOSI - Pneumonitis

<!-- image -->

Source: [ISS: adam-dsl, dae; dem]

## Infusion reactions

The incidence of infusion reactions in the KEYNOTE-204 pembrolizumab arm was consistent with the cHL Safety Dataset and was more frequent than the RSD and the CSD. Infusion related reactions were more frequent in the cHL population (5.4% in the KEYNOTE-204 pembrolizumab arm, 7.9% in the BV group and 8% in the cHL Safety Dataset) than in the RSD (2.3%) and the CSD (2.1%), characterized by a very earlier median time to first occurrence (1 day vs 44.5 in the RSD and 40 days in the CSD).

Table 904 Adverse Event Summary: AEOSI - Infusion Reactions

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                                             | KN204 Dala for Pemlroliomalit   | KN204 Dalai for Brentuximab Vedotin   | cHL Safety Dila for Pemlliamh!   | Refercnce Safely Dalsel for Pembroliamat,ll   | Curulathe Running Safety Duteset for Pembroliamaha   |
|-------------------------------------------------------------|---------------------------------|---------------------------------------|----------------------------------|-----------------------------------------------|------------------------------------------------------|
| discontimued dmg due to aserious drug-rclaiod Ddverse cwent | (0.0)                           | 2 (1.3)                               | 1 (0.3)                          | (2) 3 (0.1)                                   | (9) 3 (0.0)                                          |

<!-- image -->

Table 915 Time to onset and duration of AEOSI - Infusion Reactions

<!-- image -->

|                                                                        | KN204Dalafor Pembrolieumaltt   | KN204Dalafor BrenlximsbVedotin (9)   | CHLSafetyDat for Pembrolixumab! (W)   | Refercnco Safety Dalave ForPemboliamsbll 日 (3)   | CunulativeRunning Safety Datset for PenbroliamabM   |
|------------------------------------------------------------------------|--------------------------------|--------------------------------------|---------------------------------------|--------------------------------------------------|-----------------------------------------------------|
| Subjectsin populatlion Subjecta with Infusion Renclions                | & (5.4)                        | 251 12 (7.9)                         | GRE IE (8.0) 206.0 (287.9)            | 5884 138 (23)                                    | 8093 173 (2.1)                                      |
| Time to Ohset ofFirst Infision Renctions (days)t Men (Sd) Melian Range | 141.4(227.5) 0'1 1 o 582       | 29.3 (24.2) 22.0 22 1o 106           | 1.0 1 to 723                          | 114.5 (156.2) 44.5 1 to 723                      | 111.2(161.7) 40.0 1 1o 723                          |
| Total episodesiofInfusion Reactions                                    | 9                              | 14                                   | 42 1.35                               | 167 121                                          | 211 1.27                                            |
| Avenge Episdes per pulient Episodeduration (daya)t Melian              | 1.13 1.0                       | 1.17 1.0                             | 3.0                                   | 2.0                                              | 2.0                                                 |

Table 926 Summary of concomitant corticosteroid use for AEOSI - Infusion Reactions

<!-- image -->

|                                    | Pembmoliaimahn (N-148)   | Brenlrimab Vehlin? (IN-152)   | KN204DrinforcHLSafetyDhlaRelercnceSalety (N-389)   | Dnlseufor Pembroliaumsh!Pembmliaumubl (N-3884)   | Cumulaline Running Snfety Dnlel ar PenboliaumnhH (N-8093)   | Cumulaline Running Snfety Dnlel ar PenboliaumnhH (N-8093)   |
|------------------------------------|--------------------------|-------------------------------|----------------------------------------------------|--------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                    |                          |                               |                                                    |                                                  |                                                             | 96                                                          |
| Palienbwithoneormomlnfsion         | 8                        | 12                            | 31                                                 | 138                                              |                                                             | 173                                                         |
| Treried with syelemie colleosleold | 3 37.5                   | 9 75.0                        | 10 EZE                                             | 39                                               | 283                                                         | 51                                                          |
| Nolerledwithsuemieeonlieonlenold   | 5 62.5                   | 3 75.0                        | 12 67.7                                            | 99                                               | 71.7                                                        | 221 70.9                                                    |

## Laboratory findings

In  KEYNOTE-204,  the  frequency  and  severity  of  laboratory  test  toxicity  were  comparable  in  the pembrolizumab and BV arms, in which most shifts in the toxicity Grade from baseline were to Grades ≤2. However, in the pembrolizumab arm, shifts to Grade 3 or 4 were observed for lymphocytes decreased (Grade 3, n=6; 4.1% and Grade 4, n=7; 4.8%), alanine aminotransferase increased (Grade 3, n=8; 5.4%) and Grade 4, n=1; 0.7%), neutrophils decreased (Grade 3, n=8; 5.5% and Grade 4, n=4; 2.7%). Similar

<div style=\"page-break-after: always\"></div>

shifts to Grade 3 or 4 were observed for the BV arm. The results of clinical laboratory evaluations were consistent between KEYNOTE-204, the cHL Safety Dataset and the RSD.

Table 937 Summary of subjects with increases in highest laboratory test toxicity Grade from baseline (subjects with baseline and post-baseline measurements)

| Laboratory test                      | KN204 Data for Pembrolizuma b (n=148)   | KN204 Data for BV (n=152)   | cHL Safety Data (n=389)   | Reference Safety Dataset (n=5,884)   | Cumulative Running Safety Dataset (n=8,093)   |
|--------------------------------------|-----------------------------------------|-----------------------------|---------------------------|--------------------------------------|-----------------------------------------------|
| APTT increased                       | 4 (7.5)                                 | 5 (10.0)                    | 6 (7.2)                   | 194 (13.6)                           | 297 (13.8)                                    |
| Alanine Aminotransferase Increased   | 50 (33.8)                               | 69 (45.4)                   | 100 (41.7)                | 261 (25.3)                           | 1786 (25.4)                                   |
| Albumin decreased                    | 24 (16.4)                               | 29 (1 9.3)                  | 43 (19.3)                 | 1835 (37.3)                          | 2398 (36.1)                                   |
| Alkaline phosphatase increased       | 30 (20.5)                               | 34 (22.4)                   | 68 (27.5)                 | 1365 (27.5)                          | 1927 (27.5)                                   |
| Amylase increased                    | 0 (0.0)                                 | 0 (0.0)                     | 0 (0.0)                   | 0 (0.0)                              | 2 (25.0)                                      |
| Aspartate Aminotransferase Increased | 57 (38.5)                               | 62 (40.8)                   | 108 (44.8)                | 1421 (28.5)                          | 2052 (29.2)                                   |
| Bilirubin increased                  | 24 (16.2)                               | 13 (8.6)                    | 43 (20.2)                 | 505 (10.2)                           | 781 (11.1)                                    |
| Calcium decreased                    | 32 (21.6)                               | 24 (15.8)                   | 61 (26.2)                 | 1228 (23.2)                          | 1717 (23.5)                                   |
| Calcium increased                    | 20 (13.5)                               | 17 (11.2)                   | 44 (19.4)                 | 615 (11.6)                           | 805 (11.0)                                    |
| Creatine kinase increased            | 0 (0.0)                                 | 0 (0.0)                     | 0 (0.0)                   | 0 (0.0)                              | 1 (16.7)                                      |
| Creatinine increased                 | 42 (28.4)                               | 21 (13.8)                   | 65 (29.1)                 | 951 (19.1)                           | 1368 (19.4)                                   |
| Gamma glutamyl transferase increased | 0 (0.0)                                 | 0 (0.0)                     | 0 (0.0)                   | 1 (14.3)                             | 39 (33.9)                                     |
| Glucose decreased                    | 15 (10.1)                               | 14 (9.2)                    | 65 (26.5)                 | 485 (9.9)                            | 654 (9.5)                                     |
| Glucose increased                    | 68 (45.9)                               | 55 (36.2)                   | 151 (57.0)                | 2493 (50.8)                          | 3416 (49.4)                                   |
| Haemoglobin decreased                | 35 (23.6)                               | 50 (32.9)                   | 60 (21.0)                 | 2243 (44.4)                          | 3083 (43.0)                                   |
| Leukocytes decreased                 | 46 (31.1)                               | 67 (44.1)                   | 93 (38.8)                 | 612 (12.2)                           | 905 (12.7)                                    |
| Lymphocytes decreased                | 51 (34.9)                               | 48 (32.0)                   | 92 (34.3)                 | 1791 (38.3)                          | 2529 (37.8)                                   |
| Magnesium decreased                  | 13 (24.5)                               | 6 (12.0)                    | 43 (30.3)                 | 603 (15.8)                           | 685 (16.1)                                    |
| Magnesium increased                  | 5 (9.4)                                 | 5 (10.0)                    | 12 (10. 4)                | 265 (7.0)                            | 291 (6.9)                                     |
| Neutrophils decreased                | 41 (28.1)                               | 64 (42.7)                   | 86 (36.6)                 | 349 (7.5)                            | 536 (8.0)                                     |
| Phosphate decreased                  | 44 (30.8)                               | 27 (18.5)                   | 90 (37.7)                 | 1043 (22.1)                          | 1346 (21.3)                                   |
| Platelet decreased                   | 50 (33.8)                               | 39 (25.7)                   | 103 (40.6)                | 631 (12.6)                           | 929 (13.0)                                    |
| Potassium decreased                  | 19 (12.8)                               | 21 (13.8)                   | 46 (20.3)                 | 682 (12.9)                           | 965 (13.2)                                    |
| Potassium increased                  | 22 (14.9)                               | 12 (7.9)                    | 47 (20.6)                 | 966 (18.2)                           | 1306 (17.8)                                   |
| Prothrombin INR increased            | 4 (7.4)                                 | 5 (10.4)                    | 5 (5.8)                   | 224 (16.0)                           | 339 (15.6)                                    |
| Sodium decreased                     | 36 (24.5)                               | 30 (19.7)                   | 90 (36.1)                 | 1932 (36.2)                          | 2570 (34.8)                                   |
| Sodium increased                     | 12 (8.2)                                | 8 (5.3)                     | 25 (11. 6)                | 290 (5.5)                            | 372 (5.1)                                     |
| Triglycerides increased              | 0 (0.0)                                 | 0 (0.0)                     | 0 (0.0)                   | 808 (35.0)                           | 810 (35.0)                                    |

In  KEYNOTE-204,  there  were  10  participants  in  each  treatment  group  (6.8%  and  6.6%  in  the pembrolizumab  and  BV  groups,  respectively)  who  experienced  ' thrombocytopenia '  or  ' platelet  count decreased ' as reported by the sites as an AE. Among the 10 participants in the pembrolizumab group, 9 participants had an event outcome reported as resolved, as of the data cut-off date.

Among  these  10  participants  in  the  pembrolizumab  group,  Grade  1  events  were  experienced  by  4 participants, and Grade 2, 3, and 4 events were experienced by 2 participants each. There were no events that led to clinical sequelae nor had a fatal outcome. Among participants in KEYNOTE-204, 12 were treated with platelet infusions: 7 (4.7%) in the pembrolizumab group and 5 (3.3%) in the BV group. Most platelet infusions  were  intended  for  treatment  of  thrombocytopenia.  Concomitant  medications  for  Grade  3-4 thrombocytopenia for the 4 participants in the KEYNOTE-204 pembrolizumab arm were also provided.

In  the  RSD,  excluding  the  243  cHL  participants  from  KEYNOTE-013  and  KEYNOTE-087,  a  total  of  140 participants out of 5643 (2.5%) experienced thrombocytopenia or platelet count decreased. Of these, there were 100 participants with Grade 1 events, 20 with Grade 2 events, 9 with Grade 3 events, and 11 with Grade 4 events. There were no events that led to clinical sequelae nor had a fatal outcome. Less than 1%

<div style=\"page-break-after: always\"></div>

(17/5643) of patients received a platelet transfusion after starting pembrolizumab. In addition, a case of autoimmune thrombocytopenia has been reported after treatment with pembrolizumab in KEYNOTE-204.

## Immunogenicity

No new immunogenicity data were available.

## Analysis of Secondary Malignancies

There were no secondary malignancies identified in the KEYNOTE-204 or reported in the cHL Safety Dataset.

## Safety in special populations

## Age

In the KEYNOTE-204 pembrolizumab arm, the incidence of AEs was generally higher among older patients (&gt;=65), similar to the cHL Safety Dataset. This pattern was not observed between the age groups in the RSD and in the CRS.

Table 948 Adverse Event Summary by Age Category (&lt;65, ≥65 Years)

|                                                       | KN204 Data for Pembrolizumabit   | KN204 Data for Pembrolizumabit   | KN204 Data for Pembrolizumabit   | KN204 Data for Pembrolizumabit   | KN204DataforBrentuximab Vedotin!   | KN204DataforBrentuximab Vedotin!   | KN204DataforBrentuximab Vedotin!   | cHL Safety Data for Pembrolizumabl   | cHL Safety Data for Pembrolizumabl   | cHL Safety Data for Pembrolizumabl   | cHL Safety Data for Pembrolizumabl   | Reference Safety Dataset for Pembrolizumabtt   | Reference Safety Dataset for Pembrolizumabtt   | Reference Safety Dataset for Pembrolizumabtt   | Reference Safety Dataset for Pembrolizumabtt   | Cumulative Running Safety Dataset for Pembrolizumabff   | Cumulative Running Safety Dataset for Pembrolizumabff   | Cumulative Running Safety Dataset for Pembrolizumabff   | Cumulative Running Safety Dataset for Pembrolizumabff   |
|-------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|------------------------------------|------------------------------------|------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                                                       | <65                              | <65                              | >=65                             | >=65                             | 65                                 | 65                                 | >=65                               | >=65                                 | ≤65                                  | ≤65                                  | >=65                                 | >=65                                           | <65                                            | <65                                            | >=65 ≤65                                       | >=65 ≤65                                                |                                                         |                                                         | >=65                                                    |
|                                                       | n                                | (%)                              | n                                | (%)                              | n                                  | (%)                                | n                                  | (%)                                  | n                                    | (%)                                  | n                                    | (%)                                            | n (%)                                          | n                                              | (%)                                            | n                                                       | (%)                                                     | n                                                       | (%)                                                     |
| Subjects in population                                | 122                              |                                  | 26                               |                                  | 130                                |                                    | 22                                 |                                      | 343                                  |                                      | 46                                   |                                                | 3,385                                          | 2,499                                          |                                                | 4,640                                                   |                                                         | 3,453                                                   |                                                         |
| with one or more adverse events                       | 119                              | (97.5)                           | 26                               | (100.0                           | 121                                | (93.1)                             | 22                                 | (100.0                               | 335                                  | (97.7)                               | 46                                   | (100.0                                         | 3,268 (96.5)                                   | 2,422                                          | (96.9)                                         | 4,476                                                   | (96.5)                                                  | 3,335                                                   | (96.6)                                                  |
| with no adverse event                                 | 3                                | (2.5)                            | 0                                | ） (0.0)                          | 9                                  | (6.9)                              | 0                                  | (0.0)                                | 8                                    | (2.3)                                | 0                                    | ） (0.0)                                        | 117 (3.5)                                      | 77                                             | (3.1)                                          | 164                                                     | (3.5)                                                   | 118                                                     | (3.4)                                                   |
| with drug-related adverse events                      | 87                               | (71.3)                           | 23                               | (88.5)                           | 97                                 | (74.6)                             | 20                                 | (90.9)                               | 245                                  | (71.4)                               | 40                                   | (87.0)                                         | (69.9)                                         | 1,766                                          | (70.7)                                         | 3,161                                                   | (68.1)                                                  | 2,417                                                   | (70.0)                                                  |
| with toxicity grade 3-5 adverse events                | 50                               | (41.0)                           | 15                               | (57.7)                           | 51                                 | (39.2)                             | 15                                 | (68.2)                               | 123                                  | (35.9)                               | 24                                   | (52.2)                                         | 2.366 1,505 (44.5)                             | 1,324                                          | (53.0)                                         | 2,139                                                   | (46.1)                                                  | 1,797                                                   | (52.0)                                                  |
| with toxicity grade3-5 drug-related adverse events    | 23                               | (18.9)                           | 6                                | (23.1)                           | 28                                 | (21.5)                             | 10                                 | (45.5)                               | 52                                   | (15.2)                               | 10                                   | (21.7)                                         | 456 (13.5)                                     | 457                                            | (18.3)                                         | 657                                                     | (14.2)                                                  | 640                                                     | (18.5)                                                  |
| with serious adverse events                           | 30                               | (24.6)                           | 14                               | (53.8)                           | 25                                 | (7'61)                             | 7                                  | (31.8)                               | 81                                   | (23.6)                               | 23                                   | (50.0)                                         | 1,182 (34.9)                                   | 1,084                                          | (43.4)                                         | 1,634                                                   | (35.2)                                                  | 1,456                                                   | (42.2)                                                  |
| with serious drug-related adverse events              | 16                               | (13.1)                           | 8                                | (30.8)                           | 12                                 | (9.2)                              | 4                                  | (18.2)                               | 36                                   | (10.5)                               | 10                                   | (21.7)                                         | 346 (10.2)                                     | 310                                            | (12.4)                                         | 475                                                     | (10.2)                                                  | 442                                                     | (12.8)                                                  |
| who died                                              | 3                                | (2.5)                            | 0                                | (0.0)                            | 1                                  | (0.8)                              | 1                                  | (4.5)                                | 5                                    | (1.5)                                | 1                                    | (2.2)                                          | 144 (4.3) 21                                   | 168                                            | (6.7)                                          | 204                                                     | (4.4)                                                   | 240                                                     | (0'L)                                                   |
| who died due to a drug-related adverse event          | 1                                | (0.8)                            | 0                                | (0.0)                            | 0                                  | (0.0)                              | 0                                  | (0.0)                                | 1                                    | (0.3)                                | 0                                    | (0.0)                                          | (0.6)                                          | 18                                             | (0.7)                                          | 28                                                      | (0.6)                                                   | 33                                                      | (1.0)                                                   |
| discontinued drug due to an adverse event             | 14                               | (11.5)                           | 6                                | (23.1)                           | 17                                 | (13.1)                             | 10                                 | (45.5)                               | 33                                   | (9.6)                                | 8                                    | (17.4)                                         | 399 (11.8)                                     | 391                                            | (15.6)                                         | 523                                                     | (11.3)                                                  | 524                                                     | (15.2)                                                  |
| discontinued drug due to a drug-related adverse event | 13                               | (10.7)                           | 6                                | (23.1)                           | 15                                 | (11.5)                             | 10                                 | (45.5)                               | 28                                   | (8.2)                                | 8                                    | (17.4)                                         | 207 (6.1)                                      | 203                                            | (8.1)                                          | 270                                                     | (5.8)                                                   | 281                                                     | (8.1)                                                   |
| discontinued drug due to a serious adverse event      | 10                               | (8.2)                            | 4                                | (15.4)                           | 5                                  | (3.8)                              | 3                                  | (13.6)                               | 18                                   | (5.2)                                | 6                                    | (13.0)                                         | 287 (8.5)                                      | 285                                            | (11.4)                                         | 383                                                     | (8.3)                                                   | 377                                                     | (10.9)                                                  |

|                                                                | KN204 Data for Pembrolizumabtt   | KN204 Data for Pembrolizumabtt   | KN204 Data for Brentuximab Vedotin!   | KN204 Data for Brentuximab Vedotin!   | cHL SafetyData for Pembrolizumabl   | cHL SafetyData for Pembrolizumabl   | Reference Safety Dataset for Pembrolizumabtt   | Reference Safety Dataset for Pembrolizumabtt   | Reference Safety Dataset for Pembrolizumabtt   | Cumulative Running Safety Dataset for Pembrolizumabsf   | Cumulative Running Safety Dataset for Pembrolizumabsf   | Cumulative Running Safety Dataset for Pembrolizumabsf   | Cumulative Running Safety Dataset for Pembrolizumabsf   |
|----------------------------------------------------------------|----------------------------------|----------------------------------|---------------------------------------|---------------------------------------|-------------------------------------|-------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                                                                | ≤65                              | >=65                             | ≤65                                   | >=65                                  |                                     | ≤65                                 | >=65                                           |                                                | ≤65                                            | >=65                                                    | ≤65                                                     | >=65                                                    |                                                         |
|                                                                | n (%)                            | n (%)                            | n (%)                                 | n                                     | (%) n                               | (%)                                 | n (%)                                          | n                                              | (%)                                            | n (%)                                                   | n (%) 166                                               | n                                                       | (%)                                                     |
| discontinued drug due to a serious drug- related adverse event | 9 (7.4)                          | 4 (15.4)                         | 3 (2.3)                               | 3 (13.6)                              | 14                                  | (4.1)                               | 6 (13.0)                                       | 123                                            | (3.6)                                          | 122 (4.9)                                               | (3.6)                                                   | 168                                                     | (4.9)                                                   |

Database cutoff date for Melanoma(KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015,KN054: 020CT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024:10JUL2017,KN042:04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date forGastric (KN012-Gashic: 26APR2016, KN059-Cohort 1: 08AUG2018,KN062: 26MAR2019)

Database cutoff date for cHL(KN013-Cohort 3:28SEP2018,KN087: 21MAR2019,KN204:16JAN2020)

Database cutoff date for Bladder(KN012-Urothelial: 01SEP2015,KN045: 26OCT2017,KN052:26SEP2018)

Database cutoff date for Colorectal (KN164-Cohort A:03AUG2016)

Database cutoff date forPMBCL (KN013-Cohort 4A: 04AUG2017.KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017,KN158-Cohort E: 27JUN2019)

Database cutoff date forHCC (KN224:15MAY2018)

Database Cutoff dateforMerkelCell (P017:06FEB2018)

DatabaseCutoff date forEsophageal(KN028-CohortA4:31JAN2018,KN1S0:30JUL2018,KN181:15OCT2018)

Database Cutoff date for RenalCarcinoma (KN427: 07SEP2018)

DatabaseCutoff date forSCLC(KN15S-CohortG:27JUN2019,KN028-CohortC1:31JUL2018)

Database Cutoff date for NMIBC (non-muscle invasive bladder cancer) (KN057: 24MAY2019)

DatabaseCutoff date forTMB-H (KN158:27JUN2019)

Source: [ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

The most commonly occurring AEs among participants ≥65 years (n=26) treated with pembrolizumab are provided in Table 76. Compared with participants &lt;65 years of age treated with pembrolizumab (Table 77), participants ≥65 years of age had higher (&gt;15 percen tage point difference) rates of peripheral oedema (23.1% vs 0.8%), decreased  appetite (23.1%  vs  2.5%),  and pain  in  extremity (23.1%  vs  5.7%)  (AE incidences &lt;5% not shown in table).

Slightly higher rates of AEs for some categories were also observed among older participants compared with younger participants in the BV arm of KEYNOTE-204 (e.g., Grade 3 to 5 AEs: 68.2% vs 39.2%) and the RSD (Grade 3 to 5 AEs: 53.0% vs 44.5%).

Table 959 Subjects with Adverse Events by decreasing incidence

<!-- image -->

## Gender

In the pembrolizumab arm, the events observed in males versus females were as follows:

- Drug-related AEs in 59 (72.8%) males and 51 (76.1%) females;
- Grade 3 to 5 AEs in 34 (42.0%) males versus 31 (46.3%) females;
- SAEs in 21 (25.9%) males versus 23 (34.3%) females;

<div style=\"page-break-after: always\"></div>

- Discontinuations due to AEs in 8 (9.9%) males versus 12 (17.9%) females.

This was generally consistent across the KEYNOTE-204 pembrolizumab arm, the cHL Safety Dataset, and the RSD.

Table 96 Adverse Event Summary by Gender (Male, Female)

|                                                       | KN204 Data for Pembrolizumabit   | KN204 Data for Pembrolizumabit   | KN204 Data for Pembrolizumabit   | KN204 Data for Brentuximab Vedotin   | KN204 Data for Brentuximab Vedotin   | KN204 Data for Brentuximab Vedotin   |    |        |     | cHL Safety Data for Pembrolizumabl   | cHL Safety Data for Pembrolizumabl   | cHL Safety Data for Pembrolizumabl   | Reference Safety Dataset for Pembrolizumabit   | Reference Safety Dataset for Pembrolizumabit   | Reference Safety Dataset for Pembrolizumabit   | Reference Safety Dataset for Pembrolizumabit   | Cumulative Running Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   |
|-------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|----|--------|-----|--------------------------------------|--------------------------------------|--------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                       | M                                | M                                | F                                | F                                    | M                                    | M                                    | F  | F      | M   | M                                    | F                                    | F                                    | M                                              | M                                              | F                                              | F                                              | M                                                     | M                                                     | F                                                     |
|                                                       | n                                | (%)                              | n                                | (%)                                  | n                                    | (%)                                  | n  | (%)    | n   | (%)                                  | n                                    | (%)                                  | n                                              | (%)                                            | n                                              | n                                              | (%)                                                   | n                                                     | (%)                                                   |
| Subjects inpopulation                                 | 81                               |                                  | 67                               |                                      | 89                                   |                                      | 63 |        | 212 |                                      | 177                                  |                                      | 3,887                                          | 1,997                                          | (%)                                            | 5,416                                          |                                                       | 2,677                                                 |                                                       |
| with one or more adverse events                       | 79                               | (97.5)                           | 66                               | (98.5)                               | 86                                   | (96.6)                               | 57 | (90.5) | 207 | (97.6)                               | 174                                  | (98.3)                               | 3,756 (96.6)                                   | 1,934                                          | (96.8)                                         | 5,215                                          | (96.3)                                                | 2,596                                                 | (97.0)                                                |
| with no adverse event                                 | 2                                | (2.5)                            | 1                                | (1.5)                                | 3                                    | (3.4)                                | 6  | (9.5)  | 5   | (2.4)                                | 3                                    | (1.7)                                | 131                                            | 63                                             | (3.2)                                          | 201                                            | (3.7)                                                 | 81                                                    | (3.0)                                                 |
| with drug-related adverse events                      | 59                               | (72.8)                           | 51                               | (76.1)                               | 71                                   | (79.8)                               | 46 | (73.0) | 151 | (71.2)                               | 134                                  | (75.7)                               | 2,710                                          | (3.4) (69.7) 1,422                             | (7IL)                                          | 3,691                                          | (68.1)                                                | 1,887                                                 | (70.5)                                                |
| with toxicity grade 3-5 adverse events                | 34                               | (42.0)                           | 31                               | (46.3)                               | 39                                   | (43.8)                               | 27 | (42.9) | 75  | (35.4)                               | 72                                   | (40.7)                               | 1,894                                          | (48.7) 935                                     | (46.8)                                         | 2,659                                          | (49.1)                                                | 1,277                                                 | (47.7)                                                |
| with toxicity grade 3-5 drug-related adverse events   | 15                               | (18.5)                           | 14                               | (20.9)                               | 24                                   | (27.0)                               | 14 | (22.2) | 33  | (15.6)                               | 29                                   | (16.4)                               | 630                                            | (16.2) 283                                     | (14.2)                                         | 016                                            | (16.8)                                                | 387                                                   | (14.5)                                                |
| with serious adverse events                           | 21                               | (25.9)                           | 23                               | (34.3)                               | 18                                   | (20.2)                               | 14 | (22.2) | 55  | (25.9)                               | 49                                   | (27.7)                               | 1,534                                          | (39.5) 732 208                                 | (36.7)                                         | 2,105                                          | (38.9)                                                | 985                                                   | (36.8)                                                |
| with serious drug-related adverse events              | 14                               | (17.3)                           | 10                               | (14.9)                               | 10                                   | (711)                                | 6  | (9.5)  | 28  | (13.2)                               | 18                                   | (10.2)                               | 448                                            | (11.5)                                         | (10.4)                                         | 644                                            | (11.9)                                                | 273                                                   | (10.2)                                                |
| who died                                              | 1                                | (7D)                             | 2                                | (3.0)                                | 1                                    | (1.1)                                | 1  | (1.6)  | 4   | (6'D)                                | 2                                    | (1.1)                                | 221                                            | 91 14                                          | (4.6)                                          | 326                                            | (6.0)                                                 | 118                                                   | (4.4)                                                 |
| who died due to a dug-related adverse event           | 0                                | (0.0)                            | 1                                | (1.5)                                | 0                                    | (0.0)                                | 0  | (0.0)  | 0   | (0.0)                                | 1                                    | (0.6)                                | 25                                             | (5.7) (0.6)                                    | (0.7)                                          | 40                                             | (0.7)                                                 | 21                                                    | (0.8)                                                 |
| discontinued dug due to an adverse event              | 8                                | (66)                             | 12                               | (17.9)                               | 17                                   | (19.1)                               | 10 | (15.9) | 21  | (9.9)                                | 20                                   | (11.3)                               | 529                                            | (13.6) 261                                     | (13.1)                                         | 717                                            | (13.2)                                                | 330                                                   | (12.3)                                                |
| discontinued drug due to a drug-related adverse event | 8                                | (9.9)                            | 11                               | (16.4)                               | 16                                   | (18.0)                               | 9  | (14.3) | 18  | (8.5)                                | 18                                   | (10.2)                               | 278                                            | (TD) 132                                       | (6.6)                                          | 380                                            | (7.0)                                                 | 171                                                   | (6.4)                                                 |
| discontinued drug due to a serious adverse event      | 6                                | (7.4)                            | 8                                | (11.9)                               | 5                                    | (5.6)                                | 3  | (4.8)  | 14  | (6.6)                                | 10                                   | (5.6)                                | 386                                            | (9.9) 186                                      | (9.3)                                          | 523                                            | (9.7)                                                 | 237                                                   | (8.9)                                                 |

|                                                                | KN204 Data for Pembrolizumabit   | KN204 Data for Pembrolizumabit   | KN204 Data for Brentuximab Vedotin'   | KN204 Data for Brentuximab Vedotin'   | cHL SafetyData for Pembrolizumabl   | cHL SafetyData for Pembrolizumabl   | Reference Safety Dataset for Pembrolizumablt   | Reference Safety Dataset for Pembrolizumablt   | Reference Safety Dataset for Pembrolizumablt   | Cumulative Running Safety Dataset for Pembrolizumabff   | Cumulative Running Safety Dataset for Pembrolizumabff   | Cumulative Running Safety Dataset for Pembrolizumabff   | Cumulative Running Safety Dataset for Pembrolizumabff   |
|----------------------------------------------------------------|----------------------------------|----------------------------------|---------------------------------------|---------------------------------------|-------------------------------------|-------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                                                                | M                                | F                                | M                                     | F                                     | M                                   |                                     | F                                              |                                                | M                                              | F                                                       | M                                                       |                                                         | F                                                       |
|                                                                | n (%)                            | n (%)                            | n (%)                                 | n (%)                                 | n                                   | (%)                                 | n (%)                                          | n                                              | (%)                                            | n (%)                                                   | (%)                                                     |                                                         | (%)                                                     |
| discontinued drug due to a serious drug- related adverse event | 6 (7.4)                          | 7 (10.4)                         | 4 (4.5)                               | 2 (3.2)                               | 11                                  | (5.2)                               | 9 (5.1)                                        | 167                                            | (4.3)                                          | 78 (3.9) 232                                            | (4.3)                                                   | 102                                                     | (3.8)                                                   |

## ECOG PS

The incidence of AEs with pembrolizumab was similar between subjects with an ECOG performance status of 1 and an ECOG performance status of 0. Nevertheless drug-related AEs, Grade 3-5 AEs, deaths and SAEs were higher in subjects with ECOG PS 1. This was consistent across the KEYNOTE-204 pembrolizumab arm, the cHL Safety Dataset and the RSD.

Table 971 Adverse Event Summary by ECOG Status Category (0, 1)

|                                                       | KN204 Datafor Pembrolizumabit   | KN204 Datafor Pembrolizumabit   | KN204 Datafor Pembrolizumabit   | KN204DataforBrentuximab Vedotin'   | KN204DataforBrentuximab Vedotin'   | KN204DataforBrentuximab Vedotin'   | cHLSafety Data for Pembrolizumabl   | cHLSafety Data for Pembrolizumabl   | cHLSafety Data for Pembrolizumabl   | cHLSafety Data for Pembrolizumabl   | Reference Safety Dataset for Pembrolizumablt   | Reference Safety Dataset for Pembrolizumablt   | Reference Safety Dataset for Pembrolizumablt   | Reference Safety Dataset for Pembrolizumablt   | Reference Safety Dataset for Pembrolizumablt    | CumulativeRunningSafety Dataset forPembrolizumab   | CumulativeRunningSafety Dataset forPembrolizumab   | CumulativeRunningSafety Dataset forPembrolizumab   | CumulativeRunningSafety Dataset forPembrolizumab   |
|-------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|------------------------------------|------------------------------------|------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                                                       | [0] Normal Activity             | [0] Normal Activity             | [1]Symptoms, but ambulatory     | [1]Symptoms, but ambulatory        | [0]Normal Activity                 | [0]Normal Activity                 | [] Symptoms, but ambulatory         | [] Symptoms, but ambulatory         | [0]Nomal Activity                   | [0]Nomal Activity                   | [1] Symptoms, but ambulatory                   | [1] Symptoms, but ambulatory                   | [eoN[o] Activity                               | [eoN[o] Activity                               | [1] Symptoms, [O]Nonmal but ambulatory Activity | [1] Symptoms, [O]Nonmal but ambulatory Activity    |                                                    |                                                    | [1] Symptoms, but ambulatory                       |
|                                                       | n                               | (%)                             | n                               | (%)                                | n                                  | (%)                                | n                                   | (%)                                 | n                                   | (%)                                 | n                                              | (%)                                            | n (%)                                          | n                                              | (%)                                             | n                                                  | (%)                                                | n                                                  | (%)                                                |
| Subjects in population                                | 84                              |                                 | 63                              |                                    | 99                                 |                                    | 53                                  |                                     | 200                                 |                                     | 187                                            |                                                | 2,761                                          | 2,931                                          |                                                 | 3,723                                              |                                                    | 4,059                                              |                                                    |
| with one or more adverse events                       | 81                              | (96.4)                          | 63                              | (100.0                             | 94                                 | (94.9)                             | 49                                  | (92.5)                              | 195                                 | (97.5)                              | 184                                            | (98.4) 2,671                                   | (96.7)                                         | 2,835                                          | (96.7)                                          | 3,589                                              | (96.4)                                             | 3,923                                              | (96.6)                                             |
| with no adverse event                                 | 3                               | (3.6)                           | 0                               | (0.0)                              | 5                                  | (5.1)                              | 4                                   | (7.5)                               | 5                                   | (2.5)                               | 3                                              | (1.6) 90                                       | (3.3)                                          | 96                                             | (3.3)                                           | 134                                                | (3.6)                                              | 136                                                | (3.4)                                              |
| with drug-related adverse events                      | 57                              | (67.9)                          | 52                              | (82.5)                             | 81                                 | (81.8)                             | 36                                  | (67.9)                              | 139                                 | (69.5)                              | 144                                            | (77.0) 2,085                                   | (75.5)                                         | 1,940                                          | (66.2)                                          | 2,734                                              | (73.4)                                             | 2,642                                              | (65.1)                                             |
| with toxicity grade 3-5 adverse events                | 33                              | (39.3)                          | 31                              | (49.2)                             | 43                                 | (43.4)                             | 23                                  | (43.4)                              | 60                                  | (30.0)                              | 86                                             | (46.0)                                         | 1,112 (40.3)                                   | 1,605                                          | (54.8)                                          | 1,526                                              | (41.0)                                             | 2,243                                              | (55.3)                                             |
| with toxicity grade 3-5 drug-related adverse events   | 14                              | (16.7)                          | 14                              | (22.2)                             | 28                                 | (28.3)                             | 10                                  | (18.9)                              | 27                                  | (13.5)                              | 34                                             | (18.2) 410                                     | (14.8)                                         | 471                                            | (16.1)                                          | 561                                                | (15.1)                                             | 671                                                | (16.5)                                             |
| withserious adverse events                            | 25                              | (29.8)                          | 19                              | (30.2)                             | 18                                 | (18.2)                             | 14                                  | (26.4)                              | 48                                  | (24.0)                              | 56                                             | (29.9) 872                                     | (31.6)                                         | 1,294                                          | (44.1)                                          | 1,182                                              | (31.7)                                             | 1,761                                              | (43.4)                                             |
| with serious drug-related adverse events              | 16                              | (19.0)                          | 8                               | (12.7)                             | 12                                 | (12.1)                             | 4                                   | (7.5)                               | 26                                  | (13.0)                              | 20                                             | (10.7) 311                                     | (11.3)                                         | 325                                            | (11.1)                                          | 419                                                | (11.3)                                             | 456                                                | (11.2)                                             |
| who died                                              | 1                               | (71)                            | 2                               | (3.2)                              | 1                                  | (0'1)                              | 1                                   | (1.9)                               | 2                                   | (1.0)                               | 4                                              | (2.1)                                          | 79 (2.9)                                       | 217                                            | (7.4)                                           | 121                                                | (3.3)                                              | 304                                                | (SL)                                               |
| who died due to a drug-related adverse event          | 0                               | (0.0)                           | 1                               | (1.6)                              | 0                                  | (0.0)                              | 0                                   | (0.0)                               | 0                                   | (0.0)                               | 1                                              | (0.5)                                          | 14 (0.5)                                       | 25                                             | (0.9)                                           | 21                                                 | (0.6)                                              | 39                                                 | (1.0)                                              |
| discontinueddrug due to an adverse event              | 12                              | (14.3)                          | 8                               | (12.7)                             | 20                                 | (20.2)                             | 7 (13.2)                            | 19                                  |                                     | (9.5)                               | 22                                             | (11.8) 304                                     | (11.0)                                         | 452                                            | (15.4)                                          | 407                                                | (10.9)                                             | 585                                                | (14.4)                                             |
| discontinued drug due to a drug-related adverse event | 11                              | (13.1)                          | 8                               | (12.7)                             | 18                                 | (18.2)                             | 7                                   | (13.2)                              | 16                                  | (8.0)                               | 20                                             | (10.7) 193                                     | (7.0)                                          | 200                                            | (6.8)                                           | 257                                                | (6.9)                                              | 261                                                | (6.4)                                              |
| discontinued drug due toa serious adverse event       | 9                               | (10.7)                          | 5                               | (7.9)                              | 6                                  | (6.1)                              | 2                                   | (3.8)                               | 11                                  | (5.5)                               | 13                                             | (7.0) 198                                      | (7.2)                                          | 350                                            | (611D)                                          | 265                                                | (7.1)                                              | 460                                                | (11.3)                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source: [ISS: adam-adsl: adae]

Complications Following Post-Allogeneic Stem Cell Transplantation (SCT)

In KEYNOTE-204 , 14 and 13 patients in the pembrolizumab and BV arms respectively, underwent alloSCT after stopping treatment. Of these, 12 (85.7%) in the pembrolizumab arm and 7 (53.8%) in the BV group experienced a post allo-SCT AE. The most common AE was GVHD for  8  patients (57.1%) in the pembrolizumab arm (n=1 Grade 1, n=5 Grade 2, n=1 Grade 3, n=1 Grade 4) and for 5 patients (38.5%) in the BV group (n=1 Grade 2, n=3 Grade 3, n=1 Grade 4). No participants experienced hepatic venoocclusive disease .

Two patients, both in the pembrolizumab arm, died due to AEs: hypovolemic shock and hypoxic respiratory failure , both of which were reported by the MAH as not related to the study treatment.

In KEYNOTE-087 , 32 patients (15.2%) underwent allo-SCT; 20 of these patients experienced a post-alloSCT AE. The most common AE was GVHD (n=18): acute GVHD (n=11, including 1 hyperacute), chronic GVHD (n=2), or both (n=5). Eight patients had more than 1 event of GVHD (acute and/or chronic). Among the 30 events of GVHD , most events were Grade 1 (11 events), 13 were Grade 2, 4 were Grade 3 and 2 were Grade 5. No participants experienced hepatic veno-occlusive disease . Four patients died due to post allo-SCT AEs: acute GVHD , hyperacute GVHD , pneumonia and sepsis (n=1 each). None was considered by the MAH related to the study treatment.

In KEYNOTE-051 , 2 cHL paediatric patients received an allo-SCT after treatment with pembrolizumab. Both patients developed a post allogeneic SCT complication: Grade 2 chronic GVHD in 1 patient and Grade 2 acute GVHD in the other, approximately 4 months post-allogeneic SCT. At the time of the study, both patients were alive and the GVHD was not resolved. The investigators considered the chronic and acute GVHD as not related to pembrolizumab.

For the 48 cHL participants in KEYNOTE-051, KEYNOTE-087 and KEYNOTE-204 who received an allo-SCT after on-study pembrolizumab, a summary of the time from the last dose of on-study pembrolizumab to allo-SCT is presented for the overall population as well as whether the participant experienced a GVHD

<div style=\"page-break-after: always\"></div>

(either acute or chronic) or not. Of note, there is one participant excluded in the analysis of time since last dose of pembrolizumab to first allo-SCT due to insufficient data in the date of the allo-SCT as the month of transplant  was  missing.  Also  in  KEYNOTE-051,  there  is  only  1  participant  in  the  analysis  with GVHD compared  to  2  who  was  excluded  from  the  AE  summary  tables  because  the  onset  date  of GVHD (12.01.2020) occurred after the data cut-off (10.01.2020).

Table 982 Time to allo-SCT after the last dose of on-study pembrolizumab

<!-- image -->

Source:[PMR:adam-adsl; adbase]

In  KEYNOTE-204,  additional  information  on  the  10  allo-SCT  participants  post-pembrolizumab  who experienced  a GVHD event  are  provided.  Also,  details  on  the  mortality  status  for  all  pembrolizumab participants receiving allo-SCT, where 'transplant-related' death was considered as any death that was not reported  as  progressive  disease,  is  provided  and  includes  additional  information  on  all  14  allo-SCT participants, such as the last known contact date and follow-up time since allo-SCT. These preliminary data confirm that GVHD is a frequent AE post pembrolizumab, especially as acute GVHD (reported 8 out of 11 patients, including the subject excluded from the analysis), Grade 2 or Grade 3 predominantly. However, also chronic GVHD mild/moderate/severe has been observed (in 3 out of 11 patients). Of the fourteen transplanted patients, two patients died, and the cause of death was respiratory failure and hypovolaemic shock , respectively.

## Safety related to drug-drug interactions and other interactions

No specific drug-drug interaction (DDI) studies have been performed. However, as pembrolizumab is an IgG antibody administrated parenterally and cleared by catabolism, food and DDI are not able to influence exposure, and drugs that affect cytochrome P450 enzymes are not expected to interfere with the metabolism of pembrolizumab. Studies evaluating pharmacodynamic drug interactions with pembrolizumab have not been conducted. However, the use of systemic corticosteroids or other immunosuppressive drugs should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of pembrolizumab, although these drugs can be used to treat immune-related adverse reactions during the pembrolizumab treatment.

## Discontinuation due to adverse events

## Adverse Events and Drug-related Adverse Events leading to Treatment Discontinuation

Adverse Events Leading to Treatment Discontinuation

<div style=\"page-break-after: always\"></div>

The incidence of AEs leading to discontinuation of study treatment in KEYNOTE-204 was similar for the pembrolizumab  and  BV  groups  (13.5%  vs  17.8%),  with  the  exception  of neuropathy  peripheral (0% pembrolizumab,  5.3%  BV), peripheral  sensory  neuropathy (0%  pembrolizumab,  3.9%  BV),  and pneumonitis (6.1% pembrolizumab, 0% BV). The incidence of AEs leading to discontinuation was lower in the pembrolizumab arm respect to the BV group, after adjustment for exposure (1.03 vs 2.80 events/100 person-months). The overall incidence of AEs leading to pembrolizumab discontinuation in KEYNOTE-204 was consistent with the cHL Safety Dataset and the RSD, except for pneumonitis (6.1% in KEYNOTE-204 pembrolizumab arm, 4.4% in the cHL Safety Dataset and 1.6% in the RSD).

Table 993 Subjects with adverse events resulting in treatment discontinuation (the most frequent AEs leading to treatment discontinuation)

|                                                        | KN204 Data for Pembrolizumabtt   | KN204 Data for Pembrolizumabtt   | KN204 Data for BrentuximabVedotin   | KN204 Data for BrentuximabVedotin   | cHLSafetyDatafor Pembrolizumabl   | cHLSafetyDatafor Pembrolizumabl   | ReferenceSafetyDataset for Pembrolizumabit   | ReferenceSafetyDataset for Pembrolizumabit   | CumulativeRunning Safety Dataset for Pembrolizumab   | CumulativeRunning Safety Dataset for Pembrolizumab   |
|--------------------------------------------------------|----------------------------------|----------------------------------|-------------------------------------|-------------------------------------|-----------------------------------|-----------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                        | n                                | (%)                              | n                                   | (%)                                 | n                                 | (%)                               | n                                            | (%)                                          | n                                                    | (%)                                                  |
| Subjects in population with one or more adverse events | 148 20                           |                                  | 152                                 |                                     | 389                               |                                   | 5,884                                        |                                              | 8,093                                                |                                                      |
|                                                        |                                  | (13.5)                           | 27                                  | (17.8)                              | 41                                | (10.5)                            | 790                                          | (13.4)                                       | 1,047                                                | (12.9)                                               |
| with no adverse events                                 | 128                              | ($86.5)                          | 125                                 | (82.2)                              | 348                               | (89.5)                            | 5,094                                        | (86.6)                                       | 7,046                                                | (87.1)                                               |
| Pneumonitis                                            | 9                                | (6.1)                            | 0                                   | (0.0)                               | 17                                | (4.4)                             | 96                                           | (1.6)                                        | 124                                                  | (1.5)                                                |
| Interstitial Lung Disease                              | 2                                | (1.4)                            | 1                                   | (0.7)                               | 3                                 | (0.8)                             | 8                                            | (0.1)                                        | 15                                                   | (0.2)                                                |
| Acute Kidney Injuy                                     | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                 | (0.3)                             | 6                                            | (0.1)                                        | 10                                                   | (0.1)                                                |
| Bacteraemia                                            | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                 | (0.3)                             | 0                                            | (0.0)                                        | 1                                                    | (0.0)                                                |
| Blood BiliubinIncreased                                | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                 | (0.3)                             | 4                                            | (0.1)                                        | 11                                                   | (0.1)                                                |
| Encephalitis Autoimmune                                | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                 | (0.3)                             | 0                                            | (0.0)                                        | 1                                                    | (0.0)                                                |
| EscherichiaInfection                                   | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                 | (0.3)                             | 0                                            | (0.0)                                        | 1                                                    | (0.0)                                                |
| Infusion Related Reaction                              | 1                                | (0.7)                            | 3                                   | (2.0)                               | 3                                 | (0.8)                             | 2                                            | (0.0)                                        | 3                                                    | (0.0)                                                |
| Nephropathy                                            | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                 | (0.3)                             | 0                                            | (0.0)                                        | 1                                                    | (0.0)                                                |
| Respiratory Tract Infection Fungal                     | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                 | (0.3)                             | 0                                            | (0.0)                                        | 1                                                    | (0.0)                                                |
| Squamous Cell Carcinoma Of The Cervix                  | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                 | (0.3)                             | 0                                            | (0.0)                                        | 1                                                    | (0.0)                                                |
| Abdominal Distension                                   | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                 | (0.0)                             | 1                                            | (0.0)                                        | 1                                                    | (0.0)                                                |
| Abdominal Pain                                         | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                 | (0.0)                             |                                              | (0.0)                                        | 3                                                    | (0.0)                                                |
| Abdominal Pain Upper                                   | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                 | (0.0)                             | 1                                            | (0.0)                                        | 1                                                    | (0.0)                                                |
| Accidental Death                                       | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                 | (0.0)                             |                                              | (0.0)                                        | 1                                                    | (0.0)                                                |
| AcuteCoronary Syndrome                                 | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                 | (0.0)                             | 1                                            | (0.0)                                        | 1                                                    | (0.0)                                                |
| Acute Myocardial Infarction                            | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                 | (0.0)                             | 2                                            | (0.0)                                        | 3                                                    | (0.0)                                                |
| Acute Respiratory Failure Addison's Disease            | 0 0                              | (0.0) (0.0)                      | 0 0                                 | (0.0) (0.0)                         | 0 0                               | (0.0) (0.0)                       | 4                                            | (0.1) (0.0)                                  | 5 1                                                  | (0.1) (0.0)                                          |

Drug-related Adverse Events Leading to Treatment Discontinuation

Drug-related AEs that resulted in treatment discontinuation were reported in 12.8% of patients in the pembrolizumab arm and in 16.4% of patients in the BV group. The incidence of drug-related AEs leading to treatment discontinuation was similar except for neuropathy peripheral (0% pembrolizumab, 5.3% BV), peripheral sensory neuropathy (0% pembrolizumab, 3.9% BV) and pneumonitis (6.1% pembrolizumab, 0% BV). The incidence of drug-related AEs leading to discontinuation was lower in the pembrolizumab arm compared with BV group, after adjustment for exposure (0.98 vs 2.52 events/100 person-months). The overall incidence of drug-related AEs leading to discontinuation was higher than in the cHL Safety Dataset and the RSD (12.8% in the KEYNOTE-204 pembrolizumab arm, 9.3% in the cHL Safety dataset and 7% in the  RSD). Pneumonitis was  the  only  drug-related  AE  leading  to  discontinuation  with  a  greater  than  2 percentage point difference in KEYNOTE-204 compared with the RSD (6.1% vs 1.6%).

<div style=\"page-break-after: always\"></div>

Table 1004 Subjects with drug-related adverse events resulting in treatment discontinuation (the most frequent drug-related AEs leading to treatment discontinuation)

|                                       | KN204 Data for Pembrolizumabtt   | KN204 Data for Pembrolizumabtt   | KN204 Data for BrentuximabVedotin   | KN204 Data for BrentuximabVedotin   | cHL Safety Data for Pembrolizumabl   | cHL Safety Data for Pembrolizumabl   | Reference Safety Dataset forPembrolizumablt   | Reference Safety Dataset forPembrolizumablt   | Cumulative Running SafetyDataset for Pembrolizumab   | Cumulative Running SafetyDataset for Pembrolizumab   |
|---------------------------------------|----------------------------------|----------------------------------|-------------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                       | n                                | (%)                              | n                                   | (%)                                 | n                                    | (%)                                  | n                                             | (%)                                           | n                                                    | (%)                                                  |
| Subjects in population                | 148                              |                                  | 152                                 |                                     | 389                                  |                                      | 5,884                                         |                                               | 8,093                                                |                                                      |
| with one or more adverse events       | 19                               | (12.8)                           | 25                                  | (16.4)                              | 36                                   | (9.3)                                | 410                                           | (7.0)                                         | 551                                                  | (6.8)                                                |
| with no adverse events                | 129                              | (87.2)                           | 127                                 | (83.6)                              | 353                                  | (90.7)                               | 5,474                                         | (93.0)                                        | 7,542                                                | (93.2)                                               |
| Pneumonitis                           | 9                                | (6.1)                            | 0                                   | (0.0)                               | 17                                   | (4.4)                                | 94                                            | (1.6)                                         | 122                                                  | (1.5)                                                |
| Interstitial Lung Disease             | 2                                | (1.4)                            | 1                                   | (0.7)                               | 3                                    | (0.8)                                | 8                                             | (0.1)                                         | 15                                                   | (0.2)                                                |
| Acute Kidney Injuy                    | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                    | (0.3)                                | 5                                             | (0.1)                                         | 9                                                    | (0.1)                                                |
| Bacteraemia                           | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                    | (0.3)                                | 0                                             | (0.0)                                         | 1                                                    | (0.0)                                                |
| Blood Bilirubin Increased             | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                    | (0.3)                                | 3                                             | (0.1)                                         | 6                                                    | (0.1)                                                |
| Encephalitis Autoimmune               | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                    | (0.3)                                | 0                                             | (0.0)                                         | 1                                                    | (0.0)                                                |
| Escherichia Infection                 | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                    | (0.3)                                | 0                                             | (0.0)                                         | 1                                                    | (0.0)                                                |
| Infusion Related Reaction             | 1                                | (0.7)                            | 3                                   | (2.0)                               | 3                                    | (0.8)                                | 2                                             | (0.0)                                         | 3                                                    | (0.0)                                                |
| Nephropathy                           | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                    | (0.3)                                | 0                                             | (0.0)                                         | 1                                                    | (0.0)                                                |
| Respiratory Tract Infection Fungal    | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                    | (0.3)                                | 0                                             | (0.0)                                         | 1                                                    | (0.0)                                                |
| Abdominal Pain                        | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                    | (0.0)                                | 0                                             | (0.0)                                         | 1                                                    | (0.0)                                                |
| Addison's Disease                     | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                    | (0.0)                                | 1                                             | (0.0)                                         | 1                                                    | (0.0)                                                |
| Adrenal Insufficiency                 | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                    | (0.0)                                | 4                                             | (0.1)                                         | 7                                                    | (0.1)                                                |
| Adrenocorticotropic Homone Deficiency | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                    | (0.0)                                | 0                                             | (0.0)                                         | 1                                                    | (0.0)                                                |
| Alanine Aminotransferase Increased    | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                    | (0.0)                                | 18                                            | (0.3)                                         | 21                                                   | (0.3)                                                |
| Anaphylactoid Reaction                | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                    | (0.0)                                | 1                                             | (0.0)                                         | 1                                                    | (0.0)                                                |
| Aptyalism                             | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                    | (0.0)                                | 1                                             | (0.0)                                         | 1                                                    | (0.0)                                                |
| Arterial Thrombosis                   | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                    | (0.0)                                | 1                                             | (0.0)                                         | 1                                                    | (0.0)                                                |
| Arthralgia                            | 0                                | (0.0)                            | 0                                   | (0.0)                               | 0                                    | (0.0)                                | 6                                             | (0.1)                                         | 6                                                    | (0.1)                                                |

## Adverse Events and Drug-related Adverse Events leading to Treatment Interruption

## Adverse Events Leading to Treatment Interruption

The incidence of AEs leading to treatment interruption was similar in the KEYNOTE-204 pembrolizumab and BV arms (29.7% vs 33.6%). The most frequent AEs leading to treatment interruption were pneumonia (3.4%) and upper respiratory tract infection (3.4%) in the pembrolizumab arm, neuropathy peripheral (5.9%) and infusion-related reactions (4.6%) in the BV arm. The incidence of AEs leading to interruption of pembrolizumab was consistent between KEYNOTE-204, the cHL safety dataset and the RSD.

Table 1015 Subjects with AEs resulting in treatment interruption (most frequent AEs leading to treatment interruption)

|                                        | KN204 Data for Pembrolizumabit   | KN204 Data for Pembrolizumabit   | KN204 Data for BrentuximabVedotin   | KN204 Data for BrentuximabVedotin   | cHL SafetyData for Pembrolizumabl   | cHL SafetyData for Pembrolizumabl   | Reference Safety Dataset for Pembrolizumablt   | Reference Safety Dataset for Pembrolizumablt   | Cumulative Running Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   |
|----------------------------------------|----------------------------------|----------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                        | n                                | (%)                              | n (%)                               | n (%)                               | n (%)                               | n (%)                               | n (%)                                          | n (%)                                          | n (%)                                                 | n (%)                                                 |
| Subjects in population                 | 148                              |                                  | 152                                 |                                     | 389                                 |                                     | 5,884                                          |                                                | 8,093                                                 |                                                       |
| with one or more adverse events        | 44                               | (29.7)                           | 51                                  | (33.6)                              | 117                                 | (30.1)                              | 1,492                                          | (25.4)                                         | 2,077                                                 | (25.7)                                                |
| with no adverse events                 | 104                              | (70.3)                           | 101                                 | (66.4)                              | 272                                 | (69.9)                              | 4,392                                          | (74.6)                                         | 6,016                                                 | (74.3)                                                |
| Pneumonia                              | 5                                | (3.4)                            | 2                                   | (1.3)                               | 14                                  | (3.6)                               | 95                                             | (9:1)                                          | 129                                                   | (1.6)                                                 |
| UpperRespiratory Tract Infection       | 5                                | (3.4)                            | 6                                   | (3.9)                               | 13                                  | (3.3)                               | 39                                             | (0.7)                                          | 51                                                    | (0.6)                                                 |
| Aspartate Aminotransferase Increased   | 4                                | (2.7)                            | 1                                   | (0.7)                               | 8                                   | (2.1)                               | 62                                             | (1.1)                                          | 102                                                   | (1.3)                                                 |
| Cough                                  | 4                                | (2.7)                            | 3                                   | (2.0)                               | 5                                   | (1.3)                               | 23                                             | (0.4)                                          | 38                                                    | (0.5)                                                 |
| Pneumonitis                            | 4                                | (2.7)                            | 1                                   | (0.7)                               | 11                                  | (2.8)                               | 85                                             | (1.4)                                          | 107                                                   | (E1)                                                  |
| Alanine Aminotransferase Increased     | 3                                | (2.0)                            | 1                                   | (0.7)                               | 9                                   | (2.3)                               | 73                                             | (71)                                           | 105                                                   | (1.3)                                                 |
| Dianhoea                               | 3                                | (2.0)                            | 0                                   | (0.0)                               | 12                                  | (3.1)                               | 112                                            | (61)                                           | 149                                                   | (1.8)                                                 |
| Pyrexia                                | 3                                | (2.0)                            | 1                                   | (0.7)                               | 10                                  | (2.6)                               | 31                                             | (0.5)                                          | 44                                                    | (0.5)                                                 |
| Confusional State                      | 2                                | (1.4)                            | 0                                   | (0.0)                               | 2                                   | (0.5)                               | 6                                              | (0.1)                                          | 9                                                     | (0.1)                                                 |
| Infection                              | 2                                | (1.4)                            | 1                                   | (0.7)                               | 2                                   | (0.5)                               | 4                                              | (0.1)                                          | 7                                                     | (0.1)                                                 |
| Abscess                                | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                   | (0.3)                               | 1                                              | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Acarodermatitis                        | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                   | (0.3)                               | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Acute Kidney Injuy                     | 1                                | (0.7)                            | 0                                   | (0.0)                               | 2                                   | (0.5)                               | 15                                             | (0.3)                                          | 28                                                    | (0.3)                                                 |
| Blood Albumin Decreased                | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                   | (0.3)                               | 1                                              | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Blood Alkaline Phosphatase Increased   | 1                                | (0.7)                            | 1                                   | (0.7)                               | 1                                   | (0.3)                               | 18                                             | (0.3)                                          | 29                                                    | (0.4)                                                 |
| Blood Creatine Phosphokinase Increased | 1                                | (0.7)                            | 0                                   | (0.0)                               | 2                                   | (0.5)                               | 8                                              | (0.1)                                          | 11                                                    | (0.1)                                                 |
| Bronchial Obshuction                   | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                   | (0.3)                               | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Bronchitis                             | 1                                | (0.7)                            | 1                                   | (0.7)                               | 10                                  | (2.6)                               | 24                                             | (0.4)                                          | 29                                                    | (0.4)                                                 |
| Cardiac Failure                        | 1                                | (0.7)                            | 0                                   | (0.0)                               | 1                                   | (0.3)                               | 3                                              | (0.1)                                          | 5                                                     | (0.1)                                                 |

<div style=\"page-break-after: always\"></div>

Drug-related AEs leading to dose interruption occurred in 18.9% of patients in the pembrolizumab arm and in 28.9% of patients in the BV group. Diarrhea (n=3, 2%), AST increased (n=3, 2%) and pneumonitis (n=3, 2%) were the most common AEs leading to dose interruption in the pembrolizumab arm; neuropathy peripheral (n=9,  5.9%), infusion  reaction (n=7,  4.6%)  and neutropenia (n=4,  2.6%)  were  the  most common  AEs  in  the  BV  arm  (Table  31).  The  incidence  and  types  of  drug-related  AEs  leading  to  the interruption of pembrolizumab in KEYNOTE-204 were consistent with the cHL Safety Dataset and the RSD.

Table 1026 Subjects with drug-related adverse events resulting in treatment interruption (the most frequent drug-related AEs leading to treatment interruption)

|                                       | KN204 Data for Pembrolizumabit   | KN204 Data for Pembrolizumabit   | KN204Data for BrentuximabVedotin   | KN204Data for BrentuximabVedotin   | cHL Safety Data for Pembrolizumabl   | cHL Safety Data for Pembrolizumabl   | Reference Safety Dataset for Pembrolizumabtt   | Reference Safety Dataset for Pembrolizumabtt   | Cumulative Running Safety Dataset for Pembrolizumab   | Cumulative Running Safety Dataset for Pembrolizumab   |
|---------------------------------------|----------------------------------|----------------------------------|------------------------------------|------------------------------------|--------------------------------------|--------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                       | n                                | (%)                              | n                                  | (%)                                | n                                    | (%)                                  | n                                              | (%)                                            | n                                                     | (%)                                                   |
| Subjects in population                | 148                              |                                  | 152                                |                                    | 389                                  |                                      | 5,884                                          |                                                | 8,093                                                 |                                                       |
| with one or more adverse events       | 28                               | (18.9)                           | 44                                 | (28.9)                             | 64                                   | (16.5)                               | 837                                            | (14.2)                                         | 1,127                                                 | (13.9)                                                |
| with no adverse events                | 120                              | (81.1)                           | 108                                | (71.1)                             | 325                                  | (83.5)                               | 5,047                                          | (85.8)                                         | 6,966                                                 | (86.1)                                                |
| Aspartate Aminotransferase Increased  | 3                                | (2.0)                            | 1                                  | (0.7)                              | 6                                    | (1.5)                                | 42                                             | (0.7)                                          | 71                                                    | (0.9)                                                 |
| Dianhoea                              | 3                                | (2.0)                            | 0                                  | (0.0)                              | 8                                    | (2.1)                                | 82                                             | (1.4)                                          | 114                                                   | (1.4)                                                 |
| Pneumonitis                           | 3                                | (2.0)                            | 1                                  | (0.7)                              | 10                                   | (2.6)                                | 79                                             | (E)                                            | 98                                                    | (71)                                                  |
| Alanine Aminotransferase Increased    | 2                                | (1.4)                            | 1                                  | (0.7)                              | 5                                    | (1.3)                                | 50                                             | (0.8)                                          | 72                                                    | (0.9)                                                 |
| Confusional State                     | 2                                | (1.4)                            | 0                                  | (0.0)                              | 2                                    | (0.5)                                | 2                                              | (0.0)                                          | 4                                                     | (0.0)                                                 |
| Pneumonia                             | 2                                | (1.4)                            | 2                                  | (1.3)                              | 3                                    | (0.8)                                | 10                                             | (0.2)                                          | 19                                                    | (0.2)                                                 |
| Upper Respiratory Tract Infection     | 2                                | (1.4)                            | 2                                  | (1.3)                              | 4                                    | (1.0)                                | 4                                              | (0.1)                                          | 6                                                     | (0.1)                                                 |
| Blood Albumin Decreased               | 1                                | (0.7)                            | 0                                  | (0.0)                              | 1                                    | (0.3)                                | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Blood Allkaline Phosphatase Increased | 1                                | (0.7)                            | 1                                  | (0.7)                              | 1                                    | (0.3)                                | 10                                             | (0.2)                                          | 15                                                    | (0.2)                                                 |
| Bronchial Obstuction                  | 1                                | (0.7)                            | 0                                  | (0.0)                              | 1                                    | (0.3)                                | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Cardiac Failure                       | 1                                | (0.7)                            | 0                                  | (0.0)                              | 1                                    | (0.3)                                | 0                                              | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Colitis                               | 1                                | (0.7)                            | 0                                  | (0.0)                              | 3                                    | (0.8)                                | 29                                             | (0.5)                                          | 41                                                    | (0.5)                                                 |
| Gamma-Glutamyltransferase Increased   | 1                                | (0.7)                            | 1                                  | (0.7)                              | 1                                    | (0.3)                                | 7                                              | (0.1)                                          | 10                                                    | (0.1)                                                 |
| Hlnl Influenza                        | 1                                | (0.7)                            | 0                                  | (0.0)                              | 1                                    | (0.3)                                | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Herpes Virus Infection                | 1                                | (0.7)                            | 1                                  | (0.7)                              | 1                                    | (0.3)                                | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Infusion Related Reaction             | 1                                | (0.7)                            | 7                                  | (4.6)                              | 3                                    | (0.8)                                | 21                                             | (0.4)                                          | 27                                                    | (0.3)                                                 |
| Interstitial Lung Disease             | 1                                | (0.7)                            | 0                                  | (0.0)                              | 1                                    | (0.3)                                | 8                                              | (0.1)                                          | 11                                                    | (0.1)                                                 |
| LowerRespiratoryTractInfection        |                                  | (0.7)                            | 1                                  | (0.7)                              | 1                                    | (0.3)                                | 1                                              | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Neuropathy Peripheral                 | 1                                | (0.7)                            | 9                                  | (5.9)                              |                                      | (0.3)                                | 4                                              | (0.1)                                          | 7                                                     | (0.1)                                                 |

## Assessment of paediatric data on clinical safety

To support the safety of pembrolizumab (2mg/kg Q3W) in the paediatric population, long-term data from KEYNOTE-051 were presented. KEYNOTE-051 is an ongoing, 2-part Phase 1-2, nonrandomized, open-label, single  arm  in  paediatric  population  (aged  between 6  months to  &lt;18  years) with  advanced  melanoma, relapsed or refractory, PD-L1-positive malignant solid tumours, or cHL (the 22 participants with HL ranged in age from 10 to 17 years: four participants were 10 to 13 years of age and 18 participants were 14 to 17 years of age). A total of 162 paediatric patients were enrolled, 161 of whom (22 with cHL) received at least 1 dose of pembrolizumab.

At the cut-off date (10.01.2020), the median duration of exposure to pembrolizumab was 8-fold-longer for cHL patients (344 days) compared with patients with other tumours (43 days), with a median number of 17 pembrolizumab administrations in cHL patients vs 3 administrations in participants with relapsed/refractory tumours other than cHL. The percentage of patients who received pembrolizumab for ≥6 months and ≥12 months was 3 -4-fold higher in cHL than the other patients (72.7% and 40.9% in cHL patients vs 18% and 12.9% in the others participants). The median duration of follow-up was approximately 3-fold longer for participants with cHL (23.7 months, range 4-43.2 months) than for participants with all other tumors types (8.3 months, range 0.4-56 months), primarily due to the large number of early deaths among the other tumour types.

<div style=\"page-break-after: always\"></div>

The types and incidences of the most frequently reported AEs in KEYNOTE-051 were consistent with a heavily  pre-treated  paediatric  population  with  advanced  cancers.  Although  the  majority  of  participants (57.8%) had treatment-related AEs, the proportions of participants with Grade 3 to 5 treatment-related AEs  was  8.7%,  with  treatment-related  SAEs  was  9.9%,  and  with  treatment-related  AEs  leading  to discontinuation of study treatment was 3.7%.

The  most  frequently  reported  AEs (≥20%  of  participants)  were pyrexia (32.9%), vomiting (29.8%), headache (25.5%), abdominal pain (22.4%), anaemia (21.1%), cough (20.5%), and constipation (19.9%), the majority of them with Grade 1-2 toxicity.

Table 1037 Subjects with Adverse Events by Decreasing Incidence (Incidence ≥ 10%) (All Subjects as Treated Population - Parts I and II)

|                                                                                                                                                                                                                                                                            | All Subjects as Treated                                                                                                                                                                                                                                                    | All Subjects as Treated                                                                                                                                                                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                            | n                                                                                                                                                                                                                                                                          | (%)                                                                                                                                                                                                                                                                        |
| Subjects in population                                                                                                                                                                                                                                                     | 161                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                            |
| with one or more adverse events                                                                                                                                                                                                                                            | 155                                                                                                                                                                                                                                                                        | (96.3)                                                                                                                                                                                                                                                                     |
| with no adverse events                                                                                                                                                                                                                                                     | 6                                                                                                                                                                                                                                                                          | (3.7)                                                                                                                                                                                                                                                                      |
| Pyrexia                                                                                                                                                                                                                                                                    | 53                                                                                                                                                                                                                                                                         | (32.9)                                                                                                                                                                                                                                                                     |
| Vomiting                                                                                                                                                                                                                                                                   | 48                                                                                                                                                                                                                                                                         | (29.8)                                                                                                                                                                                                                                                                     |
| Headache                                                                                                                                                                                                                                                                   | 41                                                                                                                                                                                                                                                                         | (25.5)                                                                                                                                                                                                                                                                     |
| Abdominal pain                                                                                                                                                                                                                                                             | 36                                                                                                                                                                                                                                                                         | (22.4)                                                                                                                                                                                                                                                                     |
| Anaemia                                                                                                                                                                                                                                                                    | 34                                                                                                                                                                                                                                                                         | (21.1)                                                                                                                                                                                                                                                                     |
| Cough                                                                                                                                                                                                                                                                      | 33                                                                                                                                                                                                                                                                         | (20.5)                                                                                                                                                                                                                                                                     |
| Constipation                                                                                                                                                                                                                                                               | 32                                                                                                                                                                                                                                                                         | (19.9)                                                                                                                                                                                                                                                                     |
| Fatigue                                                                                                                                                                                                                                                                    | 31                                                                                                                                                                                                                                                                         | (19.3)                                                                                                                                                                                                                                                                     |
| Nausea                                                                                                                                                                                                                                                                     | 31                                                                                                                                                                                                                                                                         | (19.3)                                                                                                                                                                                                                                                                     |
| Diarrhoea                                                                                                                                                                                                                                                                  | 30                                                                                                                                                                                                                                                                         | (18.6)                                                                                                                                                                                                                                                                     |
| Decreased appetite                                                                                                                                                                                                                                                         | 22                                                                                                                                                                                                                                                                         | (13.7)                                                                                                                                                                                                                                                                     |
| Aspartate aminotransferase increased                                                                                                                                                                                                                                       | 21                                                                                                                                                                                                                                                                         | (13.0)                                                                                                                                                                                                                                                                     |
| Alanine aminotransferase increased                                                                                                                                                                                                                                         | 20                                                                                                                                                                                                                                                                         | (12.4)                                                                                                                                                                                                                                                                     |
| Arthralgia                                                                                                                                                                                                                                                                 | 20                                                                                                                                                                                                                                                                         | (12.4)                                                                                                                                                                                                                                                                     |
| Lymphocyte count decreased                                                                                                                                                                                                                                                 | 20                                                                                                                                                                                                                                                                         | (12.4)                                                                                                                                                                                                                                                                     |
| Asthenia                                                                                                                                                                                                                                                                   | 19                                                                                                                                                                                                                                                                         | (11.8)                                                                                                                                                                                                                                                                     |
| Back pain                                                                                                                                                                                                                                                                  | 19                                                                                                                                                                                                                                                                         | (11.8)                                                                                                                                                                                                                                                                     |
| Pain in extremity                                                                                                                                                                                                                                                          | 19                                                                                                                                                                                                                                                                         | (11.8)                                                                                                                                                                                                                                                                     |
| Pruritus                                                                                                                                                                                                                                                                   | 19                                                                                                                                                                                                                                                                         | (11.8)                                                                                                                                                                                                                                                                     |
| White blood cell count decreased                                                                                                                                                                                                                                           | 18                                                                                                                                                                                                                                                                         | (11.2)                                                                                                                                                                                                                                                                     |
| Dyspnoea                                                                                                                                                                                                                                                                   | 17                                                                                                                                                                                                                                                                         | (10.6)                                                                                                                                                                                                                                                                     |
| Every subject is counted a single time for each applicable row and column.                                                                                                                                                                                                 | Every subject is counted a single time for each applicable row and column.                                                                                                                                                                                                 | Every subject is counted a single time for each applicable row and column.                                                                                                                                                                                                 |
| A system organ class or specific adverse event appears on this report only ifits incidence meets the incidence criterion in the report title, after rounding. MedDRA preferred terms ‘Progressive Disease' and Malignant Neoplasm Progression' not related to the drug are | A system organ class or specific adverse event appears on this report only ifits incidence meets the incidence criterion in the report title, after rounding. MedDRA preferred terms ‘Progressive Disease' and Malignant Neoplasm Progression' not related to the drug are | A system organ class or specific adverse event appears on this report only ifits incidence meets the incidence criterion in the report title, after rounding. MedDRA preferred terms ‘Progressive Disease' and Malignant Neoplasm Progression' not related to the drug are |
| excluded. (Database Cutoff Date: 10JAN2020).                                                                                                                                                                                                                               | excluded. (Database Cutoff Date: 10JAN2020).                                                                                                                                                                                                                               | excluded. (Database Cutoff Date: 10JAN2020).                                                                                                                                                                                                                               |

Source:[P051V02MK3475:adam-adsl; adae]

The most frequently reported treatment-related AEs (&gt;5% of participants) were fatigue (8.7%), anemia (8.1%), pyrexia (7.5%), aspartate  aminotransferase  increased (6.8%), lymphocyte  count  decreased (6.8%), diarrhea (6.2%), alanine aminotransferase increased (5.6%), and hypothyroidism (5.6%), the majority of them with Grade 1-2 toxicity.

<div style=\"page-break-after: always\"></div>

Table 1048 . Subjects with Drugrelated Adverse Events by Decreasing Incidence (Incidence ≥ 5%) (All Subjects as Treated Population - Parts I and II)

|                                      | All Subjects as Treated   | All Subjects as Treated   |
|--------------------------------------|---------------------------|---------------------------|
|                                      | n                         | (%)                       |
| Subjects in population               | 161                       |                           |
| with one or more Adverse Events      | 93                        | (57.8)                    |
| with no Adverse Events               | 68                        | (42.2)                    |
| Fatigue                              | 14                        | (8.7)                     |
| Anaemia                              | 13                        | (8.1)                     |
| Pyrexia                              | 12                        | (7.5)                     |
| Aspartate aminotransferase increased | 11                        | (6.8)                     |
| Lymphocyte count decreased           | 11                        | (6.8)                     |
| Diarrhoea                            | 10                        | (6.2)                     |
| Alanine aminotransferase increased   | 9                         | (5.6)                     |
| Hypothyroidism                       | 9                         | (5.6)                     |
| Nausea                               | 8                         | (5.0)                     |
| Rash maculo-papular                  | 8                         | (5.0)                     |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms Progressive Disease' and 'Malignant Neoplasm Progression' not related to the dnug are excluded.

(Database Cutoff Date: 10JAN2020)

Source:[P051V02MK3475: adam-adsl: adae]

The most frequently reported Grade 3 to 5 AEs (&gt;5% of participants) were anemia (8.1%) and lymphocyte count decreased (5.6%).

Table 1059 Subjects with Grade 35 Adverse Events by Decreasing Incidence (Incidence ≥ 5%) (All Subjects as Treated Population - Parts I and II)

|                             | All Subjects as Treated   | All Subjects as Treated   |
|-----------------------------|---------------------------|---------------------------|
|                             | n                         | (%)                       |
| Subjects in population      | 161                       |                           |
| withone ormoreAdverseEvents | 76                        | (47.2)                    |
| withnoAdverseEvents         | 85                        | (52.8)                    |
| Anaemia                     | 13                        | (8.1)                     |
| Lymphocyte count decreased  | 9                         | (5.6)                     |

Every subjectis counted a single timefor each applicable row and column

A system organ class or specific adverse event appears on this report only if its incidence meets the incidence criterion in the report title, after rounding.

MedDRA preferred termsProgressive Disease' and'Malignant Neoplasm Progression' not related to the drug are excluded.

(Database Cutoff Date: 10JAN2020).

The most frequently reported SAEs (≥2% of participants) were pyrexia (6.8%), pneumonia (3.7%), pleural effusion (3.1%), device related infection (2.5%), seizure (1.9%), sepsis (1.9%), and vomiting (1.9%).

<div style=\"page-break-after: always\"></div>

Table 106 Subjects with Serious Adverse Events by Decreasing Incidence Up to 90 Days from Last Dose (Incidence ≥ 1%) (All Subjects as Treated Population - Parts I and II)

|                                                                                                                                                                                           | All Subjects as Treated                                                                                                                                                                   | All Subjects as Treated                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                           | 11                                                                                                                                                                                        | (%)                                                                                                                                                                                       |
| Subjects in population                                                                                                                                                                    | 161                                                                                                                                                                                       |                                                                                                                                                                                           |
| with one ormoreadverse events                                                                                                                                                             | 62                                                                                                                                                                                        | (38.5)                                                                                                                                                                                    |
| with no adverse events                                                                                                                                                                    | 99                                                                                                                                                                                        | (61.5)                                                                                                                                                                                    |
| Pyrexia                                                                                                                                                                                   | 11                                                                                                                                                                                        | (6.8)                                                                                                                                                                                     |
| Pneumonia                                                                                                                                                                                 | 6                                                                                                                                                                                         | (3.7)                                                                                                                                                                                     |
| Pleural effusion                                                                                                                                                                          | 5                                                                                                                                                                                         | (3.1)                                                                                                                                                                                     |
| Device related infection                                                                                                                                                                  | 4                                                                                                                                                                                         | (2.5)                                                                                                                                                                                     |
| Seizure                                                                                                                                                                                   | 3                                                                                                                                                                                         | (6:1)                                                                                                                                                                                     |
| Sepsis                                                                                                                                                                                    | 3                                                                                                                                                                                         | (6:1)                                                                                                                                                                                     |
| Vomiting                                                                                                                                                                                  | 3                                                                                                                                                                                         | (6 1)                                                                                                                                                                                     |
| Dyspnoea                                                                                                                                                                                  | 乙                                                                                                                                                                                         | (1.2)                                                                                                                                                                                     |
| Headache                                                                                                                                                                                  | 乙                                                                                                                                                                                         | (1.2)                                                                                                                                                                                     |
| Hypertension                                                                                                                                                                              | 乙                                                                                                                                                                                         | (1.2)                                                                                                                                                                                     |
| Nausea                                                                                                                                                                                    | 乙                                                                                                                                                                                         | (1.2)                                                                                                                                                                                     |
| Pneumonitis                                                                                                                                                                               | 2                                                                                                                                                                                         | (1.2)                                                                                                                                                                                     |
| Every subject is counted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only if its incidence meets the incidence | Every subject is counted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only if its incidence meets the incidence | Every subject is counted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only if its incidence meets the incidence |
| criterion in the report title, after rounding. MedDRA preferred terms 'Progressive Disease' and'Malignant Neoplasm Progression' not related to the drug are excluded.                     | criterion in the report title, after rounding. MedDRA preferred terms 'Progressive Disease' and'Malignant Neoplasm Progression' not related to the drug are excluded.                     | criterion in the report title, after rounding. MedDRA preferred terms 'Progressive Disease' and'Malignant Neoplasm Progression' not related to the drug are excluded.                     |

The most frequently reported treatment related SAEs (&gt;1% of participants) were pyrexia in 4 participants (2.5%), hypertension in 2 participants (1.2%), and pleural effusion in 2 participants (1.2%).

Death : five participants (3.1%) had 1 or more AEs that resulted in death up to 90 days after receiving the last  dose  of  pembrolizumab.  Two  participants  had  fatal  AEs  reported  by  the  investigator  as  treatment related: 1 participant had pulmonary edema and 1 participant had pneumonitis and pleural effusion . The fatal, treatment-related AE of pulmonary edema occurred in a participant experiencing concomitant sepsis . The fatal, treatment-related AEs of pneumonitis and pleural effusion occurred in a participant with extensive right chest involvement of the underlying epithelioid sarcoma.

One participant with a primary diagnosis of solid tumour NOS developed a secondary malignancy of Grade 5 adenocarcinoma  gastric ,  reported  by  the  investigator  as  not  treatment  related.  No  other  secondary malignancies were identified.

Two out of 4 participants with MSI-H solid tumours had a serious neurologic AE during the first 2 treatment cycles. Both SAEs ( seizure and myoclonus ) were reported as non-treatment related by the investigator, and no action was taken with pembrolizumab in response to the events.

AEOSIs : thirty (18.6%) participants had at least 1 AEOSI. The most frequently reported AEOSI (in ≥2.5% of  participants)  were hypothyroidism (8.1%), hyperthyroidism (3.7%), hypersensitivity (2.5%),  and pneumonitis (2.5%). Four (2.5%) participants had a Grade 3 to 5 AEOSI: 3 participants with a Grade 3 AEOSI  ( colitis,  myelitis,  and  pruritus )  and  1  participant  with  Grade  5 pneumonitis .  The  AEOSIs  were manageable  with  standard  therapeutic  strategies  or  concomitant  corticosteroids  and  among  the  30 participants who had at least 1 AEOSI, 13 (43.3%) participants had resolution of an event by the time of data cutoff.

Treatment with pembrolizumab was well tolerated; most AEs did not lead to treatment interruption . Among the 21 (13.0%) participants who had at least 1 AE resulting in treatment interruption, the most common AE and drug-related AE was alanine aminotransferase increased in 3 (1.9%) participants.

<div style=\"page-break-after: always\"></div>

An update on immunological analyses has been also provided by the MAH for paediatric cHL patients included  in  KEYNOTE-051.  Vaccinated  antibody  concentrations  and  memory  B-  and  T-cell  counts  were collected  as  part  of  the  secondary  objectives  of  KEYNOTE-051.  Analyses  of  pooled  KEYNOTE-051 participants indicate an upward trend from pre-treatment to post-treatment Cycle 4 in memory B- and Tcell counts through. Minimal changes were observed in the concentration of vaccinated antibodies from pretreatment to post-treatment Cycle 4.

In  KEYNOTE-051, 3  patients  received  an  allo-SCT  after  treatment  with  pembrolizumab  (2  paediatric patients  with  cHL).  One  cHL  patient  was  treated  with  pembrolizumab  for  12 weeks,  then  discontinued treatment while continuing to receive an 'immune checkpoint blockade' (but the name and duration were unknown).  The  allo-SCT  was  performed  11  months  after  stopping  the  pembrolizumab  treatment. Approximately 4 months post-allogeneic SCT, the patient developed a Grade 2 chronic GVHD ; the patient was alive, approximately 10 months after allo-SCT.

The other cHL patient underwent allo-SCT after receiving treatment with pembrolizumab (30 doses). On Day 644, the patient discontinued pembrolizumab and on Day 736 (about after 3 months of interruption) had an allo-SCT. GVHD prophylaxis included anti-thymocyte immunoglobulin and methotrexate. On Day 846, the patient developed a Grade 2 acute GVHD , treated with steroid; at the cut-off date, the patient was alive, but acute GVHD was not resolved. The investigator considered the chronic and acute GVHD as not related to pembrolizumab.

No additional participants in KEYNOTE-051 have received an allo-SCT after the cut-off data (10 Jan 2020).

## Comparison of cHL paediatric safety data to cumulative paediatric safety data:

AEs  among  participants  with  rrcHL  and  other  tumour  types  in  KEYNOTE-051,  are  provided  by  key categories: overall AE summary (Table 79), and overall summary of AEOSI. The data provided by the MAH showed that the patients with cHL had higher rates of drug-related AEs and dose modifications due to AEs compared with other tumour types while participants with other tumor types had higher rates of Grade 35 AEs and SAEs. They experienced higher rates of overall AEOSI and drug-related AEOSI compared with participants  with  other  tumor  types.  Nevertheless,  the  duration  of  exposure  to  pembrolizumab  was approximately 8-fold longer for participants in KEYNOTE-051 with cHL.

## Comparison of cHL paediatric safety data to the cHL safety profile in adults:

While  the  number  of  cHL  participants  in  KEYNOTE-051  is  small  (N=22),  a  comparison  of  AE  rates  in KEYNOTE-051 versus cHL participants in KEYNOTE-204 and the cHL Safety Dataset shows consistently lower rates for all AE categories in the KEYNOTE-051 cHL dataset (except for AEOSI).

<div style=\"page-break-after: always\"></div>

Table 1071 KEYNOTE-051 Adverse events summary, all subjects Parts I, II

|                                                                | Hodgkin Lymphoma   | Hodgkin Lymphoma   | Other Tumor Types   | Other Tumor Types   | Total   | Total   |
|----------------------------------------------------------------|--------------------|--------------------|---------------------|---------------------|---------|---------|
|                                                                | n                  | (%)                | n                   | (%)                 | n       | (%)     |
| Subjects in population                                         | 22                 |                    | 139                 |                     | 161     |         |
| with one or more adverse events                                | 21                 | (95.5)             | 134                 | (96.4)              | 155     | (96.3)  |
| with no adverse event                                          | 1                  | (4.5)              | 5                   | (3.6)               | 6       | (3.7)   |
| with drug-related adverse events                               | 15                 | (68.2)             | 78                  | (56.1)              | 93      | (57.8)  |
| with toxicity grade 3-5 adverse events                         | 6                  | (27.3)             | 70                  | (50.4)              | 76      | (47.2)  |
| with toxicity grade 3-5 drug-related adverse events            | 2                  | (9.1)              | 12                  | (8.6)               | 14      | (8.7)   |
| with serious adverse events                                    | 4                  | (18.2)             | 58                  | (41.7)              | 62      | (38.5)  |
| with serious drug-related adverse events                       | 2                  | (9.1)              | 14                  | (10.1)              | 16      | (9.9)   |
| with dose modificationt due to an adverse event                | 6                  | (27.3)             | 21                  | (15.1)              | 27      | (16.8)  |
| who died                                                       | 0                  | (0.0)              | 5                   | (3.6)               | 5       | (3.1)   |
| who died due to a drug-related adverse event                   | 0                  | (0.0)              | 2                   | (1.4)               | 2       | (7'D)   |
| discontinued drug due to an adverse event                      | 1                  | (4.5)              | 9                   | (6.5)               | 10      | (6.2)   |
| discontinued drug due to a dug-related adverse event           |                    | (4.5)              | 5                   | (3.6)               | 6       | (3.7)   |
| discontinued drug due to a senious adverse event               | 1                  | (4.5)              | 7                   | (5.0)               | 8       | (5.0)   |
| discontinued drug due to a senious drug- related adverse event |                    | (4.5)              | 3                   | (2.2)               | 4       | (2.5)   |

Grades are based on NCI CTCAE version 4.03

MedDRA preferred terms Progressive Disease' and Malignant Neoplasm Progression' notrelated to the drug are excluded.

Reporting for senious adverse events and serious drug-related adverse events goes through 90 days.

(Data Cutoff Date: 10JAN2020)

Table 1082 KEYNOTE-051 Adverse events summary for AEOSI, all subjects Parts I, II

|                                                                | Hodgkin Lymphoma   | Hodgkin Lymphoma   | Other Tumor Types   | Other Tumor Types   | Total   |
|----------------------------------------------------------------|--------------------|--------------------|---------------------|---------------------|---------|
|                                                                | n                  | (%)                | n                   | (%) n               | (%)     |
| Subjects in population                                         | 22                 |                    | 139                 | 161                 |         |
| with one or more adverse events                                | 9                  | (40.9)             | 21 (15.1)           | 30                  | (18.6)  |
| with no adverse event                                          | 13                 | (59.1) 118         | (84.9)              | 131                 | (81.4)  |
| with drug-related adverse events                               | 6                  | (27.3) 15          | (10.8)              | 21                  | (13.0)  |
| with toxicity grade 3-5 adverse events                         | 1                  | (4.5) 3            | (2.2)               | 4                   | (2.5)   |
| with toxicity grade 3-5 drug-related adverse events            | 1                  | (4.5) 3            | (2.2)               | 4                   | (2.5)   |
| with serious adverse events                                    | 0                  | (0.0) 4            | (2.9)               | 4                   | (2.5)   |
| with serious drug-related adverse events                       | 0                  | (0.0) 3            | (2.2)               | 3                   | (1.9)   |
| with dose modificationt due to an adverse event                | 1                  | (4.5) 4            | (2.9)               | 5                   | (3.1)   |
| who died                                                       | 0                  | (0.0) 1            | (0.7)               | 1                   | (0.6)   |
| who died due to a drug-related adverse event                   | 0                  | (0.0) 1            | (0.7)               | 1                   | (0.6)   |
| discontinued drug due to an adverse event                      | 0                  | (0.0) 2            | (1.4)               | 2                   | (71)    |
| discontinued dug due to a drug-related adverse event           | 0                  | (0.0) 2            | (1.4)               | 2                   | (1.2)   |
| discontinued dug due to a senious adverse event                | 0                  | (0.0) 2            | (1.4)               | 2                   | (7'D)   |
| discontinued drug due to a senious drug- related adverse event | 0                  | (0.0) 2            | (1.4)               | 2                   | (1.2)   |

Grades are based on NCI CTCAE version 4.03.

MedDRA preferred terms Progressive Disease' and Malignant Neoplasm Progression' notrelated to the dug are excluded.

Reporting for serious adverse events and senious drug-related adverse events goes through 90 days.

(DatabaseCutoffDate:10JAN2020).

## Post marketing experience

Data from post marketing experience have been included in the latest submitted PSURs.

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

In  the  context  of  extension  of  the  currently  approved  therapeutic  indication  of  pembrolizumab  for  the treatment of relapsed or refractory classical  Hodgkin  lymphoma (rrcHL) in adults, to an earlier line of therapy and to include paediatric patients, safety results have been presented from study KEYNOTE-204, evaluating pembrolizumab in monotherapy versus Brentuximab Vedotin (BV), in parallel to the cHL Safety Dataset, the Reference Safety Dataset (RSD) and the Cumulative Safety Dataset (CSD). To support the extension of the indication to rrcHL paediatric patients, safety data from KEYNOTE-051 have been also provided. KEYNOTE-087 was the pivotal study supporting the initial rrcHL indication in the adults. In order to evaluate potential differences in the pembrolizumab safety profile, the updated data from KEYNOTE-013 and KEYNOTE-087 have been presented separately from the overall cHL Safety Dataset, and the safety analysis from these studies have been compared with KEYNOTE-204. Some differences were observed in AEs  between  the  KEYNOTE-204  pembrolizumab  safety  dataset  and  the  study  KEYNOTE-087,  as  the incidence of SAEs and drug-related SAEs was higher in KN-204 than in the KN-087 (SAEs 29.7% vs 22.9%, respectively; drug-related SAEs 16.2% vs 8.1%, respectively). However, when adjusted for exposure, the event rates were similar. Analysis of AEOSIs revealed a similar incidence (&lt;5% difference) for all categories, including Grade 3 to 5 events, SAEs, and AEs leading to discontinuation. The overall AE profile observed in the KEYNOTE-204 pembrolizumab arm was generally consistent with KEYNOTE-013 for both overall AEs and AEOSIs, except for a higher incidence of SAEs in KEYNOTE-013 than in KEYNOTE-204 (SAEs 38.7% vs 29.7%, respectively). However, in agreement with the MAH, differences observed for some categories (all ≤10%) are likely d ue to small participant numbers in KEYNOTE-013 (n=31) and should be interpreted with caution. In conclusion, when comparing the safety data of KEYNOTE-204 with KEYNOTE-087 and KEYNOTE013, no significant differences emerged for using pembrolizumab across this cHL patient population.

In line with the Hodgkin lymphoma, the Indication Population was younger compared to the RSD and the CSD, with a median age of 35.5 years ( vs. 62 years in the other safety datasets). This population was quite heterogeneous in terms of prior exposure and response to previous therapy (in median 2 prior lines of therapy, range 1-10 in pembrolizumab arm), including previous BV or auto-SCT. In terms of prior exposure and response to previous therapy, the MAH underlined that: i) comparison of AEs by prior BV status does not allow for a meaningful comparison, as only 5 participants received prior BV in the pembrolizumab arm in  KEYNOTE-204;  ii)  rates  of  AEs  were  generally  similar  between  participants  with  and  without  prior radiation; iii) most categories of AEs occurred at similar rates, when examined by prior auto-SCT status, although a higher percentage of participants with prior auto-SCT experienced SAEs (38.2% vs 24.7%), but the  percentage  of  participants  experiencing  drug-related  SAEs  was  similar  (18.2%  vs  15.1%);  iv) participants with one prior line of therapy experienced fewer Grade 3 to 5 drug-related AEs compared with participants with 2 lines or 3 or more lines of therapy; v) although the subgroup analyses were notable for some numerical differences within several AE subcategories (i.e., age [&lt;65 vs ≥65 years; &lt;65 vs ≥65 to &lt;75 vs ≥75 to&lt;85 years], gender, race, ECOG status and region [North America vs Europe vs Japan; US vs non-US; EU vs non-EU]), the smaller number of participants within these subgroups does not allow for a meaningful comparison and no definitive conclusion can be drawn.

In terms of exposure to pembrolizumab, a longer median time on therapy was reported for cHL patients compared to the RSD and the CSD (10.02 months in the KN-204 pembrolizumab arm and 10.65 months in the cHL Safety Dataset vs 4.86 months in the RSD and 4.24 months in the CSD), with a higher number of doses administered (15 doses in KN-204 and 16 doses in the cHL Safety Dataset vs 8 doses in the RSD and 7 doses in the CSD). Overall, 67.6% of cHL population in KN-204 (n=100) were exposed to pembrolizumab for at least 6 months (vs 32.2%, n=49 in BV arm) and safety data with treatment exposure ≥12 months were available for 71 patients (48%) for pembrolizumab (vs only 17 patients, 11.2% in the BV group).

<div style=\"page-break-after: always\"></div>

In general, pembrolizumab was well tolerated among subjects with cHL. Most AEs were of low-Grade toxicity as evidenced by the low rate of subjects with toxicity Grade 3 to 5 drug-related AEs (62 [15.9%]) and with serious drug-related adverse events (46 [11.8%]) in the 389-subject cHL population.

The overall AE profile in the KEYNOTE-204 pembrolizumab group was generally consistent with the cHL Safety Dataset, except for such categories of AES (SAEs, drug-related SAEs, Grade 3 to 5 AEs and drugrelated Grade 3 to 5 AEs). The incidence of Grade 3 to 5 AEs generally differed by less than 2 percentage points between the KEYNOTE-204 pembrolizumab arm and the cHL Safety Dataset, except for the observed rate of pneumonitis (4.1% vs 1.8%, respectively). The only Grade 3 to 5 drug-related AE and SAE reported more frequently (≥2 percentage points difference) in the KEYNOTE-204 pembrolizumab arm than in the cHL Safety Dataset was pneumonitis (Grade 3 to 5 drug-related AE 4.1% vs 1.8%; SAE 5.4% vs 3.3%, respectively). The frequency and type of drug-related SAEs reported in the KEYNOTE-204 pembrolizumab arm were generally consistent with the cHL Safety Dataset, generally differing by less than 1 percentage point except for pneumonitis (5.4% vs 3.3%) and pneumonia (2.0% vs 0.8%).

Patients enrolled in KEYNOTE-204 had relapsed or refractory disease and were heavily pre-treated with chemotherapeutic agents that have a known association with pulmonary toxicities, including prior radiation exposure, bleomycin (a prior treatment in 89.2% of participants in the pembrolizumab group has been reported), and melphalan in those participants who underwent previous SCT. These findings may have contributed to the observed high rate of pneumonitis , a known immune-related event, in KEYNOTE-204 patients who received pembrolizumab. As these heavily pre-treated patients have all weakened immune systems, opportunistic infections, including pneumonia , might be a risk.

However, after adjustment for exposure, event rates in the KEYNOTE-204 and cHL Safety Dataset were similar for all AE categories.

In Keynote-204, the AEs with a notable risk difference included hypothyroidism and urinary tract infection in the pembrolizumab arm, and peripheral neuropathy , nausea and peripheral sensory neuropathy in the BV arm. These AEs were consistent with the established safety profiles of pembrolizumab in monotherapy and BV. An exception was noted for urinary tract infection and for pneumonitis with higher incidence in the KEYNOTE-204  pembrolizumab  arm  than  the  other  datasets.  While  no  definitive  explanation  for  the imbalance  observed  between  the  safety  datasets  was  identified,  the  higher  incidence  of urinary  tract infection observed in the pembrolizumab arm may be partly explained by the slightly higher proportion of females in the KEYNOTE-204 pembrolizumab arm relative to the RSD and the CSD (45.3%, 33.9% and 33.1%  respectively).  Women  are  more  prone  to urinary  infections than  men.  Additionally,  the  higher incidence of urinary tract infection could be also related to the median duration of exposure in the KEYNOTE204 pembrolizumab arm, twice as long compared with the RSD and the CSD (10.02 vs 4.86 and 4.24 months, respectively). Similarly, the higher rates of pneumonitis in the KEYNOTE-204 pembrolizumab arm than those observed in cHL safety dataset, RSD and CSD (8.8%, 6.9%, 4.1% and 3.8% respectively) may also  be  explained  by  the  median  duration  of  exposure  and/or  by  prior  radiation/melphalan/bleomycin exposure in patients in KEYNOTE-204 who received pembrolizumab, as these agents all have a known association with pulmonary toxicity

The most frequently reported drug-related AEs in the pembrolizumab arm, compared with the BV arm, were hypothyroidism (15.5% vs 1.3%), pyrexia (12.8% vs 5.9%) and pruritus (10.8% vs 5.3%), whereas the BV group showed higher incidences of drug-related neuropathy peripheral (2% vs 18.4%), nausea (4.1% vs 13.2%) and peripheral sensory neuropathy (2% vs 13.2%). The incidence and types of drugrelated AEs reported in the KEYNOTE-204 pembrolizumab safety dataset were generally consistent with the other datasets, except for pyrexia and hypothyroidism . This could be expected because pyrexia is a common B symptom associated with cHL and an increased risk of hypothyroidism could be due to previous treatment with radiation therapy. Also, acute kidney injury was reported more frequently as Grade 3 to 5 drug-related AE in the KEYNOTE-204 pembrolizumab arm than in the cHL Safety Dataset, the RSD and the CSD (1.4%,

<div style=\"page-break-after: always\"></div>

0.5%, 0.1% and 0.2%, respectively). Of note, the percentages in the KEYNOTE-204 pembrolizumab arm and the cHL safety dataset were based on 2 patients in  each  group  from  populations  of  148  and  389 participants, respectively. Details on these patients have been provided by the MAH. Both participants' clinical courses were marked by numerous AEs that developed concurrently with acute kidney injury . In both cases, the events of acute kidney injury were treated and resulted in resolution. Acute kidney injury is a known immune-related AE of pembrolizumab. Renal adverse events with PD -1 inhibitors consist mainly of  elevated serum creatinine levels, and nephritis has  been  reported in 0.3%-1.2% of patients across clinical trials ( Vardhana S et al. The Oncologist 2019;24:86-95 ). In agreement with the MAH, the observed imbalance across the datasets may be explained by the longer duration of exposure in the KEYNOTE-204 pembrolizumab arm and cHL safety dataset (10.02 and 10.65 months, respectively) compared with RSD and CSD (4.86 and 4.24 months, respectively).

SAEs were consistent across population, with pneumonia (5.4%), pneumonitis (5.4%) and pyrexia (2.7%) most frequently reported. Pneumonitis was the only more frequently reported SAE (≥2 percentage points difference)  in  the  KEYNOTE-204  pembrolizumab  group  than  the  other  safety  datasets,  for  which  the contribution of the immune dysregulation induced by lymphoma cannot be excluded.

Deaths due to AEs in KEYNOTE-204 occurred in 3 patients (2%) in the pembrolizumab arm and in 2 BV patients (1.3%), compared with 6 (1.5%) patients in the cHL Safety Dataset and 312 (5.3%) patients in the RSD. One death in the pembrolizumab group of KEYNOTE-204 was attributed to drug-related AE of pneumonia . More details have been required for all participants in KEYNOTE-204 pembrolizumab arm who died due to AEs, also providing the narrative of death that occurred in the third patient. In the case of one participant, although autopsy confirmed that pneumonia was the primary cause of death with microbiology positive  for E.coli ,  diagnostic  imaging  was  suggestive  of pneumonitis ,  for  which  related  relation  to pembrolizumab, as AEOSI, cannot be excluded. In addition, during the clinical course, the patient was treated with antibiotics and steroids that did not result in clinical improvement and, therefore, the exact aetiology of the pulmonary compromise is not clear. Similarly, for the AE of cardiac failure (reported as myocarditis ),  without  information  on  the  clinical  status  at  baseline  and  with  only  an  echocardiogram revealing  an  aortic  and  mitral  valve  disease,  it  is  difficult  to  understand  the  exact  aetiology  of  such myocarditis .  However,  the  prior  oncology  treatment  history  included  treatment  with  doxorubicin  and bleomycin that could be a potential contributing factor to the reported cardiac failure and pneumonitis .

For another participant, in agreement with the MAH, the AEs including acute GVHD , autoimmune hemolytic anemia and infections should be considered as complications associated with stem cell transplant.

The narrative for the third participant, who died due to an unknown cause, was also provided. However, for this case, the insufficient clinical information provided do not allow to assess a potential causal role for pembrolizumab and the reported events.

The incidence of AEOSI in the cHL population in KEYNOTE-204 has been reported as comparable to that in the cHL Safety Dataset (35.8% and 35.7%, respectively) but higher compared to the RSD (25.1%) and to the  CSD  (24.4%),  which  could  be  due  to  longer  exposure  and  follow-up.  In  KEYNOTE-204,  the  most frequent AEOSIs were hypothyroidism (n=28 [18.9%]), pneumonitis (n=16 [10.8%]), and hyperthyroidism (n=8 [5.4%]) in the pembrolizumab arm; infusion-related reaction (n=12 [7.9]), hypothyroidism (n=4 [2.6%]),  and pneumonitis (n=3  [2%])  in  the  BV  arm.  Most  immune-mediated  AEOSIs  were  mild  to moderate in severity and were managed with treatment interruptions and/or corticosteroids.

Hypothyroidism was the most frequently observed AEOSI across populations. The higher rate of events in cHL patients (Grade 1 and 2), as well as the shorter time to onset of the first hypothyroidism event can be justified by the frequent prior exposure to mediastinal radiation therapy. None of the events was treated with  corticosteroids.  In  the  pembrolizumab  arm  of  KEYNOTE-204,  58  participants  had  received  prior radiation at baseline while 93 participants had not received prior radiation in the ITT population. Considering that an AEOSI of hypothyroidism occurred in 28 (18.9%) patients in the pembrolizumab arm and, of these

<div style=\"page-break-after: always\"></div>

28  participants,  11  patients  had  a  past  medical  history  of  prior  radiation  therapy,  the  incidence  of hypothyroidism in participants who received prior radiation was 19.0% (11/58) compared to 18.3% (17/93) in participants who had not received prior radiation. The TSH levels reported at baseline were normal for 20  out  of  28  patients,  high  for  7  patients  and  low  for  1  patient,  suggesting  that  a  pre-existing hypothyroidism was not present for the majority of these patients. The longer duration of exposure for patients in KEYNOTE-204 may also explain the higher overall incidence of hypothyroidism compared to the RSD.

No major differences specific for the cHL population were observed in terms of events outcome, except for a higher rate of patients with a resolved status in the cHL Safety Dataset (40.9%) compared to the patients in the KEYNOTE-204 pembrolizumab arm (28.6%). A clarification has been provided by the MAH to explain the higher rate of hypothyroidism with unresolved status in KEYNOTE-204: the longer duration of followup in KEYNOTE-013 and KEYNOTE-087 (included in cHL Safety Dataset) allowed for additional information to be collected on the complete clinical course with respect to the outcome of events, in contrast to the shorter duration of follow-up in KEYNOTE-204 that may explain the higher rate of hypothyroidism with unresolved  status.  An  additional  aspect  to  consider  regarding  the  resolution  status  may  be  related  to medical judgment: while some investigators may consider an event resolved once the participant is stable on thyroid hormone replacement, others may consider the event unresolved since the requirement for treatment is still present. However, overall experience with pembrolizumab and hypothyroidism indicates that  physician  monitoring  and  thyroid  hormone  replacement  are  sufficient  to  manage  this  risk  without requiring discontinuation of therapy and for this reason, the MAH's conclusion is endorsed.

Sixteen (10.8%) participants experienced an AEOSI of pneumonitis in the pembrolizumab arm compared to 4 (2.6%) in the BV arm. The incidence of pneumonitis and the characteristics of events, in terms of time to onset, duration and type of outcome, were as expected, considering that the prior radiation exposure and the use of bleomycin may be contributing factors for the observed incidence of pneumonitis in cHL population.  The  majority  of pneumonitis events  were  Grade  3  and  below  and  resolved  with  systemic corticosteroids. There were no fatal events of pneumonitis.

Infusion related reactions were more frequent in the cHL population, especially in the BV arm (5.4% in the KEYNOTE-204 pembrolizumab arm, 7.9% in the BV group and 8% in the cHL Safety Dataset) than in the RSD (2.3%) and the CSD (2.1%), characterized by a very earlier median time to first occurrence (1 day in KN-204 vs 44.5 in RSD and 40 days in CSD). The majority of infusion reaction events did not require corticosteroid treatment.

Changes in laboratory findings in the cHL population were in line with those reported in the larger cHL datasets, mostly related with Hodgkin lymphoma and prior anti-lymphoma treatment. Further investigation has been requested on potential immunogenicity related to pembrolizumab, particularly with respect to ANA, ASMA and anti-neutrophil cytoplasmic antibodies. Rheumatic and/or systemic irAEs may occur across all  classes  of  check  point  inhibitor  (CPI),  including  pembrolizumab,  most  frequently  and  severely  with combination treatments and may be associated with other organ-specific irAEs. Since autoantibodies are not found in the majority of patients experiencing CPI-induced rheumatic and systemic disease, there is no indication to test every patient at baseline. More generally, the pre-existing antinuclear antibodies revealed no  significant  difference  in  the  development  of  irAEs  between  the  positive  and  negative  ANA  groups ( Sakaklda T et al. Clinical and Translation Oncology 2020). In the absence of clinical biomarkers predicting the occurrence of irAEs after use of PD-1/PD-L1 blockade for cancer immunotherapy, in line with the EULAR recommendation  ( Kostine  M  et  al.  Ann  Rheum  Dis  2020 ),  the  detection  of  autoantibodies  in  an asymptomatic patient would not preclude the start of CPI therapy. However, there is the particular situation of patients with thymoma who develop CPI-induced myositis and who all have anti-acetylcholine receptor and antistriated muscle antibodies detected in serum sample obtained prior to CPI therapy ( Mammen AL et al. Ann Rheum Dis 2019 ). Accordingly, as myositis may evolve into a severe irAE, testing for the presence of these antibodies before starting CPI in a patient with thymoma is recommended to identify a high risk of

<div style=\"page-break-after: always\"></div>

myositis ( Kostine M et al. Ann Rheum Dis 2020 ). To date, the MAH' explanation that there is no rationale for the screening or long-term monitoring of autoimmunity (e.g. ANA, ANCA, ASMA) prior to treatment with pembrolizumab is accepted.

The MAH has also focused on laboratory data pertaining to ' platelet count decreased ' or ' thrombocytopenia '  that  are  reported  as  AEs  for  which  clinically  meaningful  data  including  outcome, treatments received, and clinical sequelae were presented. In KEYNOTE-204,  the incidence of ' thrombocytopenia '  or  ' platelet  count  decreased '  were  6.8%  and  6.6%  in  the  pembrolizumab  and  BV groups,  respectively,  compared  to  the  RSD  in  which  a  total  of  140  participants  out  of  5643  (2.5%) experienced these AEs. Based on the data provided, no evidence of significant concern on laboratory data pertaining  to  ' platelet  count  decreased '  or  ' thrombocytopenia '  as  AEs  was  highlighted  during  the pembrolizumab treatment for the cHL patient population. Myelosuppression is a common toxicity associated with cytotoxic chemotherapy, but thrombocytopenia as immune-related adverse events (irAEs) commonly occur during the administration of immune checkpoint inhibitors (ICI) ( Delanoy N et al. Lancet Haematol. 2019 ).  In  the  KEYNOTE-204  pembrolizumab  arm,  all  four  participants  were  treated  for  Grade  3-4 thrombocytopenia,  including  one  participant  who  received  systemic  corticosteroids  and  no  participants received  immunoglobulin.  In  addition,  a  case  of  autoimmune  thrombocytopenia  was  reported  after treatment with pembrolizumab in KEYNOTE-204. However, in this case, the assessment for thrombocytopenia  is  confounded  by  disseminated  intravascular  coagulation  in  the  setting  of  patient's underlying  progressive  malignant  disease  that  are  considered  as  risk  factors  for  thrombocytopenia.  In conclusion, the management  by  platelet transfusion is a main issue in patients with severe thrombocytopenia secondary to cytotoxic chemotherapy, whereas systemic steroid and immunoglobulin administration is identified as a reasonable choice in those, due to immunotherapy. The use of systemic corticosteroids or immunosuppressants before starting pembrolizumab should be avoided because of their potential  interference  with  the  pharmacodynamic  activity  and  efficacy  of  pembrolizumab.  However, systemic corticosteroids or other immunosuppressants can be used after starting pembrolizumab to treat immune-related adverse reactions, as reported in section 4.4 of the SmPC.

No major and unexpected differences in the tolerability of pembrolizumab treatment were observed across the different ECOG PS categories, while an increased rate of drug-related AEs was observed in females compared to males (76.1% vs 72.8%). The Grade 3-5 AEs and the SAEs were slightly higher in the female population  and  the  rate  of  discontinuation  due  to  an  AE  was  almost  doubled  compared  to  the  male population.  Considering  the  small  sample  size  and  low  number  of  participants  in  the  pembrolizumab treatment  arm  by  gender  (81  males  and  67  females),  this  does  not  represent  a  clinically  meaningful comparison. Nevertheless, the gender differences in incidences AEs should be further evaluated in future procedures.

The incidence of drug-related AES, SAEs, serious drugrelated AEs in the cHL population ≥ 65 years of age was higher than in subjects &lt;65 years of age in the BV arm of KEYNOTE-204 (e.g., Grade 3 to 5 AEs: 68.2% vs 39.2%) and the RSD (Grade 3 to 5 AEs: 53.0% vs 44.5%). Compared with participants &lt;65 years of age treated with pembrolizumab, patients ≥65 years of age had higher (&gt;15 percentage point difference) rates of peripheral oedema (23.1% vs 0.8%), decreased appetite (23.1% vs 2.5%), and pain in extremity (23.1% vs 5.7%), which are expected AEs in an older population, who generally have more comorbidities compared to younger patients. However, the relatively small number of subjects who were ≥ 65 years old in the cHL Population (n=26 in the KN-204 pembrolizumab arm; n=46 in the cHL Safety Dataset) is not sufficient for a meaningful comparison with the cHL Population &lt; 65 years of age, or the larger datasets at this time and any definitive conclusion can be drawn. In section 4.2 of the SmPC, it is already  reported  that  ' Data  from  patients  ≥ 65 years  are  too  limited  to  draw  conclusions  on  cHL population '.

Overall, 48 cHL patient treated with pembrolizumab (from KEYNOTE-204, KEYNOTE-087 and KEYNOTE051) received allogenic SCT. PD-1 inhibition prior to allo-SCT may enhance allogeneic T-cell responses and

<div style=\"page-break-after: always\"></div>

augment  the  graft-versus-tumour  effect.  However,  prior  immunomodulation  may  also  increase  risk  of GVHD.  Complications  were  experienced  by  34  of  them  (with acute and/or chronic  GVHD as  the  most common AEs post allo-SCT) and a fatal outcome was reported in 6 patients (two patients, both in the KEYNOTE-204  pembrolizumab  arm,  died  for hypovolemic  shock and hypoxic  respiratory  failure ;  four patients in KEYNOTE-087 for acute GVHD , hyperacute GVHD , pneumonia and sepsis ), but none of these post allo-SCT AEs were considered by the MAH related to study treatment.

Allo-SCT  after  PD-1  blockade  appears  feasible  with  a  low  rate  of  relapse.  However,  there  may  be  an increased risk of early immune toxicity, which could reflect long-lasting immune alterations triggered by prior PD-1 blockade, as acute and chronic GVHD post allo-transplant. Approximately 30-50% of patients with cHL experience GVHD after allo-transplant ( Sure A et al. J Clin Oncol 2008 ). Several studies have reported a higher rate of acute GVHD among patients who were exposed to check point inhibitor therapy before receiving allo-SCT and the median interval between exposures to the last dose of CPI and allo-HSCT was variable, ranging between 28 and 62 days, depending on the half-life of the checkpoint inhibitor. Regardless of the mechanism of PD-1 depletion, it has been demonstrated that anti-PD-1 therapy creates a long-lasting disturbance in the composition of circulating T-cell populations. These findings would explain the absence of any apparent association between the time interval from PD-1 to transplantation and early toxicity and suggests that the use of a window period to delay HSCT for even several months after PD-1 therapy may not mitigate the impact of this therapy on allo-SCT outcomes ( Merryman RW et al, Blood 2017 ).

From the data provided by the MAH, it is highlighted that: i) overall, the median times from last dose of pembrolizumab to allo-SCT were similar, differing by ~1 month between those with GVHD and those who did not have GVHD . This suggests that the timing of the last dose of pembrolizumab in relation to the SCT could not influence the occurrence of post-transplant acute or chronic GVHD ; ii) based on these limited data from KEYNOTE-204, an association between the time from last dose of pembrolizumab and GVHD is not supported.

While it was not possible to create a control cohort for this analysis that perfectly matched with all possible salient characteristics that could influence the occurrence of acute and/or chronic  GVHD after pembrolizumab (e.g., age, disease, sex, donor, graft source, GVHD prophylaxis), we acknowledge that many possible factors could be involved in the occurrence of GVHD and it is difficult to determine because participants who receive an allo-SCT do not represent a homogeneous population. However, these data confirm that prior PD-1 blockade should not be considered a contraindication to allo-SCT in this patient population.

Otherwise, treatment with pembrolizumab in the post-alloSCT disease relapse setting is feasible but can induce early and severe AEs. Caution and careful monitoring are warranted, particularly in patients who have a history of GVHD , but additional long-term data are needed to fully evaluate the risks and benefits of using PD-1 inhibitor therapy after allo-SCT.

There were no secondary malignancies in KEYNOTE-204.

Information on pneumonits in cHL patients has been included in the SmPC (section 4.8)

## Assessment of paediatric data on clinical safety

In the KEYNOTE-051 study most participants had at least 1 AE. The types and incidences of the most frequently  reported  AEs  were  consistent  with  a heavily  pretreated  paediatric population  with  advanced cancers. No new safety signals were observed.

Although the majority of participants had treatment-related AEs, pembrolizumab was well tolerated as

<div style=\"page-break-after: always\"></div>

evidenced by the small proportions of participants with Grade 3 to 5 treatment-related AEs, treatmentrelated SAEs, and treatment-related AEs leading to discontinuation of study treatment. Approximately half of the participants had at least one Grade 3 to 5 AE. The most frequently reported treatment-related Grade 3 to Grade 5 AEs were lymphocyte count decreased and anemia .

Approximately one-third of the participants had at least 1 SAE up to 90 days after receiving the last dose of pembrolizumab. The most frequently reported treatment related SAEs were pyrexia , hypertension , and pleural effusion , each occurring in ≤4 participants. Five participants had 1 or more AEs that resulted in death. For 1 participant with fatal pulmonary edema and 1 participant with fatal pneumonitis and pleural effusion , AEs were deemed as drug-related by the investigator.

Thirty (18.6%) participants had at least 1 AEOSI. Four participants had a Grade 3 to 5 AEOSI: colitis, myelitis, pruritus (each Grade 3) and pneumonitis (Grade 5). Two participants had an AEOSI that led to discontinuation of the study treatment: Grade 3 myelitis and Grade 5 pneumonitis . Among the participants with 1 or more AEOSI, 13 (43.3%) had resolution of an event by the time of data cut-off. Among the events that had not resolved, 12 were endocrinopathies (ie, hypothyroidism, hyperthyroidism, thyroiditis, and adrenal insufficiency ) that required long-term hormone replacement therapy.

Most AEs did not lead to treatment interruption. The most frequently reported AE and treatment-related AE resulting  in  treatment  interruption  was alanine  aminotransferase  increased in  3  participants.  Three participants (2 with cHL, 1 with solid tumour NOS) received an allogeneic SCT after discontinuing treatment with pembrolizumab. Both participants with cHL received alternative systemic anticancer therapy before the allogeneic SCT and developed GVHD post allogeneic SCT. Investigators deemed the GVHD not related to pembrolizumab.

The safety results from KEYNOTE-051 were generally consistent with those reported for pembrolizumab in monotherapy in adult patients, as demonstrated in a head-to-head comparison of frequencies of AEs in KEYNOTE-051  vs  the  pembrolizumab  monotherapy  adult  safety  database  (RSD)  in  May  2019,  within variation EMEA/H/C/003820/II/0071. To support the submission of a Type II variation with the proposed indication extended to paediatric cHL patients, safety data from cHL children should be presented separately and comparison between the safety data of cHL paediatrics vs. the cumulative safety data from KEYNOTE051 and the safety profile in adults (particularly vs . the safety profile in cHL adults from the KEYNOTE-204 and the cumulative cHL Safety Dataset) should be provided, also considering differences in the therapeutic history of these patients (e.g., prior lines of therapy, more frequent radiotherapy in paediatric patients). The MAH acknowledges the question about limited paediatric data in the KEYNOTE-051 HL cohort that includes only 22 patients: the small sample size and the differences in prior therapies received compared with  adult  cHL  patients  limits  the  conclusions  that  can  be  drawn  when  comparing  this  cohort  to  other datasets. However, the data provided by the MAH comparing the cHL paediatric safety profile to cumulative paediatric safety data, showed that the patients with cHL had higher rates of drug-related AEs and dose modifications due to AEs compared with other tumour types, while participants with other tumor types had higher rates of Grade 3-5 AEs and SAEs. They experienced higher rates of overall AEOSI and drug-related AEOSI  compared  with  participants  with  other  tumor  types.  Nevertheless,  the  duration  of  exposure  to pembrolizumab was approximately 8-fold longer for participants in KEYNOTE-051 with cHL. Compared to the cHL safety profile in adults, consistent lower rates for all AE categories (except for AEOSI) could be observed.

Treatment with pembrolizumab in paediatric participants could affect the immunological competence, not only in terms of decreased number of lymphocytes (one of the most frequently reported Grade 3 to 5 AEs in paediatric patients) but also of influencing the immunological functional activities, especially in paediatric patients with a less mature immune system. The MAH provided an update of immunological analyses for paediatric cHL patients included in KEYNOTE-051. Vaccinated antibody concentrations and memory B- and T-cell counts were collected as part of the secondary objectives of KEYNOTE-051 (data cut-off of January

<div style=\"page-break-after: always\"></div>

2020). An upward trend in memory B- and T-cell counts and minimal changes in the concentration of vaccinated antibodies from pre-treatment to post-treatment Cycle 4 were observed. Taken together, these data indicate that treatment with pembrolizumab does not appear to affect immunological competence in this paediatric patient population.

The outcomes after transplant have been presented only for 2 cHL patients. This point is of importance in paediatric patients as the cure rate after allo-SCT is higher than in adults. After the cut-off date (10-JAN2020), no additional patients in KEYNOTE-051 received an allo transplant, so that an evaluation of potential cure rate in cHL paediatric patients (n=2) compared to adults is not possible.

For KEYNOTE-204, the MAH provided additional information on all 14 allo-SCT participants, such as the last known contact date, the follow-up time since the allo-SCT and details on the mortality status. In particular, the MAH provided data on the allo-SCT participants post-pembrolizumab who experienced a GVHD event. These preliminary data confirm that GVHD is a frequent AE post pembrolizumab, especially as acute GVHD (reported  8  out  of  11  patients),  Grade  2  or  Grade  3  predominantly.  However,  also chronic  GVHD mild/moderate/severe has been observed (in 3 out of 11 patients). Of the fourteen transplanted patients, two patients died, and the cause of death was respiratory failure and hypovolaemic shock , respectively. An interim  analysis  report  of  the  comprehensive  and  detailed  safety  analysis  of  adult  participants  with hematologic malignancies enrolled in MSD-sponsored studies who received an allo-SCT following therapy with pembrolizumab was submitted in December 2020. The was recommended to share the final analysis report across haematological malignancies, including paediatric and adult participants.

As of the database cut-off date of 10-JAN-2020 in KEYNOTE-051, there was no additional data available of secondary malignancy, and only one participant with a primary diagnosis of solid tumour NOS developed a secondary malignancy of Grade 5 adenocarcinoma gastric , reported by the investigator as not treatment related.  There  were  no  secondary  malignancies  identified  in  KEYNOTE-204  and  KEYNOTE-087.  For KEYNOTE-051 the MAH will plan to enrol a minimum of 20 patients within the r/r cHL cohort, for which the next data cut-off for the analysis is planned in March 2024.

## 2.5.2. Conclusions on clinical safety

The incidence of most AEs did not differ significantly between study arms, with the exception of hypothyroidism and urinary tract infection in the pembrolizumab arm and higher incidences of nausea and peripheral neuropathy in the BV group. The overall AE profile observed in the KEYNOTE-204 pembrolizumab group was generally consistent with the cHL Safety Dataset and the RSD. Despite the limited sample size, from KEYNOTE-051 study no unexpected safety signal was reported in cHL paediatric patients.

The MAH will plan to enrol a minimum of 20 patients within the r/r cHL cohort in KEYNOTE-051, for which the next data cut-off for the analysis is planned in March 2024; this study is part of the PIP agreed with the PDCO.

Finally, the MAH was recommended to share the final analysis report across haematological malignancies, including paediatric and adult participants.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 30 is acceptable.

The CHMP endorsed the Risk Management Plan version 30 with the following content:

## Safety concerns

Table 1093

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                        |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related adverse reactions (including immune related pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies)                                                                                                                                                                                      |
| Important potential risks    | For hematologic malignancies: increased risk of severe complications of allogeneic stem cell transplantation (SCT) in patients who have previously received pembrolizumab Graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic stem cell transplant (SCT) |
| Missing information          | None                                                                                                                                                                                                                                                                                                              |

Based on the data supporting the new indication, the existing list of safety concerns remains unchanged.

Existing pharmacovigilance plan and risk minimisation measures remains sufficient to mitigate the risk of keytruda in all approved indications.

## Pharmacovigilance plan

There are no ongoing or planned additional pharmacovigilance studies that are required for pembrolizumab .

## Risk minimisation measures

Table 1104: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                               | Risk minimisation Measures                                   | Pharmacovigilance Activities                                 |
|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Important Identified Risks: Immune-Related Adverse Reactions | Important Identified Risks: Immune-Related Adverse Reactions | Important Identified Risks: Immune-Related Adverse Reactions |

<div style=\"page-break-after: always\"></div>

Table 1104: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                               | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-related adverse reactions (including immune- related pneumonitis, colitis, hepatitis, nephritis and endocrinopathies) | Routine risk minimisation measures: • The risk of the immune- related adverse reactions (including immune-related pneumonitis colitis, hepatitis, nephritis, and endocrinopathies) associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. | Routine pharmacovigilance activities Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire for spontaneous postmarketing reports of all adverse events |
|                                                                                                                              | Additional risk minimisation measures: Patient educational materials                                                                                                                                                                                                                                                                                   | Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types                                                                     |

<div style=\"page-break-after: always\"></div>

Table 1104: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                                                | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance Activities                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                                                                                                                     | Important Potential Risks                                                                                                                                                                                                                                                                                                                                        | Important Potential Risks                                                                                                                                                              |
| For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab | Routine risk minimisation measures: • For Hematologic malignancies: the increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab is described in the SmPC, Section 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in the ongoing HL trials (KN087, KN204).                                              |
| GVHD after pembrolizumab administration in patients with a history of allogeneic SCT                                                          | Routine risk minimisation measures: • GVHD after pembrolizumab administration in patients with a history of allogeneic SCT is described in the SmPC, Section 4.4 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted                                                                   | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet has been updated accordingly.  The Annex II was amended to reflect extended deadline for the submission of the PAES study KN-204.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The changes to the package leaflet are limited; in particular, the key messages for the safe use of the medicinal product are not impacted. Furthermore, the design, layout and format of the package leaflet will not be affected by the proposed revisions. Therefore, these proposed revisions do not constitute significant changes that would require the need to conduct a new user consultation or abridged focus testing.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The approved therapeutic indication is: KEYTRUDA as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory cHL who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.

## 3.1.2. Available therapies and unmet medical need

The majority of patients with cHL can achieve long-term disease control/cure with frontline chemotherapy (e.g. ABVD, Stanford V or BEACOPP), yet 10 to 40% of patients still experience relapse or are refractory to the initial therapy. Salvage therapy is currently based on non cross-resistant chemotherapy regimens (e.g. DHAP, IGeV, GemOX plus dexamethasone, ICE etc.) that can re-induce remission in approximately 50-70% of patients. Long-term disease control following conventional therapy alone is, however, uncommon, and further  consolidation  with  high  dose  chemotherapy  and  ASCT  is  usually  administered  to  fit  patients. Consolidation with ASCT has been associated with long-term disease control/cure in approximately 50% of patients.

BV is approved in the EU for the treatment of adult patients with r/r cHL following ASCT or at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. The ORR with BV in this setting has been shown to be as high as 60-75% (CRR 30-34%). 5-year OS was 41% (65% for patients who obtained a CR) and 5-year PFS was 22% (52% for patients in CR). However, exposure to BV is not devoid of toxicities: peripheral sensory neuropathy (overall incidence ~40%) is the most relevant nonhematologic adverse event (AE) (see Adcetris EPAR and SmPC). BV also proved to be an effective 'bridge' to transplant (see e.g. Chen R et al, Blood 2016; Younes A et al, JCO 2012).

Prognosis after failure of salvage chemotherapy, including BV, and/or ASCT is poor. A selected subset of young and fit patients might be eligible to allogeneic hematopoietic stem cell transplant (allo-HSCT), which can still result in long-term remission in a subset of patients. However, transplant-related mortality and toxicity is not negligible.

Overall, an unmet medical need for r/r cHL patients who failed or are unfit for ASCT can be recognised.

## 3.1.3. Main clinical studies

The efficacy of pembrolizumab in the claimed indication is mainly supported by the Interim Analysis 2 results (data cutoff 16-JAN-2020, median survival follow-up of about 24.6 months) from Phase III study KN-204 (pivotal trial) comparing PFS (primary endpoint) as assessed by blinded independent central review (BICR), according to the IWG response criteria [Cheson, 2007], between pembrolizumab and BV treatment arms.

Efficacy  data  from  paediatric  study  KN-051 were also submitted to support the proposed extrapolation strategy using a model-based PK bridging analysis to in clude paediatric patients aged ≥3 years. Study KN051 was a Phase I/II study investigating pembrolizumab monotherapy in paediatric patients with solid tumours and malignant lymphomas.

<div style=\"page-break-after: always\"></div>

Updated efficacy data from phase II study KN-087 were provided to further characterise the efficacy of pembrolizumab in r/r cHL. This is a single-arm, multi-cohort, non-randomized Phase 2 study investigating the efficacy of pembrolizumab monotherapy in a heterogeneous population of patients with cHL in advanced settings of relapse. Results for study KN-087 were pivotal in supporting the currently approved indication of pembrolizumab for the treatment of r/r cHL.

## 3.2. Favourable effects

In adults (Pivotal study KN-204) pembrolizumab provided a statistically significant improvement in PFS (including clinical and imaging data post-SCT): median PFS in the ITT population of pivotal study KN-204 was 13.2 months (95%CI 10.9, 19.4) and 8.3 months (95%CI 5.7, 8.8) with pembrolizumab and BV, respectively (HR 0.65, 95%CI 0.48, 0.88, p=0.00271). The estimated 24-month PFS rates were 35.4% and 25.4% with pembrolizumab and BV, respectively. Secondary PFS analysis (excluding clinical and imaging data post-SCT), PFS sensitivity analyses and analyses based on investigator assessment were consistent.

The point estimation for ORR was numerically higher with pembrolizumab compared to BV: 65.6% (95%CI: 57.4, 73.1) vs. 54.2% (95%CI: 46.0, 62.3), respectively. The CRR was not different between treatment arms (24.5% for pembrolizumab and 24.2% for BV). The proportion of patients who received subsequent ASCT (~20%) or allogeneic HSCT (~9%) did not differ between pembrolizumab and BV. For pembrolizumab, median duration of response (DoR) was 20.7 months (range: 0.0+ to 33.2+ months) versus a median of 13.8 months (range: 0.0+ to 33.9+) with BV. The fraction of patients with response duration longer than 24 months was similar across treatment arms (47.4% vs. 42.8%).

The results from the provided preliminary PFS2 analysis were in favour of pembrolizumab (HR 0.58, 95%CI 0.38, 0.87, p=0.0037).

Regarding  PRO,  with  respect  to  the  EORTC  QLQ-C30,  from  baseline  to  Week  24  a  trend  towards  an improvement  could  generally  be  observed  with  pembrolizumab  while,  conversely,  a  trend  towards deterioration was reported in the BV arm. The prespecified time to deterioration analysis also showed an improvement with pembrolizumab in the GHS/QOL (HR 0.40, 95%CI 0.22, 0.74) and physical functioning scores  (HR  0.56,  95%CI  0.32,  0.97).  Results  with  the  EQ-5D  instrument  were  consistent  with  those reported for the QLQ-C30 questionnaire: a significant difference in the LS means favouring pembrolizumab was observed at Week 24 for the utility ( Δ 0.09 points, 95%CI 0.04, 0.14) and VAS scores ( Δ 6.12 points, 95%CI 1.91, 10.34).

Clinical outcomes in subjects with ≥2 prior lines of thera py were consistent with the primary analysis in the ITT population: the ORRs with pembrolizumab was 65.3% (95%CI 56.3, 73.6) vs. 54.4% (95%CI 45.3, 63.3). The CRR was 26.6% (95%CI 19.1, 35.2) and 21.6% (95%CI 14.7, 29.8) with pembrolizumab and BV, respectively. PFS also consistently favoured the pembrolizumab arm (HR 0.66, 95%CI 0.47, 0.92): the mPFS was 12.6 months (95%CI 8.7, 19.4) with pembrolizumab and -8.2 months with BV (95%CI 5.6, 8.8) HR 0.62-0.70). No DoR and OS data by line of therapy were provided.

Updated results from the supportive study KN-087with a median duration of follow-up of 39.5 months showed an IWG ORR by BICR of 71% (95%CI 64.3, 77) and 71.7% (95%CI 58.6, 82.5) in the overall population and in cohort 3 (BV-naïve patients), respectively. CRRs were 27.6% and 31.7%, median DoR 16.6 and 16.8 months and median PFS 13.6 and 16.8 months, respectively. Median OS was still not reached in all cohorts.

In paediatric patients (paediatric study KN-051) the ORR per IWG criteria observed in patients treated in the dedicated r/r cHL cohort (n=8) was 42.9% (3/7). Two out of 7 subjects achieved a CR. Median DoR in this cohort was not reached and median PFS (11.2 months) was overall in line with that observed in adults.

<div style=\"page-break-after: always\"></div>

The ORR per RECIST criteria in the 15 patients treated in the PD-L1 positive tumours cohort was 66.7% (with one patient reaching a CR), the median DoR and PFS were 17.4 and 12.2 months, respectively.

Among the 22 cHL participants, the ORR was 54.5% based on IWG 2007 criteria and 63.6% based on Lugano criteria. The CRR was 4.5% and 18.2% based on the IWG 2007 and Lugano criteria, respectively. Among the 12 responders by IWG 2007 criteria, the median time to response was 2.3 months and the median response duration was 17.3 months. Among the 14 responders by Lugano criteria, the median time to response was 2.1 months and the median response duration was 8.8 months. Among the 22 cHL participants, the median PFS was 8.3 months based on IWG 2007 criteria and 8.2 months based on Lugano criteria.

## 3.3. Uncertainties and limitations about favourable effects

The OS data from KEYNOTE-204 are still immature and have not been statistically tested. Immaturity of PFS2  data  and  limited  information  on  subsequent  treatment  make  difficult  to  assess  the  impact  of uncontrolled cross-over. The provided DoR analysis was not sufficiently mature (only 40% of patient were informative). Updated results from the final CSR of KEYNOTE-204 - listed as a PAES (Annex IID) - will be submitted for review in accordance with agreed timelines. Data in HL patients ≥ 65 years  are  limited; however this is adequately reflected in sections 4.2. and 5.1 of the SmPC.

Regarding the efficacy in paediatric patients, the main uncertainty is the limited number (22) of r/r cHL paediatric patients treated in study KN-051. No clinical and no PK data are available below the age of 10 with  cHL.  Descriptive  statistics  of  predicted  individual  exposure  parameters  for  paediatrics  and  adult patients shows that Cmin is about 50% higher in the 3-6 age group, although the median value is within the Q3 for adults. Further, there is a limited follow-up in the r/r cHL cohort and limited clinical data for paediatric patients who received subsequent SCT.

## 3.4. Unfavourable effects

The median duration of exposure was twice as long for patients in the pembrolizumab arm compared with the BV arm. When adjusted for exposure, event rates for most AEs tended to be higher with BV.

In  KEYNOTE-204,  the  most  frequently  reported  drug-related  AEs  in  the  pembrolizumab  arm  were hypothyroidism (15.5%), pyrexia (12.8%) and pruritus (10.8%), whereas the BV group showed higher incidences  of  drug-related neuropathy  peripheral (18.4%), nausea (13.2%)  and peripheral  sensory neuropathy (13.2%).  The  incidence  and  types  of  drug-related  AEs  reported  in  the  KEYNOTE-204 pembrolizumab arm were generally consistent with the cHL Safety Dataset and with the RSD (74.3%, 73.3% and 70.2%).

The overall incidence of Grade 3 to 5 drug-related AEs in KEYNOTE-204 was lower in the pembrolizumab arm (19.6%) than in the BV group (25%). The most frequently reported drug-related Grade 3 to 5 AEs were pneumonitis (4.1%), pneumonia (2%) and neutropenia (2%) in the pembrolizumab arm; neutropenia (7.2%), neutrophil count decreased (4.6%) and neuropathy peripheral (3.3%) in the BV arm. A higher difference  in  the  incidence  rates  of  the  other  safety  datasets  was  noted  for pneumonitis (4.1%  in  the KEYNOTE-204 pembrolizumab arm, 0.7% in the BV group, 1.8% in the cHL Safety Dataset, 1.3% in the RSD and 1.2% in the CSD).

The incidence of Serious drug-related AEs was 16.2%, with pneumonitis as the most frequently occurring AE (5.4%).

The most frequent AEOSIs were hypothyroidism (18.9%), pneumonitis (8.8%) in the pembrolizumab arm and infusion-related reaction (7.9%), hypothyroidism (2.6%), and pneumonitis (2%) in the BV arm. Most

<div style=\"page-break-after: always\"></div>

immune-mediated  AEOSIs  were  mild  to  moderate  in  severity  and  were  managed  with  treatment interruptions and/or corticosteroids. At the time of data cut-off, 50.9% of patients were reported to have AEOSIs resolved, 9.4% were resolving and 37.7% were not resolved.

Complications to allogenic HSCT (i.e, acute/chronic GVHD) were experienced in 34 out of 48 pembrolizumab treated patients who received transplantation after progression, and a fatal outcome was reported in 6 of them.

The types and incidences of the most frequently reported AEs in paediatric patients in KEYNOTE-051 were consistent with a heavily pre-treated paediatric population with advanced cancers. Although the majority of participants (57.8%) had treatment-related AEs, pembrolizumab was well tolerated as evidenced by the small proportions of participants with Grade 3 to 5 treatment-related AEs (8.7%), treatment-related SAEs (9.9%), and treatment-related AEs leading to discontinuation of the study treatment (3.7%). The most frequently  reported  treatment-related  AEs  were fatigue (8.7%), anaemia (8.1%), pyrexia (7.5%), aspartate  aminotransferase  increased (6.8%), lymphocyte  count  decreased (6.8%), diarrhoea (6.2%), alanine aminotransferase increased (5.6%), and hypothyroidism (5.6%), the majority of them with Grade 1-2 toxicity. The most frequently reported Grade 3 to 5 AEs were anaemia (8.1%) and lymphocyte count decreased (5.6%). The most frequently reported drug-related SAEs were pyrexia (2.5%), hypertension (1.2%), and pleural effusion (1.2%). The most frequently reported AEOSI were hypothyroidism (8.1%), hyperthyroidism (3.7%), hypersensitivity (2.5%), and pneumonitis (2.5%).

As of the database cut-off date of 10-JAN-2020 in KEYNOTE-051, there was no additional data available of secondary malignancy, and only 1 participant with a primary diagnosis of solid tumour NOS developed a secondary malignancy of Grade 5 adenocarcinoma gastric . There were no secondary malignancies identified in KEYNOTE-204 and KEYNOTE-087. For KEYNOTE-051, the MAH will plan to enrol a minimum of 20 patients within the r/r cHL cohort, for which the next data cut-off for the analysis is planned in March 2024.

Complications after allogenic HSCT ( acute/chronic GVHD ) were experienced in 2 cHL patients after discontinuing treatment with pembrolizumab. Both patients were alive but acute/chronic GVHD was not resolved.

## 3.5. Uncertainties and limitations about unfavourable effects

Considering the recognized risk of exacerbating GVHD related to checkpoint inhibition, data on the feasibility of allogeneic HSCT after pembrolizumab are still limited, as indicated in the sections 4.4 and 4.8 of the SmPC. After the cut-off date (10-JAN-2020), no additional patients in KEYNOTE-051 received an allo transplant, so that an evaluation of potential cure rate in cHL paediatric patients (n=2) compared to adults is not possible. An interim analysis report of the safety analysis of adult participants with hematologic malignancies enrolled in MSD-sponsored studies who received an allo-SCT following therapy with pembrolizumab was submitted in December 2020 and is currently under assessment.

The MAH is also requested to share the final analysis report across haematological malignancies, including paediatric and adult participants by December 2024. - related to the following: FDA PMR 3188-2: Characterize complications after allogeneic hematopoietic stem cell transplantation (HSCT) following pembrolizumab in at least 90 patients with hematologic malignancies, of which at least 30% had received pembrolizumab alone or in combination as the regimen immediately prior to the allogeneic HSCT conditioning regimen. Evaluate toxicities at least through transplant Day 180. Include details of prior pembrolizumab treatment and the transplant regimen. Characterize toxicities including hyperacute graftversus-host disease (GVHD), severe (Grade 3-4) acute GVHD, febrile syndromes treated with steroids, immune mediated adverse events, pulmonary complications, hepatic veno-occlusive disease and/or

<div style=\"page-break-after: always\"></div>

sinusoidal obstruction syndrome, critical illness, and transplant-related mortality. Toxicities may be characterized prospectively, or through a combination of prospective and retrospective data analysis.

## 3.6. Effects Table

Effects Table for Keytruda (pembrolizumab) as monotherapy for the treatment of adult and paediatric patients aged ≥3 years with cHL who have failed ASCT or when ASCT is not a treatment option (data cut-off: 16 Jan 2020)- study KN-204

| Effect                                          | Short description                                                                                                                     | Unit                | Treatment (Pembro 200 mg 3QW)   | Control (BV)         | Uncertainties / Strength of evidence                                                                                                                                                                                                                                                                                                                    | Refe renc es        |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------------------|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Favourable Effects                              | Favourable Effects                                                                                                                    | Favourable Effects  | Favourable Effects              | Favourable Effects   | Favourable Effects                                                                                                                                                                                                                                                                                                                                      | Favourable Effects  |
| Adults                                          |                                                                                                                                       |                     |                                 |                      |                                                                                                                                                                                                                                                                                                                                                         |                     |
| PFS by BICR (ITT population)                    | Time from randomization to PD or death whichever occurred first including clinical and imaging data following ASCT or allogeneic HSCT | months (95% CI)     | 13.2 (10.9, 19.4)               | 8.3 (5.7, 8.8)       | Consistency of results across most subgroups and sensitivity analyses in study KN-204 Clinically meaningful results vs. BV in the overall population of study KN-204 Consistency of results across pivotal and supportive studies Uncertainty regarding potentially                                                                                     | (1)                 |
| PFS by BICR (ITT population)                    | Time from randomization to PD or death whichever occurred first                                                                       | months (95% CI)     | 13.6 (11.1, 16.7)               | NA                   | Consistency of results across most subgroups and sensitivity analyses in study KN-204 Clinically meaningful results vs. BV in the overall population of study KN-204 Consistency of results across pivotal and supportive studies Uncertainty regarding potentially                                                                                     | (2)                 |
| PFS by BICR secondary (ITT population)          | Time from randomization to PD or death whichever occurred first excluding clinical and imaging data following ASCT or allogeneic HSCT | months (95% CI)     | 12.6 (13.1, 22.6)               | 8.2 (5.6, 8.4)       | lower benefit in European population                                                                                                                                                                                                                                                                                                                    | (1)                 |
| PFS by BICR (patients with ≥ 2 prior therapies) | Time from randomization to PD or death whichever occurred first                                                                       | months (95% CI)     | 12.6 (8.7, 19.4)                | 8.2 (5.6, 8.8)       | Consistency of results across most subgroups and sensitivity analyses in study KN-204 Clinically meaningful results vs. BV in the overall population of study KN-204 Consistency of results across pivotal and supportive studies Uncertainty regarding potentially                                                                                     | (1)                 |
| ORR (ITT population)                            | CR+PR rate by BICR                                                                                                                    | % (95% CI)          | 65.6% (57.4, 73.1)              | 54.2% (46.0, 62.3)   | The majority of patients was to obtain a clinical response despite the advanced setting of relapse The 95% CIs for ORR and CRR with pembrolizumab and BV in study KN-204 largely overlapped The ORR/CCR observed in the BV arm of study KN-204 were slightly inferior to those reported in the Adcetris EPAR (i.e. ORR 75% and CRR 33% by IRF analysis) | (1)                 |
| ORR (ITT population)                            | CR+PR rate by BICR                                                                                                                    | % (95% CI)          | 71% (64.3, 77.0)                | NA                   | The majority of patients was to obtain a clinical response despite the advanced setting of relapse The 95% CIs for ORR and CRR with pembrolizumab and BV in study KN-204 largely overlapped The ORR/CCR observed in the BV arm of study KN-204 were slightly inferior to those reported in the Adcetris EPAR (i.e. ORR 75% and CRR 33% by IRF analysis) | (2)                 |
| ORR (patients with ≥ 2 prior therapies)         | CR+PR rate by BICR                                                                                                                    | % (95% CI)          | 65.3% (56.3, 73.6)              | 54.4% (45.3, 63.3)   | The majority of patients was to obtain a clinical response despite the advanced setting of relapse The 95% CIs for ORR and CRR with pembrolizumab and BV in study KN-204 largely overlapped The ORR/CCR observed in the BV arm of study KN-204 were slightly inferior to those reported in the Adcetris EPAR (i.e. ORR 75% and CRR 33% by IRF analysis) | (1)                 |
| CRR (ITT population)                            | CR rate by BICR                                                                                                                       | % (95% CI)          | 24.5%, (17.9%, 32.2%)           | 24.2% (17.6%, 31.8%) | The majority of patients was to obtain a clinical response despite the advanced setting of relapse The 95% CIs for ORR and CRR with pembrolizumab and BV in study KN-204 largely overlapped The ORR/CCR observed in the BV arm of study KN-204 were slightly inferior to those reported in the Adcetris EPAR (i.e. ORR 75% and CRR 33% by IRF analysis) | (1)                 |
| CRR (ITT population)                            | CR rate by BICR                                                                                                                       | % (95% CI)          | 27.6                            | NA                   | The majority of patients was to obtain a clinical response despite the advanced setting of relapse The 95% CIs for ORR and CRR with pembrolizumab and BV in study KN-204 largely overlapped The ORR/CCR observed in the BV arm of study KN-204 were slightly inferior to those reported in the Adcetris EPAR (i.e. ORR 75% and CRR 33% by IRF analysis) | (2)                 |
| CRR (patients with ≥ 2 prior therapies)         | CR rate by BICR                                                                                                                       | % (95% CI)          | 26.6 (19.1, 35.3)               | 21.6 (14.7, 29.8)    | The majority of patients was to obtain a clinical response despite the advanced setting of relapse The 95% CIs for ORR and CRR with pembrolizumab and BV in study KN-204 largely overlapped The ORR/CCR observed in the BV arm of study KN-204 were slightly inferior to those reported in the Adcetris EPAR (i.e. ORR 75% and CRR 33% by IRF analysis) | (1)                 |
| DoR                                             | Time from first response to PD or death due to any cause, whichever occurs first in subjects who achieve a PR or better.              | Months (range)      | 20.7 (0.0+, 33.2+)              | 13.8 (0.0+, 33.9+)   | DoR in study KN-204 was not sufficiently mature The actual clinical benefit in 2 nd line non transplant eligible patients is not established                                                                                                                                                                                                            | (1)                 |
| DoR                                             |                                                                                                                                       | Months (range)      | 16.6 (0.0+, 39.1+)              | NA                   | DoR in study KN-204 was not sufficiently mature The actual clinical benefit in 2 nd line non transplant eligible patients is not established                                                                                                                                                                                                            | (2)                 |
| Paediatric patients                             | Paediatric patients                                                                                                                   | Paediatric patients | Paediatric patients             | Paediatric patients  | Paediatric patients                                                                                                                                                                                                                                                                                                                                     | Paediatric patients |
| ORR                                             | CR+PR rate by BICR using the IWG 2007 response criteria                                                                               | n % (95% CI)        | N=7 42.9% (9.9, 81.6)           | NA                   | Anti-tumour activity overall consistent with those observed in adults Efficacy in paediatric patients based on extrapolation from adults and limited paediatric data from 22 participants with HL in                                                                                                                                                    | (3)                 |
| ORR                                             |                                                                                                                                       | n % (95% CI)        | N=22 54.5% (32.3, 75.6)         | NA                   | Anti-tumour activity overall consistent with those observed in adults Efficacy in paediatric patients based on extrapolation from adults and limited paediatric data from 22 participants with HL in                                                                                                                                                    | (3)                 |
| ORR                                             | CR+PR rate by BICR using the RECIST 1.1 response                                                                                      | n % (95% CI)        | N=15 66.7%                      | NA                   | Anti-tumour activity overall consistent with those observed in adults Efficacy in paediatric patients based on extrapolation from adults and limited paediatric data from 22 participants with HL in                                                                                                                                                    | (3)                 |

<div style=\"page-break-after: always\"></div>

| Effect               | Short description                                                                                       | Unit                 | Treatment (Pembro 200 mg 3QW)        | Control (BV)   | Uncertainties / Strength of evidence                                                                                       | Refe renc es   |
|----------------------|---------------------------------------------------------------------------------------------------------|----------------------|--------------------------------------|----------------|----------------------------------------------------------------------------------------------------------------------------|----------------|
|                      | criteria CR+PR rate by BICR using the 2014 Lugano response criteria                                     |                      | (38.4, 88.2) N=22 63.6% (40.7, 82.8) | NA             | the age from 10 to 17 years (Study KEYNOTE-051)                                                                            |                |
| CRR                  | CR rate by BICR using the IWG 2007 response criteria                                                    | N % (95% CI)         | N=7 28.% (3.7, 71.0)                 | NA             | the age from 10 to 17 years (Study KEYNOTE-051)                                                                            | (3)            |
| CRR                  | CR rate by BICR using the IWG 2007 response criteria                                                    | N % (95% CI)         | N=22 4.5% (0.1, 22.8)                | NA             | the age from 10 to 17 years (Study KEYNOTE-051)                                                                            | (3)            |
| CRR                  | CR rate by BICR using the RECIST 1.1 response criteria                                                  | N % (95% CI)         | N=15 6.7% (0.2, 31.9)                | NA             | the age from 10 to 17 years (Study KEYNOTE-051)                                                                            | (3)            |
| CRR                  | CR rate by BICR using the 2014 Lugano response criteria                                                 | N % (95% CI)         | N=22 18.2% (5.2, 40.3)               | NA             | the age from 10 to 17 years (Study KEYNOTE-051)                                                                            | (3)            |
| PFS                  | Time from randomization to PD or death whichever occurred first using the IWG 2007 response criteria    | months               | N=22 8.3                             | NA             | Median PFS consistent with that observed in adults Limited sample size                                                     | (3)            |
| PFS                  | Time from randomization to PD or death whichever occurred first using the RECIST 1.1 response criteria  | months               | N=15 12.2                            | NA             | Median PFS consistent with that observed in adults Limited sample size                                                     | (3)            |
| PFS                  | Time from randomization to PD or death whichever occurred first using the 2014 Lugano response criteria | months               | N=22 8.2                             | NA             | Median PFS consistent with that observed in adults Limited sample size                                                     | (3)            |
| OS                   | Time from randomization to death                                                                        | months               | NR                                   | NA             | Limited sample size The analysis is not mature                                                                             | (3)            |
| Unfavourable Effects | Unfavourable Effects                                                                                    | Unfavourable Effects |                                      |                |                                                                                                                            |                |
| Tolerability         | Drug- related Grade ≥3 AE                                                                               | %                    | 19.6                                 | 25             | Dataset, except for hypothyroidism and pneumonitis Considering the recognized risk of exacerbating GVHD related to         | (1)            |
| Tolerability         | Drug-related SAEs                                                                                       | %                    | 16.2                                 | 10.5           | Dataset, except for hypothyroidism and pneumonitis Considering the recognized risk of exacerbating GVHD related to         | (1)            |
| Tolerability         | Death-drug related                                                                                      | %                    | 0.7                                  | 0              | Dataset, except for hypothyroidism and pneumonitis Considering the recognized risk of exacerbating GVHD related to         | (1)            |
| Tolerability         | Discontinuation drug-related SAEs                                                                       | %                    | 8.8                                  | 3.9            | Dataset, except for hypothyroidism and pneumonitis Considering the recognized risk of exacerbating GVHD related to         | (1)            |
| Tolerability         | Incidence of Hypothyroidism                                                                             | %                    | 15.5                                 | 1.3            | Dataset, except for hypothyroidism and pneumonitis Considering the recognized risk of exacerbating GVHD related to         | (1)            |
| Drug-related AEs     | Incidence of Pyrexia                                                                                    |                      | 12.8                                 | 5.9            | Dataset, except for hypothyroidism and pneumonitis Considering the recognized risk of exacerbating GVHD related to         | (1)            |
| Drug-related AEs     | Incidence of Pruritus                                                                                   | %                    | 10.8                                 | 5.3            | Dataset, except for hypothyroidism and pneumonitis Considering the recognized risk of exacerbating GVHD related to         | (1)            |
| Drug-related AEs     | Incidence of Diarrhoea                                                                                  | %                    | 9.5                                  | 4.6            | Dataset, except for hypothyroidism and pneumonitis Considering the recognized risk of exacerbating GVHD related to         | (1)            |
| Drug-related AEs     | Incidence of Pneumonitis                                                                                | %                    | 8.1                                  | 0.7            | checkpoint inhibition, data on the                                                                                         | (1)            |
| Drug-related AEs     | Incidence of Hyperthyroidism                                                                            | %                    | 5.4                                  | 0              | feasibility of allogeneic HSCT are                                                                                         | (1)            |
| Drug-related AEs     | Hypothyroidism                                                                                          | %                    | 18.6                                 | 2.6            | still limited especially for paediatric cHL population                                                                     | (1)            |
| Drug-related AEs     | Pneumonitis                                                                                             | %                    | 10.8                                 | 2.6            | Dataset, except for hypothyroidism and pneumonitis Considering the recognized risk of exacerbating GVHD related to         | (1)            |
| AEOSI                |                                                                                                         |                      |                                      |                | Hypothyroidism is reported in higher incidences than in the Reference Safety Population; Pneumonitis is reported in higher |                |
| AEOSI                |                                                                                                         |                      |                                      |                | incidences than in the Reference Safety Population                                                                         |                |

Abbreviations: AE(s): Adverse event(s); CR/CRR: Complete Response/Complete Response Rate; DoR: Duration of Response; ORR: Objective Response Rate; OS: Overall Survival; PD: Progressive Disease; PFS: Progression Free Survival; PR: Partial Response; AEOSI: Adverse Event of Special Interest.

References: (1) KEYNOTE-204 CSR. (2) KEYNOTE-087 CSR. (3) KEYNOTE-051 CSR

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

High  rates  of  long-term  disease  control/cure  are  usually  obtained  with  frontline  chemotherapy  in  cHL. Approximately half of the patients who experience relapse or have refractory disease can still achieve cure with high-dose chemotherapy followed by ASCT. The outcomes of patients who fail salvage therapy or ASCT are, however, unsatisfactory, and an unmet medical need can be recognised in this clinical setting.

The approximate 5-month gain in median PFS observed with pembrolizumab in pivotal study KN-204, which is equivalent to almost 35% reduction in the risk for progression or death, can be considered of clinical relevance.  PFS  K-M  plots did  not  show,  however,  any  clear  plateau,  confirming  that  long-term  disease control is rarely achieved in advanced stages of relapse.

Resistance to treatment is an important issue in advanced settings of r/r cHL, and ORR data showed a favourable trend with pembrolizumab, although CR rates and the % of patients who were able to received subsequent transplant were not improved compared to BV. Preliminary survival data from pivotal trial KN204 and PFS2 data, although immature, were supportive of the efficacy of pembrolizumab in this advanced setting. Further data will be provided with the submission of the final CSR as a PAES (already included in the Annex II).

With respect to safety, the incidence of most AEs did not differ significantly across treatment arms, with the exception of hypothyroidism and urinary tract infection that were more common in the pembrolizumab arm, and nausea and peripheral neuropathy that were more frequent with BV. The safety profile observed in pivotal study KN-204 was generally consistent with the overall cHL Safety Dataset and the RSD. No new safety concerns were identified.

The available efficacy data from paediatric study KN-051 are limited, as expected due to the rarity of cHL in children. On the other hand, the high unmet medical need in paediatric patients for whom chemotherapy is no longer an option is recognised and, despite the limited available data, the proposed extrapolation of treatment effect from adults to paediatric patients with cHL in advanced settings of relapse can be considered acceptable on the basis of similar prognostic and clinical characteristics of the disease, pharmacological drug effect and exposure-response relationship across all age classes.

## 3.7.2. Balance of benefits and risks

The available efficacy data from study KN-204 support the superiority of pembrolizumab vs. BV in subjects who have failed salvage chemotherapy +/- ASCT, with an acceptable safety profile.

Clinical data in paediatric patients are limited, yet the anti-tumour activity of pembrolizumab is confirmed and the overall safety profile did not differ significantly compared to what observed in adults. An extrapolation of treatment effect from adults to paediatric patients with cHL in advanced settings of relapse is considered acceptable.

## 3.7.3. Additional considerations on the benefit-risk balance

The limited available data in 2 nd  line transplant-ineligible patients were not adequate to establish a positive B/R  in this subgroup. Overall, the available data convincingly demonstrated  the  superiority of pembrolizumab vs. BV in subjects who have failed salvage chemotherapy and/or ASCT (i.e. subjects with ≥ 2 prior therapies).

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions

The overall B/R of Keytruda as monotherapy for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of the currently approved therapeutic indication for the treatment of relapsed or refractory classical Hodgkin lymphoma (rrcHL) in adults to an earlier line of therapy and to include paediatric patients - as follows:

KEYTRUDA as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.

As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The Annex II was revised to reflect extended deadline for the submission of the PAES KN-204. Revised RMP Version 30 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics, Annex II, Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I, II and IIIB and to the Risk Management Plan are recommended.

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0008/2018 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

## Similarity with authorised orphan medicinal products

The CHMP is of the opinion that Keytruda is not similar to Adcetris within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

<div style=\"page-break-after: always\"></div>

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Keytruda-H-C-3820-II-0090.